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Summary 
The Sirtuins constitute a conserved enzyme family, which is involved in the regulation of fun-
damental cellular processes like metabolic homeostasis, DNA repair or aging. In this context, 
they were linked to multiple aging-related pathologies such as neurodegenerative diseases 
and cancer. Sirtuins catalyze the NAD+-dependent hydrolysis of posttranslational acyl-modifi-
cations from protein lysine side chains. Mammalian cells possess seven Sirtuin isoforms 
(Sirt1-7), which are primarily located to either the nucleus/nucleolus (Sirt1/6/7), cytosol (Sirt2) 
or mitochondria (Sirt3/4/5). While lysine deacetylation was initially supposed to be the con-
served function of all Sirtuins, recent research has revealed a broader range of lysine deacyl-
ase activities, like demyristoylation by Sirt6 or desuccinylation by Sirt5. Of the mitochondrial 
Sirtuins, Sirt3 is a robust deacetylase, while no efficient Sirt4 activity was reported so far. Also 
the acyl-specificity of Sirt5, albeit identified as desuccinylase/demalonylase, was never sys-
tematically characterized. However, investigating Sirtuin catalysis, their influence on substrate 
proteins and relation to organismal pathophysiology demands precise knowledge about Sirtuin 
acyl-specificity. Notably, specific Sirtuin modulators provide another possibility for characteriz-
ing Sirtuins in vitro and in vivo and have a potential in prospective medical treatments of Sirtuin-
related dysfunctions like type 2 diabetes (Sirt4) or neurodegeneration (Sirt2/5). However, only 
a few specific Sirtuin modulators were developed yet. 
In this thesis, the acyl specificities of the mitochondrial Sirtuins 4 and 5 were investigated in 
collaborative projects. Our collaborators synthesized an acyl-peptide library to screen Sirt5 
activity, which revealed a superior lysine deglutarylation efficiency compared to the reported 
desuccinylase/demalonylase activities. We solved crystal structures of Sirt5 in complex with 
several acylated peptides to elucidate the molecular background of these activities. Suppos-
edly, the more strained conformation of the glutaryl-ADP-ribose product is responsible for the 
improved turnover by enhancing the rate-limiting product release. Concerning Sirt4, we 
screened activities with the same acyl-peptide library and identified the hydrolysis of 3,3-dime-
thyl-succinyl as a robust, but unphysiologic activity. Testing chemically similar acyls with a 
physiologic background revealed 3-hydroxy-3-methyl-glutaryl as a robust Sirt4 substrate acyl. 
Furthermore, this work includes the first Sirt4 crystal structures obtained by using the 
orthologue Xenopus tropicalis Sirt4, which shares a high sequence identity and the same cat-
alytic activities with the human isoform. These crystal structures revealed three interesting 
features providing deeper insights into the function and regulation of Sirt4. Firstly, Sirt4 com-
prises a significantly elongated zinc-binding domain loop, which sequence is present in all 
chordate Sirt4, but unique in the Sirtuin family. It contributes to the active-site lining and might 
be involved in Sirt4 regulation, since loop mutants showed changed catalytic turnovers. Sec-
ondly, the nucleotide-binding pocket is more positively charged compared to other isoforms, 
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which appears to correlate with a unique sensitivity among Sirtuins to physiologic NADH con-
centrations, indicating a distinct regulation mechanism for Sirt4. Thirdly, an additional channel 
to the acyl-lysine binding site was identified, which might either expand the substrate acyl-
lysine binding pocket or serve as a binding-site for regulatory molecules. 
We utilized the insights in Sirt5 structure and function to develop specific small molecule inhib-
itors in collaborative projects. Our contribution to these projects was the analysis of complex 
crystal structures to guide the inhibitor synthesis and kinetic studies performed by our collab-
orators. We chose a peptide with succinyl-lysine as a starting point and transformed this robust 
and Sirt5-specific substrate into Sirt5-selective peptide inhibitors by derivatization of the suc-
cinyl with alkyl-side chains. These inhibitory peptides initially showed weak potencies in the 
two-digit micromolar range and competed with NAD+ binding through the alkyl moieties as 
revealed by structural analysis. We rationally derivatized these inhibitors by substitution of the 
alkyl-side chains with thio-alkyls, which increased potency into the two-digit nanomolar range 
and showed a similar inhibitory mechanism in structural analysis. Since peptidic inhibitors often 
comprise poor cellular resorption and half-life, the strongest inhibitory acyl was attached to a 
lysine or lysine-mimetics to create small molecule modulators, but resulted in a decrease of 
potency by at least three orders of magnitude. However, we could obtain structural information 
about inhibitor scaffold-optimization in another collaborative structure-activity relationship 
study, which pursued a Sirtuin mechanism-based inhibition approach. Herein, short pep-
tide(-like) inhibitors were developed and structurally analyzed, which resulted in potencies in 
the sub-micromolar range. Combining this information about Sirt5 affinity hot spots around the 
lysine binding-site with the inhibitory acyls of the peptide approach should constitute a starting 
point for the development of small molecule Sirt5 inhibitors. These will contribute to the eluci-
dation of Sirt5 physiology and have a potential as therapeutics for the treatment of Sirt5-related 
diseases.
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Zusammenfassung 
Die Sirtuine sind eine konservierte Familie von Enzymen, welche in die Regulation fundamen-
taler zellulärer Prozesse wie der metabolischen Homöostase, der Aufrechterhaltung der geno-
mischen Stabilität oder dem Altern involviert ist. In diesem Zusammenhang wurden die Sirtuine 
mit mehreren alterungsbedingten Pathologien wie neurodegenerativen Krankheiten und Krebs 
in Verbindung gebracht. Sirtuine katalysieren die NAD+-abhängige Hydrolyse von posttransla-
tionalen Acyl-Modifikationen von Protein Lysin Seitenketten. Wirbeltiere weisen sieben Sirtuin 
Isoformen auf (Sirt1-7), welche primär im Nukleus/Nukleolus (Sirt1/6/7), dem Zellplasma 
(Sirt2) oder den Mitochondrien (Sirt3/4/5) lokalisiert sind. Während die Hydrolyse von Lysin-
Acetylierungen zunächst als konservierte Funktion aller Sirtuine angesehen wurde, offenbar-
ten neuere Studien, dass Sirtuine eine größere Bandbreite von Lysin-Deacylase Aktivitäten 
aufweisen, wie die Demyristoylierung durch Sirt6 oder Desuccinylierung durch Sirt5. Von den 
mitochondrialen Sirtuinen ist Sirt3 als effiziente Deacetylase bekannt, wohingegen für Sirt4 
bislang keine robuste Aktivität beschrieben wurde und die Sirt5 Acyl-Spezifität nach Entde-
ckung ihrer Demalonylase/Desuccinylase Aktivität nie umfassend charakterisiert wurde. Die 
detaillierte Kenntnis der Acyl-Präferenz ist jedoch essentiell für die Untersuchung der Sirtuin 
Katalyse, den Einfluss der Sirtuine auf ihre Substrat-Proteine und deren Zusammenhang mit 
der Pathophysiologie des Organismus. Bei solchen Untersuchungen spielen wirksame und 
Isoform-spezifische Sirtuin-Modulatoren eine bedeutende Rolle, da sie eine weitere Option für 
die in vitro und in vivo Charakterisierung der Sirtuine darstellen. Zusätzlich sind solche Modu-
latoren potentielle Therapeutika für Krankheiten, welche in Zusammenhang mit Sirtuinen ste-
hen, wie neurodegenerative Erkrankungen (Sirt2/5) oder Typ 2 Diabetes (Sirt4). Allerdings 
sind bislang nur wenige spezifische Modulatoren für Sirtuine bekannt. 
Im Rahmen dieser Doktorarbeit wurden die Acyl-Spezifitäten der mitochondrialen Sirtuine 4 
und 5 in Kollaborationsprojekten untersucht. Unsere Kollaborateure synthetisierten eine Acyl-
Peptid Bibliothek zur systematischen, kinetischen Charakterisierung der Sirt5 Acyl-Spezifität 
und entdeckten eine gesteigerte Lysin Deglutarylierungs-Effizienz gegenüber den zuvor be-
richteten Demalonylase und Desuccinylase Aktivitäten. Durch Lösen von Sirt5 Kristallstruktu-
ren in Komplex mit verschiedenen acylierten Peptiden wurde der molekulare Hintergrund die-
ser Aktivitäten analysiert. Diese legten die Hypothese nahe, dass die effizientere Lysin 
Deglutarylierung von der stärkeren Stauchung des Glutaryl-ADP-Ribose Produktes rührt, wel-
che die Katalyse-Geschwindigkeit limitierende Produkt-Freisetzung beschleunigen könnte. Die 
generierte Acyl-Peptid Bibliothek ermöglichte es uns weiterhin, die Acyl-Spezifität von Sirt4 zu 
charakterisieren, wodurch die Hydrolyse von 3,3-Dimethyl-Succinyl von Lysinen als robuste, 
aber unphysiologische Sirt4 Aktivität identifiziert wurde. Durch Experimente mit chemisch ähn-
lichen, potentiell physiologischen Acylen konnte die Hydrolyse von 3-Hydroxy-3-Methyl-Gluta-
ryl von Lysin Seitenketten als robuste Sirt4 Aktivität gezeigt werden.  
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Die vorliegende Arbeit beinhaltet zudem die ersten Kristallstrukturen von Sirt4, welche unter 
Verwendung des Xenopus tropicalis Sirt4 Orthologs gelöst werden konnten. Dieses Ortholog 
weist eine hohe Sequenzidentität zur humanen Isoform und dieselben enzymatischen Aktivi-
täten auf. Die Kristallstrukturen zeigten drei besondere Merkmale von Sirt4, welche zum bes-
seren Verständnis dieser Isoform beitragen. Erstens besitzt die Zink-Bindedomäne einen ver-
hältnismäßig langen Loop, dessen Sequenz konserviert in Chordata Sirt4 Orthologen, aber 
einzigartig in der Sirtuin-Familie ist. Dieser steuert Aminosäuren zum Aufbau des Aktivzent-
rums bei und scheint in die Regulation der Enzymaktivität involviert zu sein, da Loop-Deleti-
onsmutanten veränderte katalytische Werte zeigten. Zweitens weißt die Nukleotid-Bindeta-
sche eine positivere elektrostatische Ladung auf, was die unter den Sirtuinen einzigartige Sen-
sitivität gegenüber physiologischen NADH-Konzentrationen erklären könnte. Drittens zeigen 
die Strukturen einen zusätzlichen Kanal zum Aktivzentrum, welcher als vergrößerte Substrat 
Acyl-Lysin Bindestelle oder als Interaktionsfläche für regulatorische Moleküle dienen könnte. 
Die Einblicke in die Struktur und Funktion von Sirt5 flossen in die Entwicklung spezifischer 
Modulatoren für diese Isoform ein. Unser Beitrag war die Analyse von Komplex Kristallstruk-
turen, um die Inhibitor-Synthese und kinetischen Studien unserer Partner rational zu führen. 
Dafür wählten wir ein Peptid mit succinyliertem Lysin als Startpunkt und transformierten dieses 
robuste und Sirt5-spezifische Substrat durch Derivatisierung des Succinyls mit Alkyl-Seiten-
ketten in Sirt5-selektive Peptid-Inhibitoren. Die zunächst schwachen Inhibitoren mit Wirksam-
keiten im zweistelligen mikromolaren Bereich zeigten in den strukturellen Analysen eine Kom-
petition der Alkyl-Seitenketten mit dem Co-Substrat NAD+. Durch rationale Derivatisierung des 
Succinyls mit Thio-Alkylen konnte die Wirksamkeit der Peptid-Inhibitoren jedoch in den zwei-
stelligen nanomolaren Bereich verbessert werden, wobei diese Derivate den gleichen inhibi-
torischen Mechanismus in strukturellen Analysen zeigten. Durch Abtrennen des Peptids sollte 
der Schritt zu niedermolekularen Wirkstoffen vollzogen werden, um deren zelluläre Resorption 
und Halbwertszeit zu verbessern. Allerdings verringerte dies die Wirksamkeit um mindestens 
drei Größenordnungen, je nach Derivatisierung des inhibitorischen Acyls mit verschiedenen 
Lysin-Mimetika. In einer weiteren kollaborativen Studie, welche einen Sirtuin-Mechanismus 
basierten Ansatz der Inhibition verfolgte, wurden kleinere Peptid(-Mimetika) mit Wirksamkeiten 
im sub-mikromolaren Bereich entwickelt und strukturelle Informationen zur Optimierung des 
Inhibitor-Rückgrats rund um die Bindung im Lysin Kanal gewonnen. Die Kombination der Er-
kenntnisse über Affinitäts-Hotspots am Lysin-Kanal mit den Acylen aus dem Peptid-Inhibitoren 
Ansatz ergibt einen Startpunkt zur Entwicklung potenter und selektiver Sirt5 Kleinmolekül-In-
hibitoren. Diese werden einen wichtigen Beitrag zur Aufklärung der Sirt5 Physiologie leisten 
und besitzen Potential als Therapeutika für die Behandlung von Krankheiten, welche in Zu-
sammenhang mit Sirt5 stehen.
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1. Introduction 
1.1. Proteins and posttranslational modifications 
Proteins are key-players in many cellular functions by catalyzing complex chemical reactions, 
providing structural frameworks or tuning gene expression, to name only a few of their manifold 
tasks. Thus, changing the performance or fate of a cell requires the regulation of proteins, 
which is achieved through several means like enzyme modulation by effector molecules 1 or 
altering protein expression 2. Additionally, an outstandingly complex and adaptable machinery 
regulates proteins by attaching and removing posttranslational modifications (PTMs) on pro-
tein termini or amino acid side chains 3. 
The human genome encodes for roughly 30,000 proteins, but this diversity is tremendously 
extended by mRNA splicing and PTMs to a two to three orders of magnitude more complex, 
so called, proteome (Figure 1A) 3. PTMs include the cleavage of the protein backbone as well 
as the covalent modification of amino acids. In fact, 5% of the genes in higher eukaryotes 
encode for protein modifying enzymes and 15 of the 20 natural amino-acids are PTM targets 3. 
The best characterized PTMs are phosphorylation, glycosylation, acetylation, methylation, 
ubiquitylation and sumoylation, which are studied for more than half a century, demonstrating 
their complex roles in protein folding, degradation, stability and function (Figure 1B) 3.  
 
 
Figure 1: PTMs augment human proteome complexity and account for multifaceted effects on target pro-
teins.  (A) Illustration of the increasing complexity of the human proteome by mRNA splicing and PTMs. (B) Exam-
ples of protein modifications and their respective function (reproduced from Jensen, 2006 4 with permission of Na-
ture publishing group). 
The most prominent function of (poly-)ubiquitylation is the proteosomal degradation of target 
proteins 5,6, but also histone regulation and endocytosis of membrane proteins have been re-
ported 3,7. Glycosylation mainly occurs in eukaryotic cells and plays roles in, e.g., chaperone-
A B 
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mediated protein folding 8, signaling of cell surface proteins 9 and transcription factor regula-
tion 10. Protein phosphorylation is probably the best studied PTM and comprises multifaceted 
roles like changing ordered/disordered protein conformations, protein-ligand association/dis-
sociation and enzyme activity 3,11. 
Recent technical advances, especially in the field of high resolution mass-spectrome-
try (MS) 4,12, enabled the in-depth investigation of lysine side chain-acetylation and -acylation. 
These PTMs attracted immense scientific attention and might have as much impact on protein 
regulation as phosphorylation or glycosylation, as will be presented in the following. 
1.2. Protein lysine acetylation & acylation 
Protein acetylation on lysine side chain Nε-amines (Figure 2A) occurs in all branches of life, 
implicating an evolutionarily conserved significance 13–15. It is in the scientific focus for 50 years, 
since Allfrey and co-workers for the first time discovered reversible acetylation on histones 16. 
Thereafter, it took more than two decades to discover the first acetylated non-histone proteins, 
which were the microtubule major component α-tubulin 17, the tumor suppressor p53 18 and the 
HIV transcriptional regulator Tat 19. Since then, the technical advances in MS and the genera-
tion of acetyl-lysine antibodies to specifically enrich acetylated proteins or peptides, enabled 
the assembly of “acetylomes”, which revealed this modification to be as widespread and abun-
dant as phosphorylation 13,20–25. Interestingly, the majority of acetylation sites reside on non-
nuclear proteins and a huge number of them is present on mitochondrial proteins. In fact, since 
phosphorylation rarely occurs in mitochondria, acetylation seems to be the prevalent PTM in 
this organelle, implying key regulatory roles 25,26. 
 
Figure 2: Diversity and regulation of protein acylation. (A) Examples for known lysine side chain acylations.   
(B) Acyls are attached to lysine side chains by KATs or reactive metabolites and are removed by KDACs. 
Besides acetylation, several other lysine acylations were reported in the last decade (Fig-
ure 2A). Among those are butyrylation, propionylation 27–29 and crotonylation 30, which are 
chemically similar to acetylation, but vary in size. In contrast, the short carboxyls malonylation 
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and succinylation are chemically dissimilar due to their charged terminal group 31–33. Addition-
ally, myristoylation of lysine side chains was described and seems to play an important role in 
membrane association 34,35.  
The mechanisms of lysine acylation are not fully elucidated, but two pathways have been pro-
posed (Figure 2B). Firstly, acetyl-moieties are attached to lysine side chains by acetyl-trans-
ferases (KATs) of the three major families GCN5, CREB-Binding-Protein/p300 and MYST us-
ing acetyl-Coenzyme A (acetyl-CoA) as donor molecule 13,36. Furthermore, some KATs can 
also utilize bigger hydrophilic acyl-CoA molecules like propionyl-, butyryl- or crotonyl-CoA to 
modify lysines 28,29,37–40. It was also reported that CREB-Binding-Protein/p300 has the ability to 
catalyze lysine succinylation in vitro 41, but there are contrary implications based on a structural 
study, questioning that its aliphatic pocket can bind charged acyl-CoA variants 37. Secondly, 
several in vitro studies suggested that non-enzymatic lysine acetylation and acylation in cells 
is feasible through reactive metabolites with good leaving groups like the above-mentioned 
CoA 42–44. Indeed, the physiologic significance of this non-enzymatic pathway could be shown 
in vivo by adding the reactive precursors to cell feeds or accumulating/diminishing them by 
deleting distinct metabolic genes 44,45. Specific properties of the mitochondrial matrix like the 
alkaline pH, which increases lysine nucleophilicity, and the relatively high concentration of sev-
eral acyl-CoA species could explain the high abundance of respective lysine-acylations in mi-
tochondria 45–47. Additional to reactive CoA-species, lysine side chains can be modified by other 
reactive metabolites like acetyl-phosphate or 1,3-bisphosphoglycerate in vitro and in vivo 44,48, 
augmenting the theoretically possible diversity of lysine modifications. 
The reversible acylation of lysine side chains is counteracted by the lysine deacylases 
(KDACs) (Figure 2B), which are phylogenetically grouped in four classes in higher eukaryotes. 
Class I, II and IV are constituted by the historically termed histone deacetylases 1-11 
(HDAC1-11) 49. These utilize a zinc ion bound to the active-site, which polarizes the lysine-Nε-
acetyl carbonyl to facilitate deacetylation by hydrolysis 50,51. The KDAC Class III, in contrast, 
uses a completely different enzymatic mechanism, and is constituted by the “Sirtuins” 49. 
1.3. Deacylase Class III: The Sirtuin Family 
The name Sirtuin is derived from the yeast homolog Sir2 (Silent information regulator 2), which 
was discovered in 1987 and regulates transcriptional silencing 52. It was initially proposed to 
transfer ribose-phosphate moieties, because of its close homology to the bacterial cobalamine 
synthesis proteins cobB and cobT 53,54. Later, Frye reported the ability of Sir2 to transfer the 
adenosine diphosphate ribose (ADP-ribose) moiety of nicotinamide adenine dinucleotide 
(NAD+) to proteins 55, and, finally, Imai and co-workers (2000) showed, that Sir2 deacetylates 
the histones H3 and H4 using an NAD+ dependent mechanism 56. Recent studies showed, that 
some human Sirtuins comprise other robust lysine deacylase activities, like desuccinylation by 
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Sirt5 or demyristoylation by Sirt6 57,58. The molecular basis of these activities will be described 
later. Remarkably, homologs of Sir2 were identified in organisms ranging from archaea over 
bacteria to humans, which again implicates a vital role for reversible lysine acylation 59. A lot 
of effort was and is still spent on the investigation of Sirtuin functions, which demonstrated 
regulatory roles in DNA-repair, energy homeostasis and tumorigenesis. Furthermore, Sirtuins 
were implied to play a significant role in the process of aging (see below) 60,61. 
Mammals possess seven Sirtuin isoforms (Sirt1-7) with different primary location either in the 
nucleus (Sirt1,6), nucleolus (Sirt7), cytosol (Sirt2) or mitochondria (Sirt3,4,5) 62. However, lo-
calization can vary under certain circumstances, e.g. appearance of Sirt1 in the cytosol in dif-
ferent mouse tissues 65 or Sirt2 shuttling between cytoplasm and nucleus with implications in 
mitosis 66. Concerning the mitochondrial Sirtuins, full-length Sirt3 was detected in the cytosol 
and nucleus, whereas an N-terminal truncated form resides solely in the mitochondria 63,67. A 
shuttling of Sirt4 and 5 was not reported yet, but a cytosolic Sirt5 demalonylase activity has 
been shown in quantitative MS-experiments 68. 
1.4. Sirtuin regulatory functions 
The Sirtuins primarily raised attention because of their involvement in aging and mediation of 
lifespan extension upon caloric restriction (CR) 69. Deletion of the yeast Sir2 gene shortened 
lifespan, whereas a second copy promoted longevity 69, and similar results were obtained in 
C. elegans (homologue sir-2.1) 70,71, D. melanogaster (homologue dSir2) 72,75,76 and male mice 
(Sirt6-dependent) 77. However, other studies disproved the relation of Sirtuins with CR and 
aging in yeast, C. Elegans and D. melanogaster, which started an ongoing controversy 78–83. 
A model was proposed, in which Sirtuins are not the only mediators of CR on lifespan exten-
sion, but contribute together with other mechanisms 78. Additionally, Sirtuins are reported to 
delay aging-related diseases, diabetes and cancer 84–86 and are linked to central molecular 
functions like genomic maintenance, metabolic homeostasis or stress response 60,61, which all 
influence lifespan. 
Acylation of lysine side chains has two primary effects. First, the potentially positively charged 
lysine side chain is either neutralized (e.g. by acetylation) or becomes negatively charged (e.g. 
by succinylation). Second, it introduces sterical hindrance in the lysine’s microenvironment. 
These primary effects are responsible for the regulation of protein-ligand-, protein-DNA- or 
protein-protein-interactions, enzymatic activity or even the subcellular localization of pro-
teins 13,32,87.  
The nuclear Sirt1, 6 and 7 are involved in, e.g., transcriptional regulation and genome stabil-
ity 60,88. They deacetylate histones to regulate gene-silencing and participate in DNA repair, 
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e.g., by recruiting DNA-damage response enzymes 60,89–93, but also modulate non-histone pro-
teins like the transcriptional Hypoxia-inducible factor 1-α and 2-α to decrease the expression 
of glycolytic genes 94,95. Sirt1 controls p53 function in cell cycle arrest, apoptosis and DNA-
damage repair 96. Sirt6 was found to demyristoylate tumor necrosis factor alpha to release it 
from the membrane, which can thereafter enable one of its multifaceted effects ranging from 
apoptosis over cell survival to proliferation 58,97.  
The cytosolic Sirt2 deacetylates the main component of microtubules, α-tubulin, and thereby 
influences their stability and structure 98. Several other functions have been reported, e.g., a 
Sirt2 control function in cell cycle progression 99,100 and adipogenesis 61,101. 
1.5. Functions of mitochondrial Sirtuins 
An important regulatory role of mitochondrial processes is accounted to Sirt3, 4 and 5, since 
they are the only deacylases in mitochondria and acylations are the prevalent PTMs in this 
organelle (Figure 3) 24,25. 
 
Figure 3. Exemplary regulatory roles of the mitochondrial Sirtuins 3, 4 and 5. Sirt3 deacetylates and activates 
long-chain acyl-CoA-dehydrogenase (LCAD), acetyl-CoA synthetase 2 (AceCS2), glutamate dehydrogenase 
(GDH) and enzymes of the respiratory electron transport chain to stimulate catabolic pathways and ATP supply. 
Sirt4 inhibits GDH activity, which increases insulin secretion. Sirt5 deacylates and activates carbamoyl-phosphate 
synthase 1 (CPS1), the key entry point to the urea cycle (Figure reproduced from Verdin et al., 2010 102 with per-
mission of Elsevier). 
Sirt3 exhibits robust deacetylase activity and mainly targets metabolic enzymes. It deacety-
lates and thereby activates acetyl-CoA synthetase 2 (AceCS2) to replenish acetyl-CoA for the 
Krebs cycle or other biosynthesis pathways 103. Furthermore, Sirt3 activates complex I and II 
of the respiratory chain to enhance ATP generation 104,105, long-chain acyl-CoA dehydrogenase 
(LCAD) to stimulate fatty acid oxidation 106 and glutamate dehydrogenase (GDH) to support 
metabolic intermediate anaplerosis 107. Interestingly, Sirt3 is also involved in the regulation of 
reactive oxygen species (ROS) suppression by activating superoxid dismutase 2 (SOD2) 108. 
In summary, Sirt3 activity stimulates catabolic pathways and simultaneously represses ROS 
generation to dodge emerging cellular damage. 
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The regulatory function of Sirt4 was less studied yet. Sirt4 was reported to oppose Sirt3 by 
attenuating GDH-activity 109, which subsequently increases insulin secretion and reduces 
blood glucose levels 110. Furthermore, it deacetylates malonyl-CoA decarboxylase (MCD), 
which inhibits the turnover of malonyl-CoA to acetyl-CoA and thereby decreases fatty acid 
oxidation and promotes lipogenesis 111. It influences hepatic peroxisome proliferator-activated 
receptor α (PPARα) to decrease expression of genes involved in fatty acid catabolism 112. Ad-
ditionally, Sirt4 was reported to abolish pyruvate dehydrogenase (PDH) activity by delipoylating 
a catalytic lysine residue, which hinders the glycolysis product pyruvate to enter the Krebs 
cycle 113. In sum, Sirt4 influences metabolic pathways to favor lipid anabolism and reduce li-
polysis. Remarkably, it is the highest induced Sirtuin upon DNA-damage and facilitates repair 
mechanisms by inhibiting GDH, which contributes to cell cycle arrest 60,109.  
Only a few regulatory roles of Sirt5 have been reported, but information might increase soon, 
since its specificity for carboxylic acyls has only recently been uncovered 57. Sirt5 was reported 
to stimulate the glycolytic enzyme glycerinaldehyld-3-phosphat-dehydrogenase (GAPDH) 68, 
the ketogenic enzyme 3-hydroxy-3-methyl-glutaryl-CoA synthase 2 (HMGCS2) and lipolytic 
enzymes 114. It is important for nicotinamide adenine dinucleotide phosphate (NADPH) home-
ostasis by deacylating isocitrate dehydrogenase 2 (ICD2) and glucose-6-phosphate dehydro-
genase (G6PDH) to stimulate their NADPH production, which in turn promotes biosynthetic 
pathways or scavenges ROS by reducing glutathione 115. Furthermore, it facilitates the disposal 
of ammonia by deacylating and activating carbamoyl-phosphate synthase 1 (CPS1), the key 
entry point to the urea cycle 116. Like Sirt3, it boosts energy supply by enhancing glycolysis, 
lipolysis and ketogenesis, and protects from consequential ROS-induced cellular damage. This 
contrasts Sirt4 functions and suggests a balancing regulatory axis of metabolic processes by 
Sirt3/5 opposing Sirt4. 
1.6. Mammalian Sirtuins – Structure and enzymatic mechanism 
The highly conserved Sirtuin catalytic core is constituted by 275 amino acids, flanked by N- 
and C-terminal extensions of varying length (Figure 4A). These are long for Sirt1, where they 
comprise nuclear localization signals as well as stabilizing and regulatory domains 117,118, and 
are shorter for Sirt2-7, where they mainly function as mitochondrial (Sirt3,4,5) 116,119,120 or nu-
clear/nucleolar (Sirt6,7) 121,122 targeting sequences. The catalytic core of each isoform consists 
of a Rossmann-fold domain, typical for NAD+ binding proteins 123, and a smaller zinc-binding 
domain (Figure 4B) 124. In contrast to HDACs of Class I, II and IV, the zinc ion does not par-
ticipate in catalysis, but is important for the enzyme’s stability by clamping two β-sheets of the 
zinc-ribbon 125. The active-site is located in a cleft between the two core domains, which are 
connected by several loops (Figure 4B,C). It consists of a (poly)peptide binding groove, a 
relatively conserved NAD+ pocket and a more variable acyl-lysine binding site. A conserved 
active-site histidine is of crucial importance for NAD+ binding and activation 88,126–129.  
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Figure 4. Conserved features of Sirtuin isoforms. (A) The Sirtuins’ catalytic cores are flanked by N- and C-
terminal extensions, which consist of stabilizing and regulatory domains for Sirt1 and comprise localization se-
quences for Sirt3-7. (B) The conserved structure of the Sirtuin catalytic core consists of a Rossmann-fold (light blue) 
and a Zn2+-binding domain (cyan) connected by several loops. The active-site is located between the two core 
domains. The so-called cofactor-binding loop (dark blue) plays an important role in cofactor binding and catalysis. 
Protein (blue/cyan) and peptide (green) are shown in cartoon representation, the zinc ion as yellow sphere and the 
catalytic histidine (catalytic His) as well as the peptide acetyl-lysine and NAD+ (green) as cpk color-coded sticks 
(PDB 4FVT). (C) The surface representation of the Sirtuin catalytic core shows the binding pockets for the acylated 
peptide and NAD+, colored by electrostatic potential ranging from -10 to +10 KbT/ec (PDB 4FVT). (D) Scheme of 
the Sirtuin catalyzed deacylation reaction (NAM: nicotinamide, ac-ADP-Ribose: acylated ADP-Rbose). 
The relative conformation of Rossmann-fold and zinc-binding domain changes during cataly-
sis. Substrate binding induces a closed conformation constituting the acyl-lysine tunnel and 
positioning the reacting substrate moieties close to each other. Furthermore, it orders the ini-
tially flexible “co-factor binding loop” and forces the co-substrate NAD+ in a kinked, so called 
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“productive” conformation, which is indispensable for catalysis (Figure 4B,C) 124,130. In the first 
reaction step, the nicotinamide (NAM) moiety of NAD+ is released and the instable, not yet 
evidenced as free or highly dissociative, C1’ oxacarbenium ion is instantly attacked by the 
acetyl-lysine’s carbonyl oxygen to form an ADP-ribose-peptidyl imidate (Figure 4D) 129,131. This 
first intermediate can either be attacked on its β-face by NAM to reconstitute NAD+ or be pro-
cessed to a second, cyclic intermediate by collapse of the ADP-ribose 2’-OH group 129. Sirtuins 
favor the downstream deacetylation reaction by a conserved Phe/Tyr residue of the co-factor 
binding loop, which flips in upon NAM-release, probably expelling NAM and hindering the re-
verse reaction 132,133. Furthermore, collapse of the ADP-ribose 2’-OH is promoted by the con-
served catalytic histidine, which acts as a base to deprotonate the ADP-ribose 3’-OH subse-
quently activating its 2’-OH 128,131,134. The second, bicyclic intermediate gets hydrolyzed and 
the deacetylated protein and 2’-acetyl-ADP-ribose, which spontaneously equilibrates with 
3’-acetyl-ADP-ribose, are finally released as reaction products 131.  
1.7. Diverse Sirtuin deacylation functions 
Robust deacetylation activity was demonstrated for Sirt1, 2 and 3 61. However, the mitochon-
drial Sirt4 and 5 as well as the nuclear/nucleolar Sirt6 and 7 display very weak or undetectable 
deacetylase activity in vitro. It was reported, that Sirt4 and 6 possess ADP-ribosyltransferase 
activity 120,135,136, but a follow-up study showed that this is an inefficient side reaction for both 
isoforms 137. In recent years, crystal structures and biochemical characterizations revealed 
novel, robust functions of Sirt5 and 6, which correlates with the afore-mentioned discovery of 
new acyl-modifications on lysine side chains. 
Sirt5 was shown to efficiently turnover short carboxylic acyl modifications such as malonyl or 
succinyl 57, which have been reported as physiological lysine PMTs 31–33. Consistent with these 
studies, a recent proteomics approach demonstrated that Sirt5 knock-out (KO) mouse embry-
onic fibroblasts showed increased protein succinylation, while acetylation levels remained rel-
atively constant 138. The reason for this acyl-selectivity was revealed by crystal structure anal-
ysis. Sirt3 Phe180 caps the acyl-lysine binding site (Figure 5A), but is substituted by Ala86 in 
Sirt5, which widens the pocket (Figure 5B). Additionally, a Tyr-X-X-Arg motif at the back of the 
acyl-lysine binding site recognizes the negatively charged acyl (Figure 5B). Kinetics for Sirt5 
demalonylation and desuccinylation are in the range of other robust Sirtuin activities, like Sirt2 
deacetylation, with low micromolar KM and catalytic efficiencies of a few thousand s-1 M-1 57,139. 
Confirming the physiological relevance, experiments with Sirt5 KO mice showed that CPS1 
activity is regulated by Sirt5 desuccinylation 57. 
In contrast, Sirt6 was reported to efficiently hydrolyze long-chain fatty acyls from lysine side 
chains 58. The Sirt6/myristoyl-peptide complex crystal structure revealed a large pocket lined 
by hydrophobic residues, ideal for binding fatty acyl-lysine substrates and explaining Sirt6 
  Introduction  
 - 15 -  
specificity (Figure 5C) 58. A follow-up study reported that the low Sirt6 deacetylation activity is 
significantly increased by the addition of free long-chain fatty acids 140. Biochemical data sug-
gested that the free fatty acid binds in the hydrophobic substrate pocket, thereby increasing 
the affinity for the acetyl-lysine substrate and enhancing Sirt6 deacetylase activity. Interest-
ingly, also Sirt1-3 and 5 were shown to hydrolyze fatty acyls from lysine side chains. However, 
only Sirt6 but not Sirt1 deacetylation could be activated by the addition of free fatty acids 140.  
 
 
Figure 5: Sirtuin isoforms comprise diverse acyl-specificities due to variable acyl-lysine binding sites.         
(A) The Sirt3 acyl-lysine binding site is short due to capping by Phe180 and can accommodate short lysine modifi-
cations like an acetyl-group (ace-Lys), which fits to its strong deacetylase activity. (B) The Sirt5 acyl-lysine binding 
site is wider than in Sirt3 and a Tyr-X-X-Arg motif at the back of the pocket recognizes the negatively charged 
carboxyl function of carboxylic acyls, e.g. succinyl (succ-Lys). (C) Sirt6 comprises a broad acyl-lysine channel lined 
by hydrophobic residues facilitating long-chain fatty-acyl-lysine, e.g. myristoyl-lysine (myr-Lys), binding. The pro-
teins Sirt3 (PDB 4FVT), Sirt5 (PDB 4G1C) and Sirt6 (PDB 3ZG6) are represented in grey cartoon style with the 
proteins’ amino acids of interest shown as cpk color-coded sticks. The substrate peptides (green) are shown in 
cartoon style with the acyl-lysines as cpk color-coded sticks. Dashed lines indicate protein-ligand interactions. 
Due to these findings, it is worthwhile considering that Sirt4 and 7, which do not display robust 
in vitro deacetylase activity, bear an unrevealed primary function or can be activated by phys-
iologic small molecules in a similar way as Sirt6. Indeed, a Sirt4 in vivo deacetylation activity 
was reported 111, which suggests that this activity is stimulated by an unknown mechanism. In 
2014, Mathias and co-workers reported a delipoylase activity for Sirt4 on PDH protein and 
peptide in vitro and in vivo, but the kinetics were orders of magnitude weaker than robust pri-
mary functions of other Sirtuins 113. 
1.8. Modulation of Sirtuin activity 
Sirtuins are regulators of multiple key cellular functions and therefore have to be tightly con-
trolled 60,61. Cells achieve this by either changing Sirtuin transcription levels, by regulatory pro-
teins binding to Sirtuins, PTMs or physiological small molecules. Of these multifaceted possi-
bilities, only the small molecules will be discussed in the following due to their implications for 
drug development studies. 
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1.8.1. Physiological small molecule modulators 
The characterization of physiological small molecule modulators contributed to both charac-
terization of Sirtuin catalysis and drug development studies. The availability and redox status 
of NAD+/NADH regulates Sirtuin activity. NAD+ is the co-substrate with KM values between 
10 and 600 µM, depending on the Sirtuin isoform 129,141, which is in the range of the physiolog-
ical concentration of 300 to 400 µM NAD+ in mammalian cells 142,143. The fact that Sirtuins 
require NAD+ to catalyze lysine deacylation renders them metabolic sensors for sufficient nu-
trient supply (low NAD+ level) or starvation (high NAD+ level) 144. In contrast, NADH is a weak 
inhibitor with one-digit millimolar IC50 values for human Sirt1,2,3,5 and 6 145 and possibly also 
for the other, not yet tested isoforms due to the high conservation of the co-factor binding site. 
Molecular dynamic simulations predicted NADH binding to Sirtuins solely in an elongated, un-
productive conformation, whereas NAD+ with the oxidized NAM was more stably binding in the 
kinked, productive conformation, an essential feature for catalysis 145. A physiological pan 
Sirtuin inhibitor is NAM, which is generated by several metabolic pathways and released from 
NAD+ during the Sirtuin deacylation process as a by-product 129. NAM inhibited all tested 
Sirtuins (human Sirt1, 2, 3, 5 (desuccinylation), Sir2, Hst2, Sir2Tm) with IC50 values of 
20-140 µM 146–148, which is in the range of physiological NAM concentrations (10-400 µM) im-
plying a regulatory mechanism 149. However, a few exceptions like the bacterial Sir2Af2 (from 
Archaeoglobus fulgidus) and the human Sirt5 deacetylation function showed weak inhibition 
with IC50 values in the millimolar range. Thus, NAM appears to be a deacylase activity discrim-
inating inhibitor, but a comprehensive investigation of its effects on Sirtuins with multiple weak 
and strong activities was not performed yet. 
1.8.2. Pharmacological Sirtuin modulation 
Specific Sirtuin modulators are essential tools for the characterization of Sirtuin mechanism, 
activity and regulatory function in in vitro and in vivo experiments. Furthermore, Sirtuins are 
potential drug-targets due to their multiple physiological and pathophysiological roles in, e.g., 
neurodegenerative disorders, metabolic and aging-related diseases or cancer 61,150. Unfortu-
nately, most drug-development projects concerning Sirtuins yielded compounds lacking iso-
form specificity or exhibiting low potency 88,150, but a few exceptions (e.g. EX527) will be de-
scribed briefly below.  
Modulators extensively occupying the NAD+ pocket often lack isoform specificity due to the 
high conservation of this site in Sirtuins 124 and regularly affected other enzymes binding NAD+ 
or adenosine derivatives 88,126,150–152. Interestingly, the structures of human Sirt5 and 6 revealed 
substantial variations in the acyl-lysine binding site among the Sirtuin family, which might fa-
cilitate isoform selectivity and is therefore an attractive site for the development of specific 
modulators 57,58. 
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Notably, either Sirtuin activation or inhibition, depending on the disease or condition to be 
treated, would be required for medical purposes. In order to promote longevity, boosting Sirtuin 
activity related to lifespan extension would be desired. Concerning the medication of obesity 
or metabolic defects, activation or inhibition of a subset of mitochondrial Sirtuins would be 
helpful, since they have different regulatory functions on metabolism as described above. 
One of the first discovered and extensively studied Sirtuin compounds is the plant stilbene 
resveratrol, which activates Sirt1, 3 and 5 153,154. Similar to CR, it extended lifespan and showed 
positive health effects 155–157, but it is unclear in which extent this resulted from Sirtuin activa-
tion, since this compound targets a variety of proteins 151,158. Remarkably, resveratrol induced 
either positive, negative or no effects on Sirt1 deacetylase activity in a peptide array with ~6500 
physiological acetylation motifs 159. This adds another level of complexity to Sirtuin modulation, 
since compound effects appear not to depend only on the isoform, but also on the acyl-modi-
fication (see NAM – Sirt5) or the substrate sequence (see Resveratrol – Sirt1). 
One of the best studied Sirtuin inhibitors is EX-527 (Figure 6A,B), which inhibits Sirt1 
(IC50 0.1 µM) and has two orders of magnitude weaker potencies towards Sirt2 and 3 and no 
effect on Sirt5 160,161. It was reported to bind to the NAM pocket with NAM-like H-bonds to Ile230 
and Asp231 and inhibit Sirtuin catalysis by stabilization of the Sirtuin/inhibitor/acetyl-ADP-ri-
bose complex (Figure 6B) 160. This mechanism explains the insensitivity of Sirt5, which com-
prises substantial structural differences blocking this site for EX-527 160. 
1.8.3. Mitochondrial Sirtuin modulators 
Most initial drug development studies concerned Sirt1 and 2, whereas mitochondrial Sirtuins 
have not been extensively targeted yet 88. Concerning Sirt5, efforts were hampered due to the 
lack of in vitro assay systems, until its efficient demalonylation and desuccinylation activities 
were reported a few years ago in 2011 57. Likewise, no Sirt4 modulator was developed yet, 
since there was no robust in vitro activity reported for this isoform. Thus, only a few modulators 
for Sirt3 and 5 were discovered so far, which will be described in the following.  
Suramin was the first Sirtuin compound for which inhibition data as well as structural infor-
mation were obtained. The compound shows single-digit micromolar IC50 on Sirt1, but also 
inhibits Sirt2 and 5 with similar potencies. This can be explained by the crystal structure of 
Sirt5 with bound Suramin, which shows that the compound broadly and non-specifically targets 
the peptide-lysine and NAD+ binding sites 162,163. Furthermore, it has strong off-target effects 
on G-proteins, reverse transcriptase and growth factors 164–166, all together rendering it unusa-
ble as a specific Sirtuin modulator. 
The “extended library technology” (ELT) inhibitor class comprises the strongest Sirtuin inhibi-
tors reported so far, which unfortunately affect Sirt1, 2 and 3 equally (Figure 6A,C) 167. The 
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top compound inhibited Sirt3 with an IC50 of 4 nM. Complex crystal structures demonstrated 
that the inhibitors partially occupy the acyl-lysine tunnel and the NAM pocket 167, where its 
carboxamide forms NAM-like H-bonds to the protein (Figure 6C). Furthermore, ELTs interact 
by π-stacking of the thieno[3,2-d]pyrimidine with the highly conserved phenylalanine (Phe157 
in Sirt3) of the co-factor binding loop (Figure 6C) without affecting the loops regular confor-
mation. These compounds did not show off-target effects, which renders them starting points 
for derivatization to develop potent and selective Sirtuin inhibitors 88,167. 
SRT1720 is a potent (Ki 0.6 µM) Sirt3 inhibitor, which does not affect Sirt5, but activates Sirt1 
with a similar potency (EC1.5 0.16 µM) (Figure 6A,D) 155,168. Its mechanism towards Sirt3 has 
been extensively characterized by kinetic and structural studies. It is a competitive inhibitor 
towards the acetyl-lysine substrate and uncompetitively inhibits NAD+ binding to Sirt3. This 
was explained by complex crystal structures, which showed that SRT1720 tightly binds be-
tween the protein and the NAM-moiety of NAD+ in the Sirt3 active-site, leading to a rearrange-
ment of the co-factor binding loop and a stable, inactive Sirt3/NAD+/inhibitor complex 168. Deri-
vatization of SRT1720 is promising to yield the first selective and highly potent Sirt3 inhibitor. 
Finally, the indole GW5074 is an acyl- and possibly sequence-dependent Sirt5 inhibitor 152. It 
efficiently inhibits Sirt5 desuccinylation (IC50 20 µM), while Sirt5 deacetylation is an order of 
magnitude less potently affected (IC50 200-400 µM). Unfortunately, it has strong off-target ef-
fects on kinases and Sirt2 169, rendering it a difficult starting point for further drug development. 
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Figure 6: Examples of small molecule mitochondrial Sirtuin modulators. (A) Chemical structures of the Sirtuin 
inhibitors ELT11-c, EX-527 and SRT1720. (B) Complex crystal structure of Sirt3 with acetyl-ADP-ribose (ace-ADP-
ribose) and the inhibitor EX-527 (PDB 4BVH). EX-527 binds to Sirt3 in the NAM pocket and adjacent area with 
NAM-like H-bonding interactions to Ile230 and Asp231 (indicated by dashed lines). It inhibits Sirtuins by stabilizing 
the Sirtuin/EX-527/acetyl-ADP-ribose complex, which blocks the active site. (C) Complex crystal structure of Sirt3 
with ELT-11c (PDB 4JSR). The NAD+ analog Carba-NAD+ and the acetylated peptide were modeled from the 
Sirt3/acetyl-ACS2-peptide/carba-NAD+ complex structure (PDB 4FVT). ELT-11c binds in the acyl-lysine channel 
and part of the NAD+ binding site and thereby competitively inhibits Sirt1, 2 and 3 with high potency. ELT-11c binds 
to Sirtuins through π-stacking of the thieno[3,2-d]pyrimidine with the highly conserved phenylalanine of the co-factor 
binding loop (Phe157 in Sirt3) and NAM-like interactions (compare carba-NAD+ NAM moiety with ELT-11c pyrimi-
dine group). (D) The crystal structure of Sirt3 in complex with SRT1720 and Carba-NAD+ (PDB 4BN5) shows the 
binding of SRT1720 between Sirt3 (e.g. π-stacking to co-substrate binding loop Phe157) and co-substrate. The 
compound stabilizes the inactive Sirt3/NAD+/SRT1720 complex. Proteins are shown in grey cartoon representation 
with amino acids of interest as cpk color-coded sticks. Inhibitors are represented as cyan cpk color-coded sticks, 
while peptides, Carba-NAD+ and acetyl-ADP-ribose are shown as green cartoon and cpk color-coded sticks. 
Summarizing, there is undoubtedly need for the development of Sirtuin modulators for phar-
macological as well as scientific purposes, especially in the field of the mitochondrial isoforms, 
which were not investigated as thoroughly as Sirt1 and 2 so far.
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2. Aims of this work 
2.1. Characterization of Sirt5 acyl-specificity and Sirt5 inhibitor development 
Even though the first structure of the mitochondrial Sirtuin 5 was already solved in 2006 162, 
the first robust activities of this isoform, demalonylation and desuccinylation of target protein 
lysines, were only discovered in 2011 57. However, the acyl-specificity of Sirt5 was never sys-
tematically characterized, although this could reveal further physiologic activities, which in turn 
should stimulate investigations to uncover their regulatory function. Therefore, a collaborative 
study will be set up to synthesize a peptide-based acyl-library for screening Sirt5 activity and 
investigating the molecular background of distinct activities by crystal structure analysis of 
Sirt5/peptide complexes. 
Specific Sirt5 inhibitors would be valuable tools for biochemical investigations of Sirt5 catalysis 
or physiologic roles and might one day serve as leads for medicating Sirt5 related diseases, 
e.g., for its possible involvement in neurodegeneration 88,170. Thus, the obtained insights in 
Sirt5 structure and function should be used to develop inhibitors for this isoform. The rationale 
is to create succinyl-derivatives on a peptide lysine to transform the robust and Sirt5-specific 
substrate into Sirt5 peptide inhibitors. Our collaborators will synthesize and test the inhibitors, 
while we guide the study by crystal structure analysis revealing their inhibition mode and po-
tential for optimization. It will be necessary to truncate the peptidic part of these inhibitors to 
improve in vivo availability, which is assumed to result in a significant loss of potency. Thus, a 
collaborative structure-activity relationship (SAR) study should be performed to decrease pep-
tide-length while retaining inhibitor potency. Our collaborators will synthesize and test small 
peptide-(like) inhibitors, while we guide the process by crystal structure analysis to reveal their 
binding and inhibition mode and further potential for small molecule inhibitor development. 
2.2. Biochemical and structural studies of Sirtuin 4 
In contrast to most other Sirtuins, the mitochondrial Sirtuin 4 is poorly understood. Its structure 
could not be resolved so far and its primary enzymatic activity is unknown. However, a few 
regulatory roles of Sirt4 were discovered through in vivo studies, e.g., deacetylation of MCD 111, 
ADP-ribosylation of GDH 120 or delipoylation of PDH 113, but corresponding in vitro kinetics 
were much weaker than for primary activities of other Sirtuins. Probably, many trials to explore 
this isoform were hampered by its intrinsically high insolubility. Therefore, constructs and pro-
tocols for efficient production of human Sirt4 and, if a breakthrough cannot be achieved, Sirt4 
orthologues from other species will be established. In case of success, Sirt4 will be biochemi-
cally characterized and its deacylation activity screened using the peptide-based acyl-library 
of the Sirt5 study. Furthermore, a Sirt4 crystal structure is a major objective of this work, since 
it could provide valuable information to enable further investigations concerning Sirt4 acyl-
recognition, catalysis or physiologic regulation.
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3. Summary and discussion of results 
3.1. Systematic characterization of the Sirt5 acyl-specificity 
Ever since it was discovered, Sirt5 was supposed to be a relatively weak deacetylase with 
reported regulatory functions 107,116. Only a few years ago, Du and co-workers found that Sirt5 
features strong demalonylase and desuccinylase activity 57, which prompted studies linking 
these activities with regulatory roles 33,68,114. However, a systematic probing of Sirt5’s acyl spec-
ificity was never performed, but could unravel further physiologic activities. Therefore, our col-
laborators modified a peptide derived from the Sirt5 substrate CPS1 (CPS1-K527) with a li-
brary of acyls on its central lysine residue side chain and tested them as Sirt5 substrates in 
Michaelis-Menten kinetics. This library included a series of acyls of incremental length with 
distal carboxyl groups (Figure 7A,B) and a variety of succinyl- and glutaryl-modifications with 
small substitutions or heteroatoms in 2’ or 3’ positions (see scheme 1, 2, 3 in publication 1). 
 
peptide KM [µM] kcat [s-1] 
kcat/KM 
[M-1s-1] 
2 24.3 ± 9.1 3.9x10-4 ± 6x10-5 16 
3 416 ± 24 1.6x10-3 ± 8x10-5 4 
4 5.1 ± 1.1 1.9x10-2 ± 1x10-3 3758 
5a 3.8 ± 0.6 5.3x10-2 ± 2x10-3 13995 
6a 4.1 ± 1.0 7.7x10-2 ± 2x10-3 18699 
7 6.5 ± 1.6 1.0x10-2 ± 6x10-4 1538 
8 80.5 ± 22.9 2.8x10-4 ± 4x10-5 4 
9 409 ± 283 5.3x10-4 ± 2x10-5 1 
 
 
Figure 7: Sirt5 specificity screening and structural binding 
mode analysis of acylated peptides. (A) A CPS1-K527 peptide 
(1) was modified with an acetyl- (2), oxalyl- (3), malonyl- (4), suc-
cinyl- (5a), glutaryl- (6a), adipoyl- (7), suberoyl- (8) or pimeloyl-
group (9) on the lysine side chain. The table on the right shows 
kinetic parameters of Sirt5 towards these acylated CPS1 pep-
tides. Error is the standard deviation (s.d.) of two independent ex-
periments. (B) zSirt5/CPS1 peptide complexes with succinyl-, 
glutaryl- and adipoyl- or (C) succinyl, 3-methyl-succinyl- and 3,3-
di-methyl-succinyl-CPS1 peptide were overlaid to investigate 
their binding mode and differences in catalytic efficiency. All acyl-
lysines interacted with side chains of Sirt5 residues Tyr98/Arg101 
and Val217 backbone (except adipoyl for Val217), as indicated 
by dashed lines. zSirt5 is shown in grey cartoon style with amino 
acids of interest as cpk color-coded sticks, while peptides are 
shown as blue (succinyl), yellow (glutaryl), magenta (adipoyl), 
brown (3-methyl-succinyl) or green (3,3-di-methyl-succinyl) car-
toon with the acyl-lysine as respectively cpk color-coded sticks. 
These assays confirmed the several orders of magnitude increased catalytic efficiency of ly-
sine demalonylation (4) and desuccinylation (5a) compared to its low deacetylase (2) activity. 
Interestingly, Sirt5 exhibited even higher catalytic efficiency for the glutarylated peptide (6a) 
due to the elevated kcat compared to desuccinylation and demalonylation. Further elongation 
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of the carboxylic acyl (7-9) or the introduction of any kind of substitutions or heteroatoms re-
duced Sirt5 activity (see Table 1 in publication 1).  
Since the molecular basis of the enhanced Sirt5 deglutarylation activity was unclear, we solved 
crystal structures of zebrafish Sirt5 (zSirt5) in complex with several CPS1 peptides. zSirt5 was 
used instead of human Sirt5 (hSirt5), since it showed a high (75%) sequence identity of the 
catalytic core and crystallized more reliably. The crystals exhibited moderate diffraction around 
3 Å resolution, which allowed modeling of the complete peptide including the acyl. Structural 
analysis showed that succinyl-, glutaryl- and adipoyl-modifications tightly interacted with the 
Tyr98/Arg101 motif at the back of the Sirt5 substrate pocket and that the Val217 backbone 
carbonyl fixed the acyl-lysine Nε in a conserved position (residue numbering refers to 
zSirt5) (Figure 7B). Both observations concerning succinyl-lysine binding are in congruency 
with a reported hSirt5/succinyl-peptide crystal structure 57. Thus, the acyls need to arrange 
themselves between the two interaction motifs, leading to increasingly twisted conformations 
for glutaryl- and adipoyl-lysine compared to succinyl-lysine and weaker contact between adi-
poyl-lysine and Val217 due to a slight substrate shift (Figure 7B). Consistently, a docking 
study of our collaborators with pimeloylated and suberoylated CPS1-K527 peptides indicated 
weaker interaction and unfavorable conformations of acyl and protein side chains due to an 
extension beyond the normal acyl-lysine channel. This explains the increasingly weakened KM 
and turnover of acyls longer than glutaryl (see Figure 1b and Table 1 in publication 1). 
The kinetic analysis showed similar KM (3.8/4.1 µM), but changing kcat values for CPS1-K527 
desuccinylation (5.3 x 10-2 s-1) and deglutarylation (7.7 x 10-2 s-1). Two hypotheses were built 
on the obtained structural data, which could explain the different turnovers. First, the more 
winded acyl of the substrate glutaryl-lysine compared to the unstrained succinyl-lysine (Fig-
ure 7B) implies a more strained glutaryl-ADP-ribose product, which might prompt faster prod-
uct release, probably the rate-limiting step in Sirtuin catalysis 128. Second, a slight carbamide 
rotation was observed for glutaryl- compared to succinyl-lysine, which might enable a more 
efficient nucleophilic attack during intermediate formation. Supporting this idea, a similar rota-
tion of the carbamide’s carbonyl-function towards the NAD+ pocket correlated with decreasing 
kcat values for succinyl- (5.3 x 10-2 s-1), 3’ mono-methyl-succinyl (2.4 x 10-3 s-1) and 3,3’ di-
methyl-succinyl-CPS1 peptides (2.2 x 10-4 s-1), while all of them showed similar KM and inter-
actions with Tyr98/Arg101/Val217 (Figure 7C). 
Another independent study confirmed the Sirt5 deglutarylation activity and provided proteomic 
data evidencing lysine glutarylation as a physiologic PTM 171. Interestingly, glutarylation was 
mapped on proteins in bacteria, yeast, drosophila, mouse and human cells, which – as for 
acetylation – implies an evolutionarily conserved function 171,172. Glutarylation and succinylation 
sites significantly overlapped in samples derived from mouse liver and hyperglutarylation as 
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well as hypersuccinylation reduced CPS1 activity 57,171, both suggesting similar roles for these 
acylations. Like acetylation, also succinylation and glutarylation were abundantly found on met-
abolic proteins, underlining their presumable regulatory role as well as Sirt3’s and Sirt5’s con-
trol function in metabolic homeostasis 114,138,171,173,174.  
3.2. Development of peptidic Sirt5 inhibitors 
Despite several attempts, Sirt5 drug discovery projects so far only yielded compounds with 
weak potency or lacking isoform selectivity, e.g., GW5074, Suramin and compounds of the 
thiobarbiturate family 152,175,176. Hence, our collaborators expanded the acyl-peptide library de-
scribed in chapter 3.1 and screened for inhibitory acyls exploiting Sirt5 affinity- or selectivity-
hot spots to propose starting points for non-peptidic, drug-like inhibitor development. The suc-
cinylated CPS1-K527 peptide was used as a scaffold to target the Sirt5 Tyr/Arg motif, which is 
a distinct selectivity feature among the mammalian Sirtuins 57,176. The succinyl-moiety was 
modified by alkyls or bulky rings at positions 2’ or 3’ to transform the robust substrate into 
inhibitors. In parallel, we solved complex crystal structures of zSirt5 with inhibitory CPS1-K527 
peptides to rationalize results and guide the derivatization process. 
Initially, 3-phenyl-succinyl (3PS) was identified as a weak inhibitor of Sirt5 desuccinylation 
(Ki = 100 µM) (Figure 8A). As expected, the zSirt5 complex crystal structure showed the sub-
strate-like binding of the 3PS-CPS1 peptide to Tyr98/Arg101 and Val217, while its phenyl-
group protruded to the NAD+ pocket and clashed with modeled NAD+, which suggests a com-
petitive inhibition of substrate and co-substrate binding (Figure 8B). Follow-up trials yielded 
the more potent inhibitory acyl 3-butyl-succinyl (3BS; Ki 17.2 µM), which showed similar bind-
ing in the zSirt5 complex crystal structure and clashing of the butyl moiety with modeled NAD+ 
(Figure 8A,B). Interestingly, introducing an additional methyl group on the succinyl 3’ in-
creased potency of the weak 3PS by two orders of magnitude (3-phenyl-3-methyl-succinyl; 
3PMS; Ki 4.3 µM) (Figure 8A), yielding a potent and selective inhibitory peptide, not affecting 
Sirt1/3 and weakly inhibiting Sirt2 deacetylase activity (4% inhibition at 50 µM dose).  
Since several potent Sirtuin inhibitors like EX-527 occupy the NAM-site 160, a methyl-carba-
mate linker was introduced to move the phenyl moiety into this pocket (3(S)-Z-aminosuccinyl 
(3ZAS)) (Figure 8A,C). This approach yielded moderate potency (Ki 38 µM), but fixing the 
loose ring (indicated by its weak electron density, see SI Figure S14c in publication 1) in the 
NAM-site by adding a carboxamide function to the phenyl, similar to NAM or EX-527 88,160, and 
additional 3’-methylation like in 3PMS might yield a compound with enhanced potency. 
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Figure 8: Chemical structures and binding mode analysis of Sirt5 inhibiting acyls. (A) Chemical structures of 
inhibitory acyls, which were created by different substitutions (R) on a succinyl-lysine at the 3’-position. Ki values 
are given in bold for each derivative. Complex crystal structures of zSirt5 with (B) 3PS- (cyan) and 3BS- (yellow), 
(C) 3ZAS- (orange), (D) 3PTS- (blue) and 3BTS- (green) and (E) 3NMTS-CPS1 peptide (light blue), each overlaid 
with NAD+ (magenta) modeled from hSirt5/succinyl-H3K9/NAD+ complex (PDB 3RIY). zSirt5 (grey) and CPS1 pep-
tides are represented in cartoon style with zSirt5 amino acids of interest and acyl-lysines shown as respectively cpk 
color-coded sticks. Interactions between zSirt5 and acyl-lysines are indicated by dashed lines. 
Exchanging the polar carbamate linker on the succinyl 3’ position of 3ZAS by a more hydro-
phobic thioether function was supposed to enhance affinity. Furthermore, it enabled the syn-
thesis of a comprehensive set of 3-(alkyl-thio)-succinylated CPS1-K527 peptides by coupling 
thiols to maleinyl-lysines via Michael-addition (see Table 1 in publication 2). Addition of a 
thioether-linked phenyl (3-(phenyl-thio)-succinyl; 3PTS) or benzyl (3-(benzyl-thio)-succinyl; 
3BTS) to the succinyl 3’ position resulted in highly improved Ki values of 135 nM (3PTS) and 
170 nM (3BTS) (Figure 8A). Notably, 3S and 3R enantiomers of the chemical synthesis could 
be separated in the chromatography purification process and showed significantly different Ki 
values, but it is unclear which enantiomer of 3PTS and 3BTS is the more potent one. Complex 
structures showed a binding of 3PTS close to modeled NAD+, while 3BTS was clashing heavily 
with the NAM and NAM-ribose of modeled NAD+ (Figure 8D). However, electron density was 
too weak to distinguish enantiomers. Adding chlorines or methyls to 3PTS in meta- and para-
position (Ki 23 nM for both, Figure 8A) or introducing a bulkier naphthyl moiety instead of the 
phenyl-ring (Ki 30 nM, see compound 33.2 in Table 1/S1 in publication 2) both increased 
potency by another order of magnitude. Finally, introduction of a methylene into the linker to 
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create the 3-(2-naphthylmethyl-thio)-succinyl-CPS1-K527 peptide yielded the strongest inhib-
itor of this study (3NMTS). It showed a similar inhibition mode in the solved Sirt5 complex 
crystal structure by clashing with modeled NAD+ and for the first time reached single-digit na-
nomolar potency (Ki 7 nM) (Figure 8A,E). 
3.3. Development of Sirt5 small molecule inhibitors 
Truncation of the peptidic Sirt5 inhibitors to small molecules is desired, since it enhances drug 
properties like cell-permeability or in vivo half-life and decreases susceptibility to proteolysis 
after resorption in the body/cell 177. Thus, a collaborative SAR study was performed to optimize 
the lysine-scaffold and shrink peptide size while retaining potency. In this study, our collabora-
tors synthesized and tested the inhibitors, while we solved crystal structures to reveal their 
binding and inhibition mode. 
A lysine side chain was initially modified with a thio-glutaryl moiety, since glutaryl- and succinyl-
lysine share a comparable KM (see publication 1) and thio-succinylated peptides were shown 
to inhibit Sirt5 with single-digit micromolar IC50 178. The N-terminus was Cbz protected and the 
C-terminus modified with an ethyl-indole, which indeed yielded a moderate Sirt5 inhibitor as 
starting point of the study (IC50 25 µM, compound 1, see scheme 2 in publication 3). In the 
course of the SAR study, more than 70 compounds with different N-terminal, C-terminal and 
lysine side chain modifications were synthesized and tested by our collaborators. Strikingly, 
the first iterative cycle yielded the sub-micromolar inhibitors “compound 10” (IC50 830 nM) and 
“compound 29” (IC50 370 nM) (Figure 9A). These only differed in their lysine acylation, which 
was either a thio-glutaryl (compound 10) or a thio(urea)-glutaryl (compound 29). As expected, 
the most potent compound 29 was highly specific for Sirt5, as it did not affect any other tested 
Sirtuin at a 10 µM dose (Figure 9A). These compounds were proposed to inhibit Sirt5 by 
stalling catalysis through the slowly dissociating peptidyl-thioimidate or bicyclic intermediate, 
thereby permanently blocking the active-site 178,179. 
We solved crystal structures of Sirt5 in complex with compounds 10 and 29 to test this hypoth-
esis and to investigate the molecular details of the improved lysine-scaffold. Incubating Sirt5 
with compound and NAD+ prior to setting up crystallization trials yielded well diffracting crystals 
with around 2 Å resolution or better in combinations of hSirt5/compound29, zSirt5/com-
pound10 and zSirt5/compound29. These indeed comprised the reaction intermediates stalled 
either in the peptidyl-thioimidate or bicyclic state (Figure 9B,C and Figure 1 in publication 3). 
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Figure 9: Characterization of Sirt5 inhibitory compound 10, 29 and 49 selectivity, binding and mechanism. 
(A) Chemical structures of compounds 10 and 29 and selectivity testing of compound 29 on Sirt1/2/3 deacetylation, 
Sirt5 desuccinylation/deglutarylation and Sirt6 de-decanoylation at a 10 µM dose. (B) Zoom view of the hSirt5 ac-
tive-site with bound peptidyl-thioimidate intermediate of compound 29. Interactions between protein and com-
pound 29 are indicated by dashed lines. (C) Sirt5 bound compound 29 Cbz- and indole-moieties adopt multiple 
conformations. hSirt5 protein is shown as grey cartoon with amino acids of interest as cpk color-coded sticks in (B) 
or as surface colored by electrostatic potential (-10 (red) to +10 KbT/ec (blue)) in (C). The compound 29 peptidyl-
thioimidate intermediate is shown in orange cpk color-coded stick representation. (D) Chemical structure and se-
lectivity profile (tested against activities as in (A)) of the most potent compound 49 at a 10 µM dose. 
The improved lysine scaffold bound similarly in all of our above mentioned crystal structures 
and thus the 1.32 Å high resolution hSirt5/compound29 complex was used for structural anal-
ysis (Figure 9B,C). As predicted, the thio(urea)glutaryl-lysine interacted with 
Tyr102/Arg105/Val221 in a substrate-like manner (residue numbering refers to hSirt5). Fur-
thermore, hydrogen bonding interactions between hSirt5 backbone of Gly224, Glu225 and 
Tyr255 with N- and C-terminal extensions of the compound’s lysine could be identified, leading 
to a rigid conformation of this part, whereas the Cbz and indole groups showed higher flexibility 
(Figure 9B,C). However, introduction of the bulky indole led to 4-fold increased potency com-
pared to unsubstituted derivatives (see compounds 10 and 13, scheme 2 in publication 3), 
although its flipping conformation indicates weak binding and further potential for improvement. 
Substitution of the N-terminal Cbz with a sulfone-linked fluoro-benzene or naphthalene re-
sulted in only a maximum of 2-fold improved potency (see compounds 29 and 42/43, 
scheme 2 in publication 3) and the flexibility of the Cbz group in the crystal structure indicates 
difficulties to improve potency in this compound part. However, it was interesting to see that 
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the peptide bond can be replaced by a sulfone linker, which decreases susceptibility to prote-
olysis. In contrast, the C-terminal isopropyl-moiety is bound in a stable conformation and ex-
ploits a binding site on the Sirt5 surface. This is consistent with increasing potency from a free 
C-terminal amine over substitution with an isopropyl to a bulkier cyclobutyl moiety by more 
than an order of magnitude (see compounds 7, 10, 48, 49, scheme 2 in publication 3). 
Finally, the study yielded compound 49, which comprised the highest potency (IC50 110 nM) 
and Sirt5 selectivity (Figure 9D). 
Still, the inhibitors proposed by the afore-mentioned study comprise several weak properties 
like their size (compound 10/29/49: 637/638/674 Da) or the amounts of H-bond donors (6/7/6) 
disobeying Lipinski’s “rule of 5” 180 and thus suggesting low bioavailability. Additionally, they 
contain two to three peptide bonds, which are targets for proteolytic cleavage that by rationale 
would significantly decrease inhibitor potency. Our collaborators thus tested a series of lysine 
substitutions carrying the strongly inhibiting 3-(2-naphthylmethyl-thio)-succinyl acyl derived 
from the peptide inhibitor study (publication 2). A tripeptide still comprised a Ki of 180 nM 
(compound 40, Figure 10), while further truncation to an acetyl-/amine-protected lysine de-
creased potency to 7 µM (compound 41, Figure 10), i.e. a decrease of three orders of magni-
tude compared to the parent inhibitory CPS1-peptide (Ki 7 nM, Figure 8A). Removing the re-
sidual lysine-backbone decreased potency by another order of magnitude (compound 42, 
Ki 77 µM, Figure 10), but could partially be recovered by testing a few substitutions of the 
lysine side chains (compounds 43-46, Ki 36-79 µM, Figure 10).  
Figure 10: Small molecule inhibitors derived from the 3-(2-naphthylmethyl-thio)-succinyl inhibitory acyl. 
Chemical structures of the inhibitors and their potency (in bold) are shown. Truncation of the highly potent inhibitory 
peptide 3NMTS-CPS1-K527 (Figure 8A) resulted in an order of magnitude less potent tripeptide (compound 40, 
Ki 180 nM) and another order of magnitude less potent acetyl-/amine-protected 3NMTS-lysine (compound 41, 
Ki 7µM). Further trimming and substitutions of the lysine-scaffold yielded several small molecule inhibitors carrying 
the 3NMTS acyl with Kis in the two-digit micromolar range (compounds 42-46). 
Future studies can build on the highly potent and selective acyls identified in publication 1 
and 2, but need to improve the lysine scaffold to recover the loss of potency arising from 
peptide truncation. High-resolution structural data obtained within publication 3 can be used 
to grow and develop such small molecule scaffolds to recover potency by targeting affinity hot 
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spots around the Sirt5 lysine binding-site. Furthermore, prospective studies need to address 
the cellular resorption and in vivo half-life of such compounds, which are important features to 
enable their use not only for in vitro investigations, but also for in vivo studies or pharmacologic 
treatments of Sirt5-related pathologies like metabolic dysfunctions or neurodegeneration 88,170. 
3.4. SirReal2 is a potent and selective Sirt2 inhibitor 
Our efforts to optimize the recombinant production of human Sirt4 (hSirt4) resulted in low yields 
of about 30 µg per liter of E. Coli culture, but the purification process could be optimized to 
obtain > 95% pure and active hSirt4 protein. The ability to produce hSirt4 protein enabled the 
participation in a collaborative drug development project, which aimed to establish a selective 
and drug-like Sirt2 inhibitor. Therefore, our collaborators screened an in-house compound li-
brary and identified molecules of the aminothiazole-family as in vitro Sirt2 inhibitors with sub-
micromolar potency. Of those, SirReal2 (Sirtuin-rearranging ligand 2) was the most potent 
compound (IC50 140 nM) and did not significantly affect other Sirtuin activities (Sirt1/3 deacety-
lation, Sirt5 desuccinylation, Sirt6 demyristoylation) in vitro (Figure 11A,B), while NAM inhib-
ited all Sirtuins as a positive control. We contributed to this project by testing SirReal2 and 
NAM against Sirt4 deacetylation of acetyl-NNT397 peptide (sequence given in publica-
tion 4), which was found to yield interpretable signals in our lab. 
 
Figure 11: Characterization of the Sirt2 specific inhibitor SirReal2. (A) Chemical structure of SirReal2. (B) Se-
lectivity study of SirReal2 against Sirt1-6, revealing its isoform specificity for Sirt2. SirReal2 was tested at 0, 100 or 
200 µM dose, while NAM was tested at a 200 µM dose on Sirt1-6 except Sirt4, where it was tested at a 1 mM dose. 
Compounds were tested on Sirt1-4 deacetylation, Sirt5 desuccinylation and Sirt6 demyristoylation. (C) SirReal2 
binds in vicinity to co-substrate NAD+ and protrudes into the acetyl-lysine channel, thereby repulsing the substrate 
lysine. 
Our collaborators solved complex crystal structures of Sirt2 with SirReal2 in presence or ab-
sence of substrate and NAD+. These led to the conclusions that SirReal2 introduces major 
rearrangements in the Sirt2 structure, occupies part of the acetyl-lysine binding site and forces 
the acetyl-lysine 5 Å out of its physiological position (Figure 11C). Kinetic analysis confirmed 
that SirReal2 hampers acetyl-lysine binding, which, together with the structural Sirt2 rearrange-
ments, appears to be responsible for efficient Sirt2 inhibition. Interestingly, in vivo experiments 
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identified two inhibited Sirt2 functions upon SirReal2 treatment, BubR and α-tubulin deacety-
lation, proving the compound’s cellular availability. Therefore, SirReal2 is suitable as a modu-
lator of Sirt2 activity in in vitro and in vivo studies and could serve as a lead for prospective 
therapeutic treatments of Sirt2 related pathologies like neurodegenerative diseases (Alz-
heimer) or glioma and brain cancer 61. 
3.5. Biochemical and structural characterization of Sirt4 
In contrast to most other isoforms, the mitochondrial Sirtuin 4 is poorly understood. Its structure 
was not resolved so far and its primary activity is unknown. Deacetylase 111, ADP-ribosyltrans-
ferase 109 and delipoylase 113 activities were reported, but the in vitro kinetics of these activities 
are weak compared to robust primary functions of other Sirtuins. A sequence dependent ac-
tivity is conceivable and thus a microarray study testing 6800 different acetylated peptides as 
Sirt4 substrates was conducted 181. However, it showed a significant impact of peptide se-
quence on Sirt4 activity, but did not enhance it by the orders of magnitude, which would be 
necessary to draw level with other robust Sirtuin activities. These results and other reported 
features of Sirt4 indicating a functional deacylase activity, e.g., the conserved catalytic core 182 
or its low deacetylase 111,181 and delipoylase activity 113, suggested an unidentified, robust ac-
tivity or the necessity of a stimulating ligand, as in the case of Sirt6 140. 
Thus, hSirt4 acyl-specificity was screened using the CPS1-K527 acyl-library described in 
chapter 3.1. Initial screening at high peptide concentration in a coupled Sirtuin assay showed 
weak deacetylase activity and confirmed the slightly increased delipoylation and debiotinyla-
tion activity 113 (Figure 12A,B). Strikingly, Sirt4 showed an 8-fold increased activity towards 
the non-physiologic 3,3-dimethyl-succinyl (DMS) modification. Testing chemically similar ly-
sine acylations, which might be physiologic PTMs due to an existing reactive metabolite, iden-
tified 3-hydroxy-3-methyl-glutaryl (HMG) as a Sirt4 substrate-acyl with 3-fold improved activity 
compared to deacetylation (Figure 12A,B) (activity will be abbreviated as de-HMG-ylation in 
the following). We collaboratively demonstrated that the metabolite HMG-CoA modifies the 
model protein Cyclophilin-A (CypA) and that Sirt4 de-HMG-ylates CypA in vitro, indicating a 
physiological significance (see Figure 1e,f and SI figure 1d,e in publication 5). Confirmingly, 
an independent study proved the existence of HMG as a physiologic lysine-PTM and demon-
strated Sirt4 de-HMG-ylase activity in vivo by using HMG-lysine specific antibodies 183. 
Determining Michaelis-Menten kinetics for the above mentioned CPS1-K527 peptide sub-
strates confirmed weak deacetylation efficiency (3.7 ± 0.7 M-1 s-1) due to a very high KM, 
whereas the lipoylated peptide showed an improved KM but lower kcat with a huge error due to 
poor peptide solubility (170 ± 230 M-1 s-1) (Figure 12C). Remarkably, DMS- and HMG- modified 
CPS1-K527 peptides showed both, enhanced KM and kcat, leading to two orders of magnitude 
increased catalytic efficiencies (HMG: 546 ± 67 M-1s-1; DMS: 412 ± 41 M-1s-1) compared to 
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deacetylation (Figure 12C). These are close to the range of primary functions of other Sirtuins, 
such as Sirt2 deacetylation (1400 M-1s-1 for acetyl-H3K27 peptide) 139 or Sirt5 desuccinylation 
(2000 M-1s-1 for succinyl-GDH-K503 peptide) 57.  
 
Figure 12: Sirt4 selectivity profiling and testing mitochondrial Sirtuin activity on improved Sirt4 substrate-
acyls. (A) Chemical structure of the CPS1-K527 peptide and Sirt4 substrate acyls. (B) Screening hSirt4 activity 
towards a variety of acylated CPS1-K527 peptides. (C) Michaelis-Menten kinetics of hSirt4 for acetyl-, DL-lipoyl-, 
DMS- and HMG-CPS1-K527 peptides and (D) comparison of mitochondrial hSirt3,4 and 5 activities towards acetyl, 
DMS-, succinyl-, HMG-CPS1 and two other HMG-modified substrate peptides (HMG-MCD, HMG-NNT; peptide 
sequences are given in publication 5). 
However, testing Sirt4 activity on HMG-CPS1 peptide in an MS-based assay revealed a similar 
KM, but significantly lower vmax (see Figure 12C and SI Figure 1c in publication 5). Over time 
course assays, a significantly increasing amount of a 560 Da UV280 absorbing molecule, likely 
to be ADP-ribose, was detected in assays with HMG-, but not with acetyl-CPS1-K527 peptide. 
The discrepancy between the coupled and MS-based assay systems might thus rely on their 
different readouts. The MS-based assay detects substrate and product peptides directly, which 
contrasts the indirect detection of substrate turnover via the by-product NAM in the coupled 
assay 184. Generation of ADP-ribose as revealed by MS-based assays implies a Sirt4 glycohy-
drolase activity stimulated by HMG-CPS1-K527 peptide, and both glycohydrolase and de-
HMG-ylase activity would contribute to the strong signal in the coupled continuous assay. In 
contrast, only the acyl-hydrolysis is taken into account in the MS-based assay for quantification 
of the Sirt4 deacylation reaction. A similar effect has been reported for Hst2 assays with an 
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artificial homocitrulline-lysine peptide substrate, which yielded NAM, ADP-ribose and the re-
covered homocitrulline-lysine as products 185. However, further work is clearly necessary to 
elucidate this issue.  
Testing the specificity of mitochondrial Sirtuins towards the improved Sirt4 substrates showed 
no significant overlap of Sirt3 and 4, since the robust deacetylase Sirt3 showed negligible ac-
tivity on DMS- and HMG-CPS1 peptide. However, Sirt5 showed lower activity on DMS-CPS1 
peptide than Sirt4, but de-HMG-ylated peptides with comparable or better efficiency as Sirt4, 
depending on substrate sequence (Figure 12D). It is tempting to speculate that Sirt4 exhibits 
a not yet identified deacylase activity due to the similar Sirt4/5 de-HMGylase efficiencies, which 
contrast the clearly discriminated primary activities of the other mitochondrial Sirtuins 3 
(deacetylation) and 5 (acting on acyls with distal carboxylic groups) 88,102.  
Clearly, the crystal structure of Sirt4 would provide valuable information to unveil its activity 
and other specific features. Since crystallization trials using hSirt4 were unsuccessful due to 
low yield and solubility, the highly similar orthologues from D. rerio (zebrafish; zSirt4) and 
X. tropicalis (western clawed frog; xSirt4) were recombinantly expressed in E. Coli and purified 
for crystallization experiments. Aligning hSirt4, xSirt4 and zSirt4 catalytic core sequences 
showed roughly 80% similarity and the orthologues shared comparable activity profiles (see 
Figure 1g in publication 5). Strikingly, xSirt4 constructs yielded crystals with high resolution 
below 2 Å in presence of ADP-ribose, which enabled the determination of the first Sirt4 struc-
ture (Figure 13A,B).  
  Summary and discussion of results  
 - 32 -  
 
Figure 13: Analysis of the Sirt4 crystal structure. (A) Overall xSirt4/ADP-ribose complex structure with universal 
Sirtuin secondary structure labeling. (B) Sirt4 active-site with electron-density for the ligand ADP-ribose shown 
(2FoFc, σ = 1.0). xSirt4 is shown in green (Rossmann-fold), light-blue (zinc-binding domain) or dark blue 
(“Sirt4-loop”) cartoon representation, while important amino acids are shown as respectively domain cpk color-
coded sticks and ligands as grey cpk color-coded sticks. (C) Overlay of Sirt3 (light grey, red), 4 (grey, blue) and 
5 (dark grey, orange) structures in cartoon representation, demonstrating the different length of their zinc-binding 
domain loop. (D) Overlay of xSirt4/ADP-ribose (grey) and zSirt5/HMG-CPS1-K527 (light blue) complexes with pro-
teins and peptide shown in cartoon style and amino acids of interest, ADP-ribose and acyl-lysine shown as respec-
tively color-coded cpk sticks. The bound zinc ion is shown as a yellow sphere in (A), (B) and (D). 
The xSirt4/ADP-ribose complex resembled the typical Sirtuin overall structure with a 
Rossmann-fold and a zinc-binding domain connected by several loops and the active-site lo-
cated in between the two domains (Figure 13A). Interestingly, Sirt4 comprises an elongated 
Zinc-binding domain loop, which is highly conserved among chordate Sirt4 orthologues, but 
unique in the Sirtuin family (see alignments in Figure 2c,d or SI Figures 2c,d in publica-
tion 5) and extensive enough to contribute to the active-site lining (Figure 13A,B). The loop’s 
core can be deleted and is thus dispensable for the protein’s integrity, but mutants showed 
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slightly higher KM and increased kcat for acetyl- and HMG-CPS1-K527 peptide, suggesting a 
role in active-site dynamics (see Table 3 in publication 5). This hypothesis is supported by 
another crystal structure of an xSirt4/thioacetyl-ADP-ribose product complex, in which the 
Sirt4-loop is flexible and detached from the active-site, suggesting changing conformations 
during catalysis (see SI Figure 2e in publication 5). However, it is also flexible in another 
solved xSirt4/ADP-ribose complex, thus, determining its role in active-site dynamics clearly 
needs further investigation. 
Another Sirt4 feature is an additional entry channel on top of the acyl-lysine binding site, which 
is constituted by amino acids mostly conserved in Sirt4, while other isoforms comprise variable 
residues in this area. This structural feature is reminiscent of the hydrophobic pocket of Sirt6, 
which either enables its demyristoylation activity or probably binds free fatty acids and thereby 
enhances deacetylation 140. Although the Sirt4 and 6 channels are of different shape and size, 
a similar effect of additional ligands is conceivable. Therefore, several fatty and (di)carboxylic 
acids were tested as effectors on Sirt4 deacetylation and de-HMG-ylation and showed that 
DL-lipoic acid acts as an inhibitor at high concentrations (see SI Figure 3b in publication 5). 
Consistently, a lipoyl-lysine docked in the active-site partially occupied the acyl-lysine binding-
site and the additional channel (see Figure 3a in publication 5), which rationalizes both inhi-
bition by DL-lipoic acid and delipoylation of a substrate lysine by Sirt4. It is also conceivable 
that the channel serves as a binding site for a substrate anchor to enhance the deacylation of 
a nearby lysine residue similar to the recently reported SirTM, which ADP-ribosylates peptides 
and proteins after recognition of an adjacent biotinylation site 186. 
Since a Sirt4/peptide complex could not be crystallized, a zSirt5/HMG-CPS1-K527 complex 
was solved and overlaid with the xSirt4/ADP-ribose structure to investigate Sirt4 acyl recogni-
tion (Figure 13D). Like glutaryl-lysine, HMG-lysine is recognized by the Sirt5 Tyr-X-X-Arg-motif 
at the back of the acyl-lysine binding site. Sirt4 comprises the same motif in this region, but it 
is shifted by one helix winding, with Tyr104 pointing back to the active-site, but Arg107 away 
from it. Mutating both residues lead to a 2- to 4-fold increased KM for HMG-CPS1-K527 peptide, 
suggesting a role in acyl-recognition and a reorientation of Arg107 upon substrate-binding. 
Interestingly, Asp201 of the Sirt4-loop overlays with Arg101 of the Sirt5 Tyr-X-X-Arg motif and 
is thus in an ideal position for acyl-recognition. Therefore, acyls of varying length with terminal 
amines to complement the negative charge of Asp201 were tested, but did not show significant 
Sirt4 activity. Additionally, an Asp201Ala mutant only showed minor differences in kinetic pa-
rameters for deacetylation and de-HMG-ylation. Thus, both experimental setups indicated that 
this residue is not directly involved in acyl-recognition. It is tempting to speculate, that the Sirt4 
active-site and the zinc-binding domain loop rearrange upon substrate binding and possibly 
throughout the catalytic cycle. This would explain the influence of the offside Arg107 on 
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de-HMG-ylation activity, the lacking acyl-recognition of the well-positioned Asp201, and the 
detached loop in the xSirt4/thioacetyl-ADP-ribose product structure. 
A third structural feature of Sirt4 is a more pronounced positive charge in its nucleotide-binding 
site compared to other Sirtuins. We hypothesized, that this could influence binding of co-sub-
strate NAD+ and inhibition by NAM or NADH. The KM of 62 µM for NAD+ was within the lower 
range of 10 to 600 µM reported for Sirtuins 129,141. NAM potently inhibited Sirt4 (IC50 31 ± 2 µM), 
which strongly indicates an influence at physiologic concentrations of 10-400 µM 149, but the 
effect is comparable to other Sirtuins (e.g. IC50 Sirt1: 62 µM, Sirt3: 43 µM and Sirt5 desuccinyl-
ation: 21 µM) 146. Interestingly, in comparison to the weak effects of NADH on other Sirtuins in 
the millimolar range 145, Sirt4 is much more sensitive (IC50 126 ± 12 µM (at 500 µM NAD+)) and 
probably affected at the physiologic 30 µM free NADH in mitochondria 187. The more positively 
charged nucleotide-binding site could be the key-driver for this effect. It might facilitate NADH 
binding in an inhibiting, so called unproductive, conformation with the reduced NAM residing 
outside the so called “C-site”, which favors oxidized nucleotides for productive NAD+              
binding 145. Our data implies a unique regulation mechanism by NADH and a distinct metabolic 
sensory function of Sirt4 demanding further investigation in a cellular context. 
The last classification of Sirtuins was performed using sequence alignments by Frye in 2000 182 
(Figure 14A), but several structures of bacterial and eucaryotic Sirtuins have been determined 
since then, which could be used to structurally investigate Sirtuin phylogeny. Therefore, we 
conducted a new structure-based alignment with all known bacterial, yeast and Sirt1-6 struc-
tures. Additionally, the 195 verified UniProt chordate sequences of Sirt1-7 were aligned to this 
structure-based alignment to generate a more redundant phylogenetic tree of the Sirtuin family 
(Figure 14B).  
Figure 14: Phylogenetic trees of bacterial and eukaryotic Sirtuins. (A) Phylogenetic tree from Frye, 2000 182 
based on sequence alignments (used with permission of Elsevier). (B) New phylogenetic tree derived from a struc-
ture-based alignment supplemented with 195 sequences of chordate Sirt1-7. 
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Overall, the new tree mostly confirms the phylogenetic analysis of Frye, but displays a few 
differences (Figure 14A,B). The ancient T. maritima Sir2Tm (Frye nomenclature: T.mar) is 
now closer to the Sirt6/7 branch and Sirt5 is more separated from the bacterial Sirs like E. Coli 
CobB (E.col) and A. fulgidus Sir2Af1 (A.ful1). The latter are now grouped together with the 
other bacterial A. fulgidus Sir2Af2 (A.ful2) and P. falciparum Sir2Apf (P.fal1) in the new classi-
fication. Remarkably, both trees discriminate Sirtuins with different deacylase activity. While 
the robust deacetylases Sirt1, 2 and 3 are grouped together, the weak deacetylases Sirt4-7 
are clearly separated. Interestingly, both trees place Sirt6 and 7 on neighboring branches, 
which is reminiscent to the Sirt1-3 deacetylase branch and implies a similar structure and/or 
deacylase activity. Including more sequences and structures of ancestral Sirtuins could recon-
struct the evolution from bacterial Sirtuins to the seven mammalian isoforms and might be of 
avail to understand their function and regulatory role. 
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Chemical Probing of the Human Sirtuin 5 Active Site Reveals Its
Substrate Acyl Specificity and Peptide-Based Inhibitors**
Claudia Roessler, Theresa Nowak, Martin Pannek, Melanie Gertz, Giang T. T. Nguyen,
Michael Scharfe, Ilona Born, Wolfgang Sippl, Clemens Steegborn, and Mike Schutkowski*
Abstract: Sirtuins are NAD+-dependent deacetylases acting as
sensors in metabolic pathways and stress response. In mam-
mals there are seven isoforms. The mitochondrial sirtuin 5 is
a weak deacetylase but a very efficient demalonylase and
desuccinylase; however, its substrate acyl specificity has not
been systematically analyzed. Herein, we investigated a carba-
moyl phosphate synthetase 1 derived peptide substrate and
modified the lysine side chain systematically to determine the
acyl specificity of Sirt5. From that point we designed six potent
peptide-based inhibitors that interact with the NAD+ binding
pocket. To characterize the interaction details causing the
different substrate and inhibition properties we report several
X-ray crystal structures of Sirt5 complexed with these peptides.
Our results reveal the Sirt5 acyl selectivity and its molecular
basis and enable the design of inhibitors for Sirt5.
The reversible acetylation of lysine side chains represents
one of the most frequent posttranslational modifications in
proteins conserved from bacteria to eukaryotes.[1]Acetylation
states are regulated by the action of lysine acetyltransferases
and lysine deacetylases. One class of lysine deacetylases, the
sirtuins, require NAD+ as a cosubstrate, linking their activity
to energy levels of the cell. They transfer the acetyl group
from the lysine side chain to the 2’-hydroxyl group of the
ADP ribose moiety of NAD+ under nicotinamide release.[2]
Sirtuins are involved in many metabolic and stress response
processes, and modulators of human isoforms are interesting
drug candidates for aging-related diseases including diabetes,
cancer, and neurodegeneration.[3] Some sirtuin isoforms were
found to be specific for other acyl modifications on the lysine
side chain. Besides acetylation, modifications like propiony-
lation,[4] butyrylation,[4a] crotonylation,[5] malonylation,[6] suc-
cinylation,[7] myristoylation,[8] and 3-phosphoglycerylation[9]
were detected in vivo. The mitochondrial isoform sirtuin 5
(Sirt5) and the nuclear isoform sirtuin 6 (Sirt6) have a much
lower deacetylation activity than several other isoforms.[10]
For Sirt6 it could be demonstrated that long acyl chains, such
as myristoyl residues, represent much better substrates as
a result of improved KM values,
[10b] similar to findings for the
Plasmodium falciparum sirtuin 2A.[11]
Sirt5 was also found to remove octanoyl and decanoyl
residues from model peptides.[12] In particular, this isoform
was recently shown to be an effective demalonylase/desucci-
nylase in vitro[13] and in vivo.[6, 13b] Du et al. were able to
demonstrate that the change from acetyl to succinyl residues
in three different model peptide sequences increased catalytic
efficiencies (kcat/KM) between 75- and 1000-fold but individual
KM and kcat values could not be determined for acetylated
substrates.[13a] Crystal structure analysis identified an inter-
action between the carboxyl function of the succinylated
peptide lysine and the Sirt5 side chains of Arg105 and
Tyr102,[13a] indicating a mechanism for substrate acyl discrim-
ination. Interestingly, these residues also cause isoforms and
substrate acyl specific inhibitor effects.[14] Here we investi-
gated the effects of substrate lysine modifications in a more
systematic way and developed novel peptide-based Sirt5
inhibitors through acyl group modifications. As the peptide
we used a carbamoyl phosphate synthetase I (CPS1)-derived
sequence (1) identified through high-density peptide micro-
Scheme 1. Homologous row of dicarbonic acyl (3–9) and acetyl (2)
residues attached to the lysine side chain of CPS1 peptide 1.
[*] C. Roessler,[+] Dr. I. Born, Prof. Dr. M. Schutkowski
Department of Enzymology
Institute of Biochemistry and Biotechnology
Martin-Luther-University Halle-Wittenberg
Kurt-Mothes-Strasse 3, 06120 Halle/Saale (Germany)
E-mail: mike.schutkowski@biochemtech.uni-halle.de
T. Nowak,[+] M. Scharfe, Prof. Dr. W. Sippl
Department of Medical Chemistry, Institute of Pharmacy
Martin-Luther-University Halle-Wittenberg
Halle/Saale (Germany)
M. Pannek,[+] Dr. M. Gertz, G. T. T. Nguyen, Prof. Dr. C. Steegborn
Department of Biochemistry, University of Bayreuth (Germany)
[+] These authors contributed equally to this work.
[**] The M.S. research group thanks BMBF (ProNet-T3) for financial
support, Zˇeljko Simic´ for synthesis of HMG-modified CPS1 peptide
derivative, and Dr. Angelika Schierhorn for MALDI mass spec-
trometry. The C.S. research group thanks Oberfrankenstiftung.
Atomic coordinates and structure factors of the Sirt5–peptide
complexes were deposited in the Protein Data Bank under the PDB
codes 4UTN, 4UTR, 4UTV, 4UTX, 4UTZ, 4UU7, 4UU8, 4UUA, and
4UUB.
Supporting information for this article is available on the WWW
under http://dx.doi.org/10.1002/anie.201402679.
.Angewandte
Zuschriften
10904  2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. 2014, 126, 10904 –10908
array experiments[1] and shown to serve as a Sirt5 substrate in
its acetylated form (Scheme 1).[14a]
In Sirt5 crystal structures Arg105 adopts different con-
formations suggesting that larger acyl residues might be able
to interact with Tyr102 and Arg105, too. Therefore, we
synthesized CPS1 substrate analogues acylated at the lysine
side chain with oxalyl (3), malonyl (4), succinyl (5a), glutaryl
(6a), adipoyl (7), pimeloyl (8), and suberoyl (9) residues
(Scheme 1). Moreover, we introduced double bonds (5e–5g),
heteroatoms (6e–6g), and additional substituents to succinyl
and/or glutaryl moieties like methyl groups (5b, 5c, 6b, 6c,
6g, and 6d), methylidene groups (5e), hydroxyl groups (6d),
and amino groups (5d). Additionally, we replaced the
carboxyl group of the succinyl residue with a nitro function
(5 l) as well as a methyl group (5n) (Scheme 2 and Scheme 3).
Finally, we introduced larger substituents to the 3-position of
succinyl (5h–k and 5m) (Scheme 2) and the 4-position of
glutaryl residues (6h) (Scheme 3).
Kinetic constants for the substrates (Table 1) were
determined using an HPLC-based assay. Controls without
NAD+ under identical conditions yielded no conversion of
the substrates. Inspection of the kinetic constants uncovers
the surprising fact that the introduction of an additional
carboxyl group to the acyl chain did not significantly influence
the apparent affinity to the active site of Sirt5, as reflected by
the almost comparable KM values for 2 and 4. Instead, the
respective kcat value is increased about 50-fold demonstrating
that this modification either influences the velocity or changes
the nature of the rate-limiting step of the Sirt5-catalyzed
reaction. Insertion of one (5a) and two (6a) additional
methylene groups did not improve theKM value but increased
the kcat value 140-fold and 200-fold, respectively, as compared
to 2. Insertion of an additional methylene group (7) yields
a substrate with a similar apparent affinity to the active site
but 7-fold reduced kcat value compared to 6a. Insertion of
more methylene groups (8 and 9) resulted in substrates with
kcat values similar to that of 2 and increased KM values.
Replacement of the methyl group of the acetyl residue in 2 by
a carboxyl function (3) increased the KM value by more than
15-fold. Molecular docking of 3 shows that the distance
between the carboxyl group of 3 and Tyr102 as well as Arg105
is too large for interaction with these residues. Additionally,
one oxygen of the carboxyl group of 3 clashes with the
backbone carbonyl of Val221 which might explain why theKM
value of 3 is lower than that of 5a (Figure S9).
Scheme 2. Derivatization of 5a : A) dehydrogenation; B) replacement
of carboxyl group by methyl or nitro function; C) substitution on C3. 5 j
represents a mixture of 2- and 3-butylsuccinyl CPS1.
Scheme 3. Derivatization of 6a : A) substitutions on C3; B) substitu-
tions on C4; C) replacement of the C3-carbon by oxygen, sulfur, or
methylated nitrogen.
Table 1: Kinetic constants for differently acylated CPS1-derived peptides.
Compound KM [mm] kcat [s
1] kcat/KM [m
1s1]
2 24.39.1 3.91046105 16
3 415.824.3 1.61038105 4
4 5.11.1 1.91021103 3758
5a 3.80.6 5.31022103 13995
5b 3.10.3 2.41034105 774
5c 5.31.0 2.21048106 42
5d 130.357.2 8.41022103 644
5e 8.20.7 2.51035105 307
5 f 46.78.0 1.71031104 37
5g 191.899.0 1.51035104 8
5 l 44.817.1 5.21038104 116
6a 4.11.0 7.71022103 18699
6b 5.70.6 3.31035105 579
6c 16.33.5 1.11048106 7
6d 7.60.92 3.81031104 500
6e 10.12.0 1.01017103 9906
6 f 2.70.5 2.31027104 8613
6g 12.12.7 1.61021103 1325
7 6.51.6 1.01026104 1538
8 80.522.9 2.81044105 4
9 409.1283.0 5.31042105 1
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Obviously, 4, 5a, and 6a represent most likely physio-
logical substrates for Sirt5; this is reflected by the superior
specificity constants kcat/KM. The very similar apparent
affinities, indicated by KM values, of Sirt5 for 5a and 6a
could be confirmed by the determination of dissociation
constants (KD) using isothermal titration calorimetry (Fig-
ure S8). We found KD values of 700 50 nm and 710 110 nm
for 5a and 6a, respectively. The improved turnover of 5a
relative to that of 2 is not simply caused by the increased
length of the acyl chain because 5n showed kinetic constants
comparable to those of 2 (data not shown). Introduction of
a double bond into the succinyl residue resulted in 5 f and 5g,
which showed an about 30-fold decrease in the turnover. The
KM value is increased about 12-fold for 5 f but by more than
50-fold for 5g with a cis-configured double bond. We
compared the structure of the zebrafish Sirt5 (zSirt5)/5a
complex with docking poses of 5 f and 5g. Due to the double
bond, the acylated lysine residues are forced into a planar
orientation, which is not suited to form an optimal hydrogen
bond to Tyr102 and a salt bridge to Arg105 (Figure S17).
We solved crystal structures of zSirt5, which is highly
homologous to the less reproducibly crystallizing human
enzyme (Figure S11), in complex with 5a, 6a, and 7 to analyze
the binding details of the modifications on the lysine side
chain. The final models are composed of two zSirt5 molecules,
each complexing one zinc cation. The active site of one
molecule is occupied by the respective substrate peptide, with
a consistent salt bridge between the carboxyl group of the acyl
moiety and Arg101 as well as a hydrogen bond to Tyr98
(Figure 2a), whereas a buffer ion interacts with Arg101 in the
active site of the second zSirt5 molecule. In comparison to the
succinyl moiety of 5a, the glutaryl and adipoyl modifications
show an increasingly twisted conformation, allowing very
similar positions for the distal carboxyl group despite differ-
ent chain lengths (Figure 1a). The adipoyl modification shows
a slight movement toward the catalytic His154 to accommo-
date the broader, helically arranged carbon chain, resulting in
a strained conformation and an elongation of the conserved
hydrogen bond between the lysine e-amino group and the
Val217 main-chain carboxyl oxygen. Additional extension of
the substrate acyl chain (8 and 9) could not be bound in the
same mode as for 5a, 6a, and 7 by twisting the chain, resulting
in the loss of the conserved hydrogen bond to oxygen of
Val217 but a similar carboxyl interaction with Arg101/Tyr98.
Flexible docking of 8 and 9 indicates that Arg105 changes
its conformation to enable similar interactions. This Arg105
conformation is also observed in the Sirt5/thioacetyl-H3K9/
CHES complex structure (3RIG), showing that this confor-
mation is possible for the protein. The substrate hydrogen
bond to Tyr102 is completely lost, however. This lost
interaction and possibly a nonoptimal Arg105 conformation
thus appear to be the reasons for the weaker apparent binding
and lowered catalytic efficiencies for these substrates. Further
extending the acyl chain would lead to a complete loss of the
Arg105 interaction and to energetically unfavorable acyl
conformations due to limited space within the substrate-
binding pocket of Sirt5 (Figure 1b).
Crystal structures of 5a and 6a bound to zSirt5 revealed
that there is some space around position 3 of the acyl residue
and docking studies with 5b, 5c, and 6b, 6c suggested that
they could bind to Sirt5 similar to 5a and 6a, respectively. The
substituents do not disturb the NAD+ productive conforma-
tion, as suggested by docking studies (Figure S10) and
indicated by crystal structure analysis of zSirt5 in complex
with 5b or 5c (Figure 2). We thus tested single (5b, 5e, 5d,
and 6b) and double substitutions on this position (5c, 6c, and
6d) and replacement of the methylene moiety at position 3 by
oxygen (6e) and sulfur (6 f), and by methyl-substituted
nitrogen (6g). Introduction of heteroatoms into the acyl
chain seems to be tolerated by Sirt5 at least in position 3 of
glutaryl derivatives. Kinetic constants for 6e and 6 f are
similar to that of 6a, and for 6g similar to that for 6b.
All compounds with methyl/hydroxyl substitutions are
substrates for Sirt5 with KM values in the low micromolar
range but with dramatically reduced kcat values. Determina-
tion of kinetic constants for the cosubstrate under saturating
conditions for peptides 5a and 5b yielded very similar results
(Figure S5) with NAD+ KM values of 29.6 15.2 mm and
35.5 11.7 mm, respectively, confirming that the additional
Figure 2. Crystal structures of zSirt5 active-site with superposed 5a
(gray), 5b (dark gray), and 5c (light gray). The protein is shown only
once for clarity (zSirt5/5a complex; gray), since all protein residues
superpose well. Polar interactions between active-site residues and
substrate peptides’ acylated lysine are indicated by dotted lines.
Figure 1. a) Crystal structures of zSirt5 with superposed 5a (gray), 6a
(light gray), and 7 (dark gray). The protein is shown only once for
clarity (zSirt5/5a complex; gray), since all protein residues superpose
well. b) Docking of 8 (dark gray) and 9 (light gray) is only possible if
Arg105 adopts another conformation that is also observed in the X-ray
structure of PDB entry 3RIG. Polar interactions between ligand and
protein are indicated as dashed lines.
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methyl group in the acyl chain of the peptide substrate does
not interfer with NAD+ binding. Solving zSirt5 structures in
complex with 5b and 5c reveals molecular reasons for this
effect on kcat. Compared to the structure with 5a, the acyl side
chain in 5b and 5c is twisted to position the hydrophobic
methyl groups in appropriate active site cavities (Figure 2).
This reorientation requires a rotation of the amide bond of
the acylated lysine side chain, resulting in a carbonyl ori-
entation that is probably not optimal for the nucleophilic
attack at C1 of the ribose ring in the cosubstrate.
Determination of the respective KD values using ITC
yielded 830 170 nm and 290 40 nm for 5b and 5c, which is
very similar to theKD value for nonsubstituted parent peptide
5a, indeed confirming that the unchanged KM correctly
indicates similar affinities to the active site. In contrast,
substrate 5d showed a 30-fold increased KM value, likely due
to the positive charge of the introduced primary amino
function, since assuming that the binding is similar to that of
5b would place this function in a hydrophobic environment.
These results suggest the assumption that the chain length of
the dicarbonic acyl residue as well as the orientation of the
carboxyl group has a high impact on the kcat value but less on
the apparent affinity of the peptidic substrate.
Small acyl modifications can show significant effects on
the substrate properties, suggesting the development of
inhibitory binding groups: Exploiting the Sirt5 specific
active site cavities should make it possible to further increase
the binding affinity, in a nonproductive, inhibitory conforma-
tion, and it should enable isoform selective binding and
inhibition.
We tested the idea of introducing bulkier acyl substituents
to generate steric hindrance for NAD+ binding by analyzing
succinyl CPS1 derivatives with larger substitutions on C3 like
5j and 5h. These compounds could not be deacylated by the
enzyme even when prolonged reaction times (up to 24 h) and
higher Sirt5 concentrations (up to 2 mm) were used. Consis-
tent with our hypothesis that they still bind to the active site of
Sirt5 and block the NAD+ site, these compounds are
inhibitors for Sirt5 with Ki values of 100 45 and 17.2
1.3 mm for 5h and 5j, respectively (Table S2, Figures S6 and
S7). Solving their complex structures with zSirt5 revealed that
both modifications allow binding of the succinyl moiety like in
substrate 5a, and that these substitutions point toward the
NAD+ binding pocket (Figure S14a,b). Modeling NAD+ from
PDB ID 3RIY (Sirt5/succinyl-H3K9-peptide/NAD+[13a]) into
our zSirt5 structures shows that the modifications would clash
with ribose atoms of the NAD+ cosubstrate (Figure S18). For
5h a mixture of S andR enantiomers appear to be bound, with
slightly differing succinyl conformations but distal carboxyl
groups and the phenyl moieties still in the same position. Our
CPS1 derivatives thus reveal a novel principle for sirtuin
inhibition based on peptides, which can also reveal valuable
information for the development of small-molecule inhibitors.
Several sirtuin inhibitors, such as Ex527[15] and 4’-bromo-
resveratrol,[16] were recently shown to bind to the nicotina-
mide-accommodating C-site, indicating it as an attractive
pocket for obtaining binding affinity. We therefore attempted
to move the phenyl residue of 5h deeper into the NAD+ site,
toward the C-site, by introducing a methylcarbamate linker
between the succinyl and the phenyl group (5 i). During the
synthesis of this compound we were able to control the
stereochemistry by using Z-protected aspartic acid deriva-
tives in S and R configuration for the acylation reaction,
yielding 5 i and 5o, respectively. Testing benzyloxycarbonyl-
protected aminosuccinyl derivatives showed that 5 i is an
inhibitor for Sirt5 with about 3-fold improvedKi value (38.1
0.6 mm) as compared to 5h (Table S2). Peptide 5o is an
inhibitor with considerably reduced affinity to the active site
of Sirt5 underlining the binding specificity for the S config-
uration. A crystal structure of the complex between 5 i and
zSirt5 confirms that extending the linker in the S configu-
ration moved the phenyl ring deeper into the C-site (Fig-
ure S14c). Only the methylcarbamate linker is well defined by
electron density, while less pronounced spherical density is
observed for the phenyl moiety in the C-site. The phenyl ring
is in fact well positioned to mimic nicotinamide binding
(Figure 3) but appears to be rotationally flexible, and adding
a more nicotinamide-like carboxamide moiety to the phenyl
ring is an obvious next step to improve binding of this acyl
modification. Other large moieties can also be employed for
binding to this active site region.
Thus, introduction of a fluorenyl ring (5p) yielded an
inhibitor with similar preference for the S configuration (Ki=
46.0 0.23 mm). Also, targeting additional active site areas
could increase inhibitor affinity. Disubstitution at position 3
with a phenyl and a methyl moiety led to an about 20-fold
increase in binding affinity of 5k (Ki= 4.3 0.32 mm) com-
pared to 5h. Supposing that the observed orientation of 5h for
the phenyl group is similar, the methyl substituent at C3 can
be assumed to occupy a position similar to the second methyl
group in 5c (Figure S10), indicating it as an interesting
extension site for inhibitor development. Testing inhibition of
human sirtuin isoforms by 5k confirms that this approach
achieved selectivity for Sirt5 versus Sirt1, 2, and 3 (Table S3).
Figure 3. Crystal structure of zSirt5 active site with inhibitor 5 i (light
gray). NAD+ molecule was modeled in by an overlay with PDB
entry 3RIG (dark gray). The protein is shown only once for clarity
(zSirt5/5 i complex; gray). Polar interactions between active-site resi-
dues and substrate peptides’ acylated lysine are indicated by dotted
lines.
Angewandte
Chemie
10907Angew. Chem. 2014, 126, 10904 –10908  2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.de
Next steps in converting our peptide derivatives into small-
molecule Sirt5 inhibitors comprise removal of the peptide
part without losing sufficient affinity and replacement of the
carboxyl moiety to enable membrane passage.
Substitution of the carboxyl group by a nitro function (5 l)
resulted in about 10-fold decrease of both KM and kcat values,
that is, it is a well binding substrate. Crystal structure analysis
of its zSirt5 complex shows that the nitropropionylated lysine
indeed binds very similar to 5a (Figure S13c).
Combining this nitro substitution with our novel acyl-
based inhibition principle should now enable the systematic
development of small-molecule inhibitors for Sirt5. This
approach would lead to the first potent and selective Sirt5
inhibitors, which are anxiously awaited as research tools and
as lead compounds for drug development.
Received: February 21, 2014
Published online: August 11, 2014
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 Chemicals and general methods All chemicals were purchased from Sigma (Saint Louis, USA) if not stated otherwise. Rink amide MBHA resin was obtained from Iris Biotech (Marktredwitz, Germany). Fmoc-protected amino acid derivatives and Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) were purchased from Merck (Darmstadt, Germany). Trifluoroacetic acid was obtained from Roth (Karlsruhe, Germany). For HPLC separations solvents consisting of water (solvent A) and ACN (solvent B), both containing 0.1 % TFA were used. Eluting compounds were detected at 260 nm. Analytical runs were performed on an Agilent 1100 HPLC (Boeblingen, Germany) with a quaternary pump, a well-plate autosampler and a variable wavelength detector. 40 to 80 µl of compounds or reaction solutions were injected and separated using a linear gradient from 30 % to 60 % solvent B within 5min on a 3.0 x 7.5 mm reversed phase column (Agilent Poroshell 120 EC-C18, 2.7 µm) with a flow-rate of 0.8 mL/min. A Merck-Hitachi High Speed LC system (Darmstadt, Germany) with a Merck Hibar LiChrosorb RP-8 column (250-25 mm, 7 µm) was used for preparative separations. For separation a linear gradient from 20 % to 50 % solvent B in 60 min was used (flow-rate: 8mL/min). Eluted compounds were analyzed by LC/ESI-MS (HPLC: Agilent 1100, ESI-ion trap-mass spectrometer: BrukerDaltonics Esquire LC (Bremen, Germany)). The runs were performed with a linear gradient from 5 % to 100 % solvent B in 20 min on a Machery Nagel (Dueren, Germany) RP-C18 column (ET 125/2 Nukleosil 500-5 C18 PPN). Synthesis of CPS1 derivative 1 1 was synthesized by standard solid-phase-peptide synthesis protocols using 9-fluorenylmethoxy-carbonyl (Fmoc) protected amino acid derivatives. Rink amide MBHA resin was treated with N,N-dimethylformamide (DMF) at RT for 10 min. The Fmoc protecting group was removed with 20 % piperidine in DMF for 15 min. After washing with DMF (5 min, 5 times) the resin was incubated with 4 eq of amino acid derivative, 4 eq PyBOP and 8 eq of N,N-diisopropylethylamine (DIPEA) in DMF at RT for 45 min. The N-terminus of the glycine residue was modified using 4 eq benzoic anhydride and 8 eq DIPEA in DMF at RT for 45 min. The resin was washed with dichloromethane (DCM, 3 min, 5 times), methanol (5 min, 3 times) and again with dichloromethane (DCM, 3 min, 5 times). The peptide was cleaved from the resin and side-chain deprotected by treatment with 97 % trifluoroacetic acid (TFA) at RT for 2.5 h. Crude peptide was precipitated with cold diethylether, filtrated and dried. The peptide was purified by preparative HPLC yielding> 97 % of pure 1. Identity was confirmed by ESI-MS (calculated mass: 967.5 Da, found: 967.5 Da).   
3  
 Figure S1. Fragment MS-spectra of compound 1. Synthesis of acylated CPS1 peptide derivatives Method 1 - anhydrides Treatment of 1 with 1.5 eq of different anhydrides (Table S1) in dry DMF in the presence of 3 eq DIPEA at RT yielded the corresponding lysine-modified CPS1-peptide derivate. The mixture was stirred at RT for 4 to 16h. Ester bonds formed at tyrosine residue of 1 were cleaved by alkaline hydrolysis using sodium hydroxide. The reaction was monitored using analytical HPLC. The acylated CPS1 derivatives were purified by preparative HPLC and product-containing fractions were lyophilized. The identity of purified peptide derivatives was confirmed by HPLC-ESI-MS (Table S1 and Figure S16)  Method 2 - carboxylic acids Treatment of 1 with 1.5 eq of different carboxylic acids (Table S1) in dry DMF in the presence of 1.5 eq PyBOP and 3 eq DIPEA yielded the corresponding lysine-modified peptide derivative. The mixture was stirred at RT for 4 to 16h. The acyl residues at the tyrosine side chain of 1 and resulting mono-methyl/ethyl-ester (compound 3, 5f, 7, 8, 9; Table S1) were removed by alkaline hydrolysis using sodium hydroxide. The mono-tert-butyl-ester and the Boc-protecting groups were removed by treated with 50 % TFA in DCM to yield deprotected compounds 4 and 5d. The reaction was monitored using analytical HPLC. The modified CPS1-peptides were purified by preparative HPLC and product-containing fractions were lyophilized. The identity of purified peptide derivatives was confirmed by HPLC-ESI-MS (Table S1 and Figure S16)  Method 3 – 3-hydroxy-3-methylglutaryl-CoA Reaction mixture containing 8.6 mg of compound 1 and 1.5 eq of DL-3-hydroxy-3-methylglutaryl coenzyme A sodium salt hydrate was incubated in buffer (100 mM TrisHCl, pH 9.5) at RT for 96 h. 4-Dimethylaminopyridine (DMAP) was used as catalyst. Compound 6d was isolated 
4  
using reverse phase HPLC. Molecular weight was confirmed by MALDI-ToF and purity checked by HPLC-ESI-MS (Table S1 and Figure S16).  Table S1. Lysine modifications in CPS1 substrate peptide  1 Benzoyl-Gly-Val-Leu-Lys-Glu-Tyr-Gly-Val-amide  no. modification reagent method mass calculated for [M+H]+ [g/mol] mass found [M+H]+ [g/mol] 2 Acetic anhydride 1 1008.0 1031.4[a] 3 Ethyl-Chlorooxoacetat 2 1039.0 1022.4[b] 4 Mono-tert-butyl malonate 2 1053.1 1036.4[b] 5a Succinic anhydride 1 1067.1 1050.4[b] 5b Methylsuccinic anhydride 1 1081.1 1081.3 5c 2,2-Dimethyl succinic anhydride 1 1095.1 1095.3 5d Boc-Asp-OtBu 2 1082.1 1082.5 5e Itaconic anhydride 1 1079.1 1079.3 5f mono-Ethyl fumarate 2 1065.1 1048.4[b] 5g Maleic anhydride 1 1065.1 1048.4[b] 5h Phenylsuccinic anhydride 1 1143.2 1126.3[b] 5i N-Z-L-aspartic anhydride 1 1216.2 1199.3[b] 5j Butylsuccinic anhydride  1 1123.2 1123.3 5k 3-Methyl-3-phenyldihydrofuran-2,5-dione 1 1157.2 1157.3 5l 3-Nitropropionic acid 2 1068.1 1091.8[a] 5m S-Acetylmercaptosuccinic anhydride 1 1141.2 1163.3[a] 5o N-Z-D-aspartic anhydride 1 1216.2 1216.3 5p Fmoc-L-Asp-OtBu 2 1304.0 1304.3 
5  
no. modification reagent method mass calculated for [M+H]+ [g/mol] mass found [M+H]+ [g/mol] 6a Glutaric anhydride 1 1081.5 1064.4[b] 6b 3-Methyl glutaric anhydride 1 1095.1 1078.3[b] 6c 3,3-Dimethyl glutaric anhydride 1 1109.1 1109.3 6d HMG-CoA 3 1111.0 1111.3 6e Diglycolic anhydride 1 1083.1 1106[a] 6f Thiodiglycolic anhydride 1 1099.1 1082.3[b] 6g 4-Methylmorpholine-2,6-dione 1 1096.1 1096.5 6h N-Phthaloyl-D,L-glutamic anhydride 1 1226.2 1248.3[a] 7 Adipic acid monoethyl ester 2 1096.1 1078.5[b] 8 Pimelic acid monoethyl ester 2 1109.2 1131.3[a] 9 Suberic acid monomethyl ester 2 1123.2 1106.5[b] [a] [M+Na]+ [b] [M-NH2] + Expression and purification of human Sirt5 The expression and purification of hSirt5 was done as described by Gertz et al. [17]. Expression and purification of zebrafish Sirt5 Expression of the zebrafish Sirt5 isoform (zSirt5) used for crystallization was done as described for human Sirt5, except that E. coli BL21-CodonPlus™ (DE3) cells (Stratagene, La Jolla, CA, USA) were used for expression. Purification of His6-zSirt5(30-298) was done via cell-disruption of harvested cells in lysis buffer (50 mM Tris/HCl pH 8.5, 200 mM NaCl) followed by affinity-chromatography using Co2+-Talon beads (Clontech, Mountain View, CA, USA). Resin was washed with 20 column volumes high-salt (50 mM Tris/HCl pH 8.5, 500 mM NaCl) and low imidazole buffer (50 mM Tris/HCl pH 8.5, 200 mM NaCl, 5 mM imidazole), respectively, and target protein was subsequently eluted using high imidazole concentration (50 mM Tris/HCl pH 8.5, 200 mM NaCl, 250 mM imidazole). Pooled eluate fractions were dialyzed against 30 mM HEPES pH 6.5, 50 mM NaCl and treated with TEV-protease at 4 °C in a 1:20 ration in an overnight step, followed by reverse affinity-chromatography on Co2+-Talon to remove the hexa-Histidine tag. Flowthrough was collected, subjected to gelfiltration on a Sephacryl S-200 HR 50/100 column in 20 mM Tris/HCl pH 8.5, 150 mM NaCl and zSirt5-fractions were pooled, concentrated and stored at -80 °C. 
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HPLC based activity assay For determination of kinetic constants for the Sirt5 mediated reactions solutions containing 20 mM TRIS/HCl pH 7.8, 150 mM NaCl, 5 mM MgCl2, 0.5 mM NAD+ and varying substrate concentrations (2-200µM) were used. Deacylation was started by adding human Sirt5 to reach a final concentration of 0.5 µM. Enzyme-catalyzed reaction was stopped using TFA (1% final concentration) after 1 to 180 min of incubation at 37°C depending on substrate reactivity. Reaction mixtures containing compound 5e, 5f and 5g were stopped by pH shift through adding of 5µl sodium citrate buffer (100 mM, pH 4.0) caused by sensibility acidic hydrolysis. A control reaction (100 µM compound 4a, 0.5 µM NAD+, 0.5 µM Sirt5 in reaction buffer and 5µl sodium citrate buffer pH 4.0, 37 °C, overnight) verified that the reaction was completely stopped. The cleavage rate of the different CPS1 peptide derivatives was analyzed using analytical reversed phase HPLC. The product and substrate peaks were quantified using absorbance at 260 nm (absorption of N-terminal benzoyl moiety). The peak areas were integrated and converted to initial velocity rates calculated from the ratio of product area to total peak area. Linear regression of conversions plotted against time yielded reaction rates in µM/min (relative conversion below 20 % of substrate). Non-linear regression according to Michaelis-Menten of the reaction rates at different substrate concentrations yielded KM- and kcat-values using the program SigmaPlot (Systat Software, San Jose, USA). All measurements were done in duplicates. The analysis of kinetic constants for NAD+ was performed equally. The reaction mixtures contained 100 µM of 5a or 5b, 0.5 µM human Sirt5 and varying concentrations of NAD+ (10 - 2000 µM). The resulting velocity-substrate-plots were fitted with Michaelis-Menten-equation.    Figure S2. HPLC traces (260 nm) of 5a after different incubation times with Sirt5. Reaction conditions: 100 µM compound 5a, 500 µM NAD+ and 0.5 µM Sirt5. Detection wavelength: 260 nm. Incubation time 20 min (blue), 30 min (red), 40 min (green), 50 min (pink) and 60 min (olive green). 
7  
 Figure S3. Progress curves for 5a. Reaction conditions: 500 µM NAD+,0.5 µM Sirt5 and different concentrations of 5a (2µM – white square, 5µM – black square, 25µM – white triangle, 50µM black triangle, 75µM white spot, 100µM black spot). Reaction was monitored by HPLC.   2 3 4 5a 
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5b 5c 5d 5e 5f 5g 5l 6a 
9  
6b 6c 6d 6e 6f 6g 7 8 
10  
9  Figure S4. Kinetic characteristics for Sirt5 substrates. The reactions were performed with 0.5 µM Sirt5, 500 µM NAD+ and varying concentrations of substrates (2-150 µM). All reactions were done in duplicates. Lines represent the Michaelis-Menten-plot.  a b 
 c compound 5a 5b  KM [µM] 40.7± 5.2 25.4 ± 5.5  kcat[s-1] 6.3x10-2 ± 2x10-3 1.5x10-3 ± 7x10-5  kcat/KM [µM-1s-1] 1551 58 Figure S5. Kinetic characteristics for NAD+ with 5a (a) and 5b (b). The reactions were performed with 0.5 µM Sirt5, 100 µM compound 5a or 5b and varying concentrations of NAD+ (10-2000 µM). All reactions were done in duplicates and monitored by HPLC. The curves represent Michaelis-Menten plots resulting in kinetic constants given in (c). Determination of the inhibitor constants Ki Ki values of the inhibitors were determined recording kcat and KM values for 5a in the presence of varying inhibitor concentrations (50-250 µM). The program SigmaPlot was used for generation of the respective plots. The linear regression of the apparent KM-values against the corresponding inhibitor concentration yielded the inhibitor constant Ki.    
11  
 5h 5i 5j 5k 5m 5p 6h  
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Figure S6. Kinetic characteristics for Sirt5 inhibitors. The reactions were performed with 0.5 µM Sirt5, 500 µM NAD+ and varying concentrations of substrates/inhibitors (2-150 µM). For determination of the Ki values different concentrations of inhibitor (10µM – hexagon, 25µM - triangle down, 50 µM - triangle up, 100 µM - diamond, 250 µM- square) were used. All reactions were done in duplicates. Lines represent the Michaelis-Menten-plots.  5h  5i  5j  
13  
5k  5m  5p  6h  
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Figure S7. Secondary plots for Sirt5 inhibitors. The apparent KM and Vmax values from v/S characteristics were plotted against the corresponding inhibitor concentration. The negative Ki value can be determined as intersection with the X-axis from the KMapp/I plot respectively from the vmaxapp-1/I plot.  Table S2. Inhibition constants for different Sirt5 inhibitors. compound Ki [µM] 5h 100.0 ± 0.45 5i 38.1 ± 0.63 5j 17.2 ± 1.31 5k 4.3 ± 0.32 5m 10.6 ± 0.66 5p 46.0 ± 0.22 6h 24.9 ± 0.54 Determination of specificity of sirtuin inhibition by 5k The inhibitor specificity was tested against Sirt1-3 by determination of cleavage rates in the presence of 5k. The reaction mixture contained 20 mM TRIS/HCl pH 7.8, 150 mM NaCl, 5 mM MgCl2, 0.5 mM NAD+, 10 µM of substrate and 50µM of inhibitor 5k. Compound 2 was used as substrate for Sirt1 and 3, compound 5a for Sirt5, the peptide derivative H-PSDK(Ac)TIGGWW-NH2 derived from α-tubulin for Sirt2. Deacylation was started by adding enzyme to reach a final concentration of 0.5 µM. The reaction was stopped using TFA (1% final concentration) after 2 to 10 min of incubation at 37°C depending on substrate reactivity. The inhibition was analyzed by analytical HPLC as described above.   Table S3: Inhibition of different Sirtuins by compound 5k. sirtuin inhibition at 50 µM [%] Sirt1 < 1 Sirt2 4.23 ± 2.16 Sirt3 < 1 Sirt5 70.43 ± 11.75 Isothermal Titration Calorimetry (ITC) To minimize unspecific heat effects, human Sirt5 had to be dialyzed again against buffer A. The CPS1 peptide derivatives were then diluted with this buffer. All ITC measurements were performed at 10°C using a MicroCalVP-ITC isothermal titration calorimeter (MicroCal Inc., Northampton, USA). The sample cell (1.4 ml) was filled with a 5 µM solution of human Sirt5 and a 200-500 µM solution of peptide was loaded into the injection syringe (280 µl). Each titration experiment was started with a 300 s delay followed by 28 or 56 injections of 10 or 5 µl of the peptide solution, respectively, in intervals of 250 seconds. The sample cell was stirred at 300 rpm. Control experiments where peptide was injected in the absence of protein allowed the subtraction of heats of dilution. The data was analyzed using the Origin 5.0 software (Microcal Inc., 
15  
Northampton, USA). The corrected data were analyzed by nonlinear regression with a single-site binding model. The area under each peak of the resulting heat profile was integrated and plotted against the molar ratio of Sirt5 to titrant.   
5a 5b 
5c 5h 
16  
5i 6a  Figure S8. Isothermal titration calorimetry of different Sirt5 substrates and inhibitors. The compounds (20-100µM end concentration) were titrated into 5 µM Sirt5 diluted in dialysis buffer containing 20 mM TRIS/HCl pH 7.8, 150 mM NaCl, 5 mM MgCl2. Titration was carried out in 56 steps à 5 µl at 10°C with in an incubation time of 250 s (upper graphs). The area under each peak of the resulting heat profile was integrated and plotted against the molar ratio of Sirt5 to titrant (lower graphs). The data were analyzed by nonlinear regression with a single-site binding model.  Table S4. KD-values. compound KD [µM] 5a 0.71 ± 0.05 5b 0.83 ± 0.17 5c 0.29 ± 0.04 5h 8.20 ± 0.55 5i 5.78 ± 2.36 6a 0.70 ± 0.11 Fluorescence titration Tryptophan fluorescence titration experiments were carried out on a Hitachi F-4500 spectrometer (Tokyo, Japan) using an excitation wavelength of 280 nm. Emission was measured at 330 nm at 25°C. Peptide solution was added successively (2-10 µM end concentration) to 5 µM human Sirt5 in buffer containing 20 mM TRIS/HCl pH 7.8, 150 mM NaCl. Fluorescence intensities were recorded subsequent to reaching equilibrium for each titration step. Dissociation constants were determined using a single-site binding model. 
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Modeling The molecular structures of all peptides described in the present work were generated using the MOE 2012.10 program (Chemical Computing Group, Montreal, Canada).[18] The initial conformations resulted from energy minimization using the Amber99SB force field as implemented in MOE.[19] Two crystal structures of human Sirt5, one in complex with a succinylated peptide and NAD+, and another one with a thioacetylated peptide and CHES were retrieved from the Protein Databank (PDB code 3RIY and 3RIG). For the subsequent docking studies, all water and ligand molecules were removed and both structures were protonated and minimized using the Amber99SB force field. All dockings studies were carried out using the GOLD5.1 docking program (Cambridge Crystallographic Data Centre, Cambridge, UK) in exhaustive sampling mode.[20] The binding cavity was defined by the co-crystallized succinylated peptide. To guide the search process, the position of the co-crystallized lysine of 3RIY was used as a substructure constraint. Using Goldscore as fitness function, the co-crystallized peptides were correctly docked into the Sirt5 catalytic site.  All tested peptides were docked in both crystal structures and 20 docking poses were stored. The resulting poses were manually analyzed and docking solutions with the highest overlap to the crystal structure position of the co-crystallized peptide were selected for subsequent refinement runs. For each binding hypothesis, an energy minimization of the peptide and proximal pocket residues was carried out using the Amber99SB force field. This procedure resulted in a final docking model for each of the synthesized peptides.   Figure S9. Model of hSirt5 in complex with 3 (orange). The distances (given in Å) between the carboxyl group of 3 and proximal protein atoms are drawn as black arrows and hydrogen bonds are indicated as dashed lines. The carboxyl moiety is too far away to form hydrogen bonds to Tyr102 and Arg105.   
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Figure S10. Model of hSirt5 in complex with 5c (cyan) superimposed with the NAD+ conformation observed in the X-ray structures of hSirt5 (NAD+ from 3RIY). The distances (given in Å) between the methyl group of 5c and NAD+ in the productive conformation are drawn as black arrows and hydrogen bonds are indicated as dashed lines. The methyl group of 5c might hinder the nucleophilic attack on the C1 atom of NAD.  
 Figure S11. Sequence alignment of zSirt5 and hSirt5. Both proteins are highly similar (blue) with a sequence identity of 75%. Most of the substitutions are located in the N-terminal region (red) which comprises a ~35 residue mitochondrial localization sequence removed during transport into the organelle.  Crystallization and structure solution The zSirt5 protein (10 mg/mL; 20 mM TRIS/HCl pH 8.5, 150 mM NaCl) was co-crystallized with 1 mM CPS1-peptides at 20 °C. Protein and peptide (peptide 50 mM stocks in DMSO, 10% final DMSO concentration for crystallization) were mixed and pre-incubated for 30 min on ice before setting up hanging-drop vapor-diffusion crystallization experiments. 2 µL crystallization drops were constituted of a 2:1, 1:1 or 1:2 ratio of protein:reservoir solutions (reservoir: 18-24% PEG3350, 0.1 M HEPES pH 7.2 to 7.8; depending on the acylated peptide) and equilibrated against 250 µL reservoir. Crystals grew up to 300 x 300 x 300 µM in size in about two weeks (again depending on acylated peptide). They were transferred to a cryo-solution drop composed of the respective reservoir and peptide, supplemented with 25% glycerol, prior to shock-freezing using liquid nitrogen. Diffraction data collection was performed at BESSY II beamline MX14.1[21] (operated by the Helmholtz-Zentrum Berlin, Germany) with an MX-225 CCD (Rayonix, Evanston, IL, USA) or a Pilatus 6M detector (Dectris, Baden, Switzerland). Indexing, scaling and merging of diffraction data were done using XDS.[22] Structures were solved by molecular replacement using MolRep[23a] using human Sirt5 (PDB entry NYR) as a search model for the first zSirt5 structure, which was then used as search model for subsequent complex structures.[23b] Refinement was performed with Refmac5.[24] For refinement of structures with resolution around 3 Å or less (all complexes except for those with the 5h or 5j, respectively, as a ligand), local NCS restraints and the Prosmart function using protein chain A from PDB-ID 3RIY as a model was used during refinement.[25] Furthermore, TLS-refinement was used during the last refinement steps.[26] Manual modeling and structure validation were done with Coot.[27] Geometry parameter files for the peptides’ acylated lysine-residues were generated using the PRODRG server[28] and structure figures created with PyMol (www.pymol.org).  
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 Table S5. Data collection and refinement statistics.  zSirt5 + 5h zSirt5 + 5a zSirt5 + 6a zSirt5 + 7 zSirt5 + 5i Data processing      Space group P 65 2 2 P 65 2 2 P 65 2 2 P 65 2 2 P 65 2 2 Unit cell (a / b / c) [Å] 88.9/88.9/305.3 87.4/87.4/314.9 87.2/87./314.0 87.3/87.3/314.6 87.2/87.2/313.9 Resolution (outermostshell) 100.00 - 2.40 (2.45 - 2.40) 100.00 - 3.00 (3.10 - 3.00) 100.00 - 2.90 (3.00 - 2.90) 50.00 - 3.30 (3.40 - 3.30) 20.00 - 2.80 (2.90 - 2.80) Unique reflections (o. s.) 29005 (1681) 15155 (1362) 16586 (1549) 11477 (948) 18292 (1784) Observations (o. s.) 207062 (12353) 123469 (11516) 1164771 (11295) 114909 (9814) 191409 (19772) Completeness (o. s.) 100.0% (100.0%) 99.9% (99.9%) 99.8% (100.0%) 99.9% (100.0%) 99.6% (100.0%) Mutliplicity (o. s.) 7.1 (7.3) 8.1 (8.5) 7.0 (7.3) 10.0 (10.4) 10.5 (11.1) R-meas (o. s.) [a] 13.4% (130.5%) 19.9% (155.9%) 17.5% (133.6%) 34.7% (132.1%) 26.1% (218.0%) I/sigma (o. s.) 14.4 (1.9) 10.6 (1.5) 11.3 (1.7) 9.1 (2.4) 10.6 (1.3) Refinement      amino acids (aa range) 33 - 298 33 - 298 35 - 298 33 - 298 33 - 298 protein atoms 4026 4094 4054 4057 4103 peptide atoms 162[d] 75 76 77 86 zincs 2 2 2 2 2 waters 134 17 57 30 52 solvent atoms 20 23 17 24 32 Resolution (outermostshell) 47.85-2.40 (2.46-2.40) 75.73-3.00 (3.08-3.00) 75.53-2.90 (2.98-2.90) 48.41-3.30 (3.39-3.30) 19.87-2.80 (2.87-2.80) Rcryst[b]/ Rfree[c] 19.7 / 22.7 21.5 / 26.7 21.8 / 26.1 20.9 / 25.4 20.8 / 26.1 B factor protein [Å2] 44.271 71.169 61.104 68.418 70.707 B factor peptide [Å2] 42.196 65.457 55.932 64.548 72.053 B factor Zn [Å2] 38.195 74.475 63.590 67.170 79.355 B factor water[Å2] 37.113 39.804 57.029 23.935 43.432 B factor solvent atoms [Å2] 59.381 69.627 37.739 63.260 68.051 RMSD bond lengths / target [Å] 0.016 / 0.019 0.011 / 0.019 0.012 / 0.019 0.011 / 0.019 0.012 / 0.019 RMSD angles / target [°] 1.922 / 1.968 1.673 / 1.965 1.794 / 1.960 1.687 / 1.963 1.690 / 1.968 RMSD planes / target [Å] 0.010 / 0.021 0.008 / 0.021 0.009 / 0.021 0.009 / 0.021 0.008 / 0.021   zSirt5 + 5l zSirt5 + 5j‘[e] zSirt5 + 5b zSirt5 + 5c  Data processing      Space group P 65 2 2 P 65 2 2 P 65 2 2 P 65 2 2  Unit cell (a / b / c) [Å] 87.5/87.5/313.8 87.4/87.4/315.1 87.5/87.5/314.4 87.5/87.5/314.8  Resolution (outermost shell) 50.00 - 3.10 (3.20 - 3.10) 50.00 - 2.90 (3.00 - 2.90) 50.00 - 3.00 (3.10 - 3.00) 50.00 - 2.90 (3.00 - 2.90)  Unique reflections (o. s.) 13762 (1203) 16737 (1569) 15155 (1378) 16749 (1569)  Observations (o. s.) 158350 (12752) 135088 (9991) 78545 (7388) 211283 (20615)  Completeness (o. s.) 99.9% (100.0%) 99.9% (99.9%) 99.8% (99.9%) 99.9% (100.0%)  Mutliplicity (o. s.) 11.5 (10.6) 8.1 (6.4) 5.2 (5.4) 12.6 (13.1)  R-meas (o. s.) [a] 22.3% (137.2%) 17.9% (110.2%) 14.9% (98.8%) 17.0% (161.6%)  I/sigma (o. s.) 14.3 (2.1) 13.3 (1.9) 12.5 (2.1) 15.8 (2.0)  Refinement      amino acids (aa range) 33 - 298 33 - 298 33 - 298 33 - 298  protein atoms 4050 4083 4111 4111  
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peptide atoms 75 79 152[d] 77  zincs 2 2 2 2  waters 34 58 41 54  solvent atoms 32 28 36 24  Resolution (outermost shell) 48.38 – 3.10 (3.18 – 3.10) 48.44-2.90 (2.98-2.90) 48.39 – 3.00 (3.08 – 3.00) 48.42 – 2.90 (2.98 – 2.90)  Rcryst[b] / Rfree[c] 19.4 / 26.2 20.3 / 25.4 19.9 / 27.0 19.2 / 25.2  B factor protein [Å2] 68.693 53.300 65.068 73.805  B factor  peptide [Å2] 66.963 47.064 57.426 67.833  B factor Zn [Å2] 72.240 57.420 71.470 85.195  B factor water [Å2] 33.970 26.874 33.835 46.885  B factor solvent atoms [Å2] 62.783 49.472 62.289 73.300  RMSD bond lengths / target [Å] 0.013 / 0.019 0.011 / 0.019 0.014 / 0.019 0.013 / 0.019  RMSD angles / target [°] 1.704 / 1.963 1.558 / 1.962 1.730 / 1.967 1.709 / 1.965  RMSD planes / target [Å] 0.008 / 0.021 0.007 / 0.021 0.008 / 0.021 0.008 / 0.021  [a] with [b]. |Fobs| is the   observed and |Fcalc| the calculated structure factor amplitude. [c] Rfree was calculated from 5% of measured reflections omitted from refinement.[d] Peptide was modeled in two possible conformations. [e] Only the C2 substituted derivative of 5j was observed in the crystals.   a) b) c) Figure S12. a) Crystal structure of zSirt5 in complex with 5a. 2Fo-Fc electron density for the acylated lysine of the peptide ligand (blue) is contoured at 1σ. Polar interactions to the backbone of Val217 and the side-chains of Tyr98 and Arg101 are indicated by dotted lines; b) Crystal structure of zSirt5 in complex with 6a. 2Fo-Fc electron density for the acylated lysine of the peptide ligand (yellow) is contoured at 1σ. Polar interactions to the backbone of Val217 and the side-chains of Tyr98 and Arg101 are indicated by dotted lines; c) Crystal structure of zSirt5 in complex with 7. 2Fo-Fc electron density for the acylated lysine of the peptide ligand (magenta) is contoured at 1σ. Polar interactions to the backbone of Val217 and the side-chains of Tyr98 and Arg101 are indicated by dotted lines.  
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a) b) c) Figure S13. a) Crystal structure of zSirt5 in complex with 5b. 2Fo-Fc electron density for the acylated lysine of the peptide ligand (brown) is contoured at 1σ. Polar interactions to the backbone of Val217 and the side-chains of Tyr98 and Arg101 are indicated by dotted lines; b) Crystal structure of zSirt5 in complex with 5c. 2Fo-Fc electron density for the acylated lysine of the peptide ligand (green) is contoured at 1σ. Polar interactions to the backbone of Val217 and the side-chains of Tyr98 and Arg101 are indicated by dotted lines; c) Crystal structure of zSirt5 in complex with 5l. 2Fo-Fc electron density for the acylated lysine of the peptide ligand (dark brown) is contoured at 1σ. Polar interactions to the backbone of Val217 and the side-chains of Tyr98 and Arg101 are indicated by dotted lines.  a) b) c) Figure S14. a) Crystal structure of zSirt5 in complex with 5h. 2Fo-Fc electron density for the acylated lysine of the peptide ligand (green) is contoured at 1σ. Polar interactions to the backbone of Val217 and the side-chains of Tyr98 and Arg101 are indicated by dotted lines; b) Crystal structure of zSirt5 in complex with 5j’. 2Fo-Fc electron density for the acylated lysine of the peptide ligand (skin-coloured) is contoured at 1σ. Polar interactions to the backbone of Val217 and the side-chains of Tyr98 and Arg101 are indicated by dotted lines; c) Crystal structure of zSirt5 in complex with 5i. 2Fo-Fc electron density for the acylated lysine of the peptide ligand (dark brown) is contoured at 1σ. Polar interactions to the backbone of Val217 and the side-chain of Tyr98 are indicated by dotted lines.  
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         Figure S17. Docking of 5f (light green) and 5g (dark green) into hSirt5/5a complex. Only in case of 5f hydrogen bonds with Tyr102 and Arg105 are observed. Hydrogen bonds between ligand and protein are indicated as dashed lines.            Figure S18. Active-site supperposition of crystal structures of zSirt5 complexes with inhibitory 5j (skin coloured) and 5h (green). The protein is shown only once for clarity (zSirt5/5h complex; grey), since all protein residues superpose well.  References [17] M. Gertz, G. T. Nguyen, F. Fischer, B. Suenkel, C. Schlicker, B. Franzel, J. Tomaschewski, F. Aladini, C. Becker, D. Wolters, C. Steegborn, PLoS One 2012, 7, e49761. [18] C. C. G. Inc., Montreal, QC, Canada, 2012. [19] D. A. D. Case, T. A.; Cheatham, I. T. E.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Crowley, M.; Walker, R. C.; Zhang, W.; Merz, K. M.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; KolossvaÌ ry, I.; Wong, K. F.; Paesani, F.; Vanicek, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Mathews, D. H.; Seetin, M. G.; Sagui, C.; Babin, V.; Kollman, P. A., 2010. [20] G. Jones, P. Willett, R. C. Glen, A. R. Leach, R. Taylor, J Mol Biol 1997, 267, 727-748. [21] U. Mueller, N. Darowski, M. R. Fuchs, R. Förster, M. Hellmig, M. S. Paithankar, S. Pühringer, M. Steffien, G. Zocher, M. S. Weiss, J Synchrotron Radiat 2012, May 1, 442-449. [22] W. Kabsch, Acta Crystallogr D Biol Crystallogr 2010, 66, 125-132. [23] a) A. A. Vagin, M. N. Isupov, Acta Crystallogr D Biol Crystallogr 2001, 57, 1451-1456; b) A. Schuetz, J. Min, T. Antoshenko, C. L. Wang, A. Allali-Hassani, A. Dong, P. Loppnau, M. Vedadi, A. Bochkarev, R. Sternglanz, A. N. Plotnikov, Structure 2007, 15, 377-389. [24] G. N. Murshudov, A. A. Vagin, E. J. Dodson, Acta Crystallogr D Biol Crystallogr 1997, 53, 240-255. 
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ABSTRACT: Sirtuins are protein deacylases that regulate metabolism
and stress responses and are implicated in aging-related diseases.
Modulators of the human sirtuins Sirt1−7 are sought as chemical tools
and potential therapeutics, e.g., for cancer. Selective and potent
inhibitors are available for Sirt2, but selective inhibitors for Sirt5 with
Ki values in the low nanomolar range are lacking. We synthesized and
screened 3-arylthiosuccinylated and 3-benzylthiosuccinylated peptide
derivatives yielding Sirt5 inhibitors with low-nanomolar Ki values. A
biotinylated derivative with this scaﬀold represents an aﬃnity probe
for human Sirt5 that is able to selectively extract this enzyme out of
complex biological samples like cell lysates. Crystal structures of Sirt5/
inhibitor complexes reveal that the compounds bind in an unexpected
manner to the active site of Sirt5.
■ INTRODUCTION
Sirtuins (Sirt) represent an evolutionarily conserved family of
NAD+-dependent lysine deacylases. Seven sirtuin isoforms have
been identiﬁed in mammals, Sirt1 to Sirt7, which diﬀer in their
biochemical activities and subcellular localization. Sirt1 and
Sirt2 are localized in the nucleus and cytoplasm, Sirt3−5 are
mitochondrial enzymes, and Sirt6 and Sirt7 are localized
exclusively in the nucleus. Sirtuins catalyze diﬀerent lysine
deacylation reactions, including removal of fatty acid
modiﬁcations (Sirt1−6),1 decrotonylation (Sirt1−3),2 and
removal of 3-hydroxy-3-methylglutaryl and lipoyl residues
(Sirt4),3 but only Sirt5 possesses a strong desuccinylase,
demalonylase, and deglutarylase activity in vitro and in vivo.4
The removal of negatively charged acyl moieties by Sirt5 results
in up to 1000-fold higher catalytic activities compared to the
respective deacetylation reaction.4c
The role of Sirt5 in metabolic pathways like glycolysis,
tricarboxylic acid cycle, fatty acid oxidation, ammonia
detoxiﬁcation, reactive oxygen defense, or apoptosis makes
this enzyme an interesting target for drug development.4b,5
Deregulation or noncontrolled activation of Sirt5 is involved in
several human diseases, including cancer, Alzheimer’s disease,
and Parkinson’s disease.6 Inhibition of Sirt5 resulted in
suppressed tumor cell proliferation caused by increased
succinylation of lysine residue 498 in pyruvate kinase M2.6a
Recently, it was shown that Sirt5-mediated desuccinylase
activity is involved in pro-inﬂammatory response of macro-
phages by changing pyruvate kinase M2 enzymatic activity.7
Moreover, Sirt5 is overexpressed in human non-small-cell lung
cancer, and this overexpression is correlated with poor
prognosis.8 Eﬀectors of Sirt5 activity are therefore needed as
potential therapeutics and as chemical probes to investigate
Sirt5 function in more detail. Here we present the development
of selective and potent Sirt5 inhibitors with Ki values in the low
nanomolar range.
■ RESULTS AND DISCUSSION
The 3-phenylsuccinyl moiety on a lysine side chain represents a
speciﬁc Sirt5 inhibitor which acts by blocking the NAD+
binding pocket.4c Compound I (Figure 1) is one of the most
eﬀective and selective Sirt5 inhibitors with a Ki value of 4.3 μM.
Other reported Sirt5 inhibitors are shown in Figure 1, but
selectivity has not been determined for all of them. Inspection
of the crystal structure of zebraﬁsh Sirt5 (zSirt5) in complex
with the structurally similar 3-phenylsuccinyl-carbamoyl
phosphate synthetase (CPS1)-derived peptide (47; PDB ID
4UTV) revealed that the phenyl ring on the succinyl residue
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points to the nicotinamide binding pocket (C-pocket) but is
not able to reach the C-pocket.4c Therefore, we started to
analyze a 3-benzylsuccinyl derivative of CPS1 peptide, resulting
in 1 (Table 1) with a Ki value of 263 ± 48 nM (Table S1).
Reaction of substituted succinic anhydrides with the lysine side
chain represents a convenient route to 3-alkyl(aryl)succinyl
peptide derivatives.4c However, because of limited access to
such reagents and unsatisfactory regioselectivity of the reaction
(often 2-substituted regioisomers are formed by alternative
opening of the anhydride), we investigated another way to
substitute succinyl peptides. Maleamic acid derivatives react
with thiols, aﬀording 2-(alkylthio)succinamic acid as the sole
product.15 Because a large number of thiols are available
commercially and respective Michael addition can be
performed directly on the solid support, this method was
chosen for the preparation of a library of 3-substituted succinyl-
CPS1 peptides (Scheme 1). Treatment of resin-bound
maleylated peptides with a thiol in the presence of tertiary
base aﬀorded expected diastereomeric mixtures of 3-substituted
target peptides along with minor amounts of 2-substituted
regioisomers. Treatment with triﬂuoroacetic acid at room
temperature yielded four diastereomers/regioisomers. Surpris-
ingly, reaction products were easily separated with HPLC,
enabling convenient and simultaneous route to both (S)-3- and
(R)-3-(alkyl(aryl)thio)succinyl-CPS1 peptide derivatives (2-
substituted derivatives were formed in minor amounts and
were not isolated). For convenience, we denote inseparable
equal mixtures of diastereomers as a number N, and fast- and
slow-eluting diastereomers as N.1 and N.2, respectively.
Using this reaction, we systematically optimized the acyl
residue of the CPS1-derived peptide inhibitor (Table 1),
resulting in a Ki value of 7 nM for 35.2 (Table S1). Compound
2 showed a Ki value similar to that of 1. Nevertheless, we were
able to demonstrate that the slower-migrating diastereomer,
due to the substitution at position 3 of the succinyl residue 2.2,
is a more eﬃcient inhibitor for Sirt5, with a Ki value of 135 nM.
Insertion of one, two, or three methylene groups between the
sulfur and the phenyl ring, resulting in 15, 27, and 32,
respectively, did not improve the inhibition constants. Addi-
tionally, replacement of the phenyl ring by heterocycles (see
28−31) yielded inhibitors with Ki values between 3.5 and 11
μM. To analyze Sirt5/inhibitor interaction details, we solved
crystal structures of 15, respectively 2, in complex with zSirt5
(Figure 2 and Table S2) and compared them with the
previously solved structure of zSirt5/474c (PDB ID 4UTV).
Surprisingly, the substituents at position 3 of the succinyl group
occupy diﬀerent binding pockets (Figure 2). The benzyl group
of 15 is oriented similar to the phenyl ring of I, toward the C-
pocket, and reaches deeper into this pocket yet still cannot ﬁll it
completely. In contrast, the phenyl group of 2 is positioned
toward a hydrophobic patch formed by Ala78 and Phe219 and
opened through rearrangements of the cofactor binding loop.
Apparently, both sites can provide interactions for tight binding
and potent inhibition. To explore the binding pocket of the
phenyl ring of compound 2 in more detail, we generated all
Figure 1. Reported Sirt5 inhibitors: I,4c II,9 III,10 IV,11 V,12 VI,13 VII.14
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possible monochloro- and dichloro-substituted compounds,
resulting in 3−5 and 6−11, respectively. Substitution in the o-
position seems not to be beneﬁcial (Table 1) because it could
lead to steric clash with the protein (Figure 2), but replacement
of hydrogen by chlorine in the m- or p-position yielded
inhibitors with Ki values between 50 and 60 nM for the better
binding diastereomer. This improvement in binding is maybe
caused by beneﬁcial interactions with Sirt5 residues Phe66 and
Arg67 (Figure 2). Chloro substitution in both the p- and m-
positions led to 8, with a Ki value of 23 nM for 8.2. Flexible
docking of 8.2 into the crystal structure of zSirt5 cocrystallized
with 2 showed that the dichlorophenyl ring ﬁts perfectly into
the hydrophobic pocket formed between Arg67 and Phe219
(Figure S25). Combined m- and p-substitution using methyl
(12) and methoxy (13) moieties resulted in similar Sirt5
aﬃnities. Inspired by this substitution pattern, we created 3-(2-
naphthylthio)succinyl derivative 33.2, which represents the
most eﬃcient Sirt5 inhibitor with the 3-(arylthio)succinyl
scaﬀold (IC50 value = 40 nM). Moreover, 33.2 is selective for
Sirt5, evidenced by the fact that no eﬀect on catalysis mediated
by Sirt1, Sirt2, Sirt3, or Sirt6 could be detected with
concentration of 33.2 up to 50 μM (Figure S22). When the
Table 1. Chemical Structures of Succinyl-CPS1-Derived Peptide Inhibitors (Bz-GVLK(X)EYGV-NH2)
*Hereinafter an equal mixture of diastereomers is denoted as N, with N.1 the fast- and N.2 the slow-eluting diastereomer. **Cannot be determined
more precisely because of solubility problems.
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aryl ring in 2 was replaced by a cyclohexyl ring (14), the
resulting diastereomers showed about 500-fold reduced IC50
values.
The IC50 value of the more potent diastereomer of 3-
(benzylthio)succinyl derivative 15.2 is comparable to the IC50
value of 3-(phenylthio)succinyl derivative 2.2. This fact
prompted us to analyze substituted benzyl derivatives 16−26.
With the exception of o-chloro-substituted benzylthio derivative
16.1, all of the modiﬁcations resulted in higher IC50 values. In
contrast to the phenylthio series (compounds 2−13), the
diastereomer (regarding position 3 of the succinyl residue) with
the longer retention time is not in every case the more potent
compound. The IC50 values are very similar for both isomers in
the case of 21, 23, and 25. On the other hand, there is a >8-fold
diﬀerence in the IC50 values for 2,4,6-trimethyl-substituted
derivatives 25.1 and 25.2. Generation of the naphthyl-
methylthio derivative 35.2, homologous to the naphthyl
derivative 34.2, resulted in an improvement of inhibition,
with an IC50 value of 15.4 ± 9.5 nM, resulting in a calculated Ki
value of 7 nM. Double substitution at position 3 of the succinyl
residue can increase Sirt5’s inhibitory potency. The Ki value of
compound I (Figure 1) is about 20-fold better than the Ki value
of the respective 3-phenylsuccinyl-CPS1 peptide derivative.4c
Therefore, we decided to analyze a similar double substitution
and generated 36 by acylation of resin-bound CPS1 peptide
with 2-methyl-2-(2-naphthylthio)succinic anhydride according
to methods described in ref 4c. As mentioned above, that
method yielded four diﬀerent regio-/diastereomers (two
diastereomers with substitution at C2 of succinyl residue and
two diastereomers with substitution at C3 of succinyl residue).
We could not separate all four isomers by RP-HPLC but were
able to isolate two isomers (36.1 and 36.2) together with a
mixture of the other two isomers (36.3). We determined the
IC50 values for the three HPLC fractions of 36 and determined
IC50 values between 60 and 90 nM. Obviously, aﬃnity of 3-(2-
naphthylthio)succinyl derivatives could not be improved by
additional methyl substitutions at the same carbon atom. To
explore the importance of the succinyl carboxyl group
interacting with the arginine and tyrosine residues in the active
site of Sirt5 (Figure 2) for eﬃcient inhibition, we replaced this
carboxyl function by either a methyl group or a hydrogen,
resulting in 3-(2-naphthylthio)butyryl derivative 37 and 3-(2-
naphthylthio)propionyl derivative 38 (Table 2). Surprisingly,
both compounds are not inhibitors but rather substrates for
human Sirt5, as demonstrated by an HPLC-based activity
assay.4c
In order to deﬁne the absolute conﬁguration of the best
inhibitor, we decided to synthesize 33 in a stereocontrolled
manner. The key intermediate in this synthesis was optically
pure 4-methoxybenzyl-protected (S)-2-(2-naphthylthio)-
succinate (e), which was prepared from commercially available
(S)-malic acid (a) (Scheme 2). First, O-triﬂuoroacetyl (S)-malic
acid anhydride (b) was reacted with 4-methoxybenzyl alcohol,
aﬀording the respective monoester (c).16 Intramolecular
cyclization of the β-hydroxyl ester using Mitsunobu conditions
aﬀorded (R)-β-lactone (d), which was not isolated but treated
in situ with 2-naphthalenethiol, yielding (S)-2-(2-naphthylthio)-
succinic acid 1-(4-methoxybenzyl) ester (e). Coupling of the
acid to the resin-bound CPS1-peptide using standard DIC/
HOSu activation and cleavage of the peptide from the resin
Scheme 1. Chemical Reaction Used for the Preparation of
Peptidyl Derivatives Carrying 3-(Aryl- or Alkylthio)succinyl
Residues at the Lysine Side Chain
Figure 2. Comparison of the binding modes of 2 and 15 to a 3-
phenylsuccinyl-Lys inhibitor (47) in the Sirt5 active site. The zSirt5
complex with 2 (ligand shown in green) was overlaid with the
complexes with 15 (cyan) and with 47 (PDB ID 4UTV; yellow).
NAD+ (light blue) was modeled from a Sirt5/peptide/NAD+ complex
(PDB ID 4G1C) to indicate the C-pocket. The protein part is only
shown for zSirt5/2 in brackets (gray cartoon); dotted lines indicate
polar interactions with the acyl group, and for 2, 5, and 47 respectively,
one enantiomer was omitted for clarity.
Table 2. Chemical Structures of CPS1-Derived Peptide Inhibitors and Substrates (Bz-GVLK(X)EYGV-NH2)
**Cannot be determined more precisely because of solubility problems.
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with TFA led to a single diastereomer according to HPLC.
Figure 3 shows the HPLC chromatogram of crude reaction
product 33 using the Michael addition reaction. The two minor
peaks are the two 2-substituted succinyl derivatives, and the two
major peaks are the 3-substituted arylthiosuccinyl derivatives
33.1 and 33.2. The migration time of the reaction product
derived from e shown in Scheme 2 is comparable to that of
33.2, enabling assignment of 33.2 to the (S)-3-(2-
naphthylthio)succinyl derivative. Additionally, spiking the
reaction mixture of the Michael reaction with the product of
the stereocontrolled synthesis resulted in an increase of the area
of the signal caused by 33.2 (see Figure 3c). Encouraged by the
unique selectivity of the potent inhibition of Sirt5 by 33.2, we
decided to develop an aﬃnity probe for human Sirt5. Analysis
of crystal structures of 15 and 2 in complex with zSirt5 (Figure
2) uncovered no interaction of the N-terminal benzoyl residue
with the enzyme. Therefore, we replaced the benzoyl moiety in
33 by a spacer molecule and a biotinyl residue (compound 39),
enabling immobilization on (strept)avidin-coated surfaces
(Table 3). Mixture of 3-substituted diastereomers (compound
39) generated by Michael addition reaction yielded an inhibitor
with a Ki value of 83.2 ± 15.4 nM, but stereoisomer 39.2,
synthesized according to the method shown in Scheme 2, is a
more eﬀective Sirt5 inhibitor, with a Ki value of 13.6 ± 3.8 nM.
The inhibition is in both cases competitive regarding the
peptide substrate (Figure 4). To analyze our Sirt5 aﬃnity probe
in more detail, we used real-time, label-free surface plasmon
resonance (SPR) measurements to investigate the interaction
of surface-bound inhibitor and human Sirt5 (Figure 5).
Biotinylated peptide derivative 39.2 was immobilized on a
streptavidin-coated SPR sensorchip. Sirt5 binds to immobilized
39.2 in a dose-dependent manner (Figure 5a). Rate constants
kon = (1.3 ± 1.0) × 10
−6 M−1 s−1 and koff = (1.5 ± 0.6) × 10
−4
M−1 s−1 result in a KD value of about 0.12 nM. Binding was
Scheme 2. Synthesis of (S)-3-(Alkylthio/arylthio)succinyl Derivatives from (S)-Malic Acid
Figure 3. HPLC proﬁles of 33: (a) derived by Michael addition of 2-naphthalenethiol to maleyl-CPS1; (b) 33.2 prepared by coupling of (S)-2-(2-
naphthylthio)succinic acid-1-(4-methoxybenzyl) ester to the CPS1-peptide (Scheme 2); and (c) mixed sample containing (a) and (b).
Table 3. Chemical Structures of Biotinylated Peptides 39 and 39.2
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linear up to 100 nM, representing the evaluation range for the
rate constants (R2 = 0.9971; Figure S22). This interaction
seems to be very speciﬁc for Sirt5 because all other human
sirtuin isoforms showed negligible KD values (Figure 5b). The
higher aﬃnity of 39.2 for the active site of Sirt5 in the SPR
experiment as compared to the kinetic measurements could be
explained by the immobilization of the inhibitor leading to an
avidity eﬀect. However, in the presence of non-biotinylated
inhibitor 33.2, Sirt5 was unable to bind to surface-bound 39.2
(Figure 5c), indicating the expected peptide−substrate
competitive binding mode. Consistently, reduced but detect-
able binding was observed in the presence of 19.2, an inhibitor
with a Ki value of 714 nM, or in the presence of succinylated
CPS1-derived substrate peptide, demonstrating that surface-
bound 39.2 competes with the substrate peptide. Analyzing
interaction details of 33.2 with Sirt5 by solving a zSirt5/33.2
crystal structure (Figure 6, Figure S24, Table S2) revealed a
surprising binding mode. Although it was based on m- and p-
modiﬁed 2, the substituent of 33.2 occupies the C-pocket. Its
bulky aromatic system ﬁlls much of the pocket yet remains
ﬂexible, as indicated by fragmented electron density and higher
B factors. Further modiﬁcations that exploit polar groups, such
as an addition at position 8 of the naphthyl moiety for
beneﬁcial interaction with Asp139 (Figure 2), might be a route
for even further increased potency. Nevertheless, our data
demonstrate that the combination of a succinyl scaﬀold for
Sirt5 selectivity and a 3-(2-naphthyl)succinyl modiﬁcation for
potency yields compounds that bind Sirt5 tightly and
speciﬁcally. We reversed the assembly by regioselective
immobilization of biotinylated Sirt5 to a streptavidin-coated
sensorchip. Sirt5 was biotinylated at the N-terminus by the
trypsiligase method.17 For that purpose, we elongated Sirt5
with StrepII-tagged Tyr-Arg-His tripeptide at the N-terminus.
This introduces a recognition sequence for trypsiligase which
cleaves the Tyr-Arg bond and transfers a biotinyl-Gly to the Arg
residue, resulting in a Sirt5 variant with biotinyl-Gly-Arg-His at
the N-terminus (Figure S19d). Biotinylated Sirt5 showed
similar enzymatic activity compared to the enzyme without
modiﬁcation (Figure S20b). Treatment of the immobilized
Sirt5 with 33.2 showed a very fast association and hardly
detectable dissociation (Figure 5d), resulting in an estimated
KD value of about 10 pM. We were not able to remove bound
inhibitor by extensive washing of the sensorchip (several days).
To test the suitability of 39.2 for pull-down experiments
using more complex biological samples, we immobilized 39.2
on streptavidin-coated agarose beads and loaded the beads with
E. coli BL21 (DE3) lysate expressing Sirt5. There was no Sirt5
detected in the ﬂow-through using SDS-PAGE analysis.
Extensive washings removed a lot of diﬀerent proteins but
not Sirt5 (Figure 7a). Virtually pure Sirt5 could be eluted using
200 mM sodium hydroxide. ESI-MS analysis of the elution
fraction yielded a protein with a molecular mass of 30.798 Da
(Figure 7b), which matches the calculated mass of 30.796 Da.
Lysates of E. coli expressing either Sirt2 or Sirt3 were used for
similar pull-down experiments. There was no capture of these
two sirtuins by 39.2 detectable, as demonstrated by the empty
elution fraction lanes (Figure S18a,b). Additionally, an
equimolar mixture of Sirt2, Sirt3, and Sirt5 was applied to
Figure 4. v/[S] plots and ﬁtting curves for compounds 39 and 39.2 generated using human Sirt5 in the presence of 500 μM NAD+ cosubstrate.
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the inhibitor matrix and analyzed via SDS-PAGE (Figure S18c).
Sirt2 and Sirt3 were exclusively detected in the ﬂow-through
and the wash fractions. Protein-containing elution fractions
were analyzed using ESI-MS, and eluted protein was clearly
identiﬁed as Sirt5 (Figure S18d).
■ CONCLUSIONS
For development of more drug-like Sirt5 inhibitors, we started
to analyze the contribution of the peptide backbone to the
aﬃnity of (S)-3-(2-naphthylthio)succinyl derivatives. We
shortened the peptide sequence to a tripeptide and generated
40.2 (see Table 4) using enantiomerically pure precursor e.
This tripeptide binds 6-fold less strongly to Sirt5 as compared
to 39.2, but still with sub-micromolar inhibitory activity.
Generation of an α-acetylated lysine amide, acylated with the
(S)-3-(2-naphthylthio)succinyl moiety at the ε-amino group,
resulted in 41, showing a Ki value of 7 μM, which is about 40-
fold higher than the Ki value for 40.2, yet close to those of the
most potent Sirt5 selective inhibitors known so far. The peptide
part of the peptidic inhibitors thus contributes to aﬃnity and
potency, but omitting these contributions from our inhibitors
with optimized acyl moieties still allows for tight binding.
Further shortening by formal removal of the acetylated glycine
amide part of 41 yielded 42, which binds about 20-fold less
eﬀectively to Sirt5 as compared to 41. Replacement of the
Figure 5. Biophysical characterization of compounds 33.2 and 39.2 by surface plasmon resonance spectroscopy. (a) SPR sensorgrams demonstrating
binding of Sirt5 to immobilized 39.2. (b) Association phase of sensorgrams representing binding of diﬀerent sirtuin isoforms (1 μM) to immobilized
39.2. (c) Association phase of SPR sensorgrams representing binding of Sirt5 to the immobilized inhibitor in the presence of CPS1-derived peptide
substrate with succinyl residue on the lysine side chain (2 μM) or inhibitors 33.2 (2 μM) and 6.2 (2 μM); vehicle is PBS buﬀer. (d) Binding of
compound 33.2 to immobilized, biotinylated Sirt5. Regioselective biotinylation of the N-terminus of Sirt5 was performed via trypsiligase reaction17
(Figure S20).
Figure 6. Comparison of the binding modes of 33.2 and 15 (in the
Sirt5 active site). The zSirt5 complex with 33.2 (PDB ID 6FLG, cyan)
was overlaid with the 15 complex (PDB ID 6FKY, ligand shown in
green; one enantiomer omitted for clarity) and a Sirt5/NAD+ complex
(PDB ID 4G1C) that indicates the C-pocket. NAD+ (light blue) was
modeled from a Sirt5/peptide/NAD+ complex. The protein is only
shown for zSirt5/33.2, and dotted lines indicate polar interactions to
the acyl group.
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butylamide part in 42 by anilides (43 and 44) and benzylamide
(45) is well tolerated, resulting in similar IC50 values, indicating
potential for further improvement of this compound moiety
through focused library screens or structure-based design.
Replacement of the methyl group in 42 by a phenyl ring (46)
already improves the IC50 value more than 2-fold, and our
structural data provide a basis for further optimizing this
compound part to obtain potencies comparable to that of 41 or
even better without having the peptide backbone, which is
unfavorable for drug applications. For comparison, we analyzed
known small-molecule inhibitors IV and VII (Table 4) using
similar assay conditions. In our hands these compounds
Figure 7. Immobilized 39.2 captures Sirt5 out of E. coli lysate. (a) SDS-PAGE analysis (Coomassie staining) of 39.2 bound to streptavidin-coated
agarose interacting with E. coli BL21 (DE3) lysate expressing Sirt5. Exclusively Sirt5 was eluted from the matrix by addition of 200 mM NaOH.
Abbreviations: S, supernatant after cell rupture; FT, ﬂow-through; W, wash fractions; E, elution fractions. (b) ESI-MS analysis of the elution fraction
E2; Mcalc = 30.796 Da, Mfound = 30.798 Da.
Table 4. Chemical Structures of Tripeptide and Small Molecules
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showed much weaker aﬃnity to SIRT5 in comparison to
published values.11,14 Collectively, these results show that the
(S)-3-(2-naphthylthio)succinylamide scaﬀold represents a
useful starting point for systematic development of small
molecules that potently and selectively target Sirt5.
In this study we developed a peptide-based selective Sirt5
aﬃnity probe by optimizing the acyl moiety in a systematic
manner. Probe design was guided by analysis of a known crystal
structure of Sirt5 in complex with 47 and crystal structures
solved in this study. The developed aﬃnity probe 39.2 is able
to bind to Sirt5 in diﬀerent matrixes and environments,
accompanied by excellent selectivity and inhibitory activity. The
high potency is caused by slow dissociation rate and fast
association of the inhibitor−enzyme complex, making this
probe to a multifunctional tool for investigation of Sirt5 biology
at a new level.
■ EXPERIMENTAL SECTION
Chemicals and General Methods. Solutions of 0.1% triﬂuoro-
acetic acid (TFA) in H2O (solvent A) and 0.1% TFA in acetonitrile
(solvent B) were used as mobile phase for HPLC measurements. For
sample analysis, an Agilent 1100 HPLC with a quaternary pump, a
well-plate autosampler, and a variable-wavelength detector was used.
Separations were performed on a Phenomenex Kinetex XB C-18
column (2.6 μm, 3.0 × 50 mm) with a linear gradient from 25 to 55%
solvent B in 4 min at a ﬂow rate of 0.6 mL min−1. The compounds
were detected at 260 nm. A Shimadzu LC system with a Phenomenex
Kinetex 5 μm XB-C18 column (250 × 21.1 mm, 100 Å) was used for
puriﬁcation of peptides. The preparative separations were performed
with a linear gradient from 25 to 90% solvent B in 80 min at a ﬂow rate
of 15 mL min−1. The eluting compounds were detected at 220 and 260
nm. UPLC-MS analysis was performed using a Waters Acquity UPLC-
MS system (Milford, USA) with a Waters Acquity UPLC-MS-BEH
C18 column (1.7 μM, 2.1 × 50 mm; 30 Å). Data analysis was
performed using Waters MassLynx software. NMR spectroscopy was
carried out using a Varian Gemini 2000 spectrometer and deuterated
chloroform or deuterated dimethyl sulfoxide (DMSO). All chemicals
were purchased from Sigma-Aldrich if not stated otherwise.
Solid-Phase Peptide Synthesis. The peptide derivatives Bz-
GVLK(Ns)EYGV-NH2 and Ac-LK(Ns)A-NH2 were synthesized on an
MBHA Rink amide resin with a loading density of 0.59 mmol/g (IRIS
Biotech), using standard Fmoc-based solid-phase peptide synthesis. At
ﬁrst the resin was treated with DMF for 20 min. Next, 4 equiv of
Fmoc-protected amino acid derivatives (Anaspec) was activated with 4
equiv of HBTU and 8 equiv of DIPEA in DMF and was coupled for at
least 1 h. Afterward the Fmoc deprotection was performed two times
for 10 min with 20% piperidine in DMF followed by washing with
DMF for 5 min, ﬁve times. Finally, the amino group of glycine was
modiﬁed with 4 equiv of benzoic acid and 8 equiv of DIPEA in DMF
or 4 equiv of acetic anhydride and 8 equiv of DIPEA in DMF for 30
min. The lysine to be modiﬁed was used as the ε-nosyl (Ns, 2-
nitrobenzenesulfonyl)-protected derivative, allowing a selective on-
resin modiﬁcation of the lysine side chain. This derivative, Fmoc-
Lys(Ns)-OH, was prepared as described elsewhere.20 The nosyl
protecting group was removed by using 5 equiv of thiophenol and 5
equiv of DBU in DMF for 90 min, two times. The free lysine side
chain was modiﬁed with 4 equiv of maleic anhydride and 8 equiv of
DIPEA in DMF for 4 h, followed by washing with DMF. Afterward a
Michael addition reaction was performed with 4 equiv of mercapto
derivative (2−13, 15−35, 39, 40) and 8 equiv DIPEA in DMF
overnight. After sequential washing with DMF, DCM, methanol, and
again with DCM for 4 min, ﬁve times, each peptide was cleaved from
the resin using TFA−water solution (95:5 v/v) for 1 h, two times. The
TFA was evaporated, and the peptide was dissolved in acetic acid.
After puriﬁcation by reversed-phase HPLC, collected fractions were
analyzed with HPLC-MS and checked for purity. The purity was above
95% for all peptides (Figure S26−S105). The fractions containing
target peptide were lyophilized.
(S)-2-Hydroxysuccinic Acid 1-(4-Methoxybenzyl) Ester (c). First,
3.2 g (15 mmol, 1 equiv) of (S)-2-triﬂuoroacetoxysuccinic anhydride
(b), prepared from (S)-malic acid using a known method,18 was mixed
with 9.3 mL (75 mmol, 5 equiv) of 4-methoxybenzyl alcohol, and the
reaction mixture was stirred overnight. The resulting oil was dissolved
in 50 mL of ethyl acetate (EtOAc) and extracted several times with
saturated NaHCO3 solution. The combined aqueous phases were
washed with EtOAc and acidiﬁed with diluted HCl solution. The
mixture was extracted with DCM, and the organic phase was washed
with water, dried over Na2SO4, and evaporated, aﬀording 3.16 g of
crude ester. Recrystallization from 14 mL of EtOAc−petroleum ether
mixture (1:1) yielded 2.2 g of pure compound.
1H NMR (300 MHz, DMSO-d6): δ 7.29 (d, J = 8.7 Hz, 2H), 6.91
(d, J = 8.7 Hz, 2H), 5.03 (s, 2H), 4.34 (dd, J = 7.5, 5.1 Hz, 1H), 3.73
(s, 3H), 2.61 (dd, J = 15.8, 5.1 Hz, 1H), 2.52−2.40 (m, 1H).
(S)-2-(2-Naphthylthio)succinic Acid 1-(4-Methoxybenzyl) Ester
(e). First, 508.5 mg (2 mmol) of 1-(4-methoxybenzyl) malate and
525 mg (2 mmol) of Ph3P were dissolved in 9 mL of dry
tetrahydrofuran (THF), and the ﬂask was cooled with an ice−water
bath. To this mixture was added 393 μL (404 mg, 2 mmol) of
diisopropyl azodicarboxylate in 2 mL of THF dropwise over 5 min.
The reaction mixture was stirred overnight at room temperature. The
next day the yellow solution was cooled to −15 °C with an ice−salt
mixture, and 320 mg of crystalline 2-naphthalenethiol (2 mmol) was
added, followed by 276 mg (2 mmol) of solid K2CO3. After 20 min the
cooling bath was removed, and the mixture was stirred at room
temperature for 1 h. The product was isolated with acid−base
extraction as described in the previous procedure, to yield 0.53 g of
crude product, which contains around 25% of starting material.
Recrystallization from methanol can be used for further puriﬁcation.
1H NMR (300 MHz, DMSO-d6): δ 7.98−7.78 (m, 4H), 7.59−7.43
(m, 3H), 7.06 (d, J = 8.7 Hz, 2H), 6.75 (d, J = 8.7 Hz, 2H), 4.96 (dd, J
= 28.2, 12.1 Hz, 2H), 4.15 (dd, J = 8.6, 6.6 Hz, 1H), 3.70 (s, 3H), 2.77
(dd, J = 7.6, 2.0 Hz, 2H).
General Procedure for the Synthesis of Maleamic Acid
Derivatives 41−46. To the solution containing 20 mg (0.05 mmol)
of (S)-2-(2-naphthylthio)succinic acid 1-(4-methoxybenzyl) ester and
7 mg (0.06 mmol) of N-hydroxysuccinimide (HOSu) in 500 μL of dry
THF was added 9 μL (0.06 mmol) of N,N-diisopropylcarbodiimide.
After 30 min, 2 equiv (0.1 mmol) of the appropriate amino derivative
was added. The progress of the reaction was monitored by TLC or
HPLC. In the case of aromatic amines, longer reaction times and
addition of 2 equiv of triethylamine were necessary to achieve
satisfactory yields. After completion of the reaction, THF was
evaporated, and the residue was redissolved in 500 μL of TFA−
water (95:5 v/v) solution and left for 30 min. The reaction solution
was then concentrated in vacuo, and the residue was puriﬁed by RP-
HPLC. The fractions containing target product were lyophilized,
aﬀording pure compound.
Synthesis of 2-Methyl-2-(2-naphthylthio)succinic Anhy-
dride. This compound was prepared according to the method
described for preparation of 2-methyl-2-(4-chlorophenylthio)succinic
anhydride.19 Brieﬂy, 1.12 g (10 mmol) of citraconic anhydride and 1.6
g (10 mmol) of 2-naphthalenethiol were mixed with 1 mL of toluene,
and 4 μL of triethylamine was added. The mixture was stirred and
heated at 70−80 °C for 1 h. Volatiles were removed in vacuo, and the
residue was puriﬁed by ﬂash chromatography. Additional recrystalliza-
tion from petroleum ether−EtOAc (3:1 v/v) solution gave pure
material.
1H NMR (700 MHz, CDCl3): 8.08 (d, J = 1.9 Hz, 1H), 7.88−7.82
(m, 3H), 7.59−7.51 (m, 3H), 3.14 (d, J = 18.8 Hz, 1H), 3.07 (d, J =
18.8 Hz, 1H), 1.70 (s, 3H).
Fluorescence Inhibition Assay. The inhibitory activity of all
compounds was measured in black low-binding 96-well microtiter
plates, and each well contained 0.025−5 μM substrate Abz-
GVLK(glutaryl)AY(NO2)GV-NH2, 500 μM NAD
+, 500 nM trypsin,
10 nM SIRT5, 5% DMSO, and 0.01−20 μM inhibitor (compounds 1−
46) in assay buﬀer. The assay buﬀer contained 20 mM Tris, 150 mM
NaCl, and 5 mM MgCl2 at pH 7.8. The reaction mixture without
enzymes was incubated for 5 min at 37 °C, followed by pipetting
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01648
J. Med. Chem. 2018, 61, 2460−2471
2468
trypsin and further incubation for 5 min at 37 °C. After addition of
SIRT5, the measurements started, and the ﬂuorescence was measured
at an excitation wavelength of 320 nm and emission wavelength of 420
nm. The measurements were carried out in a plate reader (TECAN)
and in a double determination.20 IC50 values were obtained with 0.03
μM substrate, and the resulting data were ﬁtted by log(inhibitor) vs
normalized response equation:
=
+
−
Y
100
(1 10 )X( log IC )50 (1)
HPLC Assay. Reaction mixtures contained 0 μM or 50 μM
inhibitor, 500 μM NAD+, 5% DMSO, 0.1 μM SIRT1, 2, 3, 5, or 6, and
50 μM Bz-GVLK(acetyl)EYGV-NH2 for SIRT1−3, Bz-GVLK-
(succinyl)EYGV-NH2 for SIRT5, and Ac-EALPKK(myristoyl)TGG-
NH2 for SIRT6 in assay buﬀer. The reactions were performed at 37 °C
for 6 min (SIRT6), 8 min (SIRT1−3), or 10 min (SIRT5). After these
time points, reaction was stopped with TFA−water solution (1:9 v/v),
and samples were analyzed by HPLC. The stability of compounds 1−
46 was determined by incubating 50 μM inhibitor in assay buﬀer at 37
°C for 24 h and measuring by HPLC. All measurements were carried
out in duplicate.
Cloning, Expression, and Puriﬁcation of Recombinant
Proteins. Human Sirt5 was cloned with N-terminal StrepII-tag into
pET-21a(+) vector. Sirt243−356 and Sirt3114−380 were cloned with N-
terminal StrepII-tag into pET-28a(+)-vector. All proteins were
expressed using E. coli BL21 (DE3) in LB media supplemented with
ampicillin or kanamycin, respectively. Overexpression was induced by
the addition of IPTG (1 mM ﬁnal concentration) at an OD600 of 0.6.
Cells were harvested, resuspended in lysis buﬀer (100 mM Tris-HCl,
250 mM NaCl, 10 mM DTT, 1 mM EDTA, pH 8.0), and lysed by
soniﬁcation. Supernatant after centrifugation was loaded onto a
StrepTrap column (GE Healthcare, Uppsala, Sweden). The loaded
column was intensively washed before elution with 5 mM
desthiobiotin in 100 mM Tris, 250 mM NaCl, pH 8.0. Sirt5-
containing fractions were concentrated and further puriﬁed using a
Superdex 75 5/150 gel ﬁltration column (GE Healthcare). Expression
of Sirt4 was performed using the IMPACT system (NEB, Frankfurt
am Main, Germany). The corresponding gene was cloned into
pTWIN2 via SapI/PstI and transformed in E. coli ER2566 (NEB).
Overexpression was induced by the addition of IPTG (0.5 mM ﬁnal
concentration) at an OD600 of 0.6 at 16 °C for 12 h. Chitin binding-
domain-mediated aﬃnity chromatography was performed as described
in the supplier’s manual. Enzymatic activity of the expressed Sirtuin
isoforms was determined as described previously.17 Biotinylation of
Sirt5 was conducted via trypsiligase using biotinyl-4-guanidino-phenyl
ester as described previously.17
Real-Time Biomolecular Interaction Analysis. Surface plasmon
resonance spectroscopy was performed on a BIAcore X instrument
(BIAcore, Uppsala, Sweden). Biotinylated inhibitor 39.2 (100 μM in
PBS) was immobilized on an SAHC 200 M sensorchip (Xantec,
Düsseldorf, Germany). Sirt5 was injected in a dilution series using PBS
(4 mM KH2PO4, 16 mM Na2HPO4, 115 mM NaCl, pH 7.4) as
running buﬀer. Vice versa, N-terminal biotinylated Sirt5 was
immobilized on a second strepatvidin-coated sensorchip, resulting in
a surface density of approximately 1800 response units (RU), and 50
nM 39.2 in PBS was injected. Each complex formation was observed at
a continuous ﬂow rate of 30 μL/min. Kinetic parameters were
determined by ﬁtting the data to the 1:1 Langmuir binding model with
the BIAevaluation software (BIAcore). After each measurement the
inhibitor matrix was regenerated by injection of 100 μL of NaOH (200
mM).
Aﬃnity Pull-Down Experiments. A 0.5 mL bed-volume of
streptavidin-conjugated agarose (Sigma-Aldrich, Munich, Germany)
was applied to a gravity column and equilibrated with 5 CV PBS.
Agarose beads were loaded with the biotinylated inhibitor 39.2 (100
μM in PBS). After 30 min incubation, agarose was washed with 10 CV
PBST (4 mM KH2PO4, 16 mM Na2HPO4, 115 mM NaCl, 0.05%
Tween, pH 7.4). As protein samples, pellets of 20 mL induced E. coli
BL21 (DE3) cells expressing the respective Sirt isoform were
resuspended in 100 mM Tris, 250 mM NaCl, 1 mM EDTA, 10
mM DTT, pH 8.0, and lyzed by soniﬁcation. After removal of cell
debris, supernatant was applied to the inhibitor matrix. Conjugated
agarose beads were washed three times with 3 CV PBST. Bound
protein was eluted by the addition of 200 mM NaOH. Elution
fractions were analyzed by SDS-PAGE and LC-MS.
Crystal Structure Analyses. zSirt5 protein was puriﬁed by Co-
Talon aﬃnity chromatography, TEV proteolysis, reverse aﬃnity
chromatography, and gel ﬁltration as reported, with the modiﬁcation
that 0.5 mM TCEP was added to the gel ﬁltration buﬀer. For
crystallization, zSirt5 (10 mg/mL) was mixed with 1 mM inhibitory
peptide (20 mM stock in DMSO) and incubated on ice for 30 min.
Complexes were crystallized in 2 μL sitting-drop vapor diﬀusion
experiments at 20 °C using 0.1 M HEPES, pH 7.5, 20% PEG3350 as
reservoir solution. After 2−4 days, crystals were transferred to a cryo-
protection solution composed of reservoir and ligand supplemented
with 25% glycerol. Crystals were shock-frozen and diﬀraction data
collected at 100 K at BESSY II beamline MX14.1 (operated by the
Helmholtz-Zentrum, Berlin, Germany) with a Pilatus 6 M detector
(Dectris, Baden, Switzerland). Indexing, scaling, and merging were
done in XDS,21 and structures were solved by molecular replacement
with search model PDB 4UTV (zSirt5/47). Reﬁnement was done with
Refmac5,22 and manual modeling as well as structure validation were
done with Coot.23 Geometry parameters for the modiﬁed lysines were
generated using PRODRG.24
Computational Methods. The molecular structures of all
peptides described in the present work were generated using the
MOE 2014.09 program.25 The initial conformations resulted from
energy minimization using the Amber12:EHT force ﬁeld as
implemented in MOE. The crystal structure of zSirt5 in complex
with peptides 2.2 and 15.2 were considered for the ﬂexible docking
study. For the subsequent docking studies, all water and ligand
molecules were removed, and the structure was protonated and
minimized using the Amber12:EHT force ﬁeld.
All docking studies were carried out using the GOLD5.2 docking
program (Cambridge Crystallographic Data Centre, Cambridge, UK)
in exhaustive sampling mode.26 The binding cavity was deﬁned by the
cocrystallized peptide. To guide the search process, the position of the
cocrystallized succinyl-lysine of the peptides was used as a scaﬀold
constraint. Using Goldscore as ﬁtness function, the cocrystallized
peptide was correctly docked into the zSirt5 catalytic site, with RMSD
values of 1.25 Å (2.2) and 1.41 Å (15.2).
All tested peptides were docked in both crystal structures, and 100
docking poses were stored. The resulting poses were rescored using
the Amber12:EHT force ﬁeld and the MM-GB/SA approach. Partial
charges were ﬁxed using the MOE Protonate3D tool according to the
used force ﬁeld, followed by a short minimization. An in-house script
for rescoring the zSirt5−ligand complexes and calculating the binding
free energies was applied for the docking poses of ligands. During
complex minimization, heavy atoms of protein were tethered with a
deviation of 0.5 Å (force constant (3/2)kT/(0.5)2). Complexes that
showed the most favorable MM-GB/SA energy were selected and
visually analyzed using the MOE program.
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 Table S1. Ki values of compound 1-44, N.1 are fast- and N.2 are slow-eluting diastereomers 
Nr. Ki [nM] Nr. Ki [nM] Nr. Ki [nM] Nr. Ki [nM] 
1 236 ± 48.1* 11.2 290 21.2 525 33.1 382.8 ± 75.1* 
2.1 900 12.1 630 22.1 1100 33.2 30.1 ± 6.1* 
2.2 135 12.2 23 22.2 400 34.1 1100 ± 150* 
3.1 1550 13.1 4540 23.1 1075 34.2 85 ± 18* 
3.2 430 13.2 165 23.2 1060 35.1 155.2 ± 28.4* 
4.1 690 14.1 > 7000 24.1 215 35.2 7 
4.2 60 14.2 > 2000 24.2 270 36.1 45 
5.1 805 15.1 320 25.1 390 36.2 30 
5.2 50 15.2 170 25.2 370 37 > 40000 
6.1 1695 16.1 175 26.1 315 38 > 40000 
6.2 355 16.2 265 26.2 2600 39 83.2 ± 15.4* 
7.1 990 17.1 1335 27.1 295 39.2 13.6 ± 3.8* 
7.2 150 17.2 1355 27.2 1370 40  664.8 ± 78.0* 
8.1 800 18.1 510 28 11400 40.2 179.8 ± 41.1* 
8.2 23 18.2 445 29 6620 41 7012 ± 124* 
9.1 1005 19.1 620 30 3485 42 77000 
9.2 90 19.2 395 31.1 9245 43 78600 
10.1 325 20.1 2015 31.2 4375 44 45000 
10.2 43 20.2 1870 32.1 1030 45 62000 
11.1 6250 21.1 550 32.2 565 46 36280 
 * Ki values were determined using the coupled fluorescence assay all other Ki values were calculated with Cheng-Prusoff equation 
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Table S2. Data collection and refinement statistics 
 zSirt5/compound 2 zSirt5/ compound 15 zSirt5/compound 33.2 
Space group P6522 P6522 P6522 
Unit cell constants 
(Å) 
87.2, 87.2, 318.9 87.1, 87.1, 316.7 87.2, 87.2, 317.6 
Resolution (a) (Å) 50.00 – 3.30 
(3.39 – 3.30) 
50.00 – 2.98 
(3.16 – 2.98) 
20.00 – 2.50 
(2.56 – 2.50) 
Unique reflections  10989 (1671) 15459 (2399) 25573 (1857) 
Multiplicity  4.1 (4.3) 15.5 (16.0) 10.6 (11.1) 
Completeness  99.5% (99.3%) 99.8% (99.1%) 99.6% (99.9%) 
Rmeas  39.3% (121.8%) 35.8% (210.0%) 35.1% (822.4%) 
CC1/2 93.8 (49.6) 99.4 (51.3) 99.5 (12.8) 
I/I  5.0 (1.4) 9.8 (1.3) 7.2 (0.3) 
Protein atoms 4135 4103 4128 
Ligand atoms 164 166 86 
Solvent atoms 59 75 90 
Resolution (Å) 48.73 – 3.30 
(3.39 – 3.30) 
48.51 – 2.98 
(3.06 – 2.98) 
19.85 – 2.50 
(2.56 – 2.50) 
Rcryst/Rfree (b)(c) 22.2 / 28.4 19.8 / 27.5 24.9 / 31.7 
Average B- factors 
     protein 
 
 
62.3 
 
 
69.0 
 
 
74.3 
     ligands 73.8 72.4 97.6 
     solvent 35.3 47.8 75.7 
RMSD bond- 
lengths 
0.012 0.014 0.012 
RMSD angles  1.7 1.9 1.963  
(a)
 Values in parentheses refer to outermost shell. 
 
(b)
 𝑅ܿݎ𝑦ݏݐ = ∑||𝐹𝑜ܾݏ|−݇|𝐹݈ܿܽܿ||∑ |𝐹𝑜ܾݏ|  . |Fobs| is the observed and |Fcalc| the calculated structure factor amplitude. 
 
 (c)
 Rfree was calculated from 5% of reflections omitted from refinement. 
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  Figure S1. Dose-response analysis of compound 1-3 for SIRT5   
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    Figure S2. Dose-response analysis of compound 4-6 for SIRT5  
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   Figure S3. Dose-response analysis of compound 7-9 for SIRT5  
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   Figure S4. Dose-response analysis of compound 10-12 for SIRT5 
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   Figure S5. Dose-response analysis of compound 13,15,16 for SIRT5  
S10  
   Figure S6. Dose-response analysis of compound 17-19 for SIRT5  
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   Figure S7. Dose-response analysis of compound 20-22 for SIRT5  
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 Figure S8. Dose-response analysis of compound 23-25 for SIRT5 
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    Figure S9. Dose-response analysis of compound 26-29 for SIRT5  
S14  
    Figure S10. Dose-response analysis of compound 30-32 for SIRT5  
S15  
   Figure S11. Dose-response analysis of compound 33-35 for SIRT5  
S16  
    Figure S12. Dose-response analysis of compound 336,39,40 for SIRT5 
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 Figure S13. Dose-response analysis of compound 41-46 for SIRT5 
S18  
 Figure S14. Dose-response analysis of compound IV and VII for SIRT5  
 Figure S15. v/[S]-plots and fitting curves of inhibition of compound 1, mixture of 33 for SIRT5 
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 Figure S16. v/[S]-plots and fitting curves of inhibition of compound 33.1 and 33.2 for SIRT5 
S20  
 
 Figure S17. v/[S]-plots and fitting curves of inhibition of compound 34.1, 34.2, and 35.1 for SIRT5 
 
 
 
S21   Figure S18. v/[S]-plots and fitting curves of inhibition for mixture of compound 40 and stereoselective synthesized compound 40.2 and 41 for SIRT5 
S22  
 Figure S19: Immobilized 39.2 selectively captures Sirt5 out of E. coli lysate. a) SDS-Page analysis (coomassie staining) of biotinylated 39.2 bound to Streptavidin-coated agarose interacting with E.coli BL21 (DE3) lysate expressing Sirt2 in a column chromatographic manner. In contrast to Sirt5-expressing E.coli cells (figure x) no protein was eluted from the matrix indicating that Sirt2 did not bind to the inhibitor. b) Capture-studies with Sirt3-expressing E. coli cells show similar results as Sirt2: Sirt3 was not eluted from the inhibitor-matrix although Sirt3 seems to interact slightly more with the inhibitor than Sirt2 resulting in a weaker Sirt2-band in the flow through in comparison to the supernatant. c) Finally, an equimolar mixture of Sirt2, Sirt3 and Sirt5 was applied to the inhibitor-matrix in a column chromatographic manner and analyzed via SDS-Page. Sirt2 and Sirt3 were exclusively detected in the flow through and the wash fractions. Protein-containing elution fractions were analyzed via mass spectrometry (d). 
S23  
The eluted protein was clearly identified as Sirt5 (Mcalc.= 30.796 Da, Mfound= 30.798 Da).  
S…supernatant after cell rupture, FT…flow through, W…wash fractions, E…Elution fractions. 
 Figure S20. Trypsiligase-catalyzed biotinylation of Sirt5. 
 
 
S24  
 Figure S21. Biotinylated Sirt5 shows similar activity compared to the unmodified Sirt5. A) Product formation in a deacetylation assay for Bio-Sirt5 (black) and Sirt5 (red) at [substrate] = 10 µM (circle) and 50 µM (triangle), respectively. B) Specific activity of Bio-Sirt5 (0.13 s-1) and Sirt5 (0.1 s-1). Conditions: 100 nM Sirt5, [CPS1] = 10 µM, 50 µM, 20 mM Tris, 150 mM NaCl, 5 mM MgCl2 pH 7.8, T=37°C, each point represent the average of two independent measurements (deviation <1%).  Figure S22. Maximum RU shift detected at the end of the association phase plotted against Sirt5 concentration (n = 3). A) RU vs Sirt5-concentration up to 10 µM. B) Linear range (0-100 nM Sirt5). 
S25  
 Figure S23: Specificity test of compounds 33.1, 33.2, 34.1 34.2 and 40 for SIRT1-3 and 5-6. For SIRT 1-3 substrate Bz-GVLK(Acetyl)EYGV-NH2 for SIRT Bz-GVLK(Succinyl)EYGV-NH2 and for SIRT6 Ac-EALPKK(Myristoyl)TCG-NH2 were used.           
 
 
 
 
 
 
S26  
     Figure S24. Left: Crystal structure of a zSirt5/2 complex. The acyl-Lys and interacting residues are shown as sticks, and 2Fo-Fc electron density for the inhibitor is contoured at 1. Middle: Crystal structure of a zSirt5/15 complex. The acyl-Lys and interacting residues are shown as sticks, and 2Fo-Fc electron density for the inhibitor is contoured at 1. Right: Crystal structure of a zSirt5/33.2 complex. The acyl-Lys and interacting residues are shown as sticks, and 2Fo-Fc electron density for the inhibitor is contoured at 0.9.   
S27  
 Figure S25. Comparison of the top-ranked docking pose of 8.2 (colored magenta) and the crystal structure of zSirt5/2.2 (colored orange). The molecular surface of the zSirt5 binding pocket is displayed and colored according to the hydrophobicity (polar areas are colored magenta, hydrophobic areas are colored green).  
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 Figure S106. NMR-spectrum of (S)-2-hydroxysuccinic acid 1-(4-methoxybenzyl) ester 
S109  
 Figure S107. NMR-spectrum of (S)-2-(2-naphthylthio)succinic acid 1-(4-methoxybenzyl) ester 
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 Figure S108. NMR-spectrum of 2-methyl-2-(2-naphthylthio)succinic anhydride  
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Sirtuins are a family of NAD+-dependent silent information
regulator 2 (Sir2) enzymes that catalyze the removal of acyl
groups from e-N-amino groups of lysine residues in the
proteome.[1] The human genome codes for seven different
sirtuin isoforms (SIRT1-7), which are classified according to
sequence similarity and localize to different cellular compart-
ments.[2] Recently, it has become evident that different
enzyme isoforms exhibit preference for different e-N-acyl-
lysine posttranslational modifications (PTMs).[1c,d,3] Thus, e-
N-acetyllysine (Kac) functionalities are targeted primarily by
SIRT1 and 6 in the nucleus, SIRT2 in the cytoplasm, and
SIRT3 in the mitochondria.[3a] In addition, long chain acyl
groups, such as e-N-myristoyllysine (Kmyr), are also cleaved
by SIRT1-3 and 6.[4] SIRT5 has been shown to selectively
cleave e-N-carboxyacyllysine derivatives based on malonate
(Kmal),[5] succinate (Ksuc),[5b] and glutarate (Kglu).[6]
Recently, the ability of SIRT4 to cleave the negatively
charged e-N-(3-methylglutaryl)lysine (Kmg) and e-N-(3-
methylglutaconyl)lysine (Kmgc) has also been demon-
strated.[7]
Although the role of SIRT5 is not fully understood, it has
been shown to regulate several metabolic enzymes, e.g.,
carbamoyl phosphate synthetase 1 (CPS1), succinate dehy-
drogenase (SDH), and 3-hydroxy-3-methylglutaryl-CoA syn-
thase 2 (HMGCS2).[8] Additionally, SIRT5 is involved in
detoxification of reactive oxygen species, by deacylating
proteins such as SOD1,[9] IDH2, and G6PD.[10] Furthermore,
SIRT5 has been implicated in tumor growth in non-small cell
lung cancer[10b,11] and has an anti-apoptotic effect in neuro-
blastoma cells,[12] highlighting the potential of SIRT5 as
a therapeutic target.
Insight into the NAD+-dependent hydrolytic mechanism
of the sirtuins has been exploited for design of highly potent
substrate-mimicking inhibitors that contain thioamide or
thiourea functionalities, forming stalled intermediates with
ADP-ribose in the sirtuin active sites (Scheme 1A).[13]
Taking advantage of the acyl-substrate specificity of
SIRT5, this strategy has been successfully adapted to selec-
tively inhibit this isozyme (Scheme 1B).[6b,15] Here, we
performed an extensive iterative structure–activity relation-
ship (SAR) study, evaluating more than 70 compounds, which
furnished SIRT5-selective inhibitors exhibiting nanomolar
potency via a slow, tight-binding mechanism. These are the
most potent SIRT5 inhibitors reported to date; however, our
Abstract: The sirtuin enzymes are important regulatory
deacylases in a variety of biochemical contexts and may
therefore be potential therapeutic targets through either
activation or inhibition by small molecules. Here, we describe
the discovery of the most potent inhibitor of sirtuin 5 (SIRT5)
reported to date. We provide rationalization of the mode of
binding by solving co-crystal structures of selected inhibitors in
complex with both human and zebrafish SIRT5, which provide
insight for future optimization of inhibitors with more “drug-
like” properties. Importantly, enzyme kinetic evaluation
revealed a slow, tight-binding mechanism of inhibition, which
is unprecedented for SIRT5. This is important information
when applying inhibitors to probe mechanisms in biology.
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X-ray diffraction data and coordinates have been deposited with the
wwPDB (www.wwpdb.org) under accession numbers 6ENX (zSIRT5/
10), 6EO0 (zSIRT5/29), 6EQS (hSIRT5/29).
Scheme 1. A) Sirtuin hydrolytic mechanism. B) Previous mechanism-
based SIRT5 inhibitors. C) Inhibitor optimization in this study. X=O
or S, NAD+= reduced nicotinamide adenine dinucleotide, ADP=ade-
nosine diphosphate, Cbz=carboxybenzyl.
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study also highlights the necessity for thorough assessment of
inhibitor mechanism and calls into question the application of
IC50 values as the sole measure of potency for these chemo-
types.
As starting point, we chose e-N-thioglutaryllysine over
e-N-thiosuccinyllysine due to the lower KM value of glutary-
lated substrates.[6a] The a-amino group was kept Cbz pro-
tected to address the C-terminal, first by introduction of
a series of amines (1–6, Scheme 2 and Supporting
Scheme S1). Inspired by examination of co-crystal structures
of SIRT5 with a peptide substrate (PDB 3RIYand 4GIC), we
then extended the series to di- and tripeptides (7–17),
addressing the importance of side chain bulkiness, stereo-
chemistry, and presence of backbone secondary amide
(Scheme 2, gray area). The two latter proved important with
a preference for l-configuration at position i+ 1 (10 vs. 11),
Scheme 2. Subset of the structure–activity relationship study, measuring compound potency against recombinant SIRT5 as previously
described.[6a, 14] Potencies are given as IC50 values or %-inhibition at the highest tested concentration (see Figure S1 for dose-response curves).
Please consult the Supporting Information for a list of additional compounds and their potencies (Scheme S1) as well as synthetic Schemes S2–
S25.
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while the steric bulk of the side chain had
minor effect (12 vs. 14).
Furthermore, alkylation of the C-
terminal amide was beneficial for potency
and extending the structure with an i+ 2
amino acid resulted in a slight increase in
potency for compound 15. However, to
limit the peptidic nature of the ligand, we
chose 10 for further SAR. Next, we
explored modifications of the PTM and
the e-amide bond (18–29, Scheme 2,
yellow area). Inspired by work on Kac
surrogates by Cole and Denu, introducing
hydrazide[16] and urea[17] functionalities,
respectively, we designed compounds 20
and 21, as well as extended the series with
semicarbazide 22 and carbamate 23.
Compound 24 was inspired by work on
fluorinated acetamides,[17,18] and inverted
amide (25) as well as Glu(Cbz) 26 have
been introduced as side chains previous-
ly.[6b,15c] Finally, 3-methylglutaryl-mimick-
ing[7] analogues (27 and 28) were pre-
pared along with compound 29, the
thiourea analogue of 10. Collectively,
this exercise showed that thioamide- and
thiourea-based compounds were the most
potent and thus, compound 29was chosen
for individual optimization of the N-
terminal (30–44, Scheme 2, green area)
and modifications to the C-terminal N-
alkyl group (45–47, Scheme 2, cyan area).
Co-crystal structures of NAD+-
derived intermediates of both lead com-
pounds 10 and 29 in complex with SIRT5
from either zebrafish (zSIRT5) or man
(hSIRT5) were solved (Supporting
Table S1). These structures revealed
detailed insight into the binding modes
of the two compounds (Figure 1A–D).
Both structures of zSIRT5 contained the
compound (10 or 29) bound as bicyclic
intermediate with ADP-ribose, similar to
structure III in Scheme 1A (mixed with a fraction bound as
intermediate II in Scheme 1A for compound 29), and with
expected interactions of the carboxylate with Y98 and R101
(Figure 1A,B and Supporting Figure S2). Slight structural
deviations between the complexes were observed in a Zn-
domain loop, the co-factor binding loop, and helix a3,
presumably due to the subtle differences in the ligand acyl
groups. Interestingly, the structure of 29 in complex with
hSIRT5 revealed only the ADP-ribose-1’-thioimidate inter-
mediate II of Scheme 1 and no bicyclic intermediate (Fig-
ure 1C). However, the protein chains of the hSIRT5 and
zSIRT5 complexes with 29were almost identical (rmsd 0.31 
for 225 Ca atoms), and the reason for partially stalling at
different intermediate states remains to be elucidated.
Whereas thioamides have been co-crystallized with sirtuins
previously,[19] these are the first structures with thiourea-based
inhibitors. It is reassuring to observe examples for both
intermediates II and III, confirming that this functionality
behaves similarly to thioamides. Important interactions of the
compound with hSIRT5 were again the glutaryl carboxylate
with Y102 and R105 as well as the e-NH to the backbone
carbonyl of V221 and additional backbone–backbone amide
interactions (Figure 1C). Four SIRT5 chains with variations
in the rotation of the Cbz and indole moieties of the ligand
were resolved (Figure 1D). The varying end group confor-
mations are influenced by crystal packing, and the indole
positions indicate a flexibility in the SIRT5 complex that is in
agreement with the minor effect of this group observed in the
SAR.
Furthermore, the observed flexibility of the Cbz group as
well as its lack of specific interactions with the protein surface
(Figure 1D) indicated that a variety of functionalities could
Figure 1. Co-crystal structures resulting from incubation of zSIRT5 with NAD+ and inhibitors
10 or 29 as well as hSIRT5 with NAD+ and inhibitor 29. A) Superposition of co-crystal
structures of zSIRT5 with either bicyclic intermediate III (compound 10 shown in pale blue) or
an indistinguishable mixture of bicyclic intermediate III and ADP-ribose-1’-thioimidate inter-
mediate II (compound 29 shown in pale green). B) Active site zoom of the zSirt5 complexes in
panel A with interactions between protein and ligand represented as dashed lines. C) Active
site of the co-crystal structure of hSIRT5 and ADP-ribose-1’-thioimidate intermediate II with
compound 29. Hydrogen bonding interactions between protein and ligand are shown as
dashed lines. D) Surface view of the hSIRT5 complex containing the ADP-ribose–29 intermedi-
ate, showing the different positions of the Cbz and indole moieties, while the rest of the ligand
is tightly bound.
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be tested in the continued SAR.
Thus, for the ease of synthesis, we
decided to investigate the N-termi-
nal relative to compound 30, which
is devoid of the C-terminal i-propyl
group, allowing for ready prepara-
tion of the series 30–44 by solid-
phase synthesis. We included
amide, urea, and sulfonamide ana-
logues of the Cbz group, including
various lengths (30–37). Due to the
potency of 37 and the high abun-
dance of sulfonamides in approved
drugs, we prepared analogues 38–
44 as well.
In parallel, we briefly re-inves-
tigated the importance of steric
bulk at the C-terminus, now in the
context of compound 29 (45–47,
Scheme 2, cyan area). Combining
the results of these two series, we
prepared compounds 48–50 in
a final iteration, providing com-
pound 49 as the most potent inhib-
itor with an improvement in IC50
value of > 100-fold from com-
pound 1. Not surprisingly based
on the well-documented substrate
specificity of SIRT5, selected com-
pounds (29 and 48–50) exhibited
excellent selectivity for SIRT5 over
SIRT1–3 and 6 (Figure 2A). We
were then interested in gaining
insight into the kinetic behavior of
our most potent compound (49)
along with intermediate lead com-
pounds 10 and 29 as well as com-
pound 1 and patented compoundV
(Scheme 1) as a control. To achieve
this, we first performed a continu-
ous assay[14] to establish whether
the inhibition occurred at steady-
state kinetics. Not surprisingly, since this has been reported
previously for mechanism-based inhibitors of SIRT1,[20] com-
pounds 10, 29 and 49 exhibited slow, tight-binding kinetics
(Figure 2B and Supporting Figure S3). Interestingly, the less
potent compounds 1 and V behaved like standard fast-on–
fast-off inhibitors (Figure 2B and Supporting Figure S3),
indicating that the change in mechanism is not solely
associated with the thioamide or thiourea amide bond
surrogate, but rather developing as the backbone-interacting
part of the molecule gains affinity.
Nevertheless, slow binding could be associated with
interaction with NAD+ and enzyme or enzyme alone, so we
performed pre-incubation experiments of selected inhibitors
and SIRT5 with or without NAD+ to address these scenarios
and to evaluate whether compounds 19–25 exhibited slow-
binding as well (Figure 2C). Not surprisingly, the slow-
binding behavior of compounds 10, 19, 29 and 49 was
depending on the presence of NAD+, indicating that it
involves formation of the stalled intermediate. However, it is
intriguing that optimization of the scaffolds contribution to
affinity imposes a change in mechanism of inhibition.
Interestingly, the urea-containing compound 21 also exhibited
NAD+-dependent slow-binding, which may revive the use of
this functionality for future inhibitor design. The remaining
compounds did not exhibit slow-binding within the time-
frame of the pre-incubation experiments (Figure 2C).
Finally, we tested an ethylester prodrug version of
compound 29 (Et-29) for its ability to affect the degree of
lysine glutarylation in cells. However, it is unfortunately not
trivial to detect changes in either lysine malonylation,
succinylation, or glutarylation even when comparing wildtype
to a control CRISPR-Cas9 SIRT5 knockout cell line (Sup-
porting Figures S4 and S5). Further optimization of the
experimental design and subsequent evaluation of these
Figure 2. Biochemical evaluation in vitro. A) Selectivity of compounds 29 and 48–50, measured at an
inhibitor concentration of 10 mm. Acyllysines of substrates used are indicated for individual sirtuins.
B) Progression curves and data fitting for inhibition of recombinant SIRT5 by compounds 1, 29, and
49. C) Preincubation experiments of compounds 10, 19–25, 29, and 49.
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compounds in a cellular context will thus be of immediate
future interest.
In summary, we describe mechanism-based inhibitors of
sirtuin 5 that exhibit up to a 100-fold improvement in IC50
values compared to a patented reference compound included
in our assays. Importantly, we show that kinetic analyses of
inhibitors of these enzymes is important for appropriate
comparison of potencies as we disclose the first examples of
slow, tight-binding behavior for SIRT5 inhibitors. This calls
for more thorough investigations of mechanism-based inhib-
itors for all sirtuins. We also describe structural information
for the binding mode of thiourea-based sirtuin inhibitors for
the first time, which provides important insight for future
inhibitor design.
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S3  Scheme S1. Additional inhibitors for the structure–activity relationship study. Potencies are given as IC50 values or inhibition (%) at the highest tested concentration (given in brackets) HNCbzHN O
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 Scheme S2. Synthesis of thioamide building blocks 
 Scheme S3. Synthesis of tryptophan building blocks 
OHCbzHN OHN S O OtBuO O OtBuHO 1.                       , DCC    DMF, RT2. Cbz-Lys-OH, iPr2NEt    DMF, RT3. Lawesson's reagent    THF, RT1a.                      , DCC      DMF, RT
or1b.                      , DIC    DMF, RT2. Fmoc-Lys-OH    DMF, RT OHFmocHN OHN O O OtBu OHFmocHN OHN S O OtBuHO O O OtBu Lawesson's reagentTHF, RTorLawesson's reagenttoluene, 80 °CN OO OH
N OO OH
S24
S25
S26
N OO OH
H2NR, iPr2NEt, HOBt, EDCCH2Cl2, 0 °C to RTOHBocHN O HNBocHN O RNHNH
S27; R= iPr
S28; R= cyclopropyl
S29; R= cyclobutyl
S30; R= cyclopentyl
S31; R= adamant-1-yl
S32; R=MeO S33; R= iPrS34; R= cyclopropylS35; R= cyclobutylS36; R= cyclopentylS37; R= adamant-1-ylS38; R=MeO HN+H3N O RNHF3C O-OOHBocHN O HNBocHN O F3C O-ONH NH HN+H3N O NHiPrNH2, iPr2NEt, HOBt, EDCCH2Cl2, 0 °C to RT TFA, TIPS,CH2Cl2, RT
S39
S40
TFACH2Cl2, RT
S5 
 Scheme S4. Synthesis of other amino acid building blocks 
  Scheme S5. Synthesis of thioamide inhibitors, part I 
OHNBoc O O O-F3C HNNH2 OiPrNH2, iPr2NEt, HOBt, EDCCH2Cl2, 0 °C to RTOHBocHN OR HNBocHN ORS41; R= CH3S42; R= Ph HN+H3N ORF3C O-OTFACH2Cl2, RT S43; R= CH3S44; R= Ph1. iPrNH2, iPr2NEt,     HOBt, EDC    CH2Cl2, 0 °C to RT2. TFA, CH2Cl2,  RT
S451a. H2NR or TFA·H2NR,      iPr2NEt, HOBt, EDC      CH2Cl2, 0 °C to RT
or1b. H2NR, HOBt, DIC      CH2Cl2,  RT2.   TFA      CH2Cl2, RT RCbzHN OHN S O OH
1; R= NHHN HN HN N
HN HN OO
HN SN HN N SOOHN NH2
HN PhPhHN SHN NHO NH HN NHO NH HN NHO HN NHO
4; R=
10; R= 11; R= 14; R=13; R=
S4; R= 6; R=S1; R= S2; R= 5; R= S5; R=3; R= S3; R= NO NH12; R=3-hydroxyaniline, iPr2NEt, HOBt, EDC, CH2Cl2, 0 °C to RT HNCbzHN OHN S O OtBuOH HNCbzHN OHN S O OHOHTFACH2Cl2, RT
S46 S6
S24
S24
S6 
 Scheme S6. Synthesis of thioamide inhibitor, part II 
 Scheme S7. Solid phase synthesis of tripeptide thioamide inhibitors 
1. tryptamine, HOBt, DIC    CH2Cl2,  RT2. TFA    CH2Cl2, RT HNFmocHN OHN S O OHNH
S7
S26
H2N HN S OHOCbzHN HNO NHO NHChem matrix resinrink amide linker AA1TrpLysHN S OtBuOCbz NH2OR2
15; R2= 16; R2= NH2O 17; R2= NH3+OHONH2O CH3
S11; R2=S9; R2= S10; R2=S8; R2=
1a. TFA, CH2Cl2, RT 2a. AcOH, H2O
or1b. TFA, CH2Cl2, RT 2b. piperidine, DMF, RT
H2N HN S OHOCbzHN R1OAA1LysHN S OtBuOCbzSPPS
2; R1= 7; R1=NH2 HN NH2O NH 8; R1= HN NH2O 9; R1= HN NH2O OHTFACH2Cl2, RTChem matrix resinrink amide linker SPPS
-O O CF3
S7 
 Scheme S8. Synthesis of benotriazole carbothioamido reagents  Scheme S9. Synthesis of thiourea building block S50 
 Scheme S10. Synthesis of thiourea inhibitors, part I 
HCl·β-alanine t-butyl ester,  iPr2NEt,CH2Cl2, 0 °C to RTN NSNN NN N SNN NH O OtBuHCl·β-alanine ethyl ester,iPr2NEt,CH2Cl2, 0 °C to RT N SNN NH O OEtS47S47 S48
S491. HCl·β-alanine t-butyl ester,    iPr2NEt, CH2Cl2, 0 °C to RT2. Cbz-Lys-OH, DMF, RT OHCbzHN OHN S NH O OtBuCbz-Lys-OH, iPr2NEt,DMF, 40-60 °CMethod 1:Method 2: S50S47S481. H2NR or TFA·H2NR,    iPr2NEt, HOBt, EDC    CH2Cl2, 0 °C to RT2. TFA    CH2Cl2, RT HNCbzHN OHN S NH O OHRNH2 PhPhS NHO NH NHO NH29; R= S12; R=S14; R=S13; R= S15; R=V; R= OH HNCbzHN OHN O NH O OHSS16
S50
S8 
 Scheme S11. Synthesis of common intermediate S52  Scheme S12. Synthesis of thioacetamide 18  Scheme S13. Synthesis of compound Et-29  Scheme S14. Synthesis of thiourea inhibitors, part II 
HNOHN O OtBuCbzHN NHO NH HNONH3+CbzHN NHO NH-O CF3OOHOHN O OtBuCbzHN S33, iPr2NEt, HOBt, EDCCH2Cl2, 0 °C to RT TFACH2Cl2, RT
S51 S52HNOHN SCbzHN NHO NHethyl dithioacetate, iPr2NEtCH2Cl2, RTS52
18
S49,  iPr2NEtDMF, RT HNOHNCbzHN NHO NHS NH OEtOS52
Et-291. HCl·glycine t-butyl ester    or H2NR t-butyl ester    iPr2NEt, CH2Cl2, 0 °C to RT2. S52, iPr2NEt, DMF, RT3. TFA, TIPS     CH2Cl2,  RT HNOHN S NHCbzHN NHO NH O OHOHO O OH27; R=28; R=19; R=RS47
S9 
 Scheme S15. Synthesis of inhibitors 21 and 23 HNOHNCbzHN NHO NHO X OHO21; X= NH23; X= O1. HCl·β-alanine t-butyl ester or     3-hydroxy-t-butyl propanoate,    iPr2NEt, CH2Cl2, 0 °C to RT2. S52, iPr2NEt, DMF, RT3. TFA, CH2Cl2,  RTO ClONO2
S10 
 Scheme S16. Synthesis of hydrazide and semicarbazide inhibitors 
Bn2N OBnOBnOO Bn2N OBnOHOOBnONHNBn2N OO TMS OBnOBocNHNBn2N OO TMS OHOBocNHNH2N OO
H2N OHOHOO K2CO3, NaOH,NaI, BnBrH2O, reflux DIBALHTHF, –10 °C to 0 °C 1. DMSO,     oxalyl chloride,     NEt3, CH2Cl2,    –78 °C to 0 °C2. 
    THF, RT
OHOBocNHNCbzHN OO TMS
1. NaCNBH3, AcOH    CH2Cl2, RT2. Boc2O, DMAP    CH2Cl2, RT Pd/C, H2CH3OH, RT                    , NaHCO31,4-dioxane, H2O, RTHNOBocNNH2CbzHN NHO NH1. S33, iPr2NEt,     HOBt, EDC    CH2Cl2, 0 °C to RT2. TBAF    THF, 50 °C HNOHNHNCbzHN NHO NHRO OHONH OHO
1a.                                            ,      iPr2NEt, HATU, CH2Cl2, RTor1b. HCl·β-alanine t-butyl ester,       p-nitrophenyl chloroformate,      iPr2NEt, DMF, 50 °C2.   TFA      CH2Cl2, RT OtBuOHO O
; R=
; R=
N OO OCbzTMS
 




	





NH2HN OO TMSNH2NH2·H2O,4 Å molecular sievesTHF, RTO ClONO2 

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 Scheme S17. Synthesis of fluorinated inhibitors 24 and S17 
S12 
 Scheme S18. Synthesis of inverted amide inhibitor 25 
 Scheme S19. Synthesis of amide inhibitors 
OtBuOBrOHOBr OEtOAcHN OtBuOOEtOOHOCbzHN OtBuO HNOCbzHN NHO NHO OtBuHNOCbzHN NHO NHO OH HNOCbzHN NHO NHO NH OHO
S33, iPr2NEt, HOBt, EDCCH2Cl2, 0 °C to RTtBuOH, DMAP, DCCCH2Cl2, 0 °C to RT
1. NaI, acetone, reflux2.                             ,NaH, DMF,  0 °C to RT1. LiCl, H2O, DMSO, 150 °C2. LiOH, H2O, EtOH,  RT3. Acylase-I, CoCl6·6H2O    0.1M phosphate buffer pH 7.2, 37 °C4.                     , NaHCO31,4-dioxane, H2O, RTTFACH2Cl2, RT 1. HCl·β-alanine t-butyl ester,    iPr2NEt, HOBt, EDC    CH2Cl2, 0 °C to RT2. TFA, CH2Cl2, RTN OO OCbz
EtO O NHAcO OEt
S64 S65
S67S66
25S68 HNOHNCbzHN NHO NHO R OHONHCbzNHCbzO OH26; R=S18; R=1. Cbz-L-Glu-OMe or Cbz-L-Asp-OMe,     iPr2NEt, HOBt, EDC    CH2Cl2, 0 °C to RT2. aq. LiOH    THF, RT                        , iPr2NEt CH2Cl2, 0 °C to RT HNOHNCbzHN NHO NHO PhO OHOO OPh
S52
S52
S19
S13 
 Scheme S20. Synthesis of thiourea inhibitors, part III 
HNOHN O OtBuCbzHN NHO RNH HNONH3+CbzHN NHO RNH-O CF3OOHOHN O OtBuCbzHN H2NR, iPr2NEt, HOBt, EDCCH2Cl2, 0 °C to RT TFA, TIPSCH2Cl2, RT
S69; R= cyclopropyl
S70; R= adamant-1-yl
S71; R=MeO S72; R= cyclopropylS73; R= adamant-1-ylS74; R=MeO1. S48, iPr2NEt    DMF, RT2. TFA, TIPS     CH2Cl2, RT HNOHNCbzHN NHO RNHS NH OHO
45; R= cyclopropyl
47; R= adamant-1-yl
46; R=MeO
S14 
 Scheme S21. Solid-phase synthesis of N-terminal modified thiourea inhibitors 
H2N TrpLysFmoc HN TrpLysR HNTrpLysR HN NHS OtBuO HN NHS OHONHR HNO NH2O NH
1.   piperidine, DMF, RT2a. carboxylic acid, HATU, iPr2NEt, DMF, RTor 2b.                     , iPr2NEt, DMF, RTor2c. p-nitrophenyl chloroformate, H2NR, 0 °C to RT3c. iPr2NEt, DMF, RTor 2d. sulfonyl chloride, iPr2NEt, DMF, RT
SO OFO OO SO OF3C SO OOO SO OO2N
NH O SO ONSO O SO OO
NH OO SO O30; R=31; R=
32; R=
33; R=
34; R=
35; R=
36; R=
37; R=
38; R=
39; R=
40; R=
41; R=
42; R=
43; R=
44; R=
TFA, TIPSCH2Cl2, RTChem matrix resinrink amide linker
N OO OCbzOO TMS OO TMS3. iPr2NEt    DMF, 45 °C2. HCl·β-alanine t-butyl ester,      iPr2NEt, CH2Cl2, 0 °C to RTS471. TBAF     DMF, RT
SPPS
S15 
 Scheme S22. Synthesis of thiourea inhibitors 48 and 49 
HNOHN O OtBuCbzHN NHO RNHOHOHN O OtBuCbzHN TFA·H2NR, iPr2NEt, HOBt, EDCCH2Cl2, 0 °C to RT Pd/C, H2CH3OH, RT
S69; R= cyclopropyl
S75; R= cyclobutyl
S76; R= cyclopentyl HNOHN O OtBuH2N NHO RNHHNOHN O OtBuNH NHO NHSO OF S77; R= cyclopropylS78; R= cyclopentyl                          , iPr2NEtCH2Cl2, RT ClSO OF
S80
S75
1. Pd/C, H2,    CH3OH, RT2.                           ,iPr2NEtCH2Cl2, RT ClSO OF HNOHN O OtBuNH NHO NHSO OF
S77 NH OHN HN NHO NHSOOF S NH OHO1. TFA, TIPS,    CH2Cl2, RT 3. iPr2NEt    DMF, 45 °C4. TFA, TIPS,    CH2Cl2, RT1. TFA, TIPS,    CH2Cl2, RT2. HCl·β-alanine t-butyl ester,     iPr2NEt, CH2Cl2, 0 °C to RTS47 3. iPr2NEt    DMF, 55 °C4. TFA, TIPS,    CH2Cl2, RT NH OHN HN NHO NHSOOF S NH OHOS79 48
49
2. HCl·β-alanine t-butyl ester,     iPr2NEt, CH2Cl2, 0 °C to RT
S47
S16 
 Scheme S23. Synthesis of thiourea inhibitor 50 
 Scheme S24. Synthesis of urea inhibitors, part I 
HNONH3+NH NHO NHSO OF CF3-O ONH OHN HN NHO NHSOOF S NH OHONH OHN HN NHO NHSOOF S NH OtBuO TFA, TIPSCH2Cl2, RT1. HCl·β-alanine t-butyl ester,     iPr2NEt, CH2Cl2, 0 °C to RT2. S82, iPr2NEt, DMF, RT
50
S47
S83
HNOHN O OtBuNH NHO NHSO OF                         , iPr2NEtCH2Cl2, RT ClSO OFS78 TFA, TIPS,CH2Cl2, RT
S81 S82
HNOHN O OtBuCbzHN NHtryptamine, iPr2NEt, HOBt, EDCCH2Cl2, 0 °C to RTOHOHN O OtBuCbzHN HNOHN O NH RCbzHN NH HNOHN O NH RCbzHN NH
1. TFA, CH2Cl2, RT2.                                , iPr2NEt    CH2Cl2, 0 °C to RT3. HCl·H2NR, iPr2NEt    CH2Cl2, refluxN NONNTFACH2Cl2, RTOtBuO OHOO OtBu O OHS85; R=S86; R= S20; R=S21; R=
S84
S17 
 Scheme S25. Synthesis of urea inhibitors, part II                               ,    iPr2NEt, CH2Cl2, 0 °C to RT2. HCl·H2NR, iPr2NEt    DMF, 60 °C or 80 °CO-O CF3 TFACH2Cl2, RTOOHN O NHFmocHNOONH3+FmocHN N NONN OtBuO R OOHN O NHFmocHN ROHOO OtBu O OHS87; R=S88; R= S22; R=S23; R=1.
S18 
 Figure S1. Concentration–response curves for SIRT5 inhibition of representative compounds using (A) Ac-LGKglu-AMC or (B) Ac-LGKsuc-AMC as substrate, respectively. 
–2 –1 0 1 2 3050100Residual activity / % 101517121314–2 –1 0 1 2 3050100Residual activity / % 3033383937–2 –1 0 1 2 3–3050100 log[inhibitor (μM)]Residual activity / % 454647
–2 –1 0 1 2 3050100 2927282126–2 –1 0 1 2 3050100 4041424344–2 –1 0 1 2 3
–3–3 –3–3–3050100 log[inhibitor (μM)] 484950–3 –2 –1 0 1 2 3050100 log[inhibitor (μM)]Residual activity / % 29 (  0.15 μM ± 0.02 μM)48 (  0.42 μM ± 0.01 μM)49 (  0.17 μM ± 0.01 μM)50 (  0.31 μM ± 0.01 μM)V (20      μM ± 1      μM)
A
B
S19 
 Figure S2. Co-crystal structures of 29:zSIRT5.The complex crystal structure of 29:zSIRT5 is composed of four protein chains (chain A to D) per asymmetric unit, one of which comprised an indistinguishable mixture of peptidyl-thioimidate and bicyclic intermediate. 2Fo-Fc electron density (s = 1.0) is shown for the intermediate ligand of each protein chain. SIRT5 is represented as green cartoon with amino acids of interest in stick style, while the intermediates are shown in white cpk colored stick representation. 
 Figure S3. Progression curves and data fitting for SIRT5 inhibition by compound 10 and V. 0.0 0.8 1.600.075 [inhibitor] / M  k obs / min–1   Ki ~ 20 nM0 30
1.5 Compound 10[AMC] / μM  time / min  (µM)0 1.590.880.490.270.150 Ki = 13 μM ± 1 μMv i/v o
1.5[AMC] / μM  time / min  0 300 Compound V0 1 2 301 log[inhibitor (μM)]
S20 
 Figure S4. Western blot analysis of whole cell lysates after Et-29 treatment or mitochondrial enrichment. (A) Effects of Et-29 on lysine glutarylation and malonylation in HEK293T WT and crSIRT5KO cells (whole cell lysates). (B) Analysis of lysine succinylation and glutarylation in mitochondria enriched fractions of HEK293T WT and crSIRT5KO cells (Mito=mitochondrial fraction, Cyt=cytosolic fraction, WCl=Whole cell lysate). Anti-UQCRSF1 was used to analyze mitochondrial enrichment. To assess the effect of Et-29 in cells, we treated HEK293T WT and CRISPR/Cas9 SIRT5 knock out (crSIRT5KO) whole cell lysates, analyzing for changes in lysine glutarylation and succinylation levels. However, we observed no significant changes in the levels of either glutarylation or succinylation (Fig. S4A). Interestingly, no significant difference could be observed between untreated WT and crSIRT5KO cells either. Since succinyl and glutaryl modification of lysines are found on many mitochondrial proteins, we hypothesized that a larger difference in acylation levels between WT and crSIRT5KO cells could be detectable when analyzing this fraction—potentially making this a more suitable assay for evaluation of Et-29. However, mitochondrial enrichment of WT and crSIRT5KO cells did not show any significant changes in acylation levels between the cell lines either (Fig S4B). 
S21  Figure S5. Western blot analysis of whole cell lysates after Et-29, MalNAC or GSKi treatments. (A) Effects of Et-29 on lysine malonylation in HEK293T WT and crSIRT5KO cells. (B) Effects of MalNAC and GSKi on lysine malonylation in HEK293T WT and crSIRT5KO cells (initial experiment, one sample of the triplicate loaded). (C) Effects of GSKi on lysine malonylation in HEK293T WT and crSIRT5KO cells (initial experiment, all samples of the triplicate loaded). (D) Effects of GSKi on lysine malonylation in HEK293T WT and crSIRT5KO cells (second experiment, all samples of the triplicate loaded).  
S22 
Since our initial efforts were unable to detect any significant differences in glutarylation or succinylation between WT and crSIRT5KO cells, we turned our attention to lysine malonylation, which is also regulated by SIRT5. We treated cells with Et-29 and analyzed whole cell lysates for changes in malonyl-lysine levels. The results showed no significant changes in malonylation, nor were there any differences between the two cell lines (Figure S5A).  A recent report by Kulkarni et al. have demonstrated that treating cells with an acylating reagent, Malonyl-NAC (MalNAC, Figure S5B), could considerably increase lysine malonylation in cells.[1] Additionally, they showed a similar effect when treating cells with a fatty acid synthase inhibitor (orlistat), which leads to increased availability of malonyl-CoA, the acyl donor in lysine malonylation. Inspired by this study, we hypothesized that increasing the on-rate of acylation by using MalNAC (obtained from Jordan L. Meier’s lab) or the fatty acid synthase inhibitor GSK2194059 (GSKi, Figure S5B, Sigma-Aldrich, #SML1259-5MG) would increase our chances of observing changes in acylation levels between WT and crSIRT5KO cells. In our initial assay, both treatment with MalNAC and GSKi increased malonylation significantly in both cell lines (Figure S5B). However, no significant difference in malonylation was observed between the two cell lines, except when treated with a low concentration of GSKi (Figure S5C). Although these results were promising, the levels of malonylation upon GSKi treatment turned out to be considerably variable. In subsequent assays only minor or no apparent increase in malonylation could be observed (one example, Figure S5D, compare with Figure S5C). The variability in cell culture acylation response and lack of observable changes between WT and crSIRT5KO cells prevented accurate evaluation of the effect of Et-29 on SIRT5 regulated acylation in cells. Furthermore, western blot quantification of complete lanes is not an accurate representation of acylation. Consequently, probing specific SIRT5 targets or utilizing quantitative proteomics to measure changes in acylation may be more suitable assays to evaluate the effect of SIRT5 inhibitors, including prodrugs like Et-29. 
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Table S1. Kinetic parameters and dissociation constants for slow-binding inhibitors 29 and 49 derived from rate inhibition assays.   10  29  49 k–2  (min–1) 0.053 ± 0.0050  0.0080 ± 0.0098  0.0042 ± 0.0051 k2 (min–1) 0.050 ± 0.003  0.32 ± 0.08  0.41 ± 0.08 Ki,1 (µM) 0.23 ± 0.10  1.5 ± 0.8  0.62 ± 0.19        Ki (µM) ~0.022  ~0.037  ~0.006    Table S2. Data collection and refinement statistics  zSirt5/ 10-ADPr-1′-thioimidate zSirt5/ 29-ADPr-1′-thioimidate hSirt5/ 29-ADPr-1′-thioimidate Space group C2 P21 P1 Unit cell constants (Å; °) 116.5 / 38.3 / 75.6; 90.0 / 122.5 / 90.0 64.9 / 113.6 / 72.3; 90.0 / 103.2 / 90.0 40.3 / 56.0 / 123.0; 97.4 / 99.3 / 90.5 Resolution[a] (Å) 50.00–1.95 (2.00–1.95) 50.00–2.40 (2.50–2.40) 43.77–1.32 (1.40–1.32) Unique reflections  20704 (1518) 38453 (4467) 227669 (35569) Multiplicity  4.1 (4.1) 3.8 (3.8) 2.0 (1.9) Completeness (%) 99.1 (99.2) 96.2 (97.3) 91.5 (88.1) Rmeas (%) 21.3 (156.5) 25.2 (170.2) 5.9 (95.9) CC1/2 (%) 98.9 (46.3) 98.9 (51.7) 99.9 (72.3) I/sI  6.8 (1.1) 6.1 (0.9) 6.8 (1.1) Protein atoms 2088 8579 8501 Ligand atoms 80 400 640 Solvent atoms 177 193 1244 Resolution (Å) 49.11–1.95 (2.00–1.95) 48.41–2.40 (2.46–2.40) 43.77–1.32 (1.35–1.32) Rcryst/Rfree[b,c] (%) 19.5 / 24.2 25.3 / 30.5 16.0 / 20.9 Average B-factors (Å2)      protein  26.8  53.5  20.5      ligands 20.4 49.3 17.4      solvent 34.4 44.2 40.3 RMSD bond lengths 0.016  0.013  0.031 RMSD bond angles  2.0 2.0  2.9 [a] Values in parentheses refer to outermost shell. [b] !"#$%& = ()*+ ,- (./0.|||()*+|  . |Fobs| is the observed and |Fcalc| the calculated structure factor amplitude. [c] Rfree was calculated from 5% (zSirt5 complexes) or 1.1% (hSirt5 complex) of reflections omitted from refinement. 
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General experimentals All reagents and solvents were of analytical grade and used without further purification as obtained from commercial suppliers. Anhydrous solvents were obtained from a PureSolv-system. Reactions were conducted under an atmosphere of argon or nitrogen whenever anhydrous solvents were used. All reactions were monitored by thin-layer chromatography (TLC) using silica gel coated plates (analytical SiO2-60, F-254). TLC plates were visualized under UV light and by dipping in either (a) a solution of potassium permanganate (10 g/L), potassium carbonate (67 g/L) and sodium hydroxide (0.83 g/L) in water, (b) a solution of ninhydrin (3 g/L) in 3% acetic acid in water (v/v), or (c) a solution of molybdato-phosphoric acid (12.5 g/L) and cerium(IV)sulfate (5 g/L) in 3% conc. sulfuric acid in water (v/v) followed by heating with a heat gun. Vacuum liquid chromatography (VLC) was performed with silica gel 60 (particle size 15–40 µm). After column chromatography, appropriate fractions were pooled and dried at high vacuum (<2 mbar) for at least 12 hours to give obtained products in high purity (>95%) unless otherwise stated. Evaporation of solvents was carried out under reduced pressure at a temperature below 40 °C. UPLC−MS analyses were performed on a Phenomenex Kinetex column (1.7 µm, 50×2.10 mm) using a Waters Acquity ultra high–performance liquid chromatography (UPLC) system. Gradient A with eluent I (0.1% HCOOH in H2O) and eluent II (0.1% HCOOH in MeCN) rising linearly from 0% to 95% of II during t = 0.00–5.20 min was applied at a flow rate of 0.6 mL/min. Preparative reversed-phase HPLC purification was performed on a C18 Phenomenex Luna column (5 μm, 100 Å, 250×20 mm) using an Agilent 1260 LC system equipped with a diode array UV detector and an evaporative light scattering detector (ELSD). Gradient B with eluent III (H2O/MeCN/TFA, 95:5:0.1) and eluent IV (0.1% TFA in MeCN) rising linearly from 0% to 95% of IV during t = 5−45 min, then isocratically at 95% during t = 45–50 min was applied at a flow rate of 20 mL/min; or 0% to 95% of IV during t = 5−65 min, then isocratically at 95% during t = 65–70 min was applied at a flow rate of 20 mL/min. Analytical HPLC was performed on a C18 phenomenex Luna column (3 µm, 100 Å, 150×4.60 mm) using an Agilent 1100 series system equipped with a diode array UV detector. Gradient C using eluent III and eluent IV, rising linearly from 0% to 95% of IV during t = 5−35 min was applied at a flow rate of 1 mL/min. High-resolution mass spectrometry (HRMS) measurements were recorded either on a maXis G3 quadrupole time-of-flight (TOF) mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with an electrospray (ESI) source or on an Agilent 1290 UHPLC equipped with a diode array detector and coupled to Agilent 6550 QTOF mass spectrometer operated in positive electrospray or on a Bruker Solarix WR by either matrix assisted laser desorption/ionization, or electrospray ionization (ESI). Nuclear magnetic resonance (NMR) spectra were recorded either on a Bruker Avance III HD equipped with a cryogenically cooled probe (1H NMR and 13C NMR recorded at 600 and 151 MHz, respectively), a Bruker Avance III (1H NMR, 13C NMR and 19F NMR recorded at 400, 101, and 377 MHz, respectively), or a Bruker Ascend 400 MHz (1H NMR and 13C NMR recorded at 400 and 101 MHz, respectively). All spectra were recorded at 298 K unless otherwise stated. Chemical shifts are reported in ppm relative to deuterated solvent as internal standard (δH DMSO-d6 2.50 ppm; δC DMSO-d6 39.52 ppm; δH CDCl3 7.26 ppm; δC CDCl3 77.16 ppm; δH Methanol-d4 3.31 ppm; δC Methanol-d4 49.0 ppm). Assignments of NMR spectra are based on 2D correlation spectroscopy (COSY, HSQC, and HMBC spectra). Melting point measurements were performed on a Stanford Research Systems DigiMelt MPA161 apparatus. 
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Fluorescence-based in vitro sirtuin deacylase assays Materials—SIRT1 (aa 193–741 with N-terminal GST-tag, >60% purity), SIRT2 (aa 50–356 with C-terminal His-tag, >90% purity), and SIRT6 (full length with N-terminal GST-tag, >75% purity) were purchased from BPS Biosciences (San Diego, CA); SIRT3 (aa 102–399 with N-terminal His-tag; ~75% purity) and  SIRT5 (aa 37–310 with N-terminal His-tag, >90% purity) were purchased from Enzo Life Sciences (Farmingdale, NY). Purities were based on SDS-PAGE and Coomassie blue stain according to the supplier, and all enzyme concentrations given are based on stock concentrations according to the supplier. Assay buffer was prepared as described in Biomol International product sheets BML-KI-143 [http://www.enzolifesciences.com/BML-AK500/fluor-de-lys-hdac-fluorometric-activity-assay-kit/] [TRIS HCl (50 mM), NaCl (137 mM), KCl (2.7 mM), MgCl2 (1 mM), pH 8.0] with addition of BSA (1.0 mg/mL). Trypsin (10,000 units/mg, TPCK treated from bovine pancreas, T1426) was purchased from Sigma-Aldrich (Steinheim, Germany). All chemicals and solvents were of analytical grade were and used without further purification as obtained from commercial suppliers. Fluorescence-based sirtuin deacylase assays—All reactions were performed in black low binding 96-well microtiter plates (Corning half area wells), with duplicate series in each assay and each assay performed at least twice. Control wells without enzyme were included in each plate. All reactions were performed in assay buffer, with appropriate concentrations of substrates and inhibitors obtained by dilution from 3.8–50 mM stock solutions in either water or DMSO, and appropriate concentration of enzyme obtained by dilution of the stock provided by the supplier. DMSO concentration in the final assay solution did not exceed 2% (v/v) and control wells without either enzyme (negative control) or inhibitor (positive control) were included in each plate. All plates were analyzed using a Perkin Elmer Enspire plate reader with excitation at 360 nm and detecting emission at 460 nm. Fluorescence measurements (RFU) were converted to [AMC] concentrations based on a [AMC]–fluorescence standard curve, and all data analysis was performed using GraphPad Prism. End-point sirtuin 5 inhibition assays, initial screening—Relevant substrate and inhibitor was added to each well, and the experiment initiated by addition of a freshly prepared solution of sirtuin 5, for a final volume of 25 µL per well. The following final concentrations were used: SIRT5 (172 nM), Ac-LGKglu-AMC (50 µM), NAD+ (500 µM), and inhibitor (100 µM or 10 µM). The plate was incubated at 37 °C for 30 min, then a solution of trypsin and nicotinamide (25 µL, 0.4 mg/mL and 8 mM, respectively; final concentration 0.2 mg/mL and 4 mM, respectively) was added and the assay development was allowed to proceed for 15 min at room temperature, before fluorescence measurement and calculation of residual activity. End-point sirtuin 5 inhibition assays, concentration–response—Relevant substrate and inhibitor was added to each well, and the experiment initiated by addition of a freshly prepared solution of sirtuin 5, for a final volume of 25 µL per well. The following final concentrations were used: SIRT5 (172 nM), Ac-LGKglu-AMC (50 µM) or Ac-LGKsuc-AMC (50 µM), NAD+ (500 µM), and inhibitor (3-fold dilution series). The plate was incubated at 37 °C for 30 min, then a solution of trypsin and nicotinamide (25 µL, 0.4 mg/mL and 4 mM, respectively; final concentration 0.2 mg/mL and 2 mM, respectively) was added and the assay development was allowed to proceed for 15 min at room temperature, before fluorescence measurement. Residual activity was calculated, and assuming a standard fast-on/fast-off mechanism, IC50 values were obtained by fitting the resulting data to the concentration–response equation (Eq. 1).  End-point sirtuin inhibition assays, sirtuin selectivity—Using the protocol described above, SIRT1–3 (SIRT1: 250 nM; SIRT2 250 µM; SIRT3: 500 nM) and Ac-QPKKac-AMC (50 µM), SIRT5 (100 nM) and Ac-QPKKsuc-AMC (50 µM) or Ac-QPKKglu-AMC (50 µM), or SIRT6 (500 nM) and Ac-QPKKdec-AMC (50 µM) were incubated with NAD+ (500 µM) and inhibitor (100 µM or 10 µM).[16] The plate was incubated at 37 °C for 60 min, then a solution of trypsin and nicotinamide (25 µL, 5 mg/mL and 4 mM, respectively; final concentration 2.5 mg/mL and 2 mM, respectively) was added and the assay development was allowed to proceed for 90 min at room temperature, before fluorescence measurement and calculation of residual activity. vi = vbottom + vtop – vbottom1 + 10 logIC50 – log[I] hEq. 1
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End-point sirtuin 5 pre-incubation assays—Sirtuin 5 and inhibitor was pre-incubated with or without NAD+ for 5 min at rt or 15 or 30 min at 37 °C in a total volume of 40 µL, prior to addition of substrate (and NAD+ if excluded in pre-incubation), for a final volume of 45 µL. For pre-incubation excluding NAD+, the following concentrations were used: SIRT5 (113 nM during pre-incubation, giving 100 nM after substrate and NAD+ addition), inhibitor (113/100 µM, 11.3/10 µM, 1.13/1.0 µM, or 0.11/0.10 µM), substrate (0/50 µM), NAD+ (0/500 µM); For pre-incubation including NAD+, the following concentrations were used: SIRT5 (113 nM during pre-incubation, giving 100 nM after substrate addition), inhibitor (113/100 µM, 11.3/10 µM, 1.13/1.0 µM, or 0.11/0.10 µM), NAD+ (563/500 µM), and substrate (0/50 µM). The plate was incubated at 37 °C for 30 min, then a solution of trypsin and nicotinamide (5 µL, 2.0 mg/mL and 40 mM, respectively; final concentration 0.2 mg/mL and 4 mM, respectively) was added and the assay development was allowed to proceed for 15 min at room temperature, before fluorescence measurement and calculation of residual activity. Rate inhibition assays, concentration–response—Rate experiments for determination of kinetic parameters were evaluated under varying inhibitor concentrations. Sirtuin 5 was incubated with the relevant substrate, inhibitor and trypsin in assay buffer in a total volume of 50 µL per well using the following final concentrations: SIRT5 (100 nM); Ac-LGKglu-AMC (23 µM), NAD+ (500 µM) and trypsin (0.125 ng/µL). In situ fluorophore release was monitored immediately by fluorescence readings recorded every 30 seconds for 35 min at 25 °C. The data were fitted to the relevant equations (Eq. 2 or 3) to obtain either initial linear rates (n) or apparent first-order rate constant (kobs) for each inhibitor concentration. Secondary plots were then fitted to the relevant equations (Eq. 1, 4, or 5) to obtain the desired dissociation constants (Ki and Ki,1) and/or kinetic parameters (k1, k–1, k2 and k–2).  Expression and purification of hSirt5 and zSirt5 hSirt5(34-302) and zSirt5(30-298) proteins were expressed in E. coli Rosetta2 (DE3) cells and E. coli BL21-CodonPlus™ (DE3) cells, respectively, and purified through Co-Talon affinity chromatography, TEV-proteolysis, reverse affinity chromatography and gel filtration as previously reported[17], except that zSirt5 gel filtration buffer was 20 mM TRIS HCl, pH 8.5, 150 mM NaCl, 0.5 mM TCEP. Crystallization and structure solution 10 mg/mL zSirt5 or hSirt5 protein, 1 mM compound 10 or 29 and 5 mM NAD+ were mixed and pre-incubated for 30 min on ice (DMSO concentration 10% during incubation; compound stocks 20 mM in DMSO, NAD+ stock 50 mM in sodium phosphate buffer pH 8.0) before setting up sitting-drop vapor-diffusion crystallization experiments at 20 °C. Co-crystallization was achieved by using 20% PEG8000, 0.2 M MgCl2, 0.1 M TRIS HCl, pH 8.5, 0.1 M glycine for zSirt5 complexes and 30% PEG3350, 0.2 M NaCl, 0.1 M BIS-TRIS, pH 5.5, 5% 1,3-butandiol for the hSirt5 complex as reservoir solution. 2 µL crystallization drops were prepared with a 1:1 ratio of protein/ligand and reservoir solution, which were equilibrated against 200 µL reservoir solution in MRC Maxi 48-well crystallization plates (Hampton Research, Aliso Viejo, USA, # HR3-179). After 2–4 days, tiny crystal cubes (zSirt5) or large cubes, rods and bundles of rods (hSirt5) appeared. The crystals were transferred to a cryo-solution drop composed of reservoir and ligands supplemented with 25% glycerol prior to shock-freezing in liquid nitrogen and data collection. hSirt5 diffraction was mostly anisotropic, but one of the rods showed clearer diffraction images and was used for structure solution. Diffraction data collection was performed at 100 K at BESSY II beamline MX14.1[18] (operated by the Helmholtz-Zentrum Berlin, Germany) with a Pilatus 6M detector (Dectris, Baden, Switzerland) or at Swiss Light Source beamline 
kobs =Eq. 5 1 + [S]
KM[I] + Ki,1k2 [I] + k–21 + [S]KMkobs = k1Eq. 4 [I] + k–1 [P] = vsst + 1 – evin – vsskobs –kobstEq. 3[P] = vtEq. 2
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X06DA - PXIII (Paul Scherrer Institut, Villigen, Switzerland) with a Pilatus 2M-F detector (Dectris, Baden, Switzerland). Indexing, scaling and merging of diffraction data were done using XDS.[19] Structures were solved by Phaser[20]  molecular replacement with search models PDB 3RIY (hSirt5/succinyl-H3K9/NAD+ complex) for the hSirt5 complex and PDB 4UTV (zSirt5/3-phenyl-succinyl-CPS1) for the zSirt5 complexes. Refinement was performed using Refmac5[21] and manual modeling as well as structure validation were done with Coot.[22] Geometry parameters for compounds and intermediates were generated using PRODRG[23] and structure figures created with PyMOL Molecular Graphics System (Version 1.7 Schrödinger, LLC).  Cell culture and generation of crSIRT5KO cells HEK293T were obtained from Dr. Eric Verdin’s lab. The HEK293T crSIRT5KO cell line was generated with Dharmacon’s Edit-R gene engineering system that uses plasmid-driven Cas9 nuclease expression, synthetic tracrRNA and crRNA for gene of interest as per manufacturer’s protocol.  Briefly, an Edit-R hCMV-Puro-Cas9 (#U-005100-120) was co-transfected with Edit-R tracrRNA (#U-002000-120) and Edit-R crRNA’s for SIRT5 into HEK293T cells using the DharmaFECT Duo (#T-2010-03) transfection reagent. After 48 hours of transfection, positively transfected cells were selected using 2 µg/mL puromycin for 3 days and mono-clonal populations were selected using serial dilution technique. The guide sequence targeting the sense strand at sequence 5’-GAT GAG CTG CAC CGC AAG GC-3’ in Exon 5 of human SIRT5 was selected from Dharmacon’s online CRISPR RNA configurator tool (http://dharmacon.gelifesciences.com/gene-editing/crispr-rna-configurator/). Control cells underwent the same procedure as the crSIRT5KO cells, except they did not receive the gene-specific crRNA. Each clonal population was cultured and analyzed for loss of SIRT5 protein by Western blotting. Both cell lines were maintained at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM, Thermo Scientific #11965118) supplemented with 10% (v/v) fetal bovine serum (FBS, Thermo Scientific #26140079).  Western blotting and Antibodies Equal amounts of denatured protein samples (30–60 μg) were uniformly loaded and run on BioRad AnykD Criterion TGX Precast Midi Protein Gels, 14 well (#5671123), 18 well (#5671124), or 26 well (#5671125), 15–40 uL at 150–180 V for 45–60 minutes. The proteins were wet-transferred to a 0.45 μm nitrocellulose membrane in a BioRad Criterion™ Blotter at 100 V for 90 minutes at 4 °C. The membranes were blocked for 1 hour in LI-COR blocking buffer (20 mM TRIS base, 150 mM NaCl, 0.45% fish gelatin, 0.1% casein and 0.02% azide, pH 7.5). Primary antibodies (1:1000–1:2000) were diluted in LI-COR blocking buffer (containing 0.1–0.2% Tween-20) overnight at 4 °C. Membranes were washed with TRIS-buffered saline (TBS, 20 mM TRIS base, 150 mM NaCl, containing 0.1% Tween-20), 4–6 times for 5–10 minutes each. Infra-red dye-conjugated secondary antibodies were diluted 1:10,000 in LI-COR blocking buffer containing 0.1–0.2% Tween-20 and incubated for 1 hour at room temperature. Western blots were visualized on a LI-COR Odyssey CLx imager. Un-stripped blots were re-probed for loading control and image analysis to quantify band-intensity was performed using the LI-COR Image Studio software (version 3.0.12). Antibodies: anti-SIRT5 (Sigma-Aldrich #HPA022002), anti-β-actin (Cell Signaling Technologies, #3700), anti-GAPDH (Santa Cruz Biotechnology, #sc-32233), anti-UQCRFS1 (Abcam, #ab14746), anti-glutaryl-lysine (Cell Signaling Technologies, non-commercial and PTM-Biolabs #1151), anti-succinyl-lysine (Cell Signaling Technologies, non-commercial and PTM-Biolabs #401), anti-malonyl-lysine (Cell Signaling Technologies, #14942), IRDye 680RD Donkey anti-mouse IgG (LI-COR, #926-68072), and IRDye 800CW Donkey anti-rabbit IgG (LI-COR, #926-32213). Drug treatment of HEK293T WT and crSIRT5KO cells Et-29 treatment—The crSIRT5KO and WT cells at passage 11 were treated with 1 or 10 µM of Et-29 or respective volume of DMSO as control, in duplicate. Cells were plated at a density of 120,000 cell per well in 6-well plates and the SIRT5 inhibitor/DMSO were included in the plating media. After incubation for 48 hours, cells were washed in  phosphate-buffered saline (PBS, pH 7.4, Thermo Scientific #10010023) and collected in ice-cold radio immunoprecipitation assay buffer (RIPA buffer, 20 mM TRIS base, 150 mM NaCl, 0.5% 
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sodium deoxycholate, 0.1% sodium dodecyl sulphate, 0.1% triton-X-100, 1 mM EDTA, 1 mM EGTA, pH 7.4) buffer containing protease- (Sigma-Aldrich, #P8340) and/or phosphatase (Sigma-Aldrich, #P0044 and P5726) inhibitors, 10 μM Trichostatin A (Selleckchem, #S1045), 10 mM nicotinamide (Sigma-Aldrich, #N5535) and 10 mM sodium butyrate (Sigma-Aldrich, #303410). Cells were lysed by sonication (10 intermittent pulses with a probe sonicator) after which samples were vortexed and centrifuged at 14,000×g for 1 hour. Supernatants were collected and protein concentration was determined using a Bicinchoninic Acid Protein Assay Kit (BCA assay, Sigma-Aldrich # BCA1). Western blot analysis of lysine glutarylation was performed as described above.  Malonyl-NAC[1] and GSK2194069 treatement—Malonyl-NAC (MalNAC) was obtained from Jordan L. Meier’s lab. Fatty acid synthase inhibitor GSK2194069 (GSKi) was purchase from Sigma-Aldrich (#SML1259-5MG). The crSIRT5KO and WT cells at passage 11 were plated at a density of 200,000 cell per well in 6-well plates, in triplicate. After 48 hours cells were treated with MalNAC (0.5 or 1.0 mM) or GSKi (30 or 15 nM) or respective volume of DMSO as control. After incubation for 24 hours, cells were collected in RIPA buffer and western blot analysis of lysine malonylation was performed, as described above.   Mitochondrial enrichment crSIRT5KO and WT cells at passage 11 were plated at a density of 2,200,000 cells in tissue-culture dishes (100×20 mm), in triplicate. After 48 hours in culture, media was aspirated and cells were collected in ice-cold PBS (12 mL). The cell suspension was centrifuged at 1000×g for 5 minutes at 4 °C and the resulting supernatant was aspirated. The pellet was resuspended in MHS buffer (220 mM mannitol, 70 mM sucrose, 5 mM potassium-HEPES, 10 mM nicotinamide, pH 7.5, 750 µL). An aliquot (50 µL) was mixed with aq. triton-X-100 (10%, containing Halt protease inhibitors 10× (Halt, Thermo Scientific, #78441), 5 µL), representing the whole cell lysate. The remaining cell lysate was transferred to a dounce homogenizer, and stroked 50 times. The dounced suspension was pelleted at 750×g for 5 minutes at 4 °C and the supernatant was collected. The pellet was resuspended in MHS buffer (300 µL) and transferred to a dounce homogenizer and stroked 50 times. The homogenate was centrifuged at 750×g for 5 minutes at 4 °C and the resulting supernatant was pooled with the previously collected supernatant. The pooled supernatants were pelleted at 14000×g for 10 minutes at 4 °C and an aliquot (100 µL) of the supernatant was mixed with aq. Triton-X-100 (10%, containing Halt (10×), 10 µL), representing the cytosolic fraction. The remaining supernatant was aspirated and the pellet was washed with MHS buffer (200 µL) and pelleted at 14000×g for 10 minutes at 4 °C and the supernatant was aspirated. This washing step was repeated 3 times, and after the last wash the pellet was resuspended in isolation buffer (30 µL) and mixed with aq. Triton-X-100 (10%, containing Halt (10×), 3 µL), representing the mitochondrial fraction. The three fractions (whole cell lysate, cytosolic and mitochondrial) were vortexed and protein concentration was determined using a BCA assay. Western blot analysis of lysine succinylation and lysine glutarylation was performed, as described above.  Full bibliography for references with more than 10 authors in the manuscript [4a] H. Jiang, S. Khan, Y. Wang, G. Charron, B. He, C. Sebastian, J. Du, R. Kim, E. Ge, R. Mostoslavsky, H. C. Hang, Q. Hao, H. Lin, Nature 2013, 496, 110-113 [4d]  A. S. Madsen, C. Andersen, M. Daoud, K. A. Anderson, J. S. Laursen, S. Chakladar, F. K. Huynh, A. R. Colaço, D. S. Backos, P. Fristrup, M. D. Hirschey, C. A. Olsen, J. Biol. Chem. 2016, 291, 7128-7141. [5a] C. Peng, Z. Lu, Z. Xie, Z. Cheng, Y. Chen, M. Tan, H. Luo, Y. Zhang, W. He, K. Yang, B. M. M. Zwaans, D. Tishkoff, L. Ho, D. Lombard, T. C. He, J. Dai, E. Verdin, Y. Ye, Y. Zhao, Mol. Cell. Proteomics 2011, 10, M111.012658. [5d] J. Du, Y. Zhou, X. Su, J. J. Yu, S. Khan, H. Jiang, J. Kim, J. Woo, J. H. Kim, B. H. Choi, B. He, W. Chen, S. Zhang, R. A. Cerione, J. Auwerx, Q. Hao, H. Lin, Science 2011, 334, 806-809. [6a] M. Tan, C. Peng, K. A. Anderson, P. Chhoy, Z. Xie, L. Dai, J. Park, Y. Chen, H. Huang, Y. Zhang, J. Ro, G. R. Wagner, M. F. Green, A. S. Madsen, J. Schmiesing, B. S. Peterson, G. Xu, O. R. Ilkayeva, M. J. Muehlbauer, T. Braulke, C. Mühlhausen, D. S. Backos, C. A. Olsen, P. J. McGuire, S. D. Pletcher, D. B. Lombard, M. D. Hirschey, Y. Zhao, Cell Metab. 2014, 19, 605-617. 
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N
ADþ -dependent protein deacylases (sirtuins) constitute a
unique class of enzymes that are conserved from bacteria
to humans. Initially recognized as protein deacetylases,
they were recently shown to catalyse further post-translational
modifications such as demyristoylation1,2, desuccinylation3 or
ADP-ribosylation4. Through a multitude of protein substrates,
they are involved in key cellular processes, including metabolic
sensing, regulation of mitosis and aging. The human isotype
Sirtuin 2 (Sirt2) deacetylates both nuclear and cytoplasmatic
proteins and thereby functions as a major cell cycle regulator5,6,
a determinant of myelination7, a regulator of autophagy8 and a
suppressor of brain inflammation9. Generally deemed as a
tumour suppressor10,11 in some types of cancer, Sirt2 was also
shown to adopt a contrary role by promoting tumorigenesis12,13.
In addition, recent reports link Sirt2 to bacteria-induced
reprogramming of host cell gene expression14.
Owing to its multiple regulatory roles, Sirt2 has been
implicated as a potential drug target to combat cancer12,13,
neurodegeneration15,16 and inflammation7 but other reports
question the suitability of Sirt2 as a drug target17. The
physiological studies of Sirt2 have so far been hampered by the
lack of potent and isotype-specific modulators of sirtuin activity.
The biochemistry of sirtuins has been studied extensively in
recent years and three-dimensional structures of the catalytic
domain of several human isotypes provided insight into different
stages of the catalytic cycle18–23. Despite a highly conserved
amino-acid sequence and a high structural similarity of the
catalytic core between the members of the sirtuin family, recent
screening campaigns have identified several isotype-selective
inhibitors15,24–27. But for only a few of them structural
information is available (Supplementary Fig. 1a) and a strategy
for structure-based optimization of isotype-selective inhibitors
remains mostly elusive. In particular, a structure-derived
rationale for Sirt2-selective inhibition is also lacking so far.
Most recently, the first X-ray structure of Sirt2 in complex with a
potent macrocyclic peptidic inhibitor was reported, but this
inhibitor lacked the desired isotype selectivity28 and, due to its
physicochemical properties, might be of limited use for drug
discovery. In this work, we present the first crystal structures of
Sirt2 in complex with a potent and Sirt2-selective small-molecule
inhibitor with drug-like properties. The basis for the high
potency and unprecedented isotype selectivity is a ligand-
induced structural rearrangement of the active site, exploiting
an adjacent binding pocket. Along with kinetic studies, the
structures give insight into a unique and isotype-selective
inhibition mechanism. The relevance of the observed
biochemical activity is further supported by cellular studies.
Results
Identification and crystallization of SirReal inhibitors. In
search for new sirtuin inhibitors, we screened an internal com-
pound library using an in vitro assay29 based on a fluorophore-
labelled acetyl-lysine derivative for human Sirt1–3. In this
screening campaign, a family of aminothiazoles that we have
termed Sirtuin-rearranging ligands (SirReals) was discovered as
potent, Sirt2-selective inhibitors. Of these, SirReal2 (1) showed
the most promising inhibitory properties (Fig. 1a,b). AGK2 was
used as a reference inhibitor. Under the same assay conditions it
is 38-fold less potent with an IC50 of 15.4±0.7 mM. The activity of
Sirt1 or Sirt3 was not affected at 50 mM. Additional confirmation
of Sirt2-selective in vitro inhibition and binding by SirReal2 was
obtained by using non-labelled peptidic substrates in a high-
performance liquid chromatography (HPLC)-based conversion
assay (Fig. 1c, Supplementary Fig. 1b) and from thermal stability
assays, where the presence of SirReal2 led to increased melting
temperatures due to ligand-induced stabilization of the protein
(Fig. 1d). SirReal2 only inhibits Sirt2 potently with an IC50 value
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Figure 1 | SirReal2 selectively inhibits Sirt2 in a dose-dependent manner. (a) Chemical structure of SirReal2 (1). (b) Representative dose–response curve
for Sirt1–3 and SirReal2 using the substrates ZMAL (Z-Lys(Acetyl)-AMC, Sirt1-2) resp. Fluor-de-Lys (Sirt3). Compared with the peptide-HPLC assay,
SirReal2 was slightly less potent using ZMALwith an IC50 value of 0.4mM. Data are presented as mean±s.d. (n¼ 3). (c) In vitro inhibition data for SirReal2
(Sirt1–3: 100mM; Sirt4–6: 200mM) in an assay using non-labelled acyl-lysine oligopeptide as a substrate (Sirt1–4, acetyl-lysine substrate; Sirt5, succinyl-
lysine substrate; Sirt6, myristoyl-lysine substrate). A solution containing DMSO was used as a negative control, a solution with nicotinamide (NCA,
200mM or 1mM) was used as a positive control. Only the activity of Sirt2 is substantially reduced in the presence of SirReal2. Data are presented as
mean±s.d. (n¼ 2) (d) Representative thermal stability plots for Sirt2 in the presence of SirReal2 (25 mM) and either the cofactor NADþ (5mM) or an
acetyl-lysine H3 peptide (5mM). The presence of NADþ or of an acetyl-lysine peptide substrate enhances the stability of the Sirt2–SirReal2 complex
(n¼ 3). Representative thermal stability plots of Sirt2 in the absence of SirReal2 and in the presence of NADþ or an acetyl-lysine oligopeptide are shown in
Supplementary Fig. 1d. Rel., relative.
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of 140 nM and has very little effect on the activities of Sirt3-5.
Only the activity of Sirt1 (22% inhibition at 100 mM) and Sirt6
(19% inhibition at 200 mM) are slightly affected at higher SirReal2
concentrations, making SirReal2 one of the most selective sirtuin
inhibitors up to date. However, any attempts to identify a
putative-binding site and to rationalize initial structure–activity
relationships by docking to available X-ray structures of
Sirt2 were not successful. We, therefore, proceeded to determine
the structures of Sirt2-inhibitor complexes by protein X-ray
crystallography.
For that, we used a truncated form of Sirt256–356 lacking the
flexible N- and C termini. To validate the suitability of our
expression construct, we also crystallized this truncated form of
Sirt2 in the presence of ADP ribose (ADPR) and the physiological
inhibitor nicotinamide (NCA, Supplementary Fig. 2, structure
termed Sirt2–ADPR–NCA). As the binding mode of these ligands
corresponded to other published sirtuin structures in complex
with NCA30, we concluded that our expression construct was
suitable for the investigation of Sirt2–ligand interactions. Further
thermal stability experiments indicated an additional stabilization
of the Sirt2–SirReal2 complex in the presence of either NADþ or
a peptidic acetyl-lysine substrate (Fig. 1d). These findings were
the key to a successful crystallization of Sirt2 in complex with
SirReal2 that was only achieved in the presence of either substrate
or cosubstrate.
Overall structure of Sirt2–SirReal2 complexes. We solved the
structure of Sirt2 in complex with SirReal2 and the cosubstrate
NADþ (structure termed Sirt2–SirReal2–NADþ ) as well as in
complex with SirReal2 and an acetyl-lysine peptide derived from
histone H3 (residues 11–17, structure termed Sirt2–SirReal2-H3).
Both Sirt2–SirReal2 crystals belonged to different monoclinic
space groups and contained one monomer per asymmetric unit.
They had the two-domain structure typical for sirtuins-a larger
domain with a Rossmann fold and a smaller zinc-binding domain
that are separated through a large groove that constitutes the
active site (Fig. 2a). The structures are highly similar (root mean
squared deviation, r.m.s.d. (Ca atoms)¼ 0.8 Å) with the main
differences in the cofactor-binding loop and its adjacent residues
(r.m.s.d. (Ca residues 92–115)¼ 1.3 Å). In addition, we observed
the Sirt2-specific insertion (residues 289–304) that mediates
crystal contacts as was reported for the Sirt2–ADPR complex
(ADPR, PDB-ID 3ZGV19) and apo-Sirt2 (PDB-ID 1J8F, refined
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Figure 2 | SirReal2 functions as a molecular wedge locking Sirt2 in an open conformation. (a) Overlay of Sirt2–SirReal2–NADþ (slate blue) and
Sirt2–SirReal2–H3 (light grey). Both structures are very similar (r.m.s.d. (Ca atoms)¼0.8Å) and feature an open conformation. The active site is indicated
by small grey dots. (b) Superposition of Sirt2–SirReal2–NADþ (slate blue) with Sirt2–apo (PDB-ID 3ZGO, salmon, residues 34–45 are omitted for better
clarity). Both structures feature an open state despite major structural differences in the zinc-binding domain. (c) Superposition of Sirt2–SirReal2–NADþ
(slate blue) with the Sirt2-ADPR complex (PDB-ID 3ZGV, yellow, residues Tyr139-Gly141 of one hinge loop were not defined in the electron density map).
The structures display major conformational differences in the orientation of the zinc-binding domain. While the ADPR complex is in a closed state,
Sirt2–SirReal2–NADþ adopts an open state. (d) Superposition of Sirt2–SirReal2–NADþ with Sirt2 in complex with a macrocyclic peptide inhibitor S2iL5
(PDB-ID 4L3O, green). Similar to the Sirt2–ADPR complex, the Sirt2–S2iL5 complex assumes a closed conformation. While the Rossmann fold domain is
very similar in both structures, major structural differences can be seen at the zinc-binding domain and at the Sirt2-specific insertion. (e) Close-up view on
the active site using the superposition shown in a. SirReal2 (Sirt2–SirReal2–NADþ , light pink sticks; Sirt2–SirReal–H3, light cyan sticks) occupies the
extended C-site of Sirt2. Binding of SirReal2 neither prevents binding of the acetyl-lysine substrate (light blue sticks) nor the cosubstrate NADþ
(light orange sticks). The cofactor-binding loop of both structures is omitted for clarity.
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3ZGO18,19). The cofactor-binding loop in both Sirt2–SirReal2
complexes adopts a conformation similar to the one observed in
Sirt2 in complex with the product analogue ADPR (PDB-ID
3ZGV).
When compared with the available Sirt2 structures (apo-Sirt2:
PDB-ID 1J8F, 3ZGO; Sirt2-ADPR: PDB-ID 3ZGV; Sirt2–S2iL5
peptide: PDB-ID 4L3O28) the zinc-binding domains in the
Sirt2–SirReal2 structures adopt a conformation similar to the one
in apo-Sirt2 (Fig. 2b–d, Supplementary Fig. 3a–c). On binding of
the acetyl-lysine peptide substrate, the zinc-binding domain
rotates towards the Rossmann fold domain. This has been termed
as the ‘closure’ of the two domains and can be observed in several
other human and bacterial sirtuin structures in complex with an
acetyl-lysine peptide substrate20,21,31. This domain closure
induces the formation of the acetyl-lysine-binding tunnel and
the b-staple motif that mediates the acetyl-lysine peptide
substrate-sirtuin interactions32. Despite the absence of an
acetyl-lysine peptide substrate, the Sirt2–ADPR complexes also
adopt the closed conformation. This is due to the Sirt2-specific
insertion that acts as a pseudo-substrate in the crystal and
binds to the acetyl-lysine-binding site of a neighbouring Sirt2
molecule.
Despite the ‘open’ conformation of the Sirt2–SirReal2
structures, SirReal2-inhibited Sirt2 adopts a substantially different
structure from the one observed in Sirt2–apo (r.m.s.d.
(Ca atoms)¼ 1.4 Å, Fig. 2b), the complex of Sirt2 and ADPR
(r.m.s.d. (Ca atoms)¼ 1.6 Å, Fig. 2c) and the complex of Sirt2 and
the S2iL5 peptide (r.m.s.d. (Ca atoms)¼ 1.7 Å, Fig. 2d). Our
structures feature a completely new and unexpected Sirt2
conformation, where SirReal2 functions as a ‘molecular wedge’
that traps Sirt2 in the open conformation even in the presence
of an acetyl-lysine peptide substrate. We call this a ‘locked
open’ state.
SirReal2 occupies a yet-unexploited binding pocket. SirReal2
binds to the active site of Sirt2 (Figs 2e and 3) at the interface of
the Rossmann fold domain and the zinc-binding domain, the site
of the deacylation of e-amino groups of lysines. The active site of
Sirt2 has previously been divided into different sites (Fig. 3a). The
A- and B-pocket, respectively, bind the ADPR moiety, whereas
the C-pocket binds the NCA of NADþ . NADþ is able to adopt
different conformations. However, only a kinked conformation
where the NCA moiety of NADþ occupies the C-pocket is
considered productive for catalytic deacylation. The hydrophobic
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acetyl-lysine-binding tunnel is formed by several phenylalanines
and connects the NADþ -binding site to the acetyl-lysine-binding
site. The pocket adjacent to the C-pocket has been termed
extended C-site (EC-site)33.
The aminothiazole SirReal2 occupies this EC-site adjacent to
the C-pocket, which is the physiological site for product
inhibition by the feedback inhibitor NCA30 (Supplementary
Fig. 2). It binds at this highly hydrophobic site in vicinity to the
zinc-binding domain, where it does not interfere with the binding
of NCA or the NCA moiety of NADþ (Fig. 3b–d). The naphthyl
moiety of SirReal2 protrudes into the substrate channel and the
dimethylmercaptopyrimidine substituent (DMP) induces the
formation of a binding pocket beyond the EC-site. This region
is formed by two loops (residues 136–144, residues 188–191) of
the hinge region that connect the Rossmann fold domain with the
zinc-binding domain. We refer to this binding pocket in the
following as the ‘selectivity pocket’. The position of SirReal2 in
the EC-site of Sirt2 is very similar in both structures with either
NADþ or the acetyl-lysine peptide substrate (r.m.s.d. of 0.47Å),
and we will primarily describe the binding of SirReal2 in the
presence of NADþ , as this structure likely represents the
SirReal2-inhibited form of the enzyme. Structural comparison
of the available Sirt2 structures with the Sirt2–SirReal2–H3
complex can be found in Supplementary Fig. 3.
Binding of SirReal2 to the EC-site is mainly driven by
hydrophobic interactions (Fig. 3c,d). The naphthyl moiety of
SirReal2 that protrudes into the acetyl-lysine-binding site is in
van-der-Waals contacts with the NCA moiety of NADþ , Phe131,
Leu134, Ile169, Ile232, Val233 and Phe234. In the selectivity
pocket, the DMP moiety forms p–p-stacking interactions with
Tyr139 and Phe190 in the selectivity pocket that is shaped by
Ile93, Ala135, Leu138, Pro140, Phe143, Leu206 and Ile213. In
addition, Pro94 hydrogen bonds via a structural water molecule
(W40) to the carbonyl-O of SirReal2. Besides its interactions with
the Sirt2 protein, the SirReal2 inhibitor also forms an internal
hydrogen bond between the amide N–H and one of the
pyrimidine nitrogens. This results in a rigid conformation with
ideal complementarity to the active site of Sirt2.
Binding of SirReal2 to Sirt2 rearranges the active site. The
presence of SirReal2 results in a rearrangement of Sirt2’s active
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Figure 4 | SirReal1 selectively inhibits Sirt2 and functions as a molecular wedge to lock Sirt2 in an open conformation. (a) Chemical structure of
SirReal1 (2). (b) Representative thermal stability plots for Sirt2 in the presence of SirReal1 (50 mM) and either the cofactor NADþ (5mM) or an acetyl-
lysine H3 peptide (5mM). The presence of the cosubstrates enhances the stabilization of the Sirt2–SirReal1 complex (n¼ 3). Representative thermal
stability plots of Sirt2 in the absence of SirReal2 and the presence of NADþ or an acetyl-lysine oligopeptide are shown in Supplementary Fig. 1d.
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yellow lines. The cofactor-binding loop of d is omitted for clarity. A stereo image of the s-weighted 2Fo Fc electron density maps for SirReal1 and the
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site. It is more pronounced in comparison with the Sirt2 structure
in complex with ADPR (PDB-ID 3ZGV, Fig. 3e) than with the
structure of Sirt2–apo (PDB-ID 3ZGO, Fig. 3e).
A site of major rearrangement is the selectivity pocket of the
hinge region, where the DMP ring of SirReal2 is bound (Fig. 3e).
Here the loop region from Lys136–Phe143 is substantially shifted
upwards with respect to the Sirt2–apo structure and forms a lid
above the DMP moiety. These residues seem to be more flexible,
indicated by high B-factors, in structures of the closed
conformation such as the Sirt2–ADPR or Sirt2–ADPR–NCA
complexes (Supplementary Fig. 2) than in structures of the open
conformation.
Another site of SirReal2-induced rearrangement is observed in
the acetyl-lysine-binding site. Here the side chains of the residues
forming the highly hydrophobic acetyl-lysine tunnel, Tyr104,
Phe119, Phe131, Phe234 and Phe235 are shifted (Fig. 3e). In
particular, the side chains of Phe235 and Tyr104 that usually cap
the acetyl-lysine are rotated towards the surface of Sirt2.
Surprisingly, this rearrangement does not prevent Sirt2 from
binding its acetyl-lysine peptide substrate, but deacetylation and
the domain closure is blocked effectively.
Kinetic analyses of SirReal-mediated inhibition. In the
course of the investigation SirReal-mediated inhibition, we also
determined the crystal structure of another aminothiazole,
termed SirReal1 (2, Fig. 4a), in complex with Sirt2 and a different
acetyl-lysine peptide substrate. The latter is derived from
ornithine transcarbamoylase (OTC, structure termed Sirt2–
SirReal1–OTC). SirReal1 has a benzyl instead of a naphthyl-
methyl substituent on the aminothiazole and is 26-fold less potent
than SirReal2 in the same in vitro assay, but it retains high Sirt2
selectivity and shows similar behaviour in thermal stability assays
(Supplementary Fig. 1b,c, Fig. 4b). Despite the presence of a
different acetyl-lysine peptide, the structure of Sirt2–SirReal1–
OTC bears a high resemblance to the Sirt2–SirReal2 complexes
(r.m.s.d. (Ca atoms)¼ 0.44 Å to Sirt2–SirReal2–H3, 0.59Å to
Sirt2–SirReal2–NADþ , Fig. 4c). SirReal1 also locks Sirt2 in the
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Figure 5 | SirReal inhibitors suppress Sirt2 activity via a unique mechanism. (a) Superposition of Sirt2–SirReal2–NADþ with ternary sirtuin complexes
(Sir2Tm: PDB-ID 2H4F, aquamarine; Sirt3: PDB-ID 4FVT, raspberry) shows that NADþ in Sirt2–SirReal2–NADþ adopts a very similar kinked conformation
to the one observed in ternary sirtuin complexes. The NCA ribose moiety of NADþ in Sirt2–SirReal2–NADþ shares more resemblance to the position
of NCA ribose of NADþ in 2H4F than to the one in 4FVT. (b) Overlay of Sirt2–SirReal2–H3, Sirt2–SirReal1–OTC with 2H4F of Fig. 4a. The bulky naphthyl
moiety of SirReal2 forces the acetyl-lysine out of its physiological position, which can be seen in the ternary sirtuin complex of Sir2Tm, byB5Å. In this new
position, the Ne-group of the acetyl-lysine of Sirt2–SirReal2–H3 cannot hydrogen bond to the backbone carbonyl-O of the conserved Val232. The less
bulky benzyl moiety of SirReal1 allows a similar acetyl-lysine binding to Sirt2 as observed in the ternary complex of Sir2Tm. However, the presence of
SirReal1 slightly enlarges the distance between the backbone carbonyl-O of Val233 to the Ne of the acetyl-lysine, thus disabling hydrogen bond formation.
(c,d,f,g) Competition analyses of SirReal1/2-mediated inhibition. SirReal2 is a partial non-competitive inhibitor towards NADþ , while SirReal1 functions as
a NADþ -competitive inhibitor. SirReal1 and SirReal2 are both competitive to the acetyl-lysine peptide. Data are presented as mean±s.d. (n¼ 2).
(e) Structure–activity relationships (SAR) for SirReal inhibitors. Only the combination of the bulky naphthyl moiety with the DMP and the non-methylated
amide results in submicromolar Sirt2 inhibition. Inhibition data were determined using the substrate ZMAL (n¼ 3).
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open conformation and shows an almost identical interaction
pattern as observed for SirReal2 (Fig. 4d,e).
To get insights into the inhibition mechanism, we first
compared the structures of Sirt2–SirReal complexes with the
available sirtuin structures lacking inhibitors. For the cosubstrate
NADþ , the binding mode does not differ substantially. NADþ
of Sirt2–SirReal2–NADþ also adopts a kinked conformation
with a similar network of hydrophilic and hydrophobic interac-
tions as observed for NADþ or Carba-NADþ in ternary sirtuin
complexes (PDB-ID 2H4F34, Sir2Tm-Ac-Lys-p53-peptide-
NADþ , PDB-ID 4FVT23, Sirt3-Carba-NADþ -Ac-Lys-ACS-
peptide, Fig. 5a). As the main difference, the NCA ribose
moiety of Carba-NADþ is rotated B30 around its glycosidic
bond compared with NADþ in Sirt2–SirReal2–NADþ or
Sir2Tm-Ac-Lys-p53-peptide-NADþ . The binding mode of
NADþ in Sirt2–SirReal2–NADþ therefore shares a higher
resemblance to the conformation of NADþ in the ternary
complex with Sir2Tm.
The acetyl-lysine-binding modes in ternary sirtuin complexes
and Sirt2–SirReal2 structures on the other hand show substantial
differences (Fig. 5b). In uninhibited sirtuin-acetyl-lysine-peptide
structures, the acetyl-lysine-containing peptide binds in the cleft
between the zinc-binding and NADþ -binding domain, respec-
tively, inserting its acetyl-lysine into a hydrophobic tunnel that is
formed by several highly conserved phenylalanines. The binding
of the acetyl-lysine is further stabilized by a hydrogen bond
between the Ne–H of the acetyl-lysine and the backbone
carbonyl-O of a conserved valine. The hydrophobic acetyl-
lysine–binding tunnel is not formed in all Sirt2–SirReal
structures, since Phe235, which usually caps the acetyl-lysine, is
rotated B90 towards the surface. Moreover, the bulky naphthyl
moiety of SirReal2 forces the acetyl-lysine B5Å out of its
physiological position, which can be seen in ternary complexes of
sirtuins (Sir2Tm-Ac-Lys-p53-peptide-NADþ , PDB-ID 2H4F,
Sirt3-Ac-Lys-ACS-peptide-Carba-NADþ , PDB-ID 4FVT, Fig. 5b).
In the Sirt2 complex with SirReal1, the acetyl-lysine-binding
mode is different. The acetyl-lysine adopts an almost physiolo-
gical position, as it is observed in the above-mentioned ternary
sirtuin complexes. However, even in case of SirReal1, the benzyl
moiety of SirReal1 shifts the acetyl-lysine of the OTC peptide
PNVTHYFLRL LH
Sirt2-SirReal2-
NAD+
SirReal2
Sirt1-HM
SirReal2
Sirt3-HM
SirReal2
Phe143
Met296
Phe312
Cys380
Thr171
Leu206
Ile213
Leu134
Leu138
Leu103
Ile118
Ile316
Ile279
Tyr204
Val272
Gly232
Gly265
Consensus . . . :: ***:* . .*:* :*.
Sirt1 244 ---------- ------EDAV KLLQE--CKK IIVLTGAGVS VSCGIPDFRS
Sirt2 65 ---------- ------EGVA RYMQSERCRR VICLVGAGIS TSAGIPDFRS
Sirt3  126 ---------- ------QDVA ELIRARACQR VVVMVGAGIS TPSGIPDFRS
Sirt4 29 IGLFVPASPP LDPEKVKELQ RFITL--SKR LLVMTGAGIS TESGIPDYRS
Sirt5 41 ---------- ------ADFR KFFAK--AKH IVIISGAGVS AESGVPTFRG
Sirt6 35 ---------- ------WELA RLVWQ--SSS VVFHTGAGIS TASGIPDFRG
Consensus . . 
Sirt1 277 RD-GIYARLA VDFPDLPDPQ AMFDIEYFRK DPRPFFKF-- AKEIYPGQFQ
Sirt2 99 PSTGLYDN-L EKYH-LPYPE AIFEISYFKK HPEPFFAL-- AKELYPGQFK
Sirt3 160 PGSGLYSN-L QQYD-LPYPE AIFELPFFFH NPKPFFTL-- AKELYPGNYK
Sirt4 78 EKVGLYAR-T DRRP-IQHGD FVRSAPIR-- --QRYWARNF VGWPQFSSHQ
Sirt5 73 AG-GYWRK-W -------QAQ DLATPLAFAH NPSRVWEFYH YRREVMGSKE
Sirt6 67 PH-GVWTM-E ---------- ---------- --ERGLAP-- KFDTTFESAR
Consensus *. * : . * :**:* *. :*      : : ** :
Sirt1   PSLCHKFIAL SD----KEGK LLRNYTQNID TLEQVAGIQ- –RIIQCHGSF
Sirt2 145
324
206
114
91
PTICHYFMRL LK----DKGL LLRCYTQNID TLERIAGLEQ EDLVEAHGTF
Sirt3 ----DKGL LLRLYTQNID GLERVSGIPA SKLVEAHGTF
Sirt4 122 PNPAHWALST WE----KLGK LYWLVTQNVD ALHTKAGSR- –RLTELHGCM
Sirt5 PNAGHRAIAE CETRLGKQGR RVVVITQNID ELHRKAGTK- –NLLEIHGSL
Sirt6 PTQTHMALVQ LE----RVGL LRFLVSQNVD G
Consensus * *
Sirt1 368 ATASCLI--C KYKVDCE--- ---------- ---------- ----AVRGDI
Sirt2 191 YTSHCVSASC RHEYPLS--- ---------- ---------- ----WMKEKI
Sirt3 252 ASATCTV--C QRPFPGE--- ---------- ---------- ----DIRADV
Sirt4 166 DRVLCLD--C GEQTPRGVLQ ERFQVLNPTW SAEAHGLAPD GDVFLSEEQV
Sirt5 162 FKTRCTS--C GVVAENY--- ---KS--PIC PALSGKGAPE PGTQDASIPV
Sirt6 137 FVEECAK--C KTQYVRDTVV GT-------- ---------- ----MGLKAT
Consensus . :: :: : : :
Sirt1 388 FNQVVPRC-- --PRCPADEP LAIMKPEIVF FGENLPEQFH RAMKYDKDEV
Sirt2 214 FSEVTPKC-- --ED-----C QSLVKPDIVF FGESLPARFF SCMQSDFLKV
Sirt3 273 MADRVPRC-- --PV-----C TGVVKPDIVF FGEPLPQR-F LLHVVDFPMA
Sirt4 214 RSFQVPTC-- --VQ-----C GGHLKPDVVF FGDTVNPDKV DFVHKRVKEA
Sirt5 202 EKLPRCEE-- --AG-----C GGLLRPHVVW FGENLDPAIL EEVDRELAHC
Sirt6 163 GRLCTVAKAR GLRA-----C RGELRDTILD WEDSLPDRDL ALADEASRNA
Consensus *  : :*:* : . : .*
Sirt1 434 DLLIVIGSSL KVRPVALIPS SIP-HEVPQI LINREPLP-- ----------
Sirt2 255 DLLLVMGTSL QVQPFASLIS KAP-LSTPRL LINKEKAGQS DPFLGMIMGL
Sirt3 313 DLLLILGTSL EVEPFASLTE AVR-SSVPRL LINRDLVG-- ----------
Sirt4 255 DSLLVVGSSL QVYSGYRFIL TAWEKKLPIA ILNIGPTR-- ----------
Sirt5 243 DLCLVVGTSS VVYPAAMFAP QVAARGVPVA EFNTETTP-- ----------
Sirt6 208 DLSITLGTSL QIRPSGNLPL ATKRRGGRLV IVNLQPTK-- ----------
Consensus .   .
Sirt1 471 ----HL---- -HFDVELLGD CDVIINELCH RL-GGEYA
Sirt2 305 GGGMDFDSKK AYRDVAWLGE CDQGCLALAE LL-GWKKE
Sirt3 350 ----PLAWHP RSRDVAQLGD VVHGVESLVE LL-GWTEE
Sirt4 293 ----SD---- DLACLKLNSR CGELLP---- ---LIDPC
Sirt5 281 ----AT---- NRFRFHFQGP CGTTLPEALA -CHENETV
Sirt6 246 ----HD---- RHADLRIHGY VDEVMTRLMK HL-GLEIP
Figure 6 | SirReal2 selectively inhibits Sirt2 via a Sirt2-specific amino acid network. (a) Structural sequence alignment of the Sirt1–6 deacylase domain.
The residues that presumably interact with SirReal2 are highlighted in yellow if they are equivalent to the residues of Sirt2. If they differ from the residues of
Sirt2, they are highlighted in red. The structural sequence alignment was generated using T-Coffee35 and slightly modified. (b–d) Surface representation of
the binding pockets of SirReal2 in Sirt2–SirReal2–NADþ and in the homology models of Sirt1 (Sirt1-HM) and Sirt3 (Sirt3-HM). The residues that differ in
the three isotypes are represented as sticks (Sirt2, slate blue; Sirt1, brown; Sirt3, turquoise). SirReal2 is shown as light pink sticks (Sirt2–SirReal2–NADþ),
lime sticks (Sirt1-HM) and olive sticks (Sirt3-HM). Despite the highly conserved active site, the binding pockets appear in very different shapes due to
differences in the amino acid sequence. In case of Sirt1 the amino acids that contribute to an unfavourable binding of SirReal2 are Ile279, Met296, Phe312,
Ile316 and Cys380. In the case of Sirt3, the amino acids are Tyr204, Gly232, Gly265 and Val272.
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towards His187, weakening the formation of the hydrogen bond
between the Ne–H of the acetyl-lysine and the backbone
carbonyl-O of the conserved valine (distance between carbonyl-
O of valine and Ne-KAc: 3.2 Å in Sirt2–SirReal1–OTC, 2.5–2.7 Å
in ternary complexes).
To investigate the SirReal-mediated inhibition kinetics, we
performed competition analyses for SirReal1 and SirReal2
(Fig. 5c,d,f and g). SirReal2 is partially non-competitive and
SirReal1 is competitive towards NADþ (Fig. 5c,f). Both SirReal
inhibitors also exhibit acetyl-lysine competition with inhibition
constants of 0.22 mM for SirReal2 and 3.33 mM for SirReal1
(Fig. 5d,g). This is in line with the protrusion into the
acetyl-lysine-binding site that was seen in the crystal structures.
However, despite competition towards acetyl-lysine substrates or
the cosubstrate NADþ , the presence of SirReal1/2 inhibitors does
not disable Sirt2 to bind its substrates.
For further exploration of the SirReal-mediated Sirt2 inhibi-
tion, we synthesized several SirReal derivatives (SirReal3–6,
Supplementary Fig. 5, Supplementary Notes) and determined
their inhibitory potencies (Fig. 5e). Only the combined presence
of the naphthyl substituent with the DMP moiety and the non-
methylated amide leads to a submicromolar Sirt2 inhibition. The
substitution of the DMP moiety with a dimethylmercaptophenyl
substituent or the methylation of the amide-nitrogen results in a
significant loss of inhibition (4100-fold). This suggests that the
formation of the intramolecular hydrogen bond and the resulting
structural rigidity of Sirt2-bound SirReal2 are indispensable for
potent Sirt2 inhibition.
Structural aspects of isotype-selective inhibition. One striking
feature of the SirReal2-mediated inhibition is its isotype
selectivity. SirReal2 inhibits Sirt241,000-fold more potently than
Sirt1, Sirt3, Sirt4, Sirt5 and Sirt6 and it is therefore one of the
most selective sirtuin inhibitors known to date.
To analyse the basis of this high isotype selectivity, we created a
structural sequence alignment of the deacylase domain of Sirt1–6
and compared the crystal structure of the Sirt2–SirReal2 complex
with available crystal structures of sirtuins in their open
conformation (Fig. 6a, Supplementary Fig. 7a,b)35. Assuming
that SirReal2 binds to the other sirtuin isotypes in a similar
fashion as observed for Sirt2, Sirt4–6 exhibit major differences in
their amino acid sequence. The structural differences are also very
pronounced (Supplementary Fig. 7a) rationalizing the observed
lacking in vitro inhibition of Sirt4–6 by SirReal2. Sirt1 and Sirt3,
on the other hand, are phylogenetically more closely related to
Sirt2 and show only minor sequence variations36. Their
conformation is more similar to the Sirt2–SirReal2–NADþ
complex than to the conformation of the isotypes Sirt5/6
(Supplementary Fig. 7b). But they still show major structural
differences (r.m.s.d. (Ca atoms)¼ 1.6 Å). As it was not possible to
dock SirReal2 in any of the available Sirt1 and Sirt3 X-ray crystal
structures (Supplementary Methods), we wanted to probe
whether Sirt1 and Sirt3 were able to adopt a similar
conformation as observed in the Sirt2–SirReal2 structures that
would allow binding of SirReal2. This would enable us to see
whether the minor sequence variations within the deacylase
domain of Sirt1–3 would have an influence on SirReal2 binding.
Therefore, we generated homology models of Sirt1 (Sirt1-HM)
and Sirt3 (Sirt3-HM) based on our Sirt2–SirReal2 structures
(Supplementary Methods). Stereochemical analyses as well as
molecular dynamics simulations indicated high-quality model
structures, and it was indeed possible to dock SirReal2 into these
homology models (Supplementary Fig. 7c–h). However, the
docking poses of SirReal2 in Sirt1-HM and Sirt3-HM gave less
favourable docking scores compared with the requisite scores for
the docking poses of SirReal2 in Sirt2–SirReal2 structures. Here
the position and the conformation of SirReal2 were correctly
predicted (Fig. 6b). In case of Sirt1, residues Leu103, Ile118,
Leu134, Leu138 and Leu206 of Sirt2 are substituted with Ile279,
Met296, Phe312, Ile316 and Cys380 (Fig. 6c). Cys380 gives the
hypothetical selectivity pocket of SirReal2 in Sirt1-HM a very
different shape and changes its surface characteristics. The bulky
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Figure 7 | SirReal2 inhibits Sirt2 in vivo. (a) Acetylation level of the microtubule network (red) in the presence or absence of SirReal2 at a concentration of
20mM. Treatment with SirReal2 leads to hyperacetylation of the microtubule network in a similar manner as observed for the Sirt2 inhibitor AGK2.
Treatment with SirReal6 on the other hand results in no substantial change of acetylation level. The scale bar represents 5 mm (n¼4). (b) Abundance of
BubR1 after incubation with SirReal2 (n¼ 3). (c) SirReal2 does not alter p53-Lys382-acetylation after ultraviolet damage (n¼ 3). Raw immunofluorescent
images and uncropped blots are shown in the Supplementary Figs 8–10.
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Phe312 and Ile316 as well as Met296 and Ile279 also tighten the
EC-site, resulting in an unfavourable orientation of the
aminothiazole and naphthyl moieties in possible docking poses.
In the case of Sirt3, the differences are mainly located at the
selectivity pocket. Here Phe143, Thr171, Leu206 and Ile213 of
Sirt2 are substituted by Tyr204, Gly232, Gly265 and Val272
(Fig. 6d). The less bulky Gly232, Gly265, Val272 of Sirt3 form a
much wider and also more solvent-accessible selectivity pocket as
compared with the Sirt2–SirReal2 structures. In contrast to the
SirReal2-binding pockets of the homology models of Sirt1 and
Sirt3, SirReal2 bound to Sirt2 can adopt a conformation that is in
almost perfect complementarity with the protein, which is
stabilized by the intramolecular hydrogen bond between the
DMP substituent and the amide. This is not possible in Sirt1 and
Sirt3 and also rationalizes the observed isotype selectivity.
In vivo inhibition of Sirt2. To validate that SirReal2 could be
used as a tool to investigate the effects of Sirt2 inhibition in a
cellular setting, we incubated HeLa cells with SirReal2 at various
concentrations and determined the level of a-tubulin acetylation
(Supplementary Fig. 8a,b). Incubation with SirReal2, but not with
SirReal6, resulted in a significant increase of a-tubulin acetylation
consistent with an in vivo inhibition of Sirt2 as shown pre-
viously37. These changes are not as pronounced when compared
with the changes induced by the inhibition of the other main
tubulin deacetylase KDAC6 (refs 38,39). KDAC6 activity is not
affected in vitro in the presence of SirReal2 (Supplementary
Fig. 8c). To verify the observations from the western blot data,
we also visualized the acetylation level by means of
immunofluorescence microscopy. Again, the incubation with
SirReal2 resulted in a partial increase of the acetylation of
the microtubule network similar to the effects observed after
treatment with the Sirt2-inhibitor AGK2 (Fig. 7a, Supplementary
Fig. 9)39,40. SirReal6, on the other hand, does not alter
microtubule acetylation. In addition, we analysed another Sirt2
target. Recently, we reported that the stability of spindle assembly
checkpoint protein BubR1 is under control of Sirt2 (ref. 41).
A decline in BubR1 over time has been linked to mammalian
aging42. Deacetylation of Lys668 of BubR1 by Sirt2 inhibits the
ubiquitination of BubR1 and its designation to the proteasome.
Therefore, the abundance of BubR1 can be used as a functional
measure for in vivo Sirt2 inhibition. Incubation with SirReal2
indeed significantly resulted in a dose-dependent depletion
of BubR1, whereas SirReal5/6 did not influence BubR1
concentrations (Fig. 7b, Supplementary Fig. 8d,e). We also
found that SirReal2 treatment did not alter cell cycle
distribution, ruling out that the effect on BubR1 was indirect
through induction of cell cycle changes (Supplementary Fig. 8f).
To determine if SirReal2 selectively inhibits Sirt2 in vivo, we
assessed p53 acetylation following genotoxic stress (Fig. 7c,
Supplementary Fig. 10a). Acetylation of p53 occurs in response to
ultraviolet exposure to cells43 and this acetylation is regulated, in
part, by the isotype Sirt1 (refs 44,45). On exposure to ultraviolet
light, we detected an increase in acetylation of p53, which was
further increased on treatment with the pan-sirtuin inhibitor
Table 1 | Data collection and refinement statistics.
Sirt2–SirReal1–OTC* Sirt2–SirReal2–H3* Sirt2–SirReal2–NADþ *
Data collection
Space group P21 P21 I2
Cell dimensions (Å)
a, b, c (Å) 36.21, 73.75, 55.86 35.99, 73.30, 55.29 83.7, 54.51, 96.69
a, b, g () 90, 94.71, 90 90, 95.23, 90 90, 114.8, 90
Resolution (Å)w 44.43–1.45 (1.48–1.45) 44.02–1.42 (1.44–1.42) 48.28–1.88 (1.92–1.88)
Rmerge 0.126 (1.009) 0.060 (0.922) 0.068 (1.351)
Rpim 0.054 (0.471) 0.035 (0.546) 0.029 (0.583)
I/sI 9.2 (1.7) 11.9 (1.5) 19.3 (1.5)
Completeness (%) 99.9 (99.9) 99.6 (99.6) 100 (100)
CC1/2 0.995 (0.549) 0.999 (0.534) 0.999 (0.585)
Redundancy 6.5 (6.2) 3.7 (3.8) 6.6 (6.4)
Refinement
Resolution (Å) 44.43–1.45 44.02–1.42 48.28–1.88
No. of reflections 334,389 (16,809) 199,366 (10,043) 213,173 (12,962)
Rwork/Rfree (%) 26.0/28.2 18.1/18.8 20.2/24.7
No. of atoms
Protein 2,251 2,406 2,350
SirReal inhibitor 25 29 29
Ac-Lys peptide/NADþ 32 12 44
Zn2þ 1 1 1
Water 156 242 99
B-factors (Å2)
Protein 17.3 21.1 38.4
SirReal inhibitor 27.0 25.1 32.2
Ac-Lys peptide/NADþ 29.8 48.3 41.8
Zn2þ 11.7 14.8 30.7
Water 20.5 27.0 36.0
r.m.s. deviations
Bond lengths (Å) 0.012 0.008 0.014
Bond angles () 1.58 1.33 1.65
Ac-Lys, acetyl-lysine; r.m.s., root mean squared.
*Each data set was obtained from one single crystal. Sirt2–SirReal1–OTC and Sirt2–SirReal2–H3 were collected at 1.0Å at the Swiss Light Source (Villigen, Switzerland), Sirt2–SirReal2–NADþ was
collected with an in-house X-ray source at 1.5418Å.
wValues in parentheses are for highest-resolution shell.
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NCA. However, we did not observe an increase in acetylation of
p53 following treatment with SirReal2/5/6. Similarly, we also
tested if SirReal2 could inhibit Sirt3 in cells by assessing
mitochondrial protein acetylation. Sirt3 has previously been
demonstrated to regulate global mitochondrial protein
acetylation46. Following treatment with SirReal2 or NCA as a
positive control, we purified mitochondria and assessed protein
acetylation by western blotting. We found that treatment with
NCA leads to an increase in the acetylation of mitochondrial
proteins, whereas treatment with SirReal2 did not, suggesting that
SirReal2 is unable to regulate Sirt3 activity in cells
(Supplementary Fig. 10b). These results confirm the in vitro
observations and indicate that SirReal2 has a strong specificity
towards Sirt2 in vivo when compared with the other members of
Class-I sirtuins Sirt1 and Sirt3.
Discussion
There are many indications that sirtuins play an important role in
neurodegeneration, cancer, bacterial infections and inflammation
and that a modulation of Sirt2 activity could be a new strategy for
pharmaceutical intervention. However, the physiological func-
tions of Sirt2 are far from being completely understood and
conclusive evidence for the suitability of Sirt2 as a pharmaceutical
target is, at least in some cases, missing. To further explore Sirt2
function in a cellular environment, there is a definite need for
selective and potent Sirt2 modulators.
So far, most sirtuin modulators lack either potency, selectivity
or drug-like physicochemical properties. Recent screening
campaigns have identified several potent and/or selective
inhibitors15,24–26; however, with the exception of the
macrocyclic peptide S2iL5, it is not clear how these inhibitors
bind to Sirt2. And although several X-ray structures of sirtuins in
complex with inhibitors have been reported lately28,33,47–51, these
structures do little to reveal a rationale for a Sirt2-selective
inhibition.
With the identification of the SirReal inhibitors, we establish
the structural basis for Sirt2-selective inhibition and report a new
potent Sirt2-selective inhibitor scaffold. As noted above, the
intramolecular hydrogen bond between the amide of the
aminothiazole and a nitrogen atom of the DMP moiety gives
the inhibitor a rigid form that can act as a molecular wedge
locking the enzyme conformation with subsequent Sirt2 inhibi-
tion. Not only essential for the potency, the intramolecular bond
also seems to play an important role for the compound’s Sirt2
selectivity, as it can only be formed when bound in perfect
complementarity to the active site of Sirt2. This seems not to be
possible if bound to Sirt1 or Sirt3.
Another important aspect alongside the internal hydrogen
bond of SirReal-mediated Sirt2 inhibition is the exploitation of
the selectivity pocket by SirReal inhibitors. The only other
isotype-selective sirtuin inhibitors with known structures,
CHIC-35 (Sirt1-selective)48, EX-527 (Sirt1-selective)33 and
SRT1720 (Sirt3-selective)49 either bind to the EC-site and/or to
the acetyl-lysine-binding site but neither the indole inhibitors nor
SRT1720 or any of the inhibitors whose binding modes have been
elucidated by means of X-ray crystallography occupy the
selectivity pocket (Fig. 6). This pocket is formed by two loops
that connect the Rossmann fold domain with the smaller zinc-
binding domain. The residues that form this pocket significantly
differ within the sirtuin family and targeting this pocket may
present a new strategy for selective sirtuin inhibitor design. These
particular findings would not have been discovered with the use
of computational methods and the available Sirt2 structures.
In conclusion, with the identification of SirReal2, we provide
an isotype-selective drug-like inhibitor with optimized potency
and physicochemical properties in comparison with previously
published Sirt2 inhibitors (Supplementary Table 1). We estab-
lished valuable structural insights into selective Sirt2 inhibition
and show that SirReal2 inhibits Sirt2 in vivo without affecting the
activity of the other Class-I sirtuins Sirt1 and Sirt3. The observed
selectivity towards Sirt3 may, in part, stem from a lack of
penetration into the mitochondria but the cellular net result is as
desired. SirReal2 may therefore be used for further cellular studies
to probe Sirt2 biology. Our findings may constitute the basis for
further selective sirtuin inhibitor development and provide a new
tool for sirtuin biology.
Methods
Cloning. The gene sequences coding for human Sirt256–356 (Uniprot: Q8IXJ6) or
human Sirt3118–395 (Uniprot: Q9NTG) were cloned in a modified pET15b vector
that contained His10-Tag instead of a His6-Tag and a cleavage site for TEV protease
instead of one for thrombin.
Protein expression and purification. Human Sirt1133–747 (Uniprot: Q96EB6),
human Sirt225–389, human Sirt3101–399, human Sirt534–302 (Uniprot: Q9NXA8)
and human Sirt613–308 (Uniprot: Q8N6T7) were purified as described before47,52,53.
Human Sirt425–314 (Uniprot: Q9Y6E7) was expressed and purified as described
before54 with the exception that autoinduction with 0.2% (w/v) lactose in TB media
was used for expression.
Sirt256–356 and Sirt3118–395 were expressed in E. coli strain
BL21(DE3)Codonplus RIPL cells overnight at 18 C. Overexpression was induced
with isopropyl-b-D-thiogalactoside (0.1mM) at an OD600 of 0.6. Cells were
harvested, resuspended in lysis buffer (Sirt256–356: 50mM Tris/HCl, 500mM NaCl,
5% (v/v) glycerol, 5mM b-mercaptoethanol, pH 8.0; Sirt3118–395: 50mM HEPES,
500mM NaCl, 5% (v/v) glycerol, 5mM b-mercaptoethanol, pH 7.5) and lysed
using a microfluidizer (Microfluidics). After the removal of cell debris, the
supernatant was applied to a HisTrapFF 5ml column (GE Healthcare), washed
intensively before TEV protease (excess) was applied directly on the column. After
an overnight digestion at 4 C, the digested protein was eluted with lysis buffer,
concentrated and further purified using a Superdex S75 26/60 gel filtration column
(Sirt256–356: 25mM Tris/HCl, 150mM NaCl, pH 8.0; Sirt3118–395: 25mM
HEPES, 200mM NaCl, 5% (v/v) glycerol, 5mM b-mercaptoethanol, pH 7.5).
Sirtuin-containing fractions were collected and concentrated to 20mgml 1. All
purification steps were monitored using SDS-polyacrylamide gel electrophoresis
(SDS–PAGE). Protein concentration was determined by the Bradford assay (Roth).
In vitro sirtuin assay. Initial screens were conducted with a high-throughput
fluorescence-based assay using the substrate ZMAL (Z-Lys(Acetyl)-AMC) that was
synthesized according to published procedures29. For this human Sirt1133–747,
human Sirt225–389, human Sirt3101–399 or Sirt3118–395 were mixed with assay buffer
(50mM Tris/HCl, 137mM NaCl, 2.7mM KCl, 1mM MgCl2, pH 8.0), b-NADþ
(final assay concentration 500mM), the substrate ZMAL (final assay concentration
10.5 mM from a 12.6mM stock solution in DMSO) and the respective inhibitor in
DMSO at various concentrations or DMSO as a control (final DMSO
concentration 5–20% (v/v)). The mixture was incubated at 37 C for 4 h, with
agitation at 150 r.p.m. Deacetylation was then stopped by the addition of a solution
containing NCA and trypsin (50mM Tris/HCl, 100mM NaCl, 6.7% (v/v) DMSO,
trypsin 5.5 U ml 1, 8mM NCA, pH 8.0, 60 ml) and the mixture was then incubated
for tryptic digestion of the deacetylated product to release the fluorophor (20min,
37 C, 150 r.p.m.). Then the fluorescence intensity was measured in a microplate
reader (BMG Polarstar, lex 390 nm, lem 460 nm). The amount of inhibition was
determined with respect to the mixture with only DMSO. IC50 values were
determined with Graphpad Prism software using a non-linear regression to fit the
dose–response curve. SirReal1 and SirReal2 were also tested for Sirt1–3 inhibition
with a non-labelled acetyl-lysine peptide substrate (based on a-tubulin with two
additional tryptophans (residues 36–44, H-PSDK(Acetyl)TIGGWW-NH2, 10 mM,
Supplementary Methods). SirReal2 was also tested for Sirt5–6 inhibition with non-
labelled acyl-lysine peptide substrates (Sirt5: Benzoyl-GVLK(Succinyl)EYGV-NH2,
10 mM; Sirt6: Ac-EALPKK(Myristoyl)TGG-NH2, 10 mM) The substrate was
incubated (10min,B0.5 mM Sirt1/2/3/5/6, 500mM b-NADþ , 5–20% (v/v) DMSO,
50mM Tris/HCl, 137mM NaCl, 2.7mM KCl, 1mM MgCl2, pH 8.0), stopped by
the addition of trifluoroacetic acid (TFA, 10% (v/v), final concentration 1% (v/v)).
The components of the stopped reaction mixture were separated by HPLC (Agilent
1100, Phenomenex reversed phase column Kinetex RP18 2.7 mm, 50 3mm) using
a linear gradient of acetonitrile (20–60% (v/v) acetonitrile, 0.1% (v/v) TFA,
0.6mlmin 1). Peaks of acetylated and deacetylated substrate were quantified by
absorption at 280 nm. Sirt4-dependent deacetylation reactions were performed
with an acetylated Nnt397-peptide (H-NITKLLK(Acetyl)AISPDK-NH2, 250 mM,
GL Biochem., in 50mM Tris/HCl, 150mM NaCl, pH 7.5). Samples were taken
between 0 and 45min and reactions were stopped by mixing 1:1 with 0.5% (v/v)
TFA. The samples were then diluted to a peptide concentration of 5 mM with 0.1%
(v/v) formic acid and analysed on an EASY-nLCII connected to a LTQ mass
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spectrometer (Thermo Fisher Scientific). Peptides were separated by a linear
gradient of acetonitrile (0–100% (v/v), 0.1% (v/v) TFA, 300 nlmin 1) on a reprosil
C18 reversed phase column. Peak areas of acetylated and deacetylated peptides
were extracted using Skyline55. A solution with DMSO was used as a negative
control while a solution with the physiological inhibitor NCA served as a positive
control (Fig. 1c). Owing to the lack of a suitable screening assay for human Sirt7,
we focused our studies on isotypes Sirt1–6. Fluor-de-Lys assays (Enzo Life
Sciences) were conducted according to the manual using the HDAC8 Fluor-de-Lys
deacetylase substrate (BML-KI178-0005).
Protein crystallization. All crystallization trials were performed in 96-well plates
(Intelli-Plate 96-3 Low Profile, Art Robbins Instruments) using an Oryx nano
pipetting robot (Douglas Instruments). Reservoir solutions were precooled to 4 C
and screens were then pipetted at 20 C.
For co-crystallization experiments with SirReal1 and SirReal2, a solution of the
truncated Sirt256–356 (20mgml 1 final concentration) was preincubated with a
saturated aminothiazole solution (100mM stock solution in DMSO, 1–2% (v/v)
DMSO final concentration) in the presence of H3 peptide (100mM stock solution
in 25mM HEPES, 200mM NaCl, 5% (v/v) glycerol, pH 7.5, 2mM final
concentration, derived from acetylated Histone H3 (residues 11–17), Peptide
Specialty Laboratories), acetylated OTC oligopeptide (100mM stock solution in
DMSO, 2mM final concentration, derived from ornithine transcarbamoylase
(residues 83–92), Peptide Specialty Laboratories) or b-NADþ (Sigma-Aldrich,
100mM stock solution in 25mM Tris/HCl, 150mM NaCl, pH 8.0, 10mM final
concentration) for 60min at 4 C, centrifuged (4 C, 10min, 16,100 g) and
crystallized. Sirt2–SirReal1–OTC–peptide complex crystallized in 25% (w/v)
polyethylene glycol (PEG) 3,350 and 0.1M Bis–Tris buffer at pH of 6.5 and 4 C,
Sirt2–SirReal2–H3–peptide complex crystallized in 2.8M (NH4)2SO4 and 0.1M
Tris/HCl buffer at pH 9.0 and 4 C. For both conditions, a protein solution to
reservoir solution ratio of 1:3 was used. The Sirt2–SirReal2–NADþ complex
crystallized in 0.1M KSCN, 30% (w/v) PEG MME 2,000 at 4 C with a protein
solution to reservoir solution ratio of 3:1. The crystals were mounted in nylon loops
and if required, cryoprotected by the addition of 20% (v/v) of glycerol before flash
cooling in liquid nitrogen.
Crystals of Sirt2 in complex with ADPR (13mgml 1 final concentration,
20mM ADPR, 1M stock solution in 1M Tris/HCl buffer at pH 9.0) were obtained
using 18% (w/v) PEG 10,000 and 0.1M Bis–Tris buffer at pH 5.75 and 20 C. The
crystals formed after 1 day and were then soaked in a buffer containing 18% (w/v)
PEG 10,000, 0.1M Bis–Tris buffer at pH 5.75, 200mM NCA for 30min. They were
then mounted in nylon loops after addition of glycerol to a final concentration of
20% (v/v) before flash cooling in liquid nitrogen.
Data collection and processing. Data were collected at beamline X06SA (Sirt2–
SirReal2–H3 complex) or X06DA (Sirt2–SirReal1–OTC complex, Sirt2–ADPR–
NCA complex) with Pilatus detectors (Dectris) at the Swiss Light Source (Villigen,
Switzerland). All experiments were carried out at 100 K with oscillations of 0.25 or
0.5 at an X-ray wavelength of 1.0 Å. The Sirt2–SirReal2–NADþ complex was
determined from data collected on a MicroMax 007HF rotating anode X-ray
generator (Rigaku) at an X-ray wavelength of 1.5418Å, equipped with a mar345
image plate detector (Mar Research). All data sets were processed with Imosflm56
or XDS57 and scaled based on the CC* criterion58 using Aimless56.
Structure solution and refinement. All structures were solved by molecular
replacement using either MOLREP59 or PHASER60 with a monomer of
Sirt2–ADPR (PDB-ID 3ZGV)19 or the initial Sirt2-aminothiazole-structure
(Sirt2–SirReal2–H3) as a search model. Model building was carried out using
Coot61 and the structure was refined with REFMAC5 (ref. 62). Ligands were
generated using the Grade Web Server (Global Phasing Ltd., Cambridge). All
structures were validated using the Molprobity server63.
Sirt2–SirReal1–OTC was refined to a final Rwork of 26.0% and Rfree of 28.2%
with 98% of all amino acids of the refined model found in the most favored regions
of the Ramachandran plot. Sirt2–SirReal2–H3 was refined to a final Rwork of 18.1%
and Rfree of 18.8% with 98% of all residues falling into the most-favoured region of
the Ramachandran plot. The Sirt2–SirReal2–NADþ complex was refined to a final
Rwork of 20.2% and Rfree of 24.7% with 97% of all residues in the most-favoured
Ramachandran plot regions. Finally, the Sirt2–ADPR–NCA complex was refined to
a final Rwork of 21.1% and Rfree of 23.9% with 98% of all residues in the most
favored Ramachandran plot regions. All structures do not have Ramachandran
outliers. Further data collection and refinement statistics are found in Table 1
(Sirt2–SirReal1–OTC, Sirt2–SirReal2–H3, Sirt2–SirReal2–NADþ ) and in
Supplementary Table 2 (Sirt2–ADPR–NCA).
Most of the residues of all new structures are well defined in the electron density
maps except for some parts of the flexible cofactor-binding loop (residues 96–120,
Sirt2–SirReal2–NADþ , Sirt2–SirReal2–H3, Sirt2–SirReal1–OTC) and parts of
the Sirt2-specific insertion loop (residues 295–305, Sirt2–SirReal2–NADþ ,
Sirt2–SirReal2–H3, Sirt2–SirReal1–OTC). The weak density for NADþ in the
Sirt2–SirReal2–NADþ complex may also be due to partial hydrolysis of NADþ
and the formation of different conformers. The visible amino-terminal histidine
and methionine visible in the Sirt2–ADPR–NCA complex and Sirt2–SirReal2–
NADþ complex structures originate from the NdeI restriction site of the modified
pET15b vector. s-weighted Fo Fc electron density OMIT maps were generated
with the Phenix suite64. Images were prepared with Pymol (The Pymol Molecular
Graphics System, Version 1.6, Schro¨dinger, LLC), r.m.s.d. values were calculated
with SUPERPOSE65 and the surface of the binding pockets was generated using
HOLLOW66. The two-dimensional representation of the interactions of NCA with
Sirt2 were generated with LigPlotþ 67.
Determination of kinetic parameters for SirReal1/2. For SirReal-inhibition
kinetics, a mixture of a-tubulin peptide substrate (residues 36–44, H-PSDK
(Acetyl)TIGGWW-NH2, 2.5–75 mM, for details about the a-tubulin peptide
synthesis see Supplementary Methods), b-NADþ (5–1,500 mM), SirReal1/2
(various concentrations in 50mM Tris/HCl, 137mM NaCl, 2.7mM KCl, 1mM
MgCl2, 5% (v/v) DMSO, pH 8.0) was incubated (37 C). The reaction was started
by the addition of human Sirt256–356 (2mM), stopped after 1–50min with TFA
(10% (v/v), final concentration 1% (v/v)) and analysed by HPLC as described
above. The peak areas were integrated and converted to initial velocities calculated
from the peak areas as the fraction of deacetylated peptide from total peptide. From
this, reaction rates in mM min 1 were obtained by linear regression, while Km and
kcat were obtained directly from Michaelis–Menten plots using Graphpad Prism
software. b-NADþ (500 mM) was used for the determination of the kinetic
parameters for the peptide substrate, 100 mM of peptide substrate was used for the
determination of the kinetic parameters for b-NADþ .
Thermal shift assays. Human Sirt256–356 (0.2mgml 1 final concentration) was
mixed with or without ligand containing buffer (25mM Tris/HCl, 150mM NaCl,
5% (v/v) DMSO, 1:4,000 Sypro Orange, pH 8.0) in absence or presence of
b-NADþ (100mM stock solution in 25mM Tris/HCl, 150mM NaCl, pH 8.0, final
assay concentration 5mM) or acetylated H3-peptide (100mM stock solution in
25mM HEPES, 200mM NaCl, 5% (v/v) glycerol, pH 7.5, final assay concentration
5mM). Fluorescence was monitored during a temperature ramp from 25–95 C
(1 Cmin 1) using a Bio-Rad iCycler iQ5 (4titude, FrameStar 96-well plates,
4ti-0771, 4titude qPCR Seal, 4ti-0560). Melting temperatures were determined
according to published procedures68 using Graphpad Prism software.
Cell cultivation. HeLa cells (DSMZ accession no. 057) and U2OS cells (ATCC
accession no. HTB-96) were grown in Dulbecco’s modified Eagle’s medium (PAA)
containing 10% (v/v) fetal calf serum (FCS, PAA), 1% (v/v) penicillin (PAA), 1%
(v/v) streptomycin (PAA), 1% (v/v), L-glutamine (PAA) at 37 C in a 5% (v/v) CO2
atmosphere.
Tubulin acetylation. HeLa cells were plated in petri dishes (5 cm, PAA), incubated
overnight to a confluency of 30–40% and then treated with SirReal2 dissolved in
RPMI1640 medium supplemented with fresh 20% (v/v) FCS (PAA), 1% (v/v)
penicillin (PAA), 1% (v/v) streptomycin (PAA), 1% (v/v), L-glutamine (PAA),
1% (v/v) DMSO for 5 h at various concentrations. Cells were then washed with
prewarmed PBS (2ml), lysed in SDS–PAGE sample buffer (70 ml, 50mM Tris/HCl,
0.5mM EDTA, 1 Complete Protease Inhibitors (Sigma-Aldrich), 2% (v/v)
IGEPAL (Sigma-Aldrich), 2% (w/v) SDS, 10% (v/v) glycerol, 50mM NCA
(Sigma-Aldrich), 3.3 mM trichostatin A (Sigma-Aldrich), 50mM DTT, 0.01% (w/v)
bromophenol blue, pH 6.8) and sonicated (5min). Cell samples were then
separated using SDS–PAGE (12.5% (w/v) polyacrylamide), transferred to an
activated nitrocellulose membrane (Bio-Rad), blocked with non-fat dry milk
(Roth, 5% (w/v), TBS, 0.1% (v/v) Tween 20) and probed with an anti-acetyl-a-
tubulin antibody (1:1,000, Sigma-Aldrich, T6793) and an anti-GAPDH antibody
(1:2,000–1:5,000, Sigma-Aldrich, G9545) as a loading control (Fusion SL, peqlab).
An uncropped blot is shown in Supplementary Fig. 8.
Abundance of BubR1. HeLa cells plated in six-well plates were treated with
SirReal2 dissolved in FCS (1% (v/v) DMSO, 16 h) at various concentrations. Cells
were washed with PBS, lysed in IPLS (50mM Tris/HCl, 150mM NaCl, 0.5mM
EDTA, 0.5% (v/v) NP-40, pH 7.5, supplemented with Complete protease inhibitors
(Roche)). Samples were pelleted and resuspended in 1 SDS–PAGE sample buffer
and heated (95 C, 5min). Cell samples were separated using SDS–PAGE (10%
(w/v) polyacrylamide), transferred to a nitrocellulose membrane (Bio-Rad),
blocked with non-fat dry milk (Roth, 5% (w/v), TBS, 0.1% (v/v) Tween 20) and
probed with the anti-BubR1 (1:5,000, BD Biosciences, 612502) and anti-tubulin
(1:5,000, Sigma-Aldrich, T5168) as a loading control. Uncropped blots are shown
in the Supplementary Fig. 8.
Immunocytochemistry. HeLa cells that were incubated with SirReal2 (20 and
50 mM), SirReal6 (50 mM), AGK2 (Sigma-Aldrich, 20 mM) or DMSO as a control in
Dulbecco’s modified Eagle’s medium supplemented with 10% FCS, antibiotics and
DMSO (1% (v/v)) for 4 h, were fixed with ice-cold methanol (10min), washed with
PBS and blocked with PBS supplemented with 0.1% (v/v) Triton-X-100 and 5%
(v/v) FCS (30min). Cells were then stained with an anti-acetyl-a-tubulin antibody
(Sigma-Aldrich, T6793) and then probed with a secondary Alexa 546
conjugated anti-mouse-antibody (Invitrogen). Nuclei were counterstained with
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7263 ARTICLE
NATURE COMMUNICATIONS | 6:6263 |DOI: 10.1038/ncomms7263 | www.nature.com/naturecommunications 11
& 2015 Macmillan Publishers Limited. All rights reserved.
DAPI (40 ,6-diamidino-2-phenylindole). Coverslips were mounted with Fluor-
oMount (Sigma-Aldrich) and sealed with DPX Mountant (Sigma-Aldrich). Images
of the mounted samples were acquired on a Leica DM500 microscope equipped
with a Leica DFC 395 FX camera and HBO 100W lamp40. The microscope was run
with the Leica Application Suite 4.4.0 software. Chroma UV filter set (No. C40888)
and Leica N2.1 filter set (No. 513832) were used for DAPI and Alexa 546 signal
acquisition, respectively, with a HCX FL Fluotar 40x/0.75 (dry) objective. Further
details about the equipment and the settings that were used to acquire the images
are found in the Supplementary Methods section. Unprocessed images are found in
Supplementary Fig. 9.
p53 Acetylation. U2OS cells (ATCC accession no. HTB-96) were seeded and
cultured until they reached 90% confluency. Cells were then pretreated for 1 h with
NCA (Sigma-Aldrich), SirReal2, SirReal5 or SirReal6 at the indicated concentra-
tions, and then subsequently exposed to 20 J cm 2 ultraviolet light. Cells were
incubated for an additional 6 h in the presence of the inhibitor and then lysed in
IPLS (50mM Tris/HCl, 150mM NaCl; 0.5mM EDTA; 0.5% (v/v) NP-40; 1
Complete Protease Inhibitors (Roche), pH 8.0) and resuspended in 1 Laemmli
Buffer. Samples were then separated on SDS–PAGE, transferred to a nitrocellulose
membrane (Bio-Rad), blocked with non-fat dry milk (Roth, 5% (w/v), TBS, 0.1%
(v/v) Tween 20) and probed with anti-acetyl-p53 K382 (Cell Signaling, #2522),
anti-p53 DO.1 (Santa Cruz Biotechnology, sc-126) and anti-vinculin (Cell Sig-
naling, #4650) as a loading control. Uncropped blots are shown in the
Supplementary Fig. 10.
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1  Structures and inhibition data for sirtuin inhibitors with published structural information, in vitro inhibition data for SirReal1/2 and thermal stability plots for Sirt2. 
(a) Chemical structures and IC50 or kd values of sirtuin inhibitors with known binding modes: nicotinamide1, indoles (EX-527, CHIC-35)2-4, ELT inhibitors5, SRT17206,7, 4’-bromoresveratrol8 and the macrocyclic peptide S2iL59. (b) Dose-response curves for Sirt2 inhibition in an HPLC-based absorption assay in the presence of SirReal1/2 using a non-labeled acetyl-lysine oligopeptide based on D-tubulin. Data are presented as mean ± s.d. (n=2). (c) In vitro inhibition data for Sirt1-3 in the presence of SirReal1 (100 μM) using an HPLC-based absorption assay with a non-labeled acetyl-lysine oligopeptide based on D-tubulin as a substrate. A solution containing DMSO was used as a negative control. SirReal1 shows a preference to inhibit Sirt2 but also affects the activity of Sirt1/3 at higher concentrations. Data are presented as mean ± s.d. 
(n=2). (d) Representative thermal stability plots of Sirt2 in the presence of either the cosubstrate NAD+ or an acetyl-lysine oligopeptide. The presence of either NAD+ or an acetyl-lysine oligopeptide only leads to a slight stabilization of Sirt2 as compared to a combination of SirReal2 and cosubstrate or the substrate, respectively (n=3, Fig. 1d).    
 
Supplementary Figure 2 Nicotinamide (NCA) of Sirt2-ADPR-NCA occupies the C-pocket and interacts over a network of highly conserved residues with Sirt2. (a) Superposition of the overall structure of Sirt2-ADPR-NCA (pale green) with the Sirt2-ADPR complex (PDB-ID 3ZGV10, yellow). Both structures are very similar (r.m.s.d. (CĮ atoms) = 0.44 Å) and resemble a ‘closed’ conformation, due to the binding of the Sirt2-specific insertion that acts as a pseudo-substrate for the neighboring Sirt2-molecule. The active site of Sirt2 is shown as small grey dots. Residues Tyr139-Gly141 of Sirt2-ADPR (PDB-ID 3ZGV) were not defined in the electron density map. 
(b,d) NCA (brown sticks) occupies the C-pocket in vicinity of ADPR (deep blue sticks). (c) The amide of the nicotinamide is tightly bound via hydrogen bonds to Ile169 and Asp170 while the pyridine ring undergoes SSstacking with Phe96. (d) Electron density maps of ADPR (overall 
B-factor 21.9 Å2) and NCA (overall B-factor 46.3 Å2) of Sirt2-ADPR-NCA. The position of the pyridine ring is more flexible relative to the amide as its B-factors are significantly higher than the B-factors of the amide (B-factor(Phenyl ring): 49.1 Å2; B-factor(amide): 41.1 Å2). The V-weighted 2Fo-Fc electron density map is contoured at 1.0 V. A stereo image of d as well as a V-
NAD+ -binding                Zinc-binding     domain                         domain   CLOSED    CLOSED Sirt2-ADPR-NCAADPR of Sirt2-ADPR-NCANCA of Sirt2-ADPR-NCASir2Tm-p53-NCAPDB-ID 1YC5Sir2Af2-NAD+-NCAPDB-ID 1YC2
Sirt2-ADPR-NCAADPR of Sirt2-ADPR-NCANCA of Sirt2-ADPR-NCASirt2-ADPRPDB-ID 3ZGVa                                                      b
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weighted Fo-Fc electron density OMIT map for ADPR and NCA are shown in Supplementary Fig. 4a,b. (e) The interactions of NCA with Sirt2 and its position within the C-pocket is similar to the ones observed in other sirtuin structures in complex with nicotinamide (Sir2Tm-Ac-Lys-p53-NCA, PDB-ID 1YC511, light orange, Sir2Af2-NAD+-NCA, PDB-ID 1YC211, teal). However, in contrast to nicotinamide of Sir2Tm-Ac-Lys-p53-NCA and Sir2Af2-NAD+-NCA the amide moiety and the phenyl ring of nicotinamide of Sirt2-ADPR-NCA do not lie in the same plane. The cofactor-binding loop in b,d,e is not shown for better clarity.   

 
Supplementary Figure 3  SirReal2 functions as a molecular wedge and locks Sirt2 in an open conformation. (a-c)  Superposition of Sirt2-SirReal2-H3 with Sirt2-apo (PDB-ID 3ZGO10,12, salmon, residues 34-45 are omitted for better clarity), Sirt2 in complex with ADP ribose (PDB-ID 3ZGV, yellow, residues Tyr139-Gly141 were not defined in the electron density map) and the Sirt2-S2iL5-peptide complex (PDB-ID 4L3O9, green). The active site is shown as small grey dots. As seen in Fig. 2 of the main article, the Sirt2-SirReal2 complex adopts an open state comparable to Sirt2-apo and in contrast to the Sirt2-ADPR and Sirt2-S2iL5 complex. Sirt2-SirReal2-H3 bears more resemblance to Sirt2-apo (r.m.s.d. (CĮ atoms) = 1.3 Å) than to the Sirt2-ADPR complex (r.m.s.d. (CĮ atoms) = 1.8 Å) or the Sirt2-S2iL5 peptide complex (r.m.s.d. (CĮ atoms) = 1.6 Å). (d) Comparison of the interactions of SirReal2 in Sirt2-SirReal2-H3 (light cyan) with SirReal2 in Sirt2-SirReal2-NAD+ (light pink). Interacting residues are represented as sticks (Sirt2-SirReal2-H3: light grey; Sirt2-SirReal2-NAD+: slate blue). Binding of SirReal2 is almost identical (r.m.s.d. of 0.47 Å) in both structures. This is also true for the positions of the 
NAD+ -binding                Zinc-binding     domain                         domain       CLOSED            LOCKED OPEN Sirt2-ADPR: CLOSEDSirt2-SirReal2-H3: LOCKED OPENapo-Sirt2: OPENSirt2-SirReal2-H3: LOCKED OPEN
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Cofactor-binding loop
SirReal2-interacting residues of the Sirt2-SirReal2 structures except for Phe96 which is forced to adopt a different position upon NAD+-binding. Hydrogen bonds are shown as dashed yellow lines. (e)Electron density maps for SirReal2 (pale cyan sticks, overall B-factor of 25.1 Å2) and the acetyl-lysine peptide substrate (light blue sticks, overall B-factor of 48.3 Å2). The V-weighted 2Fo-Fc electron density map is contoured at 1.0 V. A stereo image of e as well as a V-weighted 
Fo-Fc electron density OMIT map for SirReal2 and the Ac-Lys-H3 oligopeptide is shown in Supplementary Fig. 5a,b.  

 
Supplementary Figure 4  Stereo images of the V-weighted 2Fo-Fc electron density and the V-weighted Fo-Fc OMIT maps of presented inhibitors, cosubstrates and substrates. Wall-eyed stereo representation of the electron density of the ligands of (a) the Sirt2-ADPR-NCA structure and the Sirt2-SirReal2-NAD+ complex (c). Sirt2-ADPR-NCA is presented as a pale green cartoon and ADPR and NCA is shown as dark blue and dark brown sticks. Sirt2-SirReal2-NAD+ is presented as a slate blue cartoon and SirReal2 and NAD+ are shown as light pink and light orange sticks.  The surface of Sirt2-SirReal2-NAD+ of c is colored according to its hydrophobicity (red color indicating increasing hydrophobicity). The V-weighted 2Fo-Fc maps are contoured at 1.0 V and shown as grey mesh(b,d) The V-weighted Fo-Fc electron density OMIT maps are contoured at 3.0 V (ADPR, SirReal2) or 2.0 V(NCA, NAD+) and shown as green mesh. The cofactor-binding loop of a-d is omitted for clarity.
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 
Supplementary Figure 5  Stereo images of the V-weighted 2Fo-Fc electron density and images of the V-weighted Fo-Fc OMIT map of the Sirt2-SirReal2-H3 and Sirt2-SirReal1-OTC complexes. (a,c) Wall-eyed stereo representation of the electron density maps of the ligands of the Sirt2-SirReal2-H3 structure (a) and the Sirt2-SirReal1-OTC (c) complex. Sirt2-SirReal2-H3 is presented as a light grey cartoon and SirReal2 and the Ac-Lys-H3 oligopeptide are shown as light cyan and light blue sticks. Sirt2-SirReal1-OTC complex is presented as a brown cartoon and SirReal1 and the Ac-Lys-OTC oligopeptide are shown as pale yellow and light green sticks. The V-weighted 2Fo-Fc maps are contoured at 1.0 V and shown as grey mesh. (b,d) The V-weighted Fo-Fc electron density OMIT maps are contoured at 3.0 V (SirReal2), 2.0 VAc-Lys-H3, SirReal1) or 1.5 VAc-Lys-OTC) and shown as green mesh. The poor electron density for the acetyl-lysine oligopeptides as well as the one of SirReal1 is probably due to a low occupancy. The cofactor-binding loop of a-d is omitted for clarity.  
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 
Supplementary Figure 6  Synthesis scheme for SirReal inhibitors. Preliminary tests with SirReal2 were performed with the commercially available compound (Chembridge, compound ID 7881488). For further characterization it was synthesized in our laboratory as the other SirReal inhibitors. Starting with the diazotization of aniline (1.1) for SirReal1/3 or 
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D-naphthylamine for SirReal2/4/5/6 (1.2), the D-chloropropanals (2) were generated via a Meerwein reaction13,14.  Condensation of thiourea (SirReal1-5) or 1-methylthiourea (SirReal6) and the D-chloropropanals (2) led to formation of the aminothiazoles (3.1 / 3.2) which were then chloroacetylated to (4.1 / 4.2 ), followed by a nucleophilic substitution15 with 2-mercapto-4,6-dimethylpyrimidine, 2-mercaptopyrimidine or 3,5-dimethylthiophenol to yield SirReal1-6. Identity and purity of all SirReal inhibitors were confirmed by 1H-, 13C-NMR, mass spectrometry respectively, and high performance liquid chromatography (HPLC) analysis. All synthesized SirReal inhibitors were of a purity of at least 95%. Spectroscopic data for all synthesized SirReal inhibitors can be found in the Supplementary Notes section. Reagents and conditions: (a) NaNO2, HCl, water, 0 °C, 20 min; (b) acrolein, CuCl2 u2 H2O, NaHCO3, acetone, 20 °C, 3 h, 9% yield; (c) thiourea or 1-methylthiourea, ethanol, reflux, 2 h, 56% yield or 38%, respectively; (d) chloroacetyl chloride, DIPEA, acetonitrile, 20 °C, 2 h, 98% yield; (e) 2-mercaptopyrimidine, 2-mercapto-4,6-dimethylpyrimidine or 3,5-dimethylthiophenol, Na2CO3, KI, DMSO, 20 °C, 2 h, 80%, 89% or 13% yield.   
 
Supplementary Figure 7  Structural comparison of the Sirt2-SirReal2-NAD+ complex with structures of available crystal structures of other sirtuins, stereochemical analysis, r.m.s.d. plots for molecular dynamics (MD) simulations of the Sirt1/3 homology models and the Sirt2-SirReal2-H3 structure. (a,b) Superposition of the Sirt2-SirReal2-NAD+ complex with crystal structures of Sirt5 (red, PDB-ID 2B4Y16) and Sirt6 (orange, PDB-ID 3PKI17) in their open conformation (a) and with crystal structures of Sirt1 and Sirt3 (b, Sirt1-apo, brown, PDB-ID 4IG918; Sirt3-apo, raspberry, PDB-ID 3GLS19). All structures adopt the ‘open’ conformation and show main differences in the conformation of the zinc-binding domain while the NAD+-binding domain adopts a very similar conformation. The structural differences of the Sirt2-SirReal2-NAD+ complex are more pronounced when compared to the crystal structures of Sirt5/6 than to the ones of Sirt1/3. This is also reflected by r.m.s.d. values: compared to Sirt5/6 (r.m.s.d. (CĮ atoms) = 1.8–1.9 Å); to Sirt1/3 (r.m.s.d. (CĮ atoms) = 1.6 Å). The C-terminal regulatory segment of Sirt1 is omitted for clarity. (c) PROCHECK stereochemical analysis of the Sirt1 homology model. 91.1% of the ) and < angles of the protein backbone are located in the most favored 
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regions, 8.1% are in the additional allowed regions and two residues are in the disallowed regions of the Ramachandran plot. Outlier residues are located outside of the binding pockets. 
(d) PROCHECK stereochemical analysis of the Sirt3 homology model. 92.2% of the ) and < angles of the protein backbone are located in the most favored regions, 6.5% are in the additional allowed regions and three residues are in the generously allowed regions of the Ramachandran plot. (e-h) r.m.s.d. plots for MD simulations of the Sirt1 homology model (e), of the Sirt3 homology model (f), of the Sirt2-SirReal2-H3 crystal structure with SirReal2 (g) and without SirReal2 (h). The black line represents the r.m.s.d. value calculated for backbone heavy atoms (CD, C and N) of the whole protein. The red line represents the r.m.s.d. value calculated for backbone heavy atoms of pocket residues only. The green line represents the r.m.s.d. value calculated for the heavy atoms of the inhibitor SirReal2.   
 
Supplementary Figure 8  SirReal2 induces a tubulin hyperacetylation and a significant depletion of BubR1. (a) Representative western blot of HeLa cell lysates after incubation with SirReal2 at the indicated concentrations. Ro318220 was used as a positive control20. The western blot was cut in half at around 40 kDa to detect acetyl-tubulin and GAPDH separately. (b) Quantification of the relative hyperacetylation after incubation with SirReal2. (c) In vitro inhibition data for the ‘classical’ KDAC1 and KDAC6. SirReal2 does not affect the activity of both KDACs. Only the positive control Trichostatin A (TSA) significantly inhibits both KDACs. 
(d) Representative western blot of HeLa lysates after incubation with SirReal2 at the indicated concentrations. SirReal2 induces a reduction of the spindle assembly checkpoint protein BubR1. 
(e) Statistical analysis of the abundance of BubR1 after incubation with SirReal2. At a SirReal2 concentration of 50 μM, BubR1 is significantly reduced in relation to the DMSO control. This is in line with a Sirt2-inhibition in vivo. (f) Cell cycle analysis after incubation of SirReal2 at the indicated concentrations. Treatment with SirReal2 did not alter the cell cycle. A description of 
the cell cycle analysis can be found in the Supplementary Methods section. Colorplus™ Prestained Protein Ladder (New England Biolabs, tubulin hyperacetylation) and EZ-Run™ Prestained Rec Protein Ladder (Fisher Scientific, BubR1) were used as molecular weight markers. All data are presented as mean ± s.d. (n=3). *P < 0.05 as compared to the control.    
 
Supplementary Figure 9  SirReal2 induces tubulin-hyperacetylation in HeLa cells. Representative combined and raw images show that treatment with SirReal2 at a concentration of 20 μM and 50 μM induces hyperacetylation of the microtubule network as compared to the DMSO control. The effects are similar to the ones observed for the treatment with the Sirt2 inhibitor AGK221. Treatment with SirReal6 on the other hand results in no substantial change of 
           Combined image                                      Ac-tubulin                                    DAPI stainingDMSO controlSirReal2, 20 μMSirReal2, 50 μMSirReal6, 50 μMAGK2, 20 μM
acetylation level (n=4). The scale bar represents 10 μm .   
 Supplementary Figure 10  SirReal2 does not alter the acetylation of p53-Lys382 or mitochondrial proteins. (a) Representative western blot of U2OS cell lysates after incubation with SirReal2. SirReal2 does not affect p53-Lys382-acetylation whereas treatment with nicotinamide, a pan-sirtuin inhibitor, results in an increase of p53-Lys382-acetylation (n=3). (b) Representative western blot of whole cell extracts and mitochondrial extracts of HEK293 cells. Treatment with SirReal2 does not alter the mitochondrial lysine-acetylation while incubation with the pan-sirtuin inhibitor nicotinamide leads to an increase of mitochondrial lysine acetylation. Sirt3 was used as a loading control. Sirt3 is enriched in the mitochondrial extracts as expected (n=3). EZ-Run™ Prestained Rec Protein Ladder (Fisher Scientific) was used as a molecular weight marker.  
SUPPLEMENTARY TABLES 
Supplementary Table 1 Physicochemical properties and selectivity profiles of sirtuin inhibitors (Supplementary Fig. 1).  SirReal2 EX-5272,3 CHIC-352,4 ELT inhibitor 11c5 ELT inhibitor 285 ELT inhibitor 315 SRT17206,7 4’-bromo-resveratrol8 S2iL59 Target values IC50/kd for Sirt2 [μM] 0.14 20 2.4 0.003 0.01 0.001 n.d.* n.d. * 0.001  Selectivity  Sirt1/ Sirt2/ Sirt3 (fold)  > 1,000 1 > 1,000  1 200 500  1 23 > 833  1.3 1 1.3  1.5 1 3.3  4 1 7  activation n.d.* 1  1 n.d.* 3†  n.d.* 1 1  Molar mass [g/mol] 420 249 263 487 389 383 470 291 2,039 < 500 log P22 4.63 2.76 3.1 2.18 0.78 2.76 2.62 4.13 0.4 < 5 H-donors 1 2 2 3 2 2 2 2 31 < 5 H-acceptors 4 1 1 6 5 6 5 0 23 < 10 Number of atoms 49 30 33 59 54 46 57 28 266 20-70 n.d. – not determined; † - inhibition substrate-dependent Among sirtuin ligands with structural data available, SirReal2 presents the most potent and Sirt2-selective inhibitor. Its physicochemical properties as well as its selectivity make SirReal2 a suitable compound for studies on Sirt2 in vivo. 
Supplementary Table 2: Refinement statistics for the Sirt2-ADPR-NCA complex structure.  
  Sirt2-ADPR-NCAb 
Data collection  Space group P21 21 21 Cell dimensions (Å)      a, b, c (Å) 77.60, 77.96, 114.30 
DEJ (q)  90, 90, 90 Resolution (Å)a 34.74–1.87 (1.91–1.87) 
Rmerge 0.123 (1.247) 
Rpim 0.051 (0.530) CC1/2 0.995 (0.639) 
I/VI 8.2 (1.3) Completeness (%) 100 (100) Redundancy 6.8 (6.5) 
 
 
Refinement  Resolution (Å) 34.74–1.87 No. reflections 393,009 (23,929) 
Rwork / Rfree (%) 21.1 / 23.9 No. atoms      Protein 4,754     ADP ribose 72     Nicotinamide 9     Zn2+ 2     Other entities 30     Water 138 
B-factors (Å2)      Protein 42.6     ADP ribose 23.1     Nicotinamide 46.4     Zn2+ 54.6     Other entities 36.4     Water 34.5 R.m.s. deviations      Bond lengths (Å) 0.012     Bond angles (q) 1.58  a Values in parentheses are for highest-resolution shell. b Data were obtained from one single crystal and were collected at 1.0 Å at the Swiss Light Source (Villigen, Switzerland).   
SUPPLEMENTARY NOTE 1 
COMPOUND CHARACTERIZATION DATA 
SirReal1 - N-(5-Benzylthiazol-2-yl)-2-((4,6-dimethylpyrimidin-2-yl)thio)acetamide 
1H NMR  (400 MHz, DMSO-D6): G11.53 (bs, 1H), 7.34–7.28 (m, 2H), 7.26-7.20 (m, 3H), 7.12–7.10 (m, 1H), 6.85 (s, 1H), 4.08 (s, 2H), 3.93 (s, 2H), 2.53 (s, 6H); 13C NMR (100 MHz, DMSO-D6): G 169.72, 167.96, 167.20, 157.17, 139.34, 134.16, 132.43, 128.63, 128.39, 126.68, 116.85, 34.37, 32.98, 23.82; HRMS (m/z): [M + Na]+ calcd. for C18H18N4NaOS2, 393.0814; found, 393.0815; overall yield 9%; isolated mass 24 mg. 
 
SirReal2 - 2-((4,6 -Dimethylpyrimidin-2-yl)thio)-N-(5-(naphthalen-1-ylmethyl)thiazol-2-
yl)acetamide 
1H NMR (400 MHz, CDCl3): G 11.45 (bs, 1H), 8.05–8.00 (m, 1H), 7.89–7.84 (m, 1H), 7.80–7.76 (m, 1H), 7.51–7.46 (m, 2H), 7.45–7.38 (m, 2H), 7.07 (s, 1H), 6.83 (s, 1H), 4.53 (s, 2H), 3.90 (s, 2H), 2.52 (s, 6H); 13C NMR  (100 MHz, CDCl3): G 169.79, 167.95, 167.11, 156.63, 135.15, 134.92, 133.91, 132.14, 131.50, 128.73, 127.71, 126.73, 126.15, 125.66, 125.51, 123.61, 116.82, 34.31, 30.43, 23.78; HRMS (m/z): [M + Na]+ calcd. for C22H20N4NaOS2, 443.0971; found, 443.0973; overall yield 5%; isolated mass 45 mg.  
SirReal3 - N-(5-Benzylthiazol-2-yl)-2-(pyrimidin-2-ylthio)acetamide 
1H NMR  (400 MHz, DMSO-D6): G 12.23 (bs, 1H), 8.58 (d, J = 4.8 Hz, 2H), 8.17–8.12 (m, 1H), 7.96–7.90 (m, 1H), 7.86–7.80 (m, 1H), 7.58–7.43 (m, 4H), 7.31 (s, 1H); 7.17 (t, J = 4.8 Hz, 1H), 4.55 (s, 2H), 4.12 (s, 2H); 13C NMR  (100 MHz, DMSO-D6): G 170.38, 166.67, 158.21, 156.94, 136.56, 135.13, 133.93, 131.84, 131.42, 129.01, 127.77, 127.02, 126.63, 126.23, 126.11, 124.28, 117.89, 34.46, 29.82; HRMS (m/z): [M + Na]+ calcd. for C20H16N4NaOS2, 415.0659; found, 415.0659; overall yield 18%; isolated mass 102 mg. 
SirReal4 - N-(5-(Naphthalen-1-ylmethyl)thiazol-2-yl)-2-(pyrimidin-2-ylthio)acetamide 
1H NMR (400 MHz, CDCl3): G 11.00 (bs, 1H), 8.66 (d, J = 4.9 Hz, 2H), 7.34–7.29 (m, 2H), 7.26–7.21 (m, 3H), 7.16–7.14 (m, 1H), 7.12 (t, J = 4.9 Hz, 1H), 4.08 (s, 2H), 3.99 (s, 2H); 
13C NMR (100 MHz, CDCl3): G 170.64, 166.73, 157.81, 157.25, 139.09, 133.38, 132.78, 128.70, 128.40, 126.80, 117.58, 34.35, 32.96; HRMS (m/z): [M + Na]+ calcd. for C16H14N4NaOS2, 365.0501; found, 365.0503; overall yield 11%; isolated mass 24 mg.  
SirReal5 - 2-((3,5 -Dimethylphenyl)thio)-N-(5-(naphthalen-1-ylmethyl)thiazol-2-yl)acet-
amide 
1H-NMR (400 MHz, DMSO-D6): G 12.13 (bs, 1H), 8.18–8.08 (m, 1H), 7.97–7.89 (m, 1H), 7.87–7.80 (m, 1H), 7.57–7.42 (m, 4H), 7.29 (s, 1H), 6.95 (s, 2H), 6.80 (s, 1H), 4.55 (s, 2H), 3.83 (s, 2H), 2.17 (s, 6H); 13C-NMR (100 MHz, DMSO-D6): G 167.38, 156.69, 138.56, 136.50, 135.20, 135.00, 133.95, 132.00, 131.44, 129.02, 128.37, 127.79, 127.02, 126.64, 126.44, 126.23, 126.11, 124.26, 36.31, 29.82, 21.16; HRMS (m/z): [M + Na]+ calcd. for C24H22N2NaOS2, 441.1066; found, 441.1068; overall yield 2%; isolated mass 9 mg.  
SirReal6 - 2-((4,6-Dimethylpyrimidin-2-yl)thio)-N-methyl-N-(5-(naphthalen-1-ylmethyl)-
thiazol-2-yl)acetamide 
1H-NMR (400 MHz, DMSO-D6,): G 8.16–8.09 (m, 1H), 7.96–7.89 (m, 1H), 7.86–7.79 (m, 1H), 7.56–7.42 (m, 4H), 7.38 (s, 1H), 6.92 (s, 1H), 4.55 (s, 2H), 4.36 (s, 2H), 3.74 (s, 3H), 2.25 (s, 6H); 13C-NMR (100 MHz, DMSO-D6): G 169.23, 168.57, 167.38, 158.54, 136.50, 134.48, 133.94, 133.23, 131.45, 129.00, 127.77, 127.00, 126.59, 126.20, 126.07, 124.28, 116.48, 34.94, 34.36, 29.79, 23.65; HRMS (m/z): [M + Na]+ calcd. for C23H22N4NaOS2, 457.1127; found, 457.1128; overall yield 21%; isolated mass 92 mg.  
SUPPLEMENTARY METHODS 
Homology Modeling . Homology models of human Sirt1241–512 (UniProt: Q96EB6) and human Sirt3122–395 (Uniprot: Q9NTG7) were generated using the Sirt2-SirReal2-H3 and Sirt2-SirReal2-NAD+ crystal structures as templates. 10 protein conformations were generated and evaluated with the Modeller program version 9.1123. The model showing the most favorable DOPE (Discrete Optimized Protein Energy) assessment score24 was selected. The stereochemical quality of the models was validated with PROCHECK25 (Supplementary Fig. 6). All parameters indicate high-quality model structures. Assignment of correct protonation state and energy minimization of the homology models were carried out in MOE 2012.10226.  
Molecular dynamics s imulations. Molecular dynamics (MD) simulations were carried out for the Sirt2-SirReal2-H3 X-ray structure in uncomplexed form (inhibitor and substrate deleted) and in complex with SirReal2 (substrate deleted) as well as for the Sirt1 and Sirt3 homology models (uncomplexed) using the program AMBER 12 and the AMBER 2003 force field27. Missing residues in the Sirt2 structures were modelled using the loop search module of Modeller. Atom types and AM1-BCC atomic charges28 were generated for the ligand using the Antechamber module. Ligand parameters were obtained from the general AMBER force field GAFF29. Preparation of the ligand-protein complex, addition of counter ions, solvation, preparation of parameter/topology and coordinate files was carried out using the LEaP module in AMBER. Parameters and libraries for zinc binding residues were defined as previously described30. The system was solvated using the water model TIP3BOX31 and a margin of 10 Å. Two consecutive steps of minimization were carried out. In the first step 3,000 iterations (first 1,000 steepest descent and then 2,000 conjugate gradient) and in the second step 4,000 iterations (first 2,000 steepest descent and then 2,000 conjugate gradient) were applied to the 
system. In the first step, atom coordinates for the amino acid residues and ligand atoms were restrained to their initial coordinates with a force constant of 500 kcal mol-1Å-2 to relieve the unfavorable van-der-Waals contacts in the surrounding solvent and thus to minimize the positions of the water molecules and ions. In the second step, restraints to atoms were removed and the whole system was minimized freely to relieve bad contacts in the entire system.  The temperature of the system was then equilibrated at 300 K through 100 ps of MD with a time step of 2 fs per step. A constant volume periodic boundary was set to equilibrate the temperature of the system by the Langevin dynamics32 using a collision frequency of 1 psí1 during the temperature equilibration routine. The protein and ligand atoms were restrained to the initial coordinates with a weak force constant of 10 kcal mol-1Å-2. The final coordinates obtained after temperature equilibration step were then used for a 20 ns MD routine during which the temperature was kept at 300 K by the Langevin dynamics using a collision frequency of 1 ps-1. Constant pressure periodic boundary was used to maintain the pressure of the system at 1 bar using isotropic pressure scaling with a relaxation time of 2 ps. During the temperature equilibration and MD routines a non-bonded cut-off distance of 10 Å was used applying the Particle Mesh Ewald (PME) method33 for calculating the full electrostatic energy of the periodic system and the SHAKE algorithm34 to adjust the constraints of  all bonds involving hydrogen.  
Docking studies . All protein structures were prepared by using the Structure Preparation module in MOE 2012.10226. Hydrogen atoms were added, for titratable amino acids the protonation state was calculated using the Protonate 3D module in MOE. All protein structures were energy minimized using the AMBER99 force field using a tethering force constant of 1.5 kT V-2 with (V = 0.5 Å) for all atoms during the minimization. Water molecules and ligand atoms except the zinc ion were removed from the structures. Docking 
studies were performed using the Glide program (Schrödinger Suite 2012-5.8)35. All sirtuin structures were superimposed on their backbone atoms using the Superpose module in MOE 2012.10226. The position of the inhibitor SirReal2 in the crystal structure was used to define the binding site (10 Å radius). 20 docking poses were calculated for each ligand. All other options were left at their default values. The bestͲranked pose from each docking run was included in the analysis and visually inspected together with the protein structure using the program MOE 2012.10226. The applied docking protocol used in Glide was able to correctly reproduce the location and conformation of the inhibitor SirReal2 in the corresponding X-ray structures (SirReal2: 0.32 Å and 0.31 Å, respectively). In case of the generated homology models of human Sirt1 and Sirt3 the docking protocol gave docking poses with less favorable Glide SP scores and larger deviations from the conformation and location observed in the Sirt2-SirReal2-H3 structure. To compare the three sirtuins we selected for both homology models docking poses that showed a comparable interaction with the residues of the extended C-site and the selectivity pocket. Docking of SirReal2 to the available crystal structures of Sirt1 and Sirt3 (apo-form and different inhibitor-complexes) was not possible due to the limited size of the extended C-site and the selectivity pocket (data not shown).  
Synthesis of D-tubulin derivative H-PSDK(Ac)TIGGWW-NH 2. The peptide (residues 36–44 of D-tubulin with two additional C-terminal tryptophans) was synthesized with standard solid-phase-peptide synthesis using 9-fluorenylmethoxy-carbonyl (Fmoc) amino acids. The Rink amide MBHA resin was incubated with N,N-dimethylformamide (DMF) at RT for 20 min while stirring. The Fmoc group was removed by incubation with 20% (vol/vol) piperidine in DMF at RT for 15 min under stirring. After washing with DMF (5 min, 5 times) the resin was incubated with 4 equivalents (eq) of amino acid, 4 eq N,N,Nƍ,Nƍ-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) and 8 eq N,N-diisopropylethylamine (DIPEA) in DMF at RT for 45 min under stirring. After washing the resin with DMF (5 min, 
5 times), Fmoc deprotection and amino acid coupling were repeated until the last amino acid was coupled and the Fmoc group was removed. The resin was washed with dichloromethane (DCM, 3 min, 5 times), methanol (5 min, 3 times) and DCM (3 min, 5 times). The peptide was cleaved from the resin and deprotected by incubation with 97% (vol/vol) trifluoroacetic acid (TFA) at RT (1 h, 2 times). Cleaved peptide was precipitated with cold diethylether, filtrated and dried. The peptide was purified by semi-preparative HPLC (Merck-Hitachi High Speed LC system) using a Merck Hibar LiChrosorb RP-8 column (250–25 mm, 7 μm). For separation a linear gradient from 20–50% (vol/vol) acetonitrile (ACN) with 0.1% (vol/vol) TFA in 60 min was applied (flow-rate: 8 ml min-1). The purification yielded > 97% of pure peptide. Identity was confirmed by MALDI-MS (calculated mass: 1186.5 Da, found: 1187.5 Da).   
In vitro KDAC1/6 assay. Inhibition tests with SirReal2 and KDAC1/6 were conducted with a high-throughput fluorescence-based assay using the substrate ZMAL (Z-Lys(Acetyl)-AMC)36. ZMAL (12.6 μM final concentration) was mixed with assay buffer (50 mM Tris/HCl, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 0.1 mg mL-1 BSA, 5–10% (vol/vol) DMSO, 50 μL, pH 8.0) and SirReal2. A solution that contained DMSO was used a negative control. A solution with trichostatin A (TSA, Enzo Life Sciences) was used a positive control. The reaction was started through the addition of KDAC1 (Enzo Life Sciences, 10 μL) or KDAC6 (Enzo Life Sciences, 10 μL) and incubated (37 °C, 90 min, 150 rpm). To assure initial state conditions the substrate conversion was adjusted to 10–30% prior to inhibition tests. The reaction was stopped by the addition of a solution containing trypsin and TSA (50 mM Tris/HCl, 100 mM NaCl, 0.2% (vol/vol) DMSO, trypsin 5.5 U μL-1, 16.5 μM TSA, pH 8.0, 60 μL) and further incubated (37 °C, 20 min, 150 rpm). Then fluorescence intensity of the released fluorophore of the deacetylated lysine derivative was measured in a microplate 
reader (BMG Polarstar, Oex 390 nm, Oem 460 nm). The amount of inhibition was determined with respect to the mixture with only DMSO.  
Immunocytochemistry equipment and settings. The signal of Alexa 546 and DAPI of the same region were acquired with constant illumination parameters as grayscale 8-bit 600 dpi tiff files (1600u1200 pixels). Alexa 546 was acquired after 639.1 ms with a gamma factor of 0.65 without multiplying. The gain was set to 1. DAPI-stained images were acquired after about 20 ms with the same parameters as the one for Alexa 546 image acquisition. The temperature in the microscope room was kept at RT. Representative regions of each samples were processed with Adobe Photoshop CS2 to generate images in RGB mode by copying the appropriate original greyscale images to the blue (nuclei, DAPI) and the red (acetylated D-tubulin signal, Alexa 546) channel, respectively. As adjustment, a minimal background subtraction was applied on all images during processing in the same manner. The resolution was changed from 600 dpi (source images) to 450 dpi without resampling (Fig. 7 of the main article). LUT (CLUT) of grayscale images of the acetylated D-tubulin signal and of the DAPI signal are shown in Supplementary Fig. 8.  
Cell Cycle Analysis . HeLa cells were treated as described in the Abundance of BubR1 section of the main article. Cells were harvested by trypsinization, washed in PBS, and fixed in ice-cold 70% (vol/vol) ethanol, and stored at –20 ºC for 2 h. Fixed cells were pelleted, washed in PBS, and stained in propidium iodide buffer (0.1% (wt/vol) sodium citrate, 0.3% (vol/vol) Triton X-100, 0.01%  (wt/vol) propidium iodide, 0.02 mg mL-1 RNase A) as described previously37 for 30 min. Stained cells were subjected to flow cytometric analysis using a FACSCaliber (BD Biosciences) and analyzed by FlowJo software (Tree Star, Inc.). 
 
Cell cultivation. HEK-293 cells (ATCC accession no. CRL-1573) were grown in Dulbecco’s modified Eagle’s medium (DMEM, PAA) containing 10% (vol/vol) fetal calf serum (FCS, PAA), 1% (vol/vol) penicillin (PAA), 1% (vol/vol) streptomycin (PAA), 1% (vol/vol), L-glutamine (PAA) at 37 °C in a 5% (vol/vol) CO2 atmosphere. 
 
Mitochondrial extra ction. HEK-293 cells (ATCC accession no. CRL-1573) were treated with nicotinamide or SirReal2 at the indicated concentrations for 16 h. Cells were washed in PBS and lysed in 5 packed cell volumes of lysis buffer (20 mM HEPES/KOH, 250 mM sucrose; 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT; 0.1 mM PMSF, 1uComplete Protease Inhibitor Cocktail (Roche), pH 7.5). Cells were then homogenized in a Dounce homogenizer and 10% (vol/vol) of sample was removed for use as whole cell extract (WCE). To the remaining lysate, unbroken cells and nuclei were removed by centrifugation (10 min, 800g). The supernatant was transferred and centrifuged (10 min, 7,000g) to pellet mitochondria. Mitochondria were washed twice in lysis buffer, repeating centrifugation after each wash, followed by resuspending washed mitochondria in lysis buffer. NP-40 was added to both whole cell extracts and mitochondria fractions to a final concentration of 0.5% (vol/vol) and lysates were incubated at 4qC for 30 minutes. Lysates were cleared by centrifugation, protein concentrations were quantitated and normalized with 1uLaemmli Buffer. Whole cell and mitochondrial extracts were separated on SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad), blocked with non-fat dry milk (Roth, 5% (wt/vol), TBS, 0.1% (vol/vol) Tween 20), and probed with anti-acetyl-lysine (Cell Signaling, #9814) and anti-Sirt3 (Cell Signaling, #2627) as a control for mitochondria enrichment and loading.  
Statistical analysis . Statistical analysis for the BubR1 abundance and hyperacetylation of 
D-tubulin were performed with t-test option of Microsoft Excel using a one-tailed distribution. 
For that the intensity of the bands were quantified (Fusion SL, peqlab) and normalized to the respective loading control.
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ARTICLE
Crystal structures of the mitochondrial deacylase
Sirtuin 4 reveal isoform-speciﬁc acyl recognition
and regulation features
Martin Pannek1, Zeljko Simic2, Matthew Fuszard1, Marat Meleshin2, Dante Rotili3, Antonello Mai3,
Mike Schutkowski2 & Clemens Steegborn1
Sirtuins are evolutionary conserved NAD+-dependent protein lysine deacylases. The seven
human isoforms, Sirt1-7, regulate metabolism and stress responses and are considered
therapeutic targets for aging-related diseases. Sirt4 locates to mitochondria and regulates
fatty acid metabolism and apoptosis. In contrast to the mitochondrial deacetylase Sirt3 and
desuccinylase Sirt5, no prominent deacylase activity and structural information are available
for Sirt4. Here we describe acyl substrates and crystal structures for Sirt4. The enzyme
shows isoform-speciﬁc acyl selectivity, with signiﬁcant activity against hydro-
xymethylglutarylation. Crystal structures of Sirt4 from Xenopus tropicalis reveal a particular
acyl binding site with an additional access channel, rationalizing its activities. The structures
further identify a conserved, isoform-speciﬁc Sirt4 loop that folds into the active site to
potentially regulate catalysis. Using these results, we further establish efﬁcient Sirt4 activity
assays, an unusual Sirt4 regulation by NADH, and Sirt4 effects of pharmacological
modulators.
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eversible acetylation of protein Lys side-chains is a post-
translational modiﬁcation in all domains of life. More than
7000 mammalian acetylation sites are known, and many of
them regulate various target functions1,2. Among the protein Lys
deacetylases, sirtuins form the evolutionary deﬁned class III. They
catalyze an unusual, NAD+-dependent deacetylation reaction,
coupling their activity to the metabolic state3. The seven mam-
malian sirtuin isoforms are primarily located in nucleus (Sirt1, 6,
7), cytosol (Sirt2), or mitochondria (Sirt3, 4, 5), and they regulate
processes from metabolism to stress responses2,4. Sirtuins have
further been implicated in aging-related diseases, such as meta-
bolic disorders and neurodegeneration, and are considered
potential therapeutic targets5,6.
Sirt4 acts as a metabolic regulator. It inhibits malonyl-CoA-
decarboxylase (MCD), which represses fatty acid oxidation and
promotes lipid anabolism6,7, and it inhibits pancreatic glutamate
dehydrogenase (GDH) to regulate insulin secretion8,9. Sirt4 fur-
ther inhibits pyruvate dehydrogenase (PDH)10 and stimulates
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Fig. 1 Sirt4 deacylation activities. a Chemical structures of CPS1 peptide and Lys acylations; from top: acetylation, butyrylation, DMS-ylation, HMG-
ylation. For the complete set of acyl modiﬁcations see Supplementary Fig. 1a. b Sirt4-dependent deacylation of differently acylated CPS1 peptides. (n= 2;
error bars: s.d.). c Sirt4 titrations with CPS1 substrate peptide carrying an acetyl, lipoyl, HMG, or DMS modiﬁcation, respectively. (n= 2; error bars: s.d.). d
Comparison of Sirt3, 4, and 5 deacylation activities against substrate peptide with acetyl, succinyl, DMS, or HMG modiﬁcation, respectively. (n= 2; error
bars: s.d.). e Intact protein mass spectrometry of HMG-ylated CypA (unmodiﬁed molecular weight 18,012 Da). f Sirt4-dependent deacylation reactions
with increasing amounts of untreated and HMG-ylated CypA protein, respectively, as a substrate. (n= 2; error bars: s.d.). g Comparison of the acyl
selectivities of Sirt4 from human (hSirt4), clawed frog (xSirt4), and zebraﬁsh (zSirt4) using CPS1 peptide substrates featuring an acetyl, succinyl, DMS,
itaconyl, HMG, or lipoyl modiﬁcation, respectively. (n= 2; error bars: s.d.)
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mitochondrial ATP production11. Due to these effects on energy
metabolism, Sirt4 is considered a therapeutic target for metabolic
dysfunctions6,7. Furthermore, Sirt4 displays tumor suppressor
activity through downregulation of glutamine metabolism and
has been implicated in several cancer types6,12.
Sirtuins are increasingly recognized as deacylases with isoform-
speciﬁc acyl selectivities, catalyzing removal of acylations emer-
ging as posttranslational protein modiﬁcations, such as succiny-
lation or crotonylation13–15. While Sirt1–3 are strong
deacetylases, Sirt5 shows low-deacetylation activity and acts pri-
marily as a desuccinylase and deglutarylase13,15,16, and Sirt6
deacetylates histones but displays more prominent demyr-
istoylation activity17. Similarly, Sirt4 features weak deacetylation
activity, which appears to regulate MCD7, but for most of its
functional effects the catalyzed target modiﬁcation appears to
differ or is unknown6. It can inhibit PDH through delipoyla-
tion10, but the catalytic efﬁciency for this reaction appears much
lower than for other primary sirtuin activities13. ADP-
ribosyltransferase activity was also described for Sirt4 and Sirt6,
but it is also inefﬁcient and appears to constitute a side-
activity8,18, so that a prominent Sirt4 enzyme activity remains to
be identiﬁed.
Sirtuins share a conserved catalytic core of ~275 amino acids19.
Isoform-speciﬁc N-terminal and C-terminal domains contribute
to regulation and cellular localization6,20. In Sirt4, the core has no
C-terminal appendage and only a short, ~28 residue N-terminal
extension that serves as mitochondrial localization sequence6,9.
The sirtuin core comprises a Rossmann-fold subdomain and a
smaller Zn2+-binding module21,22. NAD+ and the acylated sub-
strate polypeptide are bound, with moderate sequence selectivity,
to a cleft between the subdomains, accompanied by closure
movements of the subdomains and a ﬂexible “cofactor-binding
loop”1,21–24. The ribose then releases nicotinamide (NAM), and
via an 1′-O-alkylimidate and a bicyclic intermediate the products,
deacetylated polypeptide and 2′-O-acyl-ADP-ribose, are
formed3,19. This mechanism was deduced from biochemical
studies and crystal structures including human Sirt1, 2, 3, 5, and
63,19,21,22,25,26, and it applies to all sirtuin-dependent deacyla-
tions. The isoform differences in preferred substrate acyls are
caused by binding of the acyl moiety to an active site channel with
isoform-speciﬁc features. For Sirt4, however, a lack of structural
and enzymatic data hampers insights in Sirt4 acyl speciﬁcity and
regulation.
Here we report crystal structure and enzymatic characteriza-
tion of Sirt4. We identify an evolutionary conserved, Sirt4-speciﬁc
acyl selectivity and dehydroxymethylglutarylation (de-HMG-
ylation) as a potential physiological activity. A structure of Sirt4
from X. tropicalis reveals an unusual acyl binding site and a Sirt4-
speciﬁc, potentially regulatory loop. Using these insights, we
analyze and rationalize Sirt4 modulator effects and identify a Sirt4
regulation by NADH.
Results
Sirt4 shows an isoform-speciﬁc acyl preference. The seven
mammalian sirtuins vary in their sequence and acyl pre-
ferences16,19. The Sirt4 deacylation activities reported so far,
deacetylation and delipoylation, were weak, with orders of mag-
nitude lower kcat/KM values as for other sirtuin/substrate acyl
pairs7,10,15. Testing ~6800 mammalian acetylation site sequences
yielded no dramatic activity improvements1. We therefore asked
whether other acyl modiﬁcations would yield deacylation efﬁ-
ciencies expected for a physiologically dominant Sirt4 activity.
Testing Sirt4 against an acyl library of CPS1 (carbamoyl phos-
phate synthetase 1)-Lys527 peptides in a coupled enzymatic assay
monitoring NAM release from NAD+ 27 indeed revealed a
particular speciﬁcity proﬁle (Fig. 1a, b, Supplementary Fig. 1a).
Consistent with previous reports1,7,10, Sirt4 showed low-
deacetylation activity but higher activity against lipoylated and
biotinylated substrate (Fig. 1b). Further increased activity was
obtained with butyryl and octanoyl substrate, but the highest
activity—eightfold stronger than deacetylation—was observed
with a 3,3-dimethylsuccinyl (DMS) substrate.
Comparing DMS to acyl moieties physiologically occurring as
activated CoA-thioesters, and thus potentially modifying protein
Lys side chains28,29, revealed the 3-hydroxy-3-methylglutaryl
(HMG) group as most closely related. Testing HMG-modiﬁed
CPS1-Lys527 peptide indeed yielded Sirt4 activity similarly to
DMS-CPS1 substrate (Fig. 1b), approximately threefold higher
than for acetyl peptide and with the expected NAD+ dependency
(Supplementary Fig. 1b). To analyze the mechanistic basis of
these differences, we compared through Michaelis-Menten
kinetics the improved substrates, HMG- and DMS-CPS1, with
lipoyl- and acetyl-CPS1 (Fig. 1c, Table 1). Consistent with
previous data10,16, catalytic efﬁciency kcat/KM for acetyl-CPS1 was
low (3.7± 0.7 M−1 s−1; Table 1). Sirt4 activity was strongly
increased for DMS-CPS1 (412± 41M−1 s−1) and HMG-CPS1
(546± 67M−1 s−1). Strikingly, the preferred acyls showed com-
parable turnover rates to acetyl substrate but increased apparent
afﬁnities (two orders of magnitude lower KM; Fig. 1c, Table 1).
Interestingly, lipoyl-CPS1 yielded an only slightly lower kcat/KM
(170± 230M−1 s−1), two orders of magnitude higher than a
previously published value10, due to a better KM in our study,
comparable to those for the DMS/HMG modiﬁcations (Table 1).
These results indicate that lipoylated substrates bind much better
to Sirt4 than so far known, but DMS/HMG still yield 3–5-fold
higher efﬁciencies due to faster turnover. Importantly, the
catalytic efﬁciencies with the DMS/HMG substrates are close to
those of robust sirtuin activities, such as Sirt2-dependent
deacetylation (e.g., 1400M−1 s−1 for histone H3-K2730). Sirt4
thus features signiﬁcant deacylation activity and appears to
discriminate acyl substrates mainly via their apparent binding
afﬁnity.
Sirtuin-dependent NAM release from NAD+ is normally
coupled to deacylation. However, when we analyzed Sirt4-
dependent turnover of HMG-CPS1 through MS detection of
substrate and product peptide parallel to monitoring NAD+
hydrolysis, HMG-CPS1 deacylation corresponded only to ~40 %
of the NAD+ turnover (Supplementary Fig. 1c). For Sirt4-
dependent conversion of acetyl-CPS1, in contrast, no discrepancy
to NAD+ hydrolysis was observed (Supplementary Fig. 1c). Sirt4
thus shows signiﬁcant NAD+-dependent de-HMG-ylation activ-
ity, but it catalyzed even slightly better HMG-stimulated NAD+
glycohydrolysis as an unusual, deacylation independent sirtuin
activity.
We next compared the selectivities of the mitochondrial
sirtuins Sirt3, 4, and 5 against CPS1 peptides carrying HMG-
modiﬁcations and DMS-modiﬁcations or the generic Sirt3 and
Table 1 Kinetic parameters for Sirt4 and acyl substrates
kcat (10
−3 s−1) KM (μM) kcat/KM (M
−1 s−1)
Acetyl-CPS1 8.7± 0.7 2341± 270 3.7± 0.7
Acetyl-DLATa NDa ND (>2500)a 0.2± 0.0 (estimated)a
Lipoyl-CPS1 1.7± 0.3 10.1± 13.6 170± 230
Lipoyl-DLATa 1.8± 0.1a 239± 51a 7.7± 1.3a
DMS-CPS1 7.3± 0.1 17.7± 1.5 412± 41
HMG-CPS1b 5.3± 0.1 9.7± 1.0 546± 67
aValues from10
bNot corrected for HMG-stimulated NAD+ hydrolysis
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5 substrate modiﬁcations acetylation (Sirt3) and succinylation
(Sirt5). Sirt4 showed the previous preference for DMS and HMG
modiﬁcations, and very low-activity against acetylated or
succinylated peptide (Fig. 1d). Sirt3, in contrast, featured
pronounced selectivity for the acetyl modiﬁcation, minor activity
against DMS substrate, and no turnover with HMG and succinyl
substrate (Fig. 1d). The other way round, Sirt5 showed no activity
against acetyl substrate but high activity against succinyl peptide,
and lower but still signiﬁcant activity against DMS- and HMG-
CPS1 consistent with reported parameters for HMG substrate
(KM= 8 μM, kcat/KM= 500M−1 s−1)15. Sirt5 activity against
HMG-CPS1 thus exceeds that of Sirt4 mainly due to faster
turnover, and this Sirt5 activity appears even higher with other
peptide sequences, but it is still 60–80% lower than the enzyme’s
desuccinylase activity (Fig. 1d). In summary, Sirt4 shows a
particular acyl preference proﬁle: it shares de-HMG-ylation but
no desuccinylation activity with Sirt5 and shows no activity
overlap with Sirt3, and it features unusual activity against DMS
substrate and for HMG-stimulated NAD+ hydrolysis. This
distinct proﬁle suggests that there might be additional protein
Lys acylations that are speciﬁcally removed by Sirt4.
HMG-CoA acylates and Sirt4 de-HMG-ylates proteins. Acetyl
transferases employ acetyl-CoA for modifying proteins. However,
acetyl-CoA can also non-enzymatically modify proteins, and
some other acyl-CoA, such as succinyl-CoA, do so even more
efﬁciently, likely causing the emerging variety of protein acyla-
tions14,28,29,31. We thus analyzed whether HMG-CoA efﬁciently
acylates peptides and proteins. HMG-CoA titrations revealed
CPS1 peptide acylation with a bimolecular rate constant of (4.0±
0.8)×10–10 μM−1 s−1, more than twice as fast as with acetyl-CoA
(k= (1.5± 0.4)×10–10 μM−1 s−1)29, in agreement with a recent
study reporting more efﬁcient protein acylation by glutaryl- and
HMG-CoA as compared to acetyl-CoA28. Incubating recombi-
nant Cyclophilin A (CypA) as a model protein with HMG-CoA
resulted in 1–7 HMG-modiﬁcations as detected by intact protein
mass spectrometry (MS; Fig. 1e) and conﬁrmed by MS/MS
analysis of tryptic peptides, consistent with the protein’s seven
known Lys acetylation sites (Uniprot entry P62937).
To analyze whether Sirt4 is able to remove HMG modiﬁcations
not only from peptides but also from HMG-ylated protein, we
tried to de-HMG-ylate CypA. Modiﬁed and unmodiﬁed CypA
was incubated with Sirt4, in the presence and absence of NAD+,
and the deacylation was monitored in the coupled enzymatic
assay27. Unmodiﬁed CypA as substrate did not yield a signiﬁcant
deacylation signal, whereas HMG-CypA substrate resulted in a
strong, substrate concentration dependent signal (Fig. 1f) that
showed the expected dependency on the co-substrate NAD+
(Supplementary Fig. 1d). To conﬁrm that NAD+-dependent
CypA de-HMG-ylation causes or signiﬁcantly contributes to the
NAM release monitored in this assay, we also analyzed the
reaction by intact protein mass spectrometry. Incubation with
Sirt4 indeed caused a shift toward CypA species carrying fewer
HMG-ylations (Supplementary Fig. 1e), conﬁrming the deacyla-
tion. We thus conclude that HMG-CoA is reactive toward
proteins and that Sirt4 can de-HMG-ylate the modiﬁed proteins,
consistent with recently published work that furthermore
conﬁrmed the physiological occurrence of protein HMG-ylation
and Sirt4-dependent de-HMG-ylation28,32.
Crystal structure of Sirt4. For insights in the molecular basis of
Sirt4’s substrate preference and other isoform-speciﬁc features,
we solved a Sirt4 crystal structure. Trials to crystallize our human
Sirt4 protein construct (residues 25–314), which comprises the
catalytic core with native C-terminus but lacks 24 residues of the
N-terminal mitochondrial localization sequence (MLS; residues
1–289), were not successful. Therefore, we used the Sirt4 ortho-
logues from Xenopus tropicalis (clawed frog; xSirt4) and Danio
rerio (zebraﬁsh; zSirt4) as model systems. They show signiﬁcant
sequence deviations only in the ~30 N-terminal residues (Sup-
plementary Fig. 2a), consistent with their function as MLS, which
tend to show low-sequence conservation33. Within the catalytic
core (hSirt4: 32–312; xSirt4: 31–314; zSirt4: 28–310), however, the
sequence identity with hSirt4 is 67% (xSirt4; similarity 81%) and
Table 2 Data collection and reﬁnement statistics
xSirt4/ADPr xSirt4/thioacetyl-ADPr zSirt5/HMG-CPS1
Space group C2221 C2221 P6522
Unit cell constants a= 69.4 Å, b= 74.7 Å, c= 109.7 Å a= 69.0 Å, b= 74.9 Å, c= 109.6 Å a= b= 87.5 Å, c= 316.9 Å
Resolutiona 20.00–1.58 Å (1.62–1.58 Å) 20.00–1.80 Å (1.85–1.80 Å) 50.00–3.10 Å (3.20–3.10 Å)
Unique reﬂections 39,280 (2868) 26,585 (1932) 13,919 (1214)
Multiplicity 5.1 (5.2) 6.8 (7.1) 10.3 (10.8)
Completeness 99.8% (99.9%) 99.7% (99.9%) 99.9% (99.9%)
Rmeas 3.6% (85.3%) 5.5% (104.4%) 24.8% (151.2%)
CC1/2 (%) 100.0 (70.4) 99.9 (70.4) 99.4 (59.8)
I/σI 23.7 (2.1) 18.3 (2.1) 10.2 (1.6)
Protein atoms 2285 2177 4138
Ligand atoms 37 40 173
Solvent atoms 285 179 68
Resolution 19.73–1.58 Å (1.62 Å – 1.58 Å) 19.74–1.80 Å (1.85–1.80 Å) 48.67–3.10 Å (3.18–3.10 Å)
Rcryst/Rfree
bc 15.2%/18.6% 15.5%/20.8% 19.6%/26.6%
Average B-factors
Protein 30.9 39.4 73.4
Ligands 21.8 30.4 74.3
Solvent 41.6 46.3 48.5
RMSD bond-lengths 0.03 0.03 0.01
RMSD bond-angles 2.6 2.4 1.5
aValues in parentheses refer to outermost shell
b Rcryst ¼
P
Fobsj jkj jFcalc jjP
Fobsj j
. |Fobs| is the observed and |Fcalc| the calculated structure factor amplitude
cRfree was calculated from 5% of reﬂections omitted from reﬁnement
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65% (zSirt4; similarity 78%), respectively (Supplementary Fig. 2a).
Consistent with the high sequence conservation, xSirt4 and
zSirt4 showed the same acyl preferences as hSirt4 (Fig. 1g),
conﬁrming that this acyl selectivity is an evolutionary conserved
Sirt4 feature and that xSirt4 and zSirt4 are suitable models for the
mammalian enzyme.
xSirt4 yielded well diffracting crystals in presence of ADP-
ribose (ADPr). The xSirt4/ADPr structure was solved through
Patterson searches with Sir2Af1 (PDB entry 4TWI) and reﬁned at
1.58 Å resolution to Rcryst/Rfree values of 15.2%/18.6% (Table 2).
The xSirt4 overall structure shows the typical sirtuin architecture
with Rossmann-fold domain and smaller Zn2+-binding module,
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Fig. 2 Crystal structure of xSirt4. a Overall structure of the xSirt4/ADPr complex, with Rossmann-fold domain (green), Zn2+-binding domain (cyan), and a
Sirt4-speciﬁc loop (blue) indicated. ADPr is shown as sticks, colored according to atom type. Secondary structure elements are numbered equivalent to
other sirtuins, elements missing in xSirt4 are indicated by brackets. b xSirt4 active site, with conserved sirtuin catalytic residues and key residues of the
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region in Sirt4 sequences from various chordates (Full alignment: Supplementary Fig. 2c). d Section of a structure-based alignment of Sirt1–6, extended by
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with the active-site located in between them and harboring the
nucleotide that is well deﬁned by electron density (Fig. 2a, b). The
six-stranded β-sheet of the Rossmann-fold domain provides a
docking patch for the nucleotide, orienting the reacting ribose
close to the conserved catalytic sirtuin residue His160 (Fig. 2b;
numbering refers to xSirt4 if not stated otherwise). Due to the
occupied nucleotide binding site, the cofactor-binding loop
between α2 and α3 is in the “closed” conformation23, positioning
the conserved Phe/Tyr (Tyr73) on top of the ADPr ribose.
Thermal denaturation shift experiments showed signiﬁcant
Sirt4 stabilization by NAD+ or ADPr, while substrate peptide
and NAM had no pronounced effects (Supplementary Fig. 2b),
indicating that the nucleotide-induced closed conformation
stabilizes the protein and facilitates crystallization.
A Sirt4-speciﬁc loop and additional active site entry. Com-
paring the Sirt4 structure to other sirtuin isoforms reveals as most
striking difference an extended, ~12 residues Sirt4 loop in the
Zn2+-binding module, between α8 and α9 (residues 195–206;
Fig. 2a). The loop is oriented deep into the catalytic core and
contributes to the active site lining (Fig. 2b). A sequence com-
parison of all higher eukaryotic Sirt4 orthologs in the UNIPROT
database shows a high overall sequence homology (89%), and in
particular a strict conservation of the presence and even sequence
of this loop (G(L/V)APDGDVFL(T/S)(D/E)EQ motif; Fig. 2c,
Supplementary Fig. 2c). Structure-based comparison of human
Sirt1–6, with human Sirt7 and Sirt1–7 sequences from other
chordates added based on homology, shows that the loop is
absent in all other sirtuin isoforms (Fig. 2d, Supplementary
Fig. 2d), and we therefore refer to it as “Sirt4-loop”. The
structure-based comparison shows that the Sirt4-loop is extended
compared to a much smaller Sirt5 surface loop, and to a short
turn in other isoforms, and only the Sirt4-loop is thus able to
reach the active site (Fig. 2b, e). Removing the loop (Δ189–214
and Δ192–212) yielded insoluble protein, but deleting the loop’s
core (Δ196–205, Δ198–203) or replacing it with a GSS linker
(Δ196–205 + GSS) resulted in soluble and active protein, which
shows that the extended loop is not essential for Sirt4’s structural
integrity. The variants tended to show higher KM values for the
peptide substrate and at the same time slightly increased turnover
(Table 3), which indicates that the loop contributes to substrate
binding and restricts catalytically relevant active site dynamics
(see also below). In a second xSirt4 structure, solved in complex
with the product analog 2′-thioacetyl-ADPr, the Sirt4-loop was
not deﬁned by electron density (Table 2, Supplementary Fig. 2e),
indicating that it is either ﬂexible or can assume several con-
formations. Both xSirt4 complexes were solved from the same
crystal form, with residues 191–207 not participating in crystal
contacts, excluding that crystal packing causes the loop differ-
ences. The Sirt4/2′-thioacetyl-ADPr structure might thus suggest
that the loop is released from the active site during product
formation, but functions and triggers of Sirt4-loop conformations
remain to be studied in more detail.
Another unusual feature of the Sirt4 catalytic core is a channel
that branches off from the acyl-Lys binding tunnel and leads to
the protein surface (Fig. 3a, b). It is lined by residues from α4 and
the preceding loop (86-ArgArgProIle, Glu93), α5 (Ala100, 103-
ArgTyr, Arg107), and Ala199/Asp203 from the Sirt4-loop
(Fig. 3a). They are mostly conserved in Sirt4, but differ in other
isoforms (Fig. 3b). In Sirt6, the Sirt4 channel area is blocked by its
isoform-speciﬁc N-terminus, but lack of α4, part of α5, and both
loops results in a differently oriented, wide cleft that accom-
modates myristoyl substrates and activators34. Sirt1–3 and Sirt5
contain structure elements sized comparable to Sirt4, except for
the missing Sirt4-loop, with sequences similar to each other but
differing from Sirt4 (Fig. 3b, Supplementary Fig. 2d). The
resulting fold in Sirt1–3 and Sirt5 comprises a more wiggled
α3/α4 loop folded against α5 and blocking the Sirt4 channel area
(Supplementary Fig. 3a). The Sirt4 channel has a small positively
charged patch at the outer entrance but is generally rather
hydrophobic, and we speculate that it contributes to accommo-
dation of longer substrate acyls. Modeling a Sirt4/lipoyl-Lys
complex indeed places the distal lipoyl end into the bottom of the
channel (Fig. 3a), supporting an acyl binding function and
rationalizing Sirt4’s delipoylation activity. Interestingly, the
channel could also accommodate a lipoyl group entering from
outside as a substrate anchor, in a scenario related to SirTM,
which catalyzes ADP-ribosylation of targets only after their
lipoylation35. Furthermore, the channel might serve as a binding
site for regulatory metabolites, similar to Sirt6 activation by free
fatty acids16. Testing the effects of fatty acids, lipoic acid, and the
ketone bodies beta-hydroxybutyrate and acetoacetate indeed
revealed that free lipoic acid inhibits Sirt4’s deacetylation and
de-HMG-ylation activity (Supplementary Fig. 3b). However, the
role of the Sirt4 channel in this and/or other regulation
mechanisms remains to be studied in detail.
Using our structure-based alignment of Sirt4 and other
structurally characterized sirtuins, extended by chordate
Sirt1–7 sequences (Fig. 2d, Supplementary Fig. 2d), we analyzed
phylogenetic relationships. The phylogenetic tree (based on
208 sequences; Fig. 3c) conﬁrms some classiﬁcations based purely
on sequence information36 but also reveals modiﬁcations. Sirt4
forms a separate class (class II in ref. 36) that is almost equally
distant to classes I (Sirt1–3), III (Sirt5), and IV (Sirt6/7), despite
its partial deacylation activity overlap with Sirt5. Prokaryotic
Table 3 Kinetic parameters for xSirt4 wild-type and variantsa
xSirt4 variant Acetyl-CPS1 KM (μM) Acetyl-CPS1 vmax (10
−3 s−1) HMG-CPS1 KM (μM) HMG-CPS1 vmax (10
−3 s−1)
Wild-type 663± 69 12.9± 0.6 6.8± 0.9 15.9± 0.4
Delta 196–205 + GSS 541± 51 10.7± 0.4 9.7± 0.7 18.4± 0.3
Delta 196–205 1599± 563 15.7± 3.4 8.5± 0.6 17.2± 0.2
Delta 198–203 1104± 110 17.1± 0.9 10.1± 0.7 19.9± 0.3
D201A 707± 127 9.1± 0.8 11.3± 1.4 13.0± 0.3
D203A 925± 136 10.5± 0.8 9.0± 1.1 14.1± 0.3
Y73F 640± 71 8.8± 0.4 9.0± 1.0 24.1± 0.5
R101A ND ND 23.2± 1.3 13.3± 0.2
Y104F 643± 40 13.3± 0.4 15.3± 1.3 15.2± 0.3
R107A 1097± 159 11.0± 0.9 17.2± 1.8 14.2± 0.3
Y104F R107A 918± 72 18.5± 0.8 22.6± 2.6 15.7± 0.4
N108A 1104± 254 14.8± 1.9 19.3± 2.8 12.2± 0.4
aNot corrected for HMG-stimulated NAD+ hydrolysis
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sirtuins form a cluster in the Sirt5 branch, separate from chordate
Sirt5 and almost equidistant to Sirt4. The Sirt6/7 branch also
comprises a prokaryotic member, Sir2Tm. The three subclusters
for the strong deacetylases Sirt1, 2, and 3 are clearly separated
from the other branches but contain yeast enzymes, indicating
that a deacetylase developed still early during evolution and
diversiﬁed further, possibly reﬂecting the prominent role of
acetylation among the protein acylations. All other branches
appear to constitute subfamilies with mostly weak deacetylases,
which developed different acyl preference proﬁles for each cluster
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that remained conserved in later stages of evolution as indicated
by our Sirt4 ortholog comparison. These major branches
apparently separated early during evolution, consistent with a
variety of acylations occurring non-enzymatically28,29,31 and thus
likely being evolutionary early posttranslational modiﬁcations
that existed before the protein modifying enzymes emerged.
Sirt4 nucleotide and acyl binding sites. All sirtuins share NAD+
as an essential cosubstrate, but the Sirt4 nucleotide binding site
differs from those of other isoforms. The Sirt4-loop tightens the
entry of the C-site, where the conserved Asp145 recognizes the
NAM moiety of NAD+25, and its tip around Pro200 will have to
rearrange slightly to allow productive NAD+ binding (Supple-
mentary Fig. 3c), consistent with a switch function. However,
NAD+ titrations revealed similar apparent NAD+ afﬁnities for
wild-type Sirt4 (KM= 70± 14 μM for xSirt4; 62± 14 μM for
hSirt4) and a Sirt4 loop deletion variant (KM= 66± 9 μM; Sup-
plementary Fig. 3d), suggesting that a regulatory factor stabilizing
the inactive conformation might be missing, consistent with the
loop variability observed in our structures (see above). Positive
electrostatic potential in the nucleotide site supports binding of
the negatively charged ligand in all isoforms, but in Sirt4 the
positive potential is more pronounced than in most isoforms
(Fig. 3d, Supplementary Fig. 3e), rationalizing its low KM(NAD+)
within the 14–600 μM range reported for sirtuins15,37,38. Sirt4’s
cosubstrate site might also facilitate binding of NADH, compared
to NAD+, due to its lacking positive charge at the nicotinamide,
and we indeed ﬁnd a distinctive sensitivity of this sirtuin isoform
to NADH (see below). In the peptide binding cleft, Sirt4 also
features positive potential in regions accommodating the sub-
strate sequence immediately N-terminal and C-terminal from the
substrate acyl-Lys (Supplementary Fig. 3f). Consistently, peptide
array studies with its weaker deacetylase activity had shown a
Sirt4 substrate sequence preference for polar residues around the
acetyl-Lys, in particular with negative charges in positions +1/2
and −3/41.
In the active site, Sirt4 comprises the conserved sirtuin catalytic
residues His160 and the Leu/Thr/Val (Thr231) whose backbone
oxygen orients the substrate through a hydrogen bond to the acyl-
Lys ε-amide (Fig. 2b)15. The cofactor-binding loop in “closed”
conformation23 positions the conserved Phe/Tyr (Tyr73) on top
of the ribose, shielding this reacting group. Mutating Tyr73 to the
Phe found in most sirtuins increased kcat (Table 3), conﬁrming its
catalytic relevance and indicating that its hydroxyl group might
contribute to an auto-inhibitory mechanism. In the region
accommodating a distal carboxyl group in short and medium
long dicarboxylates, such as HMG, mildly positive electrostatic
potential rationalizes the afﬁnity of such substrates (Fig. 3d).
Attempts to solve a Sirt4 structure in complex with substrate
peptide to study acyl recognition details failed, possibly due to the
lacking stabilization by this ligand (Supplementary Fig. 2b), but
we were able to solve a complex of zebraﬁsh Sirt5 (zSirt5) with
HMG-CPS1 peptide. The structure, reﬁned at 3.1 Å resolution to
Rcryst/Rfree values of 19.5%/26.6% (Table 2, Fig. 3e), reveals a
similar substrate conformation as in zSirt5/glutaryl-CPS1. The
HMG length is reduced through a helical conformation, albeit
with opposite handedness compared to glutaryl-CPS1, to position
the 3-hydroxy and 3-methyl moieties toward Ile138/His154 and
Tyr98/Val216, respectively (Fig. 3e, Supplementary Fig. 3g). The
distal carboxylate interacts with Tyr98 and Arg101, which also
recognize the carboxylates of succinyl and glutaryl substrates15.
Interestingly, Sirt4 also features such a Tyr-X-X-Arg motif in α5.
The Sirt4 motif is shifted one helix turn, however, with Sirt4-
Tyr104 oriented back to the region occupied by Sirt5-Tyr98, but
Sirt4-Arg107 pointing away from the acyl channel (Fig. 3f). Sirt4
residues in the positions of Sirt5-Tyr98/Arg101 would be Asn108
and Gly111. Due to a slightly different conformation, however,
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Gly111 is shifted and the area of Sirt5-Arg101 is occupied by the
Sirt4-loop residue Asp201 (Fig. 3f), which would result in close
contacts between the carboxylates of Asp201 and an HMG
substrate. To test the roles of these residues, we analyzed
deacetylation and de-HMG-ylation kinetics of xSirt4 Ala variants
(Table 3). Exchanging Asp201 or Asp203 caused only a moderate
decrease in apparent HMG-peptide afﬁnity, consistent with Sirt4-
loop deletion effects. They thus appear not directly involved in
substrate binding but to rearrange dynamically, as expected from
the repellent effect Asp201 would have on substrate carboxylates
and in line with our crystallographic results. Consistently, testing
β-Ala-, γ-aminobutyryl-, and 6-aminocaproyl-CPS1 substrates
(Supplementary Fig. 1a), which have positively charged end
groups that could favorably interact with Asp201 in this position,
yielded no Sirt4-dependent deacylation (Supplementary Fig. 3h).
Replacing Tyr104 (to Phe) or Arg107 of the Sirt4 Tyr-X-X-Arg
motif had a stronger, approximately twofold effect on HMG-
peptide KM values, and a Tyr104Phe/Arg107Ala double mutant
even showed an additive effect (Table 3). They thus seem to
contribute—directly or indirectly—to substrate binding despite
Arg107’s orientation away from the active site. In fact, replacing
the neighboring Asn108, which points toward the acyl channel,
caused a signiﬁcant, approximately threefold decrease in apparent
HMG-substrate afﬁnity, suggesting a contribution to acyl binding
and possibly an indirect role for Arg107, via its salt bridge to the
Sirt4-loop residue Asp203 (Fig. 3f). Interestingly, mutating
Arg101 from a 101-ArgArgArg-103 motif on the opposite side
of Tyr104 caused a strong, approximately fourfold decrease in
apparent HMG-peptide afﬁnity (Table 3), indicating an impor-
tant role in substrate recognition despite its distance to the acyl
site. These results indicate that as in Sirt5, α5 plays a key role in
Sirt4 acyl recognition. Residue differences seem to contribute
directly to their different acyl selectivity proﬁles, but also to a
more dynamic Sirt4 acyl site, which we speculate to adapt to acyl
substrates (α5 N-terminus) and to contribute to a regulatory
Sirt4-loop function (α5 center).
Sirt4 substrates and structure enable modulator studies. Our
insights in Sirt4 catalytic activity and structure now enable
activity studies for Sirt4 modulator development and a structure-
based analysis of compound effects. Using the HMG-CPS1 pep-
tide, we analyzed the effects of the Sirt1 activators resveratrol and
SRT172039,40, the moderately Sirt1 selective inhibitors Ex527 and
sirtinol25,41, and the pan sirtuin inhibitor suramin42,43. At 10 and
100 μM compound concentration, respectively, there was no
signiﬁcant effect for resveratrol, Ex527, and sirtinol (Fig. 4a).
Suramin caused potent Sirt4 inhibition, similar to its effects on
other sirtuin isoforms42,43, and 100 μM SRT1720 led to a weak
signal decrease but with a high error and signiﬁcant effect already
in a control reaction, indicating a compound incompatibility with
the coupled enzymatic assay used here. Suramin is a huge poly-
anionic compound occupying the complete active site of sirtuins
and other targets44. Ex-527, in contrast, is accommodated by a
small region around the C-site25, and an overlay of Sirt3/Ex-527
with our Sirt4 structure rationalizes Sirt4’s insensitivity (Fig. 4b):
The compound would clash with its A ring with Pro200 from the
Sirt4-loop, and omitting the A ring and instead attaching the
carbamide via a methylene group to ring B might yield a Sirt4-
speciﬁc compound.
As a convenient and complementary, ﬂuorescence-based
alternative to the coupled enzymatic assay with HMG-peptides,
we established substrate and assay corresponding to the popular
“Fluor-de-Lys” (FdL) deacylation assays19. Attaching the HMG
group to a Lys with Z-protected amino group and 7-
aminomethylcoumarin (AMC) coupled to the carboxyl group,
analog to the Sirt1–3 acetyl substrate Z-MAL45, yielded an HMG-
FdL substrate readily accepted by Sirt4 and sensitively monitored
via ﬂuorescence using the FdL procedure19. Testing suramin with
the HMG-FdL substrate conﬁrmed the potent Sirt4 inhibition
observed in the coupled enzymatic assay (Fig. 4c), and a dose-
response experiment yielded an IC50 of 1.8± 0.2 μM (Supple-
mentary Fig. 4a). Assays with SRT1720 showed no incompat-
ibilities in control reactions and revealed that the compound has
no effect on Sirt4 activity (Fig. 4c). We then employed the FdL-
like Sirt4 assay for studying the effects of NAM and NADH,
which are not compatible with the coupled assay. NAM appears
to act as a physiological regulator for most sirtuin isoforms37, and
a NAM dose-response experiment with Sirt4 revealed potent
inhibition with IC50= 13± 2 μM (Fig. 4d). The effect on Sirt4 is
even more potent than on other isoforms37,46 and possibly
supported by the Sirt4-loop at the NAM accommodating C-site
entrance. An NADH dose-response experiment (Fig. 4e), cor-
rected through NADH spiking controls for its ﬂuorescence
overlap with AMC47, also indicated pronounced Sirt4 inhibition
(IC50= 126± 12 μM at 500 μM NAD+). Analyzing the NADH
titration with the robust MS assay conﬁrmed this Sirt4 inhibition
potency (IC50= 142± 54 μM; Supplementary Fig. 4b) that
exceeds NADH effects on other sirtuins (IC50 1.3–27.9 mM)
47,48, consistent with Sirt4 nucleotide site features (see above and
discussion). The response of Sirt4 activity to NADH levels around
~30 μM, which is estimated to be the mitochondrial concentra-
tion of free NADH47, suggests NADH or the NAD+/NADH ratio
to act as a physiological Sirt4 regulator.
Discussion
Posttranslational modiﬁcations are a ubiquitous mechanism of
protein regulation and rely on activated metabolites, which are
now realized also to cause non-enzymatic modiﬁcations14,28,29,49.
For emerging acyl modiﬁcations, such as succinylation and cro-
tonylation, acyl-CoAs act as major activated metabolites14 whose
concentrations thus inﬂuence modiﬁcation levels, together with
deacylating enzymes. Elevated HMG-CoA levels in a HMG-CoA-
Lyase deﬁciency model indeed increased protein HMG-ylation28,
and similar changes are expected under fasting conditions and
during ketogenic protein catabolism, suggesting that de-HMG-
ylating enzymes will regulate target functions during starvation.
Sirtuins convert several acyl substrates but with isoform-speciﬁc
selectivity proﬁles15,38, and we ﬁnd that Sirt4 also has a particular
acyl preference proﬁle. It shares de-HMG-ylation activity with
Sirt5 but they differ, e.g., in their desuccinylase activity, and
Sirt3–5 might have developed complementary selectivities to
cover a range of acyls reﬂecting the variety of activated metabo-
lites in mitochondria. Sirt5’s higher de-HMG-ylation activity
might suggest that other, even better Sirt4 substrate acyls might
exist, but also shared deacylation activities can be complementary
due to sirtuin differences in substrate sequence preference and
tissue distribution1,50. The substrate acylations might be acci-
dental “damage”, which would render sirtuins repair enzymes,
but many of them regulate dedicated target functions, consistent
with speciﬁc regulatory effects of sirtuins4,6. The additional
HMG-dependent NAD+ hydrolase activity of Sirt4 could serve a
signaling function, similar to NAD+ depletion caused by poly-
(ADP-ribose) polymerases, but a functional role of this unusual
sirtuin activity remains to be studied further.
Sirtuin isoforms differ in acyl channel architecture and
dynamics. Sirt5 provides a rather rigid binding site for succiny-
lations, but related dicarboxylate modiﬁcations can adapt to this
site, rationalizing Sirt5’s activity against glutarylations15,51 and
HMG-ylations (present study). Sirt6, in contrast, has a long,
hydrophobic channel to accommodate myristoyl substrates, and
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also the smaller channels in Sirt2 and, in particular, Sirt3 can
rearrange to efﬁciently accommodate and hydrolyze longer acy-
lations such as myristoylations23,38,52,53. Sirt4 seems even more
adaptable. Sirt4 structure and mutagenesis data suggest that,
similar to Sirt513, the α5 center contributes to acyl recognition,
but in Sirt4 even the remote α5 N-terminus inﬂuences acyl
binding. Furthermore, the α5 center is connected via an Arg107/
Asp203 salt bridge to the Sirt4-loop, an isoform-speciﬁc element
of the Sirt4 acyl site, and the Sirt4-loop further to the nucleotide
binding loop through the packing of Pro200 on the auto-
inhibitory Tyr73. The Sirt4-loop assumes at least two states in our
structures and for productive NAD+ binding it indeed has to
rearrange (Supplementary Figs. 2e, 3c)—possibly triggered by a
yet to be identiﬁed activator in a physiological setting—which will
induce conformational changes in the acyl site. Shifting Asp201
away from the conventional acyl binding pocket should support
binding of dicarboxyl substrates such as HMG-ylations. A com-
plete loop release, possibly, would open an area accommodating
longer acyls in other isoforms53 and could extend the observed
Sirt4 deoctanoylation activity to longer modiﬁcations. Interest-
ingly, Sirt4 accommodates extended lipoyl modiﬁcations as sub-
strates despite its length restriction for fatty acids, likely by
exploiting a Sirt4-speciﬁc channel branching off from the con-
ventional acyl pocket. The bulkier lipoyl group might exploit this
channel better than slim alkyl chains, and the two acyl sites might
serve, alternatively or even in combination, to expand the acyl
substrate spectrum of Sirt4. Interestingly, a lipoyl moiety would
also ﬁt into the Sirt4-speciﬁc channel coming from outside, as a
target label in analogy to the bacterial sirtuin SirTM, which ADP-
ribosylates targets only after their lipoylation35, or as a potential
regulatory metabolite (this study). Sirt4 substrate selection indeed
appears dominated by KM, and its de-HMG-ylation activity is still
slightly lower than major activities of other sirtuin isoforms. Our
comparison of HMG-peptides indicates a relevance for the sub-
strate sequence, consistent with Sirt4 deacetylation studies1,
indicating that better de-HMG-ylation substrates might exist.
Sequence differences might in fact account for our higher Sirt4-
dependent delipoylation and Sirt5-dependent de-HMG-ylation
activity compared to other studies10,32. It will be interesting to see
whether better Sirt4 substrate sequences or acylations can be
identiﬁed, and further mechanistic studies, supported by our
structural data, should enable a full understanding of Sirt4-loop
and acyl channel, their substrate adaptations, and possible
external triggers that would regulate Sirt4.
Our Sirt4 substrates and assays enabled analyzes on drug
effects and physiological Sirt4 regulators. The continuous coupled
assay allows excellent quantiﬁcation27, and the FdL assay pro-
vides a sensitive set-up that is easily parallelized for screening
campaigns19. Using these assays, we ﬁnd a very potent NAM
inhibition for Sirt4, which renders it the isoform most sensitive to
NAM regulation so far46,54. Physiological NAM concentrations
are assumed to reach up to 100 μM54, which would inhibit Sirt4
almost completely, and in vivo Sirt4 activity will thus strongly
depend on NAM levels. It will be interesting to see how Sirt4
contributes to the physiological effects of NAM. We further ﬁnd
that Sirt4 activity seems sensitive to physiological NADH levels or
the NAD+/NADH ratio. Sirtuin regulation by NADH or NAD
+/NADH had been suggested based on inhibitory NADH effects
on other isoforms but was discarded due to its weak potency
(IC50≥ 1.3 mM; Ki≥ 0.7 mM), which rules out signiﬁcant in vivo
effects at assumed NADH concentrations (~30 μM in mito-
chondria) and NAD+/NADH ratios (10:1 and higher)47,48. We
now ﬁnd an at least one order of magnitude higher NADH
sensitivity for Sirt4, which causes signiﬁcant effects under such
conditions, and it will be exciting to see how this Sirt4-speciﬁc
regulation contributes to its function. Mechanistically, NADH
likely inhibits through nucleotide site binding in an extended,
non-productive conformation also observed for NAD+ under
certain conditions25 (Supplementary Fig. 3c). It places the NAM
moiety outside the C-pocket—which prefers oxidized nucleotide
due to its conserved negative charge—into regions that show
positive electrostatic potential, in particular in Sirt4, which favors
NADH over NAD+. Assays and structural insights also provide a
basis for Sirt4 modulator development. The identiﬁed nucleotide
binding site differences should enable Sirt4-speciﬁc inhibition, for
example through Ex-527 derivatives that can enter Sirt4’s tigh-
tened C-site. The particular Sirt4 acyl site could be exploited with
thio-DMS-Lys, analog to the alkylimidate forming thio-acetyl
peptides for deacetylases25, and the additional Sirt4 channel
provides another docking site for speciﬁc small molecule inhibi-
tors and possibly also activators. Such Sirt4 modulators would be
excellent tools for physiological studies and lead compounds for
drug development, for example for diabetes treatment7.
Methods
Chemicals. If not stated otherwise, chemicals were from Sigma (St. Louis, MO,
USA).
Expression and puriﬁcation of Sirt4 and Sirt5 proteins. hSirt4(25–314) in
pQE30 coding for an N-terminal His6-tag, and xSirt4(32–315) and zSirt4(29–310)
in a modiﬁed pET-19b coding for an N-terminal His6-SUMO-tag (see Supple-
mentary Table 1 for primer sequences), were expressed in Escherichia coli
CodonPlus(DE3) (Agilent, Santa Clara, CA, USA) in LB medium supplemented
with 100 µM zinc acetate. Cells were resuspended in 50 mM Tris/HCl pH 7.5, 200
mM NaCl (and 20% glycerol for xSirt4) and lysed by adding lysozyme and sodium
desoxycholate and subsequent pressure homogenization in an Emulsiﬂex-C5
(Avestin, Ottawa, Canada). After centrifugation (75,000×g, 4 °C, 1 h), supernatants
were incubated for 1 h with NiNTA beads in presence of 10 mM imidazole. After
transfer in a column, the resin was washed with 20 column volumes (CV) 50 mM
Tris/HCl pH 7.5, 500 mM NaCl and 20 CV 50mM Tris/HCl pH 7.5, 200 mM
NaCl, 10 mM imidazole, and the protein eluted with 50 mM Tris/HCl pH 7.5, 200
mM NaCl, 250 mM imidazole.
For hSirt4(25–314), the buffer of the eluted protein was changed to 50 mM Tris/
HCl pH 7.5, 30 mM NaCl in a HiPrep Desalting Column (GE Healthcare, Chicago,
IL, USA) and the sample applied to a SOURCE15S cation exchange column (GE
Healthcare). The proteins were eluted in a linear gradient 30–1000 mM NaCl and
Sirt4 fractions were pooled and diluted ﬁvefold with 50 mM Tris/HCl pH 7.5. Sirt4
was then loaded on a HiTrap Heparin column (GE Healthcare) and eluted with a
linear gradient 30–1000 mM NaCl. The protein was concentrated to ~1mgml−1 in
a Microsep concentrator (Pall Corporation, Port Washington, NY, USA), ﬂash-
frozen in liquid nitrogen, and stored at −80 °C.
For xSirt4(32–315) and zSirt4(29–310) eluted from the NiNTA material, the
buffer was changed to 50 mM Tris/HCl pH 7.5, 200 mM NaCl, (supplemented with
20% glycerol for xSirt4) in a HiPrep Desalting column and subjected to Senp2-
proteolysis for 30 min on ice. The protein was loaded on a HisTrap HP 1 mL
column (GE Healthcare) and eluted with 50 mM Tris/HCl pH 7.5, 200 mM NaCl,
30–50 mM imidazole. It was subsequently subjected to gel ﬁltration on a Superdex
75 10/300 GL (xSirt4) or Superdex 200 10/300 GL (zSirt4) column (both GE
Healthcare) in 25 mM Tris/HCl pH 7.5, 150 mM NaCl (+20 % glycerol for xSirt4),
concentrated in a Microsep concentrator, ﬂash-frozen in liquid nitrogen, and
stored at −80 °C. xSirt4 single-site variants were generated using the QuickChange
protocol (see Supplementary Table 1 for primer sequences) and veriﬁed by DNA
sequencing, and the proteins were produced as described for wild-type xSirt4.
zSirt5(30–298) was expressed in E.coli and puriﬁed through Talon afﬁnity
chromatography, TEV-proteolysis, reverse afﬁnity chromatography, and gel
ﬁltration on a Sephacryl S-200 column15.
Synthesis of Lys- and peptide-based substrates. HMG-ylated peptides CPS1
(Bz-GVL(acyl-K)EYGV-NH2), MCD (Ac-TSYLGS(HMG-K)IIKASE-NH2), and
NNT (Ac-NITKLL(HMG-K)AISPDK-NH2) were synthesized using Fmoc-based
solid-phase peptide synthesis protocols. Fmoc-Lys(Nosyl)-OH was used as building
block enabling selective on resin deprotections and acylations using HMG-
anhydride. As acyl peptide library, the panel of acyl CPS1-Lys527 peptides
described in ref. 15 was used and extended through analog synthesis of β-Ala-
CPS1, γ-aminobutyryl-CPS1, 6-aminocaproyl-CPS1, butyryl-CPS1, octanoyl-CPS1,
lipoyl-CPS1, and biotinyl-CPS1.
The Sirt4 substrate Z-Lys(HMG)-AMC (MC3659; 5-(((S)−5-(((benzyloxy)
carbonyl)amino)-6-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-6-oxohexyl)
amino)-3-hydroxy-3-methyl-5-oxopentanoic acid) was synthesized by reaction
between the (S)-benzyl (6-amino-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-
oxohexan-2-yl)carbamate (Z-Lys-AMC), prepared as reported in literature55, and
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the commercially available 3-hydroxy-3-methylglutaric (HMG) anhydride in dry
THF in the presence of DIPEA at room temperature (Supplementary Fig. 5). All
chemicals were purchased from Aldrich Chimica, Milan (Italy), and were of the
highest purity. Z-Lys-AMC (170 mg, 0.388 mmol) was dissolved at 0 °C in 4 mL
dry THF together with diisopropylethylamine (DIPEA) (140 μL, 0.777 mmol)
under nitrogen atmosphere. A solution of 3-hydroxy-3-methylglutaric anhydride
(67 mg, 0.777 mmol) in dry THF (4 mL) was added dropwise at 0 °C, and the
resulting mixture was left under stirring at room temperature overnight. At the end
of the reaction, water (10 mL) was added, the resulting mixture was made acidic
(pH ∼2) with potassium bisulphate 1M and then extracted with ethyl acetate (6 ×
10 mL). The collected organic phases were washed with brine (2 mL), dried, and
concentrated under reduced pressure to provide a crude residue that was puriﬁed
by a silica gel ﬂash chromatography (SNAP 25, Biotage Isolera One) using a linear
gradient of methanol (3–25%) in chloroform, giving the expected compound Z-Lys
(HMG)-AMC as a white solid, with a yield of 72%. Melting point was determined
on a Buchi 530 melting point apparatus and is uncorrected. 1H- and 13C-NMR
spectra were recorded at 400MHz (1H) respective 100MHz (13C) on a Bruker AC
400 spectrometer; reporting chemical shifts in δ (p.p.m.) units relative to the
internal reference tetramethylsilane (Me4Si). All compounds were routinely
checked by TLC and 1H-NMR. TLC was performed on aluminum-backed silica gel
plates (Merck DC, Alufolien Kieselgel 60 F254) with spots visualized by UV light.
Yield of reaction refers to the puriﬁed product. Mass spectrum was recorded on an
API-TOF Mariner by Perspective Biosystem (Stratford, TX, USA), and samples
were injected by a Harvard pump, using a ﬂow rate of 5−10 μL min−1, in the
Electrospray system. Elemental analysis was performed by a PE 2400 (Perkin-
Elmer) analyzer and has been used to determine purity of the described compound,
which is >95%. Analytical result is within ±0.40% of the theoretical value.
mp 128–129 °C; yield 72%. 1H-NMR (DMSO) δ 1.18 (s, 3H, C(OH)CH3),
1.32–1.41 (m, 4H, CHCH2CH2CH2CH2NH), 1.61–1.67 (m, 2H,
CHCH2CH2CH2CH2NH), 2.33 (s, 2H, C(OH)(CH3)CH2CONHCH2), 2.38–2.41
(m, 5H, CH2COOH and coumarin-CH3), 3.04 (m, 2H, CH2CONHCH2), 4.15 (m,
1H, α-CH), 5.04 (s, 2H, OCH2Ph), 6.28 (s, 1H, C–H coumarin), 7.18–7.37 (m, 5H,
C–H phenyl ring), 7.51–7.54 (m, 1H, C–H coumarin), 7.67 (m, 1H, C–H
coumarin), 7.73 (d, 1H, Z–NHCHCO), 7.80 (bs, 1H, C–H coumarin), 8.01 (t, 1H,
CH2CONHCH2), 10.61 (bs, 1H, CONH-coumarin). 13C-NMR (DMSO) δ: 174.2,
172.6, 170.9, 161.4, 156.5, 154.2, 153.5, 142.5, 136.8, 128.6 (2C), 128.2 (2C), 127.8,
124.5, 116.7, 112.5, 110.7, 105.2, 71.5, 66.8, 54.1, 47.6, 46.9, 39.1, 30.5, 29.7, 27.4,
22.5, 18.9. Anal. (C30H35N3O9) Calcd. (%): C, 61.95; H, 6.07; N, 7.22. Found (%): C,
62.03; H, 6.05; N, 7.19. MS (ESI), m/z: 580 (M−H)−.
CypA modiﬁcation and de-HMG-ylation and intact protein MS. The recombi-
nant CypA was prepared through expression of a full-length CypA construct in
pQE70 (Qiagen) in E. coli M15 cells and puriﬁcation by ion exchange chromato-
graphy on Fractogel EMD DEAE-650(M), Fractogel TSK AF-Blue, and Fractogel
SO3–650(M) (Merck Millipore)29. CypA protein (0.4 mgml−1) was modiﬁed using
8 mM HMG-CoA in 100 mM Tris-HCl buffer pH 8.3 at 37 °C for 4 h. Formation of
HMG-ylated protein was conﬁrmed by peptide-MS analyzes after tryptic digest29,
and by intact HMG-CypA mass analyzes through HPLC-coupled ESI-MS56. For
intact mass determination, 25 µM HMG-CypA in 10 mM Tris/HCl pH 7.5, 50 mM
NaCl was HPLC-separated with the setting described below for peptide MS, using a
30 min gradient from 1 to 55% buffer B (90% ACN, 9.9% H2O, 0.1% FA; buffer A:
5% ACN, 94.9% H2O, 0.1% FA) followed by 1 min of 55–90% buffer B with 70 µL
min−1 ﬂow-rate. MS-analyzes were done with the settings described for peptide
assays (below), except that the IntactProtein script was activated, which reduces
CEM to 100. Acquired data were extracted with PeakView and deconvoluted in
MassLynx in the range of 950–1500 m/z using the MaxEnt I algorithm to a reso-
lution of 1 Da. Peak intensity values were recorded and overlaid using MassLynx.
For MS-based CypA deacylation analyzes, 50 µM HMG-modiﬁed CypA was
incubated for 2 h at 37 °C with 20 µM hSirt4 and 2 mM NAD+, as well as 0.5 mg
mL–1 nicotinamidase to prevent Sirt4-inhibition by released nicotinamide. Control
reactions without Sirt4 were incubated for 22 h. All reactions were stopped through
mixing 1:1 with 0.5% TFA and analyzed by ESI-MS as described above56. CypA de-
HMG-ylations in the coupled continuous assay were performed as described for
peptide-based assays.
Peptide- and FdL-based activity assays. The coupled continuous assay was
performed as reported27. Brieﬂy, assays in 20 mM sodium phosphate buffer pH 7.8
contained 5 µM hSirt4 or 3–5 µM xSirt4, 0.05 mgml−1 nicotinamidase, 2 Uml–1
GDH, 3.3 mM a-ketoglutarate, 0.2 mM NADPH, 10% DMSO, and NAD+ at 2 mM
or as indicated, and substrate peptide at 500 µM or as indicated. Reactions were
monitored in microplates at room temperature for 1 h through absorption mea-
surements at 340 nm in a LAMBDAScan plate reader (MWG Biotech, Ebersberg,
Germany).
The Fluor-de-Lys (FdL) assay was performed at 37 °C in 25 mM Tris/HCl, 150
mM NaCl with 1 µM hSirt4, 500 µMHMG-FdL substrate and 500 µMNAD+. After
20 min, developer solution (2 mM NAM and 10mgmL−1 trypsin) in assay buffer
was added 1:1 and samples were incubated for 45 min at room temperature.
Fluorescence was measures using a FluoDia T70 with excitation wavelength 365
nm and emission wavelength 465 nm.
For MS and UV analyzes of deacylation reactions, samples were prepared as
described for the coupled continuous assay, stopped by mixing 1:1 with 0.5% TFA
after 0 and 60 min, diluted to 20 µM peptide using 0.1% FA, and analyzed by
HPLC-separation using a Shimadzu Prominence UFLC (Shimadzu, Duisburg,
Germany) coupled to ESI-MS and UV detection. Samples were washed on a
Piccolo Proto 200 C4 5 μm 2.5 × 0.5 mm trap column (Higgins Analytical,
Mountain View, California) and subsequently subjected to a Jupiter C4 5 μm 300 Å
150 × 1mm analytical column (Phenomenex, Torrance, California) for reversed
phase separation, with 99.9% H2O, 0.1% TFA as buffer A and 99.9% ACN, 0.1%
TFA as buffer B. Peptides were eluted over a 20 min gradient from 1 to 55% buffer
B, followed by 1 min from 55 to 90% buffer B with 70 µLmin−1 ﬂow-rate. UV-
detection was done using a Shimadzu SPD-20A detector at 280 nm. MS analysis
was performed by ESI-TOF-MS on an AB Sciex TripleTOF 5600+ mass
spectrometer (Sciex, Darmstadt, Germany) with a DuoSpray Ion Source using the
following settings: ﬂoating voltage of 5500 V and declustering potential of 100 with
one TOF experiment summing over four time bins. We detected in a mass range
from 300 to 2500 m/z. XIC of substrate and product peptides were extracted using
their respective mass in singly, doubly, or triply charged state within a window of
0.2 m/z in PeakView version 1.2.0.3.
Thermal denaturation shift assays. Thermal shift assays were performed in 96-
well PCR plates using 3 µM xSirt4 (32–315) or 3 µM zSirt4 (29–310) and SYPRO
orange (Thermo Fisher, Waltham, MA, USA) covered with 15 µL mineral oil.
Heating and ﬂuorescence measurements were performed in a FluoDia T70 with 1 K
steps from 20 to 73 °C (excitation: 465 nm, emission: 580 nm). The data were
analyzed in GraFit (Erithacus Software Ltd, Horley, UK) by nonlinear ﬁtting using
a two state model.
Statistical information. Data points for activity assays were determined in
duplicates, and all experiments were done in at least two repetitions.
Sirt4 crystallization and structure determination. xSirt4(32–315) protein (5mg
ml−1 in 25mM Tris/HCl 7.5, 150mM NaCl, 20% glycerol) was incubated with 10
mM ADPr (xSirt4/ADPr complex) or 1 mM thioacetyl H3K9 peptide and 5mM
NAD+ (xSirt4/thioacetyl-ADPr complex) on ice for 30min. The xSirt4 complexes
crystallized at 4 °C in sitting drops (1:1 ratio protein to reservoir solution) with 100
mM BICINE pH 8.5, 20% PEG6000 (xSirt4/ADPr) or 500mM Na/K-tartrate, 0.5%
PEG5000MME, 100mM TRIS/HCl pH 8.5 (xSirt4/thioacetyl-ADPr) as reservoir.
zSirt5 (10mgmL–1 in 20mM TRIS/HCl pH 8.5, 150mM NaCl) was incubated with
1mM HMG-CPS1-peptide (10% v/v DMSO ﬁnal concentration) on ice for 30min
and crystallized in sitting drops at 20 °C using 20% PEG3350, 100mM HEPES pH 7.6
as reservoir solution. Crystals appeared within 3 days (xSirt4) or 2 weeks (zSirt5), were
transferred to a drop of reservoir solution supplemented with the co-crystallization
ligand and 25% glycerol for 1min, and ﬂash-frozen in liquid nitrogen.
Data collection was done at BESSY II beamline MX14.1 (operated by the
Helmholtz Zentrum Berlin, Germany) using a wavelength of 0.912 Å and a Pilatus
6M detector (Dectris, Baden, Switzerland). Indexing, scaling and merging of
diffraction data was performed with XDS57. Structures were solved by molecular
replacement with PHASER58 using as a search model a Sir2Af1/peptide complex
(PDB-Code 4TWI59) for xSirt4/ADPr, this initial xSirt4 structure for xSirt4/
thioacetyl-ADPr, and a zSirt5/peptide complex (PDB ID 4UTV15) for zSirt5/HMG-
CPS1. Reﬁnement was performed with Refmac560, using partially anisotropic B-
factors and TLS for the protein chain and the Zn ion for the xSirt4/ADPr complex.
Models were built and validated using Coot61 and structure ﬁgures were generated
with PyMol (Schrödinger, LLC). Docking of Lipoyl-Lys in the xSirt4/ADPr active-
site was done with LeadIT (BiosolveIT GmbH, Sankt Augustin, Germany).
Sequence alignments and phylogenetic trees. Structure-based sequence align-
ments were created using STRAP with the integrated Aligner3D algorithm62, and
manual editing and phylogenetic tree generation were done with BioEdit63. Con-
servation levels were mapped on the xSirt4 structure surface using ConSurf64.
Data availability. Structure factors and reﬁned structures have been deposited
with the Protein Data Bank (http://www.rcsb.org/pdb) under accession codes 5OJ7
(xSirt4/ADPr), 5OJN (xSirt4/thioacetyl-ADPr), and 5OJO (zSirt5/HMG-CPS1).
Other data are available from the corresponding author upon reasonable request.
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Supplementary Figure 1. Enzymatic activity of Sirt4. a, Peptide acyl library for Sirt4 
activity screening. A peptide derived from human CPS1 (residues 524-531) was modified 
with the given acyls (R) on its lysine ε-amino group (covalent linkage indicated by dotted 
lines). b, hSirt4-dependent deacylation reactions with acetyl-, DMS- and HMG-CPS1 peptide 
substrate performed in presence and absence of 2 mM NAD
+
 to confirm their NAD
+
 
dependency. (n=2; error bars: s.d.) c, Analysis of Sirt4-dependent de-HMG-ylation and 
deacetylation by MS detection of substrate and product peptide (left). The identical de-HMG-
ylation analyzed in the coupled enzymatic assay is shown on the right. (n=2; error bars: s.d.)  
d, NAD+ titration of the hSirt4-dependent de-HMG-ylation of HMG-CypA as a substrate 
protein. Error bars indicate the correlation coefficient of the linear fit of assay progression. 
(n=2; error bars: s.d.) e, Intact protein MS analysis of Sirt4-dependent de-HMG-ylation of 
HMG-CypA. The ratios (left) of lower to higher HMG-modification levels (numbered in 
spectra on the right) increased in presence of Sirt4 but not in control reactions without 
enzyme. 
 
 
 
  
3  
 
a 
   b                          
4  
c 
 
    
 
5  
d 
 
          
6  
e   
Supplementary Figure 2.   Sirt4 conservation and structure. a, Sequence alignment of 
hSirt4, xSirt4 and zSirt4 showing high conservation except for the N-terminal MLS. The 
coloring encodes conservation (BLOSUM62 score). b, Melting temperatures of xSirt4 with 
various ligands in thermal denaturation shift assays. HMG-FdL, CPS1 peptide, and DMSO 
control contained 10% DMSO. (n=2; error bars: s.d.) c, Multiple sequence alignment of all 
chordate Sirt4 sequences available from UniProt. The coloring encodes conservation 
(BLOSUM62 score). Numbering and secondary structure elements are from xSirt4. 
d, Structure-based sequence alignment of the catalytic cores of Sirt1-7 and bacterial sirtuins. 
Our xSirt4/ADPr complex, the most similar structures of human Sirt1,2,3,5,6 and of the 
bacterial sirtuins (determined using PDBeFOLD) were aligned, the alignment refined 
manually according to conserved secondary structure elements, and subsequently all chordate 
sequences of Sirt1-7 available from UniProt were added. Sequences of the structurally 
characterized sirtuins (highlighted by underlining and *) and four representative sequences of 
Sirt1-7 are shown. Coloring indicates conservation (BLOSUM62 score). Numbering and 
secondary structure elements are from xSirt4. e, Crystal structure of an xSirt4/thioacetyl-
ADP-ribose complex (green). The Sirt4-loop features a different conformation than in the 
Sirt4/ADPr complex (grey) and is largely undefined as indicated by the 2Fo-Fc electron 
density contoured at 1 (gray mesh). 
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Supplementary Figure 3. Active site features. a, Overlay of xSirt4 (grey surface) and as a 
representative of other isoforms Sirt3 (PDB ID 3GLR; yellow sticks), showing that the Sirt4 
channel is blocked in other isoforms. b, Effect of metabolites on xSirt4-dependent 
deacetylation (top) and de-HMGylation activity (bottom). Metabolites were tested in the 
coupled enzymatic assay, except for lipoic acid (*), which was incompatible and therefore 
examined in MS-based assays. (n=2; error bars: s.d.) c, Overlay of xSirt4 (grey cartoon and 
sticks) with NAD
+
 in productive conformation (cyan sticks) from an overlaid Sir2Tm 
complex (PDB ID 4BUZ) and non-productive NAD
+
 (green) from an overlaid Sirt3 complex 
(PDB ID 4BV3). d, NAD+ titrations for xSirt4 wildtype (wt) and Sirt4-loop deletion mutant 
(198-203) with HMG-CPS1 peptide substrate. (n=2; error bars: s.d.) e, Inner surfaces of the 
nucleotide binding sites of Sirt1-6, colored by electrostatic potential calculated with APBS2.1 
in PyMOL using PDB IDs 4KXQ (Sirt1), 5D7O (Sirt2), 4BN4 (Sirt3), our xSirt4 structure, 
PDB IDs 3RIY (Sirt5) and 3K35 (Sirt6). ADPr complexes were used for comparability, 
except for Sirt5 (Sirt5/ADPr complex in open conformation) where we used a Sirt5/succinyl-
H3K9/NAD
+
 complex. ADPr/NAD
+
 are shown as sticks. The surfaces are colored according 
to electrostatic potential (red/-15 to blue/+15 kBT/e). f, xSirt4 surface colored by electrostatic 
potential calculated using APBS2.1 in PyMOL (red/-15 to blue/+15 kBT/e). ADP-ribose is 
shown as white sticks, and a glutaryl-CPS1 peptide from an overlaid zSirt5 complex (PDB ID 
4UTR) is shown in pale green. g, Overlay of the active sites of the zSirt5/HMG-CPS1 
complex (white, light-blue ligand) with zSirt5/glutaryl-CPS1 (orange; PDB ID 4UTR). Polar 
contacts are indicated by dashed lines. h, xSirt4-dependent deacylation of CPS1-K527 
peptides carrying modifications with a positive charge at the distal end (acyl structures shown 
in Supplementary Fig. 1a). Activities are normalized to acetyl-CPS1 substrate. (n=2; error 
bars: s.d.)  
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Supplementary Figure 4. Sirt4 inhibition. a, Suramin titration to determine the IC50 for 
hSirt4 in the FdL-like de-HMG-ylation assay. (n=2; error bars: s.d.) b, NADH-dependent 
Sirt4 inhibition analyzed with HMG-CPS1 substrate in the MS-based assay. (n=2; error bars: 
s.d.) 
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Supplementary Figure 5. Reaction scheme for synthesis of the fluorogenic Sirt4 substrate 
Z-Lys(HMG)-AMC (HMG-FdL). 
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Supplementary Table 1 – Primer sequences 
Primer Sequence 
hSirt4_25_BamHI_forward TATAGGATCCTCGAAAGCCTCCATTGGGTTATT 
hSirt4_314_HindIII_reverse TATAAAGCTTTCAGCATGGGTCTATCAAAG 
xSirt4_21_NdeI_forward ATACATATGAGCCACAAATCCCACCTTGCATTGTC
AG 
xSirt4_32_NdeI_forward ATACATATGGTCCCTGCATGTCCCCCACCAAATC 
xSirt4_315_XhoI_reverse TATACTCGAGCTATTGGTCCTGTAGCAATATGTGT
GGCAATAC 
xSirt4_D201A_forward GTTGGCTCCCGCGGGTGATGTCTTTCTGAC 
xSirt4_D201A_reverse TGTACCCAACCGAGGGCGCCCACTACAGAA 
xSirt4_D203A_forward AGGGCTACCACGCCAGAAAGACTGTCTAC 
xSirt4_D203A_reverse AGGGCTACCACGCCAGAAAGACTGTCTAC 
xSirt4_Y73F_forward GGAATCCCAGACTTTCGCTCAGAAGGG 
xSirt4_Y73F_reverse CCCTTCTGAGCGAAAGTCTGGGATTCC 
xSirt4_R101A_forward GAGTCAGGCTGCAGCACGGAGATATTGGG 
xSirt4_R101A_reverse CCCAATATCTCCGTGCTGCAGCCTGACTC 
xSirt4_Y104F_forward GCTGCAAGACGGAGATTTTGGGCTCGTAACTTTG 
xSirt4_Y104F_reverse CAAAGTTACGAGCCCAAAATCTCCGTCTTGCAGC 
xSirt4_R107A_forward CGGAGATATTGGGCTGCGAACTTTGTAGGATG 
xSirt4_R107A_reverse CATCCTACAAAGTTCGCAGCCCAATATCTCCG 
xSirt4_Y104F-R107A_forward CAGGCTGCAAGACGGAGATTTTGGGCGGCGAAC
TTTGTAGGATGGCCTAG 
xSirt4_Y104F-R107A_reverse CTAGGCCATCCTACAAAGTTCGCCGCCCAAAATC
TCCGTCTTGCAGCCTG 
xSirt4_N108A_forward GAGATATTGGGCTCGTGCGTTTGTAGGATGGCCT
AG 
xSirt4_N108A_reverse CTAGGCCATCCTACAAACGCACGAGCCCAATATC
TC 
xSirt4_Δ189-214_forward GGTTTCTGAATCTCAATGGATCTAGTCAGGTCCCA
GCCTGTACCAAGTG 
xSirt4_Δ189-214_reverse GGCTGGGACCTGACTAGATCCATTGAGATTCAGA
AACCTTTCCTGCAGC 
xSirt4_Δ192-212_forward CTCAATCCATCCTGGGGTAGTTCTGACTTTCAGGT
CCCAGCCTGTACC 
xSirt4_Δ192-212_reverse GGGACCTGAAAGTCAGAACTACCCCAGGATGGAT
TGAGATTCAGAAAC 
xSirt4_Δ196-205_forward CCTGGAATGAGCAGGCACTGACAGATGAGCAGG 
xSirt4_Δ196-205_reverse CCTGCTCATCTGTCAGTGCCTGCTCATTCCAGG 
xSirt4_Δ196-205+GSS_forward CAATCCATCCTGGAATGAGCAGGCAGGCTCTTCT
CTGACAGATGAGC 
xSirt4_Δ196-205+GSS_reverse GTCTGACACCTGCTCATCTGTCAGAGAAGAGCCT
GCCTGCTCATTCC 
xSirt4_Δ198-203_forward GAGCAGGCACATGGGGTCTTTCTGACAGATG 
xSirt4_Δ198-203_reverse CATCTGTCAGAAAGACCCCATGTGCCTGCTC 
zSirt4_29_NdeI_forward ATACATATGGTTCCTGCAAGTGGCTCCTTTGACTC
CAG 
zSirt4_310_XhoI_reverse TATACTCGAGTCAGGACAGTTTAATGGCTGGCAG
CACTTCTCC 
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